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Methyltransferases represent a class of enzyme responsible for the modification of 
biomolecules through the transfer of individual methyl units.  The cofactor, S-adenosyl-
L-methionine (SAM), serves as the methyl source for the vast majority of these enzyme-
catalyzed reactions.  These transformations have broad implications for many biological 
processes, ranging from the biosynthesis of essential cellular metabolites and 
pharmaceutically relevant natural products to the regulation of gene expression and 
protein function through the modification of nucleic acids and polypeptides.  In addition, 
the malfunction of methyltransferase activity has been strongly implicated in a number of 
disease states including developmental disorders and carcinogenesis. As such, there has 
been significant effort in recent years to better understand these enzymes, their substrates, 
and the biological effects associated with their activity.  Despite increased interest, the 
study of these processes has proven difficult using traditional biochemical or genetic 
techniques.  In light of this, the research described herein has been aimed at the 
development of novel chemical tools and approaches for the study of these enzymes, with 
an emphasis on protein methyltransferases (PMTs).  This research can be broadly 
categorized into two main focuses: (i) the implementation of Bioorthogonal Profiling of 
Protein Methylation (BPPM), in which substrates of specific PMTs are determined 
through the use of engineered enzymes, SAM analogues and bioorthogonal chemistry; 
and (ii) the development of a selenium-based SAM analogues, one of which has shown 
broad compatibility toward a wide variety of wild-type enzymes including: protein, 
nucleic acid and small-molecule methyltransferases.  With these tools in hand, novel 
substrates for the G9a and GLP1 protein lysine methyltransferases have been identified, 
and a versatile selenium-based SAM mimic has demonstrated potential as a useful tool 
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CHAPTER 1: INTRODUCTION 
 
1.1 METHYLTRANSFERASES: VERSATILE ENZYMES WITH DIVERSE 
SUBSTRATES 
Methyltransferases are enzymes characterized by their ability to transfer one or 
more single-carbon methyl groups onto their substrates.  Although genetically and 
structurally diverse, the overwhelming majority of these enzymes utilize S-adenosyl-L-
methionine (SAM) as a cofactor and methyl source1 for the modification of essentially 
every type of biomolecule, including: natural products, lipids, carbohydrates, nucleic 
acids, and proteins. 1-4 The first SAM-dependent methyltransferase identified was 
nicotinamide N1-methyltransferase (originally dubbed nicotinamide methylkinase due to 
the reconstituted enzyme system’s reliance on ATP and methionine), which was 
identified in 1951 by G. L. Cantoni and is responsible for the generation of N1-
methynicotinamide.5 Since then, SAM-dependent enzymes responsible for the 
methylation of the vast array of additional substrates have been characterized.6 In the 
wake of these discoveries, a broader understanding of the biological functions influenced 
by these enzymes is currently being pursued.   
Over the past decade, one of the most intensely examined topics of research 
related to methyltransferase activity has been epigenetic regulation of gene expression.  
In eukaryotes, DNA is normally found bound to octomeric histone protein (histones H2A, 
H2B, H3, and H4) complexes, which wind the genomic material into compact structures 
known as nucleosomes (the basic unit of chromatin).  The theory of epigenetic regulation 
stipulates that, through the modification of DNA, histones, and other factors, eukaryotic 
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gene expression can be tightly controlled and regulated through the modulation of 
chromatin structure.7 Along with other modifications (phosphorylation, acetylation, 
ubiquitylation, etc.), methylation is thought to play an essential role in this process, 
particularly through the methylation of genomic DNA and the histone proteins that bind 
and sequester it.8, 9 In the context of this theory, methylation marks, deposited by protein 
or nucleic acid methyltransferases (‘writers’), serve as binding motifs for specific methyl-
recognizing proteins (‘readers’).7 These reader proteins may then interact with a variety 
of other effectors, such as chromatin remodelers, DNA repair proteins, or transcription 
factors, in order to elicit a response.  In recent years, however, several of these writer 
enzymes have been found to methylate non-histone targets as well.10 Research focused on 
the discovery and study of these non-histone targets is the primary topic of this 
dissertation, and a more detailed discussion of these enzymes and their substrates is 
provided in section 1.3. 
 Another area of research related to these enzymes is in the field of natural product 
methyltransferases (NPMTs).  These enzymes represent the most diverse class of 
methyltransferases across species and are involved in the biosynthesis of a vast array of 
metabolites and pharmaceutically relevant compounds, where the addition of a methyl 
group is often essential for altering the pharmacological properties of the natural 
product.6 Classic examples may include such enzymes as phenylethanolamine N-
methyltransferase or histamine N-methyltransferase, which are responsible for the 
methylation of norepinephrine and histamine, respectively.  However, there are hundreds 
of natural products that rely upon the activity of NPMTs for their biosynthesis.  Indeed, 
NPMT activity can be found across essentially every class of natural product, with 
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biosynthetic activities ranging from essential metabolites, alkaloids, terpenoids and 
polyketides, up to nonribosomal peptides (NRPs) and ribosomally synthesized and 
posttranslationally modified peptides (RiPPs).6, 11-13   
 
Figure 1.1: Representation of the scope of biological transmethylation reactions catalyzed by SAM-
dependent methyltransferases.  The sulfonium-methyl group (in red) of SAM is chemically reactive and 
transferable to a wide variety of proteins, nucleic acids, and small-molecules. 
 
1.2 S-ADENOSYL-L-METHIONINE: CHEMISTRY AND FUNCTION 
 S-Adenosyl-L-methionine (Figure 1.1) was first described by G. L. Cantoni in 
1953 as the chemically active source of transferable methyl groups in the biosynthesis of 
N1-methynicotinamide.5, 14 This discovery was brought about by the earlier observations 
that methionine was serving as a methyl source and that ATP was required for its 
activation, which together helped to inform its structural identity.15 The biosynthesis of 
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Methionine adenosyltransferase, MAT; or methionine activating enzyme, MAE), which 
transfers the sulfur group of methionine to the C-5’ position of ATP, yielding SAM and 
generating phosphate/diphosphate as byproducts.16 SAM synthetase is ubiquitously found 
across all of domains of life, with the exception of some parasitic species that take up 
SAM produced by their hosts.17, 18  
 In terms of chemical reactivity, SAM’s ability to function as a methyl source 
stems from the presence of its high-energy sulfonium group, which imparts sufficient 
electrophilic character to the adjacent methyl group in order to make it susceptible to 
nucleophilic attack by suitable nucleophiles.14 Enzymatic transfer of the sulfonium-
methyl group to oxygen, nitrogen, and sulfur nucleophiles is traditionally thought to 
occur through an SN2-like mechanism, proceeding through a trigonal planar transition 
state.19 In recent years, however, a number of SAM-dependent methyltransferases have 
been described that utilize radical-based mechanisms to carry out their transformations.  
These enzymes make use of [4Fe-4S] clusters and the relatively low bond cleavage 
energies between the sulfonium-carbon bonds of SAM to generate a 5’-deoxyadenosyl 
radical. This key intermediate can in turn abstract a proton from the target substrate, 
activating it for subsequent modification.20 Due to the high reactivity of their 
intermediates, radical-SAM methyltransferases are capable of methylating carbons that 
might not otherwise be nucleophilic.  This can be exemplified by the activity of enzymes 
such as RlmN or Cfr, which are capable of methylating C-2 and C-8, respectively, of 
adenosine in bacterial 23S ribosomal RNA.20 
 In addition to SAM’s function in transmethylation reactions, it is also involved in 
several other biochemical pathways.  The first major pathway is polyamine biosynthesis, 
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which is thought to play a key role in cell survival and DNA repair.21 In this pathway, the 
α-aminobutyrate moiety of SAM is first decarboxylated through the activity of 
adenosylmethionine decarboxylase, forming adenosylmethioninamine.22 Subsequent 
enzymatic transfer of the propylamine group to putrescine or spermidine yields 
spermidine or spermine, respectively.  Another major pathway dependent on the chemical 
reactivity of SAM is the biosynthesis of ethylene, a crucial signaling molecule in plants.  
Also referred to as the Yang cycle (after its discoverer), ethylene biosynthesis relies upon 
the activity of 1-aminocyclopropane-1-carboxylate (ACC) synthase to convert the α-
aminobutyrate group of SAM to ACC.  Carbon dioxide and hydrogen cyanide are then 
eliminated from this intermediate through the activity of ACC oxidase to yield ethylene.23 
Due to its intrinsic reactivity, however, SAM is also subject to spontaneous 
degradation via several routes (Figure 1.2).  The first and most prominent route occurs 
through intramolecular lactonization of the α-aminobutyrate moiety of SAM, yielding 5’-
methylthioadenosine and homoserine lactone.24 This pathway is highly pH dependent, 
demonstrating a roughly 10-fold rate enhancement corresponding to the relative pKa’s of 
SAM’s amino acid moiety.25 In the second route, the chiral sulfonium center of (S,S)-
SAM (the biochemically active epimer of SAM) is capable of racemization to afford the 
(R, S) epimer of SAM, which is incompatible towards enzymatic transmethylation 
reactions.26 Lastly, SAM is capable of depurination via base-promoted deprotonation of 
C-5’ in ribose, yielding 5’-ribosylmethionine and adenine.27 The relatively high acidity of 
the C-5’ protons, which have an apparent pKa of ~11.5, is thought to result from the 
presence of the sulfonium group directly adjacent.25, 28 
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Figure 1.2: Inherent degradation pathways associated with SAM reactivity. Route (a) involves 
intramolecular lactonization of the carboxylate with the γ-carbon of SAM’s α-aminobutyrate moiety.  
Route (b) takes place through racemization of the sulfonium group.  Route (c) is the result of a concerted 
reaction dependent on deprotonation of C-5’. 
 
SAM Analogues 
 With an appreciation for the biochemistry of SAM in mind, several groups 
(including ours) have explored the use of SAM analogues as potential tools for the study 
of SAM-dependent methyltransferases.29-35 Development of these analogues has focused 
on substitution of the transferable methyl group with a variety of different functionalized 
R-groups in order to explore their enzyme compatibility. Generally, these analogues can 
be categorized into four major structural groups (based on substitution at the carbon β to 
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Figure 1.3: Representation of the various classes of SAM analogues.  (a) The four general classes of 
SAM analogues studied to date.  As a general trend, β-sp3- and β-sp1-hybridized analogues are unreactive 
or unstable, respectively.  Both β-sp2- and β-carbonyl-hybridized analogues have been reported to be active 
as enzyme cofactors. (b) The rationale behind the observed β-sp2- and β-carbonyl-analogue activity 
involves transition state stabilization during alkyl transfer. 
 
Initial studies by Dalhoff and colleagues were the first to examine the cofactor 
reactivity of a subset of these SAM analogues towards several wild-type DNA 
methyltransferases.29 Findings from this initial report established that SAM analogues 
containing β-sp3-hybridized substituents are typically inactive towards wild-type 
methyltransferases; whereas β-sp2 and β-sp1 hybridized analogues remain active, 
assuming their R-groups do not contain too much steric bulk and are stable (see chapter 
3). The proposed rationale behind this observation stems back to the mechanism 
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was originally thought that conjugation of the p orbital formed during the transition state 
to the adjacent π system in these analogues facilitates the SN2 transfer reaction.29 This 
notion has held true through future studies as well, with β-sp3 analogues demonstrating 
no activity towards other classes of methyltransferase.32 Together with observations by 
our group and others, these findings have helped to inform the design and synthesis of 
additional SAM analogues containing chemical handles compatible with bioorthogonal 
chemistry (see section 1.5).   
 
1.3 PROTEIN METHYLTRANSFERASES 
Despite the recent groundswell of interest in determining the roles that they play 
in epigenetic processes, many protein methyltransferases (PMTs) do not appear to be 
limited to histone modification. In fact, several of these putative histone 
methyltransferases have thus far demonstrated no activity towards recombinant histones, 
histone peptides, or nucleosomes.   As such, it has become increasingly appreciated that 
these enzymes may have a much broader variety of substrates beyond histones. Coupled 
with the recent identification of numerous demethylating enzymes, protein methylation is 
now implicated as key signaling modification akin to phosphorylation or ubiquitylation.10, 
36 Numerous reports have surfaced in recent years describing non-histone targets for 
methyltransferases previously characterized as ‘histone methyltransferases’. For example, 
the GLP1, G9a, SET8 and several other methyltransferases have all been shown to 
methylate the tumor suppressor p53 protein in order to modulate its function.37-39 
Furthermore, a handful of other proteins modified by lysine or arginine ‘histone’ 
methyltransferases have been identified, including: ERα, NF-κB, DNMT1, STAT3, 
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FOXO1, and p300, to name a few.36 This information has gradually lead to a 
reclassification of these eukaryotic “histone methyltransferases” as general “protein 
methyltransferases”, in order to more accurately describe their function.  
 This shift should come as no surprise, however, as a number of dedicated non-
histone protein methyltransferases have been studied for decades and are known to play 
important roles in basic biological phenomena.  For example, bacterial chemotaxis is 
regulated, in part, through the modification of glutamate residues in methyl-accepting 
chemotaxis proteins (MCPs) by the CheR protein glutamylmethyltransferase.40 MCPs are 
integral membrane proteins that act as receptors for chemoattractants or chemorepellants 
in order to transmit chemical information from the surrounding environment to the 
flagellar machinery.  It is now known that posttranslational modification of these 
receptors may dramatically alter sensitivity towards their ligands and thus dictate whether 
a cell remains motile or is stationary.  In addition, the methylation of the C-terminal 
carboxylate group in the Ras GTPase, which is an important driver for some cancers, is 
thought to be crucial for its localization and activity.41 This modification is carried out by 
isoprenylcysteine carboxyl methyltransferase following prenylation and proteolysis of the 
C-terminal CAAX motif of Ras, and is thought to aid in the localization of Ras to target 
membranes by masking the negative charge of the carboxylate. Lastly, protein 
methylation has more recently been implicated in host immune response evasion by some 
enteropathogenic bacteria.  Following invasion of a host cell, some enteropathogenic E. 
coli strains are capable of secreting numerous effector proteins via type III secretion 
systems.  One such effector, NleE, was recently shown to disrupt NF-κB signaling, which 
is important for the upregulation of pro-inflammatory cytokines, through SAM-dependent 
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cysteine methylation of the human TAB2 and TAB3 adaptor proteins.42 Specifically, 
NleE targets and inactivates key zinc-coordinating cysteine residues required for the 
structural integrity of N-terminal Npl4 zinc finger domains in TAB2/3, which are critical 
for downstream signaling and activation of NF-κB. Together, these examples serve to 
illustrate the scope of functions that can be influenced by the activity of PMTs.   
As a primary focus of the research outlined herein, my work has been in the 
pursuit of developing novel tools and techniques for the study of methyltransferases, with 
a partial emphasis on protein lysine methyltransferases as a model system.  As such, a 
detailed description of the structure and function of these enzymes will be provided in the 
following subsection. 
 
Protein Lysine Methyltransferases (PKMTs) 
 The human genome is thought to encode for roughly 50 methyltransferases 
capable of methylating the ε-amino group of lysine.43 Interestingly, most of the PKMTs 
in humans contain a conserved catalytic domain known as the SET (suppressor of 
variegation 3-9, enhancer of zeste and trithorax) domain, with the exception being the 
DOT1L protein.  Generally speaking, the SET domain contains two distinct binding sites: 
(i) a cofactor-binding site for SAM, and (ii) a peptide-binding groove for enzyme 
substrates.  In most cases, these pockets are found on opposite faces of the SET domain, 
separated by a hydrophobic channel lined with tyrosine and phenylalanine residues.44 In 
terms of catalytic mechanism, it is thought that the target lysine residue is positioned 
inside this hydrophobic channel during recognition of the target polypeptide, where it 
comes into close proximity with the methyl group of SAM.  Subsequent deprotonation of 
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the ε-amino group by an adjacent conserved tyrosine then activates the target lysine for 
transmethylation.45 Furthermore, because these enzymes contain two distinct binding 
pockets for cofactor and peptide, many are capable of transferring multiple methyl groups 
to the target lysine in a processive manner. As a result, many PKMTs are further 
classified by the number of methyl groups they typically transfer to a specific residue (i.e. 
mono-, di-, or tri-methyltransferases).  
Although the specific substrates of all human PKMTs have not yet been fully 
determined, many have been shown to methylate lysine residues on histones, including 
histone H3 K4, K9, K27, K36, and K79, as well as histone H4 K20.8, 45 For example, the 
G9a, GLP1, SUV39H1, SUV39H2, SETDB1, and SETDB2 enzymes are all capable of 
di/tri-methylating K9 of histone H3.  Furthermore, both G9a and GLP1 have also been 
shown to methylate H3K27.  In contrast, the SET8 and SET7/9 enzymes have been 
classified as histone mono-methyltransferases and are capable of methylating H4K20 and 
H3K4, respectively.8 While not clear in all cases, the methylation of H3K4, H3K36 and 
H3K79 have typically been associated with transcriptional activation, whereas H3K9, 
H3K27, and H4K20 methylation are associated with repression.  
 Although the detailed physiological mechanisms are not yet known, the activity of 
some PKMTs have been strongly implicated in human disease.  In addition to the 
examples listed in the sections above, dysregulation or deletion of several PKMTs has 
been associated with a number of pathogenic states, particularly cancer development and 
progression. EZH2 (enhancer of zeste homologue 2; a H3K27 PKMT), for example, is 
thought to act primarily as a transcriptional repressor and is overexpressed in several 
cancers including lymphoma, breast, and prostate cancer.46, 47 In contrast, retinoblastoma 
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protein-interacting zinc finger 1 (RIZ1; a H3K9 PKMT), which is involved in cell-cycle 
arrest and apoptosis, and has been shown to be down-regulated or deleted in breast, liver, 
cervical and colon cancers.48 
 Several developmental disorders have also been tightly associated with PKMT 
function.  One such disorder, Kleefstra syndrome (a.k.a. 9q34 deletion syndrome), has 
been directly attributed to the deletion of the GLP1 H3K9 methyltransferase from the end 
of chromosome 9.49 Although rare, the physical and neurological symptoms of this 
disorder are quite severe, and are characterized by heart, genital and renal defects, as well 
as seizures, facial hypoplasia, and severe mental retardation.  Indeed, knockout of GLP1 
in transgenic mouse models resulted in embryonic lethality due to severe growth 
defects.50 Furthermore, postnatal knockdown of GLP1 in the forebrain neurons of mice, 
although not lethal, resulted in a significant impairment of cognitive and adaptive 
abilities.51 With these examples in mind, it is clear that PMT dysfunction is likely related 
to a wide variety of human disease states. Thus, much recent research has been aimed at 
the development of new ways to study the targets and functions of PMTs. 
 
1.4 CONVENTIONAL APPROACHES TO STUDY METHYLTRANSFERASE 
ACTIVITY 
 Given its importance in fundamental biological processes and implication in 
human disease, numerous tools and approaches have previously been applied or 
developed in order to study methyltransferases.52 Many of these technologies retain 
inherent limitations, however, due to complex protein interactions required for 
methyltransferase activity and the chemically subtle nature of the methyl mark.  These 
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approaches will be discussed in the following subsections, along with descriptions of 
their advantages and drawbacks. 
 
Enzyme-Coupled Assays 
 One approach used to examine methyltransferase activity has been to monitor the 
formation of the transmethylation reaction byproduct, S-adenosyl-L-homocysteine (SAH).  
This can be achieved through enzyme-coupled detection assays in several ways: (i) 
enzymatic conversion of SAH to L-homocysteine, which can then be reacted with a 
fluorogenic dye, and (ii) luminescent assays relying on the activity of luciferin/luciferase.   
In the first format, enzymatic reactions containing a methyltransferase, known 
substrates, and SAM or SAM analogues are allowed to progress.  Following completion 
of the reaction, the resultant product mix will contain methylated peptide and SAH.  SAH 
may then be hydrolyzed to L-homocysteine and adenosine through the activity of SAH 
hydrolase (SAHH).  The resultant free thiol of L-homocysteine is then covalently coupled 
to a Michael-accepting coumarinic dye (CPM), which results in a quantifiable fluorescent 
signal at specific excitation and emission wavelengths.53, 54 For the second assay, 
although the initial experimental setup is similar to that of the first, SAH is instead 
converted into adenosine triphosphate (ATP) through the activity of several enzymes.  
Adenine is first liberated from SAH through the activity of 5’-methylthioadenosine/SAH 
nucleosidase (MTAN).  Then, through the activity of adenine phosphoribosyl transferase 
(APRT), the liberated adenine is converted to adenosine monophosphate (AMP) prior to 
transformation into ATP by a third enzyme, pyruvate orthophosphate dikinase (PPDK).  
Subsequent reaction between ATP and luciferin/luciferase yields a chemiluminescent 
	   14	  
signal. It should be noted that this assay is extremely sensitive, with a detection limit of 
0.3 pmol for SAH.55 Together, these approaches have several advantageous qualities, 
including rapid high-throughput formatting and versatility between different enzymes, 
cofactor analogues, and substrates.  However, some limitations do exist, such as a general 
incompatibility with thiol-based reducing agents (due to reactivity towards the CPM dye), 
high background signals, and a potential for false positives. 
  
Antibody-Based Approaches 
 Antibodies developed against specific methylated antigens provide a powerful 
and convenient way to detect the presence of modified residues within proteins or 
peptides.  Indeed, many antibodies for methyl-lysine and methyl-arginine residues are 
commercially available and can be easily applied for western blot analysis, enzyme-
linked immunosorbent assays (ELISA), or chromatin immunoprecipitation (ChIP) 
experiments.56, 57 To date, numerous studies have relied upon these antibodies to detect 
methylation patterns both in vitro and in vivo.  Despite their widespread use and high 
sensitivity, however, several concerns arise in some circumstances.  These include issues 
such as antibody specificity and sequence dependence; where an antibody developed 
against a specific epitope may cross react with an irrelevant structural feature, or not 
interact at all with a peptide of slightly different amino acid sequence, leading to false 
positives and negatives.  Another common concern relates to the processivity of many 
lysine or arginine methyltransferases, in which a specific antibody may not be able to 
differentiate between mono-, di-, or tri- methylated residues.  Lastly, the problem of 
enzyme redundancy is a common issue, especially when examining methylation in vivo.  
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In living systems, there are often multiple PMTs capable of methylating the same 
residue.56 For example, G9a, GLP1, SUV39H1/2, and SETDB1/2 are all capable of di/tri-
methylating histone H3K9.8 Even when combined with genetic approaches, such as 
knockdown or knockout of specific methyltransferases, attempting to correlate a change 
in observable methylation patterns can be challenging.  
 
Isotopic Labeling 
 The use of isotopically labeled SAM as a means to monitor enzyme activity has 
been a mainstay for much of the biochemical research on PMTs.  Use of radioactive 3H-
SAM in particular has been a versatile means of measuring enzyme kinetics and is often 
used for screening potential PMT inhibitors in vitro.52, 58, 59 Non-radioactive deuterated 
SAM (CD3-SAM) has also proven to be a powerful tool for the study of PMT activity, 
especially when combined with mass spectrometry-based detection, as is the case in 
SILAC (stable isotope labeling with amino acids in cell culture) experiments.60 Although 
a powerful tool for in vitro study and top-down proteomic analysis of methylated proteins, 
some drawbacks do exist.  First, kinetic measurements using 3H-SAM are often very 
labor intensive and require the handling of hazardous radioactive materials. Second, 
radiometric and proteomic studies via SILAC approaches are sometimes unable to clearly 
attribute observable methylation marks to the activity of specific enzymes.   
 
Array-Based Technologies 
 To date, several attempts have been made towards the development of peptide- or 
protein-based arrays for the determination of PMT substrates.  These arrays have utilized 
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a variety of different detection methods, including fluorescently labeled antibodies, 
recombinant methyl-binding protein domains, and autoradiography.  In 2008, Rathert and 
colleagues reported the synthesis of peptide arrays containing methylated peptides from 
known substrates of the G9a PKMT.  Using recombinant GST-HP1β (a methyl-lysine 
binding chromodomain-containing ‘reader’ protein) coupled to αGST antibodies, the 
authors were able to demonstrate array-based detection of many previously reported 
substrates of G9a.61   In 2011, Levy and colleagues expanded upon this approach using 
ProtoArray® technology (Invitrogen), which contain 9,500 purified recombinant human 
proteins arrayed on nitrocellulose slides.  These slides were treated with a recombinant 
human PKMT, SETD6, in order to methylate potential substrates. Detection of substrates 
was performed using two methods: (i) autoradiographic detection from 3H-SAM used 
during the enzymatic reaction, and (ii) antibody-based detection using fluorescently 
labeled pan-methyl-lysine antibodies.  Following in vitro validation, the authors were 
able to detect six previously unreported substrates for the SETD6 enzyme.62 
 Although this array-based approach has been able to identify novel PMT 
substrates, major drawbacks still persist. First, many of the proteins spotted on 
commercially available arrays do not contain full-length protein sequences; meaning 
potential methylation sites could be easily overlooked.  Second, these approaches still 
often utilized antibody-based detection methods, which are limited according to the 
issues discussed in the previous subsection.  Lastly, transmethylation reactions on protein 
arrays generally use highly purified recombinant PMTs.  This is potentially problematic, 
as it is currently known that many PMTs act as members of larger multimeric protein 
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complexes63 and, in some cases, the presence of other protein factors is essential for 
proper enzyme activity and specificity.   
  
 In summary, current methods for studying PMTs are often limited by similar 
complicating factors, namely: (i) redundant PMT activity in vivo, (ii) difficulty dissecting 
the processive methylation activities of some PMTs, and (iii) a reliance on multimeric 
complex formation for relevant PMT activity and specificity.  With these factors in mind, 
research in the Luo laboratory has been focused on the development of alternative, 
chemistry-based methodologies as a means of determining or functionalizing the 
substrates of specific methyltransferases.  With this technology in hand, the ultimate goal 
of our research is to gain a better understanding of the biological processes associated 
with PMT activity. 
 
1.5 RESEARCH OBJECTIVES 
 With an appreciation for the physiological roles of methyltransferases in 
fundamental biological processes and the limitations of current methodologies available 
for their study, the research presented herein is directed towards two primary objectives. 
The first has involved the development of a technique for the unambiguous determination 
of enzyme-specific methyltransferase substrates, termed Bioorthogonal Profiling of 
Protein Methylation (BPPM). This approach combines cofactor analogue development, 
enzyme engineering, and bioorthogonal chemistry in order to covalently modify specific 
enzyme targets for subsequent enrichment and analysis.64 The second objective has 
focused on expanding the non-natural cofactor repertoire for methyltransferases through 
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the use of selenium-based SAM analogues, which were hypothesized to exhibit superior 
chemical properties in comparison to some sulfur-based SAM analogues.  Included in 
this objective was the development of a SAM cofactor mimic for direct application 
towards the study of wild-type methyltransferases.34   
 
(i) Development and Application of BPPM Technology 
Inspired by the “Bump and Hole” strategy popularized by the Shokat laboratory65, 
our group has envisioned a chemical-biology approach (BPPM) for the identification of 
novel PMT substrates.  BPPM relies upon crystallographic data and activity-based 
screening methods in order to rationally engineer a specific methyltransferase to be able 
to utilize non-natural SAM analogues.  Ideally, these analogues should contain a 
chemical handle compatible with bioorthogonal chemistries, such as Cu(I)-catalyzed 
azide-alkyne cycloaddition (CuAAC) reactions, and not be compatible with wild-type 
methyltransferases.  After reintroduction of an engineered enzyme back into the cellular 
milieu and supplying it with a compatible SAM analogue, enzymatically labeled 
substrates can then be conjugated to fluorescent or affinity-based chemical probes and 
identified by fluorescence imaging or MS-MS analysis prior to target validation using 
conventional biochemical approaches, such as those described in section 1.4. 
As a model system for the development of this technology, our initial research 
focused on the G9a and GLP1 PKMTs.  As discussed in chapter 2, we have successfully 
engineered both enzymes to allow them to utilize a number of cofactor analogues.  
Furthermore, proteomic analysis of G9a- and GLP1-labeled substrates in HEK293T cell 
lysates has successfully confirmed a number of novel substrates for these enzymes.64 
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Figure 1.4: General diagram of chemical-biology-based approaches to the study of biological 
transmethylation reactions. Bottom panel, the bioorthogonal approach (BPPM) to identify PMT 
substrates involving protein engineering and bulky SAM analogues.  Top panel, the selenium-based SAM 
analogue, ProSeAM, demonstrates potential as a chemical reporter for wild-type enzymes and is 
complimentary to BPPM. 
 
(ii) Selenium-Based SAM Analogue Development 
 A cornerstone of our research focuses on the development of SAM analogues in 
order to examine their compatibility towards wild-type or engineered methyltransferases.  
Unfortunately, many of the initial sulfur-based SAM analogues reported in the literature 
required the presence of an sp2-hybridized carbon β to the sulfonium-center in order to be 
enzymatically active.29, 32 Furthermore, many β-sp1-hybridized SAM analogues have 
demonstrated significant instability at physiologically relevant pH ranges.34, 35 These 
features have, in essence, restricted structural variants of SAM analogues to those 
containing β-sp2 or β-carbonyl-hybridized carbons.  In an effort to expand the number of 
cofactor analogues available to the scientific community, we proposed substituting the 
reactive sulfonium-center with a selenonium moiety as a means of overcoming these 
limitations. Because the chemistry of the selenonium group is similar to that of a 
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hybridzed carbons, thus making them compatible with engineered methyltransferases, 
and (b) circumvent the instability inherent in β-sp1-hybridized cofactors.  As a result of 
this objective, we have been able to successfully develop a selenium-based SAM cofactor 
mimic, ProSeAM,34 which has demonstrated compatibility with a wide variety of protein 
and natural product methyltransferases.12  
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CHAPTER 2: ENGINEERING THE G9a AND GLP1 
PROTEIN LYSINE METHYLTRANSFERASES FOR BPPM 
 
2.1 INTRODUCTION 
 PKMTs utilize the SAM cofactor as a methyl donor to modify the ε-amino group 
of target lysine residues in a variety of different protein substrates.  Methylation of these 
residues may occur processively, resulting in mono-, di-, or tri-methyl lysine, each of 
which may be associated with different biological outcomes through interaction with 
specific methyl-lysine binding proteins.1, 2 Furthermore, the activities of several of the 
~50 PKMTs in humans have been implicated in numerous biochemical processes and 
human diseases such as modulation of protein function, epigenetic regulation of gene 
transcription, carcinogenesis, and developmental disorders.2-5 Despite their importance in 
human health, a detailed understanding of the full substrate profiles of these enzymes has 
remained elusive, in part, due to limitations in current biochemical and genetic 
methodologies (section 1.4).  To address this problem, our group has envisioned a 
strategy for determining the substrates of specified methyltransferases, termed 
bioorthogonal profiling of protein methylation (BPPM). In order to demonstrate the 
utility of this strategy, it was first applied to the G9a and GLP1 PKMTs as model system.  
Much of the work presented in this chapter was performed in close collaboration with a 
former member of the Luo lab, Dr. Kabirul Islam, and has been previously published.6, 7 
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Figure 2.1: Schematic Description of Bioorthogonal Profiling of Protein Methylation (BPPM) 
Technology.  In the context of this design, designated PMTs can be engineered to selectively utilize 
‘click’-able SAM analogues to functionalize their targets for subsequent study. 
 
Bioorthogonal Profiling of Protein Methyltransferases (BPPM) 
 Given limitations inherent in many traditional biochemical techniques to 
determine PMT substrates, our group proposed a novel chemical biology-based approach 
for the elucidation of substrates for specific PMTs, termed BPPM.  The rationale for 
BPPM technology has its foundation in the ‘bump and hole’ strategy popularized by the 
Shokat group to study kinase activity,8, 9 in which a mutation in the active site of an 
enzyme allows for the accommodation of a specific non-natural substrate or cofactor 
(Figure 2.1).  Based on this principle, the aim of BPPM was to first rationally engineer 
the G9a and GLP1 enzymes, through crystal structure-guided site-directed mutagenesis, 
in order to allow them to utilize non-natural SAM analogues.  Ideally, these analogues 
would contain chemical handles attached to the carbon that is enzymatically transferred 
to the target protein.  In fact, a library of these analogues had been previously synthesized 
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and characterized by our lab and others, and is often used for screening procedures 
(Figure 2.3).6, 7, 10-12 Following reintroduction of the engineered enzyme back into a 
biological system, this would allow for the subsequent visualization or identification of 
enzyme-specific methylation targets through bioorthogonal chemistry, proteomics, and 
traditional biochemical methods. 
 
The G9a and GLP1 PKMTs 
 The G9a and GLP1 (G9a-like protein 1) enzymes were identified in 2001 and 
2002, respectively, and were amongst the first histone H3K9 di/tri-methyltransferases to 
be reported.13, 14 The overall domain structures of these enzymes are quite similar, with 
both containing glutamate/aspartate rich and cysteine rich regions near their N-termini, 
followed by several tandem ankyrin repeat domains and the canonical catalytic SET 
domains near their C-termini (Figure 2.2b).15 Furthermore, both enzymes have been 
shown to form multimeric complexes in vivo with one another, other methyltransferases 
(SETDB1 and SUV39H1), and additional protein factors such as the Wiz (widely-
interspaced zinc finger containing) protein.15, 16  
 To date, several non-histone targets have been reported for these enzymes, which 
serve to highlight their biological importance. For example, these enzymes are known to 
methylate the ACINUS (apoptotic chromatin condensation inducer in the nucleus) protein, 
which has been shown to be essential for apoptotic chromatin condensation,17 as well as 
Reptin, which is a RuvB-like DNA helicase thought to be part of the NuA4 histone 
acetyltransferase complex.18 It has also been recently demonstrated that G9a and GLP1 
di-methylate the tumor suppressor protein p53 at lysine 373, which serves to inhibit its 
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function and could potentially contribute to carcinogenesis in some cell types.19 
Furthermore, these enzymes have been shown to methylate DNA cytosine 
methyltransferase 3A, as well as myogenic regulatory factor MyoD to regulate skeletal 
muscle differentiation.20, 21 All told, the function of these enzymes has currently been 
implicated in chromatin remodeling, silencing of proviral and tumor suppressor genes, 
regulating skeletal muscle and neuronal differentiation, and establishing de novo DNA 
methylation.15, 21 Furthermore, these enzymes’ relevance to human disease has also been 
implicated in developmental disorders, cancer development and progression, and 
addiction (Figure 2.2a). However, a deeper understanding of their biological functions 
requires a more comprehensive appreciation for the spectrum of substrates that they can 
potentially modify. With this in mind, we set about examining current crystal structure 
data in order to inform our BPPM engineering strategy.   
  G9a and GLP1 both contain canonical SET domain structures sharing a high 
degree of homology.15, 22 The catalytic channel is composed of several conserved 
phenylalanine and tyrosine residues including: Y1124, Y1142, F1144, F1195, F1209, 
Y1211, and F1215 in GLP1; and Y1067, Y1085, R1109, F1152, Y1154, and F1158 in 
G9a (Figure 2.2c).2 Furthermore, the F1209 and F1152 residues in GLP1 and G9a, 
respectively, have previously been shown to serve as regulators of enzyme processivity.23 
Also known as the ‘switch’ position, this conserved residue is often a tyrosine in lysine 
mono-methyltransferases and phenylalanine in di/tri-methyltransferases. With this 
information in hand, a number of potential candidate residues in or around the cofactor-
binding pocket were selected for enzyme engineering including: Y1124, Y1142, F1144, 
Y1211, F1215, and W1216 in GLP1; and Y1067, Y1085, F1087, F1138, F1152, Y1154, 
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F1158, and W1159 in G9a.  Following identification of suitable mutant/analogue pairs, 
implementation in cellular systems and subsequent target identification were performed. 
 
Figure 2.2: Overview of the G9a and GLP1 PKMTs.  (a) Biological processes thought to be influenced 
by the activity of the G9a and GLP1 PKMTs.  (b) Domain organization of the G9a and GLP1 PKMTs. K, 
potential automethylation sites; E, glutamate-rich region; E/D, glutamate/aspartate-rich region; Cys, 
cysteine-rich region; Pre, pre-SET domain; SET, SET domain; Post, post-SET domain.15 (c) 
Crystallographic data highlighting key residues located in the SAM-binding pocket and hydrophobic 
catalytic channel. SAH, S-adenosyl-L-methionine. 
 
2.1 MATERIALS AND METHODS 
General Material and Methods 
Chemical synthesis of cofactor analogues is detailed in chapter 6, or has been 
reported previously.6, 7, 11 Polyacrylamide gels (12%/18% Tris HCl) and pre-stained 
ladders were purchased from Bio-Rad Laboratories. Cell culture media was purchased 
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from Gibco or Fisher Scientific. Streptavidin SepharoseTM was purchased from GE 
Healthcare. Recombinant human histones were purchased from New England Biolabs.  
EDTA-free protease inhibitor was purchased from Roche Applied Science. CuAAC 
labeling reagents and azido-conjugated teramethylrhodamine were purchased from 
Aldrich and Invitrogen, respectively.  Azido-azo-biotin for pull-down experiments was 
synthesized and purified by Gil Blum, as described previously.24, 25 Click-iT biotin-DIBO 
alkyne was purchased from Invitrogen. Histone H3 peptide (aa1-21; 
ARTKQTARKSTGGKAPRKQLAGGK) was synthesized by the Proteomics Resource 
Center at Rockefeller University. MALDI-MS spectra were collected on a Voyager-DE 
STR (Applied Biosystems, Framingham, MA, USA) MALDI-TOF mass spectrometer.  
In order to analyze peptide samples, 1µL of reaction mixture was added to 1 µL of 
saturated α-cyano-hydroxycinnamic acid (Protease Biosciences) on a MALDI plate and 
allowed to air dry.  Spectra were then gathered using delayed extraction in positive ion 
mode.  Desorption was achieved using a 337 nm nitrogen laser with a 3ns pulse width. 
 
Protein Expression and Purification 
 N-terminal His6-tagged methyltransferase SET domains of human GLP1(aa 951-
1235) and G9a (aa 913-1193) were obtained as a generous gift from Dr. Jingrong Min at 
the University of Toronto.26 Mutants for these enzymes were generated using 
QuickChange (Stratagene) site-directed mutagenesis kits according to manufacturer’s 
instruction and confirmed via DNA sequencing.  Mutant and native enzymes were then 
expressed and purified in E. coli Arctic Express (DE3) strain (Novagen) using a pET28a-
LIC kanamycinR vector.  Single colonies were selected and grown at 37 oC in 5 mL Difco 
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LB culture medium containing 50 µg/mL kanamycin overnight.  These starter cultures 
were then added to 1 L culture medium and allowed to grow at 30 oC to and OD600 of 
approximately 0.6-0.7.  Expression was then induced through the addition of 0.6 mM 
IPTG and 25 µM ZnSO4 and the cultures were allowed to shake at 10 oC for 24 hours.  
All mutant and native enzymes were purified according to the following protocol: 
harvested cells were suspended in 50 mM Tris HCl (pH = 8.0) containing 50 mM NaCl, 5 
mM β-mercaptoethanol, 10% glycerol, 25 mM imidazole, and Roche protease inhibitor 
cocktail.  Cells were then lysed using a French Press Cell Disruptor (Thermo) and 
centrifuged at 13,000 g for 45-60 mins at 4 oC.  The supernatants were then subjected to 
gravity-flow purification over Ni-NTA agarose resin (Qiagen) according to 
manufacturer’s instruction. All column-bound extracts were washed with six column 
volumes of washing buffer containing 50 mM Tris-HCl (pH = 8.0), 50 mM NaCl, 5 mM 
β-mercaptoethanol, and 25 mM imidazole.  Proteins were then eluted with buffer 
containing 50 mM Tris HCl (pH = 8.0), 50 mM NaCl, 5 mM β-mercaptoethanol, and 400 
mM imidazole, and further purified by size-exclusion chromatography (Superdex-75, GE 
Healthcare) using buffer containing 25 mM Tris HCl (pH = 8.0), 200 mM NaCl, and 15% 
glycerol. Finally, purified proteins were concentrated using Amicon Ultra-10K 
centrifugal filter devices, and protein concentration was determined via Bradford assay 
(BioRad) with BSA as a standard.  All enzymes were stored at -80 oC and thawed on ice 
prior to use.  
 
In vitro Methyltransferase Assay with Recombinant Enzymes 
Enzymatic reactions (20 µL) were setup containing 1 µM enzyme, 10 µM histone 
H3 peptide, and 100 µM cofactor or cofactor analogue in 50 mM Tris HCl (pH = 8.0) 
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buffer at 25 oC.  Samples were then subject to MALDI-MS analysis as described above.  
For reactions containing full length histone as substrate, 1 µM GLP1 Y1211A or G9a 
Y1154A mutant was incubated with 20 µM recombinant histone H3 and 100 µM cofactor 
for 2 hours at 25 oC in buffer (40 µL) containing 50 mM Tris HCl (pH = 8.0) and 1 mM 
TCEP prior to trypsin digestion and LC/MS-MS analysis. 
 
Cloning and Mutagenesis of Full-Length Human G9a and GLP1 
For expression in eukaryotic cells, pCDNA3-FLAG vector encoding full-length 
human G9a were obtained as a generous gift from Dr. Jing Huang at the National Cancer 
Institute (NCI).  Incorporation of full-length human GLP1 into the pCDNA3-FLAG 
vector was achieved by first installing a KPNI restriction site in its pFLAG-CMV2 vector 
using the QuickChange (Stratagene) site-directed mutagenesis kit according to 
manufacturer’s instruction.  Subsequent cloning was performed using KPNI and 
ECORI.HF restriction enzymes and confirmed by DNA sequencing. Y1211A and 
Y1154A mutants were generated on these mammalian vectors as described above.  
 
Steady-State Kinetic Measurements 
 Confirmation of relative ionization efficiencies for independently synthesized R-
modified histone H3 peptides was reported previously.27 Reactions (10 µL) were 
initialized by addition of 1 µM recombinant enzyme into buffer (50 mM Tris HCl pH = 
8.0) containing 25 µM histone H3 peptide (aa 1-21) and various concentrations of 
cofactor.  MALDI matrix solution (1 µL) was then spotted and allowed to dry on a 
MALDI plate prior to addition of samples.  At each time interval, 1 µL of sample was 
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applied to the MALDI plate on top of the previously spotted matrix solution. An 
additional 1.5 µL acetonitrile containing 0.1% TFA was added to each sample spot to 
ensure complete quenching of the reactions. The resultant sample spots were then air 
dried at room temperature and quantified by MALDI-TOF mass spectrometry as 
described above.  Data was analyzed by first calculating the %Modification*min-1 for 
time-dependent experiments based on integrated peak areas observable in the MS. These 
data were then converted to Rate (min-1) by multiplying by a factor of 0.25 (conversion 
of %Modification to µM of modified peptide) and then dividing the concentration of the 
enzymes.  These rates were plotted against cofactor concentration, with kcat and KM 
calculated according to the standard Michaelis-Mentin formula. 
 
Fluorescent Labeling of G9a/GLP1 Substrates  
 HEK293T cells transfected with GLP1 Y1211A, G9a Y1154A, or empty vector 
control were lysed via sonication (Misonix Ultrasonic Liquid Processor with a single 15 
minute pulse at 65% amplitude).  For samples containing recombinant G9a Y1154A or 
GLP1 Y1211A (2 µM), mock treated HEK293T cell lysates were used. Crude lysates 
were then centrifuged at 15,000 g for 45 minutes at 4 oC and the supernatant collected.  
Total protein concentrations in the supernatant were then calculated via Bradford assay as 
described above.  Lysate (40 µg total protein) in 20 µL was incubated with 50 µM Hey-
SAM or 250 µM Ab-SAM for 1-2 hours. Upon completion of the reaction, samples were 
passed through a detergent removal spin column and eluted with buffer containing 50 
mM Tris HCl (pH = 8.0), 10% glycerol, 2 mM TCEP, and Roche protease inhibitor 
cocktail.  
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 Samples treated with Hey-SAM were subjected to CuAAC according to the 
following procedure.  CuAAC reaction was conducted using 100 µM Azido Rhodamine. 
100 µM TBTA ligand, 1 mM CuSO4 and 2.5 mM TCEP as final concentrations. 
Following a 1 hour reaction time, samples were precipitated with 600 µL methanol, 200 
µL chloroform, and 400 µL water, then washed with 600 µL volumes of methanol 3 
times.  Protein pellets were allowed to air dry before being dissolved in protein loading 
buffer and subjected to SDS-PAGE.  
 Samples (whole cell lysates, modified histone proteins or peptides) treated with 
Ab-SAM were subjected to strain-promoted azide-alkyne cycloaddition (SPAAC) 
according to the following procedure.  Modified samples were directly treated with 100 
µM Click-It TAMRA-DIBO alkyne (no. C10410, Invitrogen) and shaken gently for 1 
hour at room temperature in the absence of light.  Following the reaction, protein samples 
were precipitated with 600 µL methanol, 200 µL chloroform, and 400 µL water, then 
washed with additional volumes of methanol 3 times.  The resulting pellet was allowed to 
air dry for 15 minutes at room temperature, before being dissolved in protein loading 
buffer and resolved by SDS-PAGE. 
 After separation by SDS-PAGE, gels were washed with 10% acetic acid, 40% 
methanol, 50% water solution prior to visualized of fluorescently labeled proteins.  Gels 
were imaged using an Amersham Biosciences Typhoon 9400 fluorescence imager 
(excitation = 532 nm, 580 nm filter, and 30 nm band-pass).  Gels were lastly stained with 
Coomassie Blue to confirm protein loading. 
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Autoradiography Assay for GLP1 and G9a Substrates 
 Reactions (20 µL) were carried out at 25 oC overnight in buffer containing 50 mM 
Tris HCl (pH = 8.0) with 2.25 µM [methyl-3H]-SAM and 2 µM recombinant G9a or 
GLP1 in the presence of various substrates. Following the reaction, samples were 
resolved by SDS-PAGE and analyzed by autoradiography.  Non-histone human 
substrates were obtained either from Origene Technologies (ACLY, PRMT5, IDH1), 
Abnova (TARS, PKIM1/2, Nucleolin, HAT1, EEF1A1, and HNRPK), or were gifts from 
Dr. Martin Walsh (POLR2A) and Dr. Hening Lin (PARP1). 
 
Protein Crystallization and X-ray Structure Determination 
 Crystallographic experiments were performed by our collaborator, Dr. Jinrong 
Min. In brief, purified GLP1 Y1211A enzyme (10 mg/mL) was complexed with SAH 
and H3K9 Nε-allyl peptide at 1:5:5 molar ratio of enzyme:SAH:peptide and crystallized 
using hanging drop vapor diffusion method at 20 oC by mixing 1 µL of the protein 
solution with 1 µL of the reservoir solution containing 20% PEG 4000, 10% isopropanol 
and 0.1 M HEPES (pH = 7.5).  X-ray diffraction data were collected at 100K at the 
beamline23ID of Advanced Photon Sources (APS), Argonne National Laboratory.  Data 
were processed using the HKL-2000 suite. The structure was solved by molecular 
replacement using MOLREP, using the crystal structure of GLP1 (PDB code 2IGQ) as 
the search model.  ARPw/ARP was used for automatic model building and REFMAC 
was used for structure refinement.  Graphics program COOT was used for model building 
and visualization.  Crystal diffraction data and refinement statistics are given in Table 2.1.  
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Table 2.1: Crystallographic Data and Refinement Statistics. 
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Proteomics Analysis of G9a/GLP1 Labeled Substrates in HEK293T Cells 
HEK293T cell lysates of 10 mg from mock-transfected, GLP1 Y1211A-, and G9a 
Y1154A-transfeted cells were incubated with 50 µM Hey-SAM in a total 5 mL volume 
for 2 hours at ambient temperature (22 oC). Methanol of 25 mL was then added into each 
sample and kept at -80 oC overnight. The resultant samples were centrifuged for 30 min 
at 4,000 rpm.  Supernatant was then removed and protein pellets were washed with 15 
mL cold methanol. The pellets were air-dried for 25 min and re-dissolved with 4.5 mL 
SDS buffer containing 50 mM TEA (pH = 7.4), 150 mM NaCl, 4% SDS and 1×Roche 
protease inhibitor. Into the samples was added 0.5 mL click cocktail (100 µL of 5 mM 
azido-azo-biotin in DMSO, 100 µL of 100 mM TCEP, 250 µL of 2 mM of TBTA in 
DMSO, and 100 µL of 50 mM of CuSO4). The click reaction was performed for 1.5 hrs 
and the samples were mixed with 25 mL methanol and kept at -80 oC overnight. The 
samples were resuspended in 1 mL SDS buffer (50 mM TEA pH = 7.4, 150 mM NaCl, 
4% SDS, 1×Roche protease inhibitor and 10 mM EDTA), followed by the addition of 2 
mL of the dilution buffer (50 mM TEA (pH = 7.4), 150 mM NaCl, 1% Brij97, and 
1×Roche protease inhibitor). Streptavidin bead of 100 µL in the dilution buffer was 
mixed with the protein samples and rotated end-over-end at ambient temperature (22 °C) 
for 1 h. The resultant mixture was further diluted with 10 mL PBS buffer supplemented 
with 0.2% SDS and centrifuged at 2,000 rpm for 2 min. The streptavidin beads were 
washed with the buffer containing 10 mL PBS and 250 mM ammonium bicarbonate 
buffer (ABC) and then transferred into 1.5 mL micro centrifuge tubes. The resultant 
streptavidin beads were treated with the freshly-prepared reduction buffer (500 µL of 8 M 
urea, 25 µL of 200 mM TCEP, and 25 µL of 400 mM iodoacetamide) for 40 min in dark, 
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followed by the washing with 250 mM ABC buffer. The bead-immoblized proteins were 
treated twice with 250 µL of the elusion buffer (25 mM Na2S2O4, 1% SDS and 250 mM 
ABC) for 30 minutes. Eluted samples were analyzed by LC-MS/MS as described below. 
For Ab-SAM treated lysates, 10 mg total protein of mock-, Y1211A-, and 
Y1154A- transfected HEK293T cell lysates was used. These samples were incubated 
with/without 200 µM of Ab-SAM for 2 hours at room temperature. Lysates were then 
precipitated, washed, resuspended and treated with 200 µM of Click-iT biotin DIBO 
alkyne (cat. no. C10412, Invitrogen) and gently shaken for 1 hour at room temperature. 5 
mL methanol was added to each sample and kept at -80 °C overnight. Precipitated 
proteins were centrifuged for 30 min at 4000 rpm at 4 °C and washed twice with 5 mL of 
cold methanol. Protein residues were dried for 20 min and resuspended with 400 µL of 
dilution buffer (50 mM triethylamine at pH 7.4, 150 mM NaCl, Roche protease inhibitor 
cocktail, 0.5% SDS) with brief sonication. Protein concentration was determined by 
Bradford assay. Twenty-five microliters of streptavidin bead in dilution buffer was added 
to the remaining protein and rotated end-over-end at room temperature for 1 hour. 
Samples were diluted with 10 mL of PBS buffer supplemented with 0.2% SDS and 
centrifuged for 2 min at 2000 rpm. Beads were successively washed with 10 mL of PBS 
and 250 mM ABC buffer and transferred to 1.5 mL micro centrifuge tubes. 40 µL of 1× 
sample buffer (Bio-RAD) was added and heated at 100 °C for 10 min. Prior to heating 
the streptavidin bound proteins with loading buffer, beads were treated with freshly made 
reduction buffer (500 µL of 8 M urea, 25 µL of 200 mM TCEP, and 25 µL of 400 mM 
iodoacetamide) for 40 min in dark and washed thoroughly with ABC buffer. The eluted 
proteins were separated on SDS-PAGE. Each lane on the 1D SDS PAGE was cut into 
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seven pieces, which were subjected to in-gel digestion. The gel bands ware reduced with 
25 mM of DTT, and then alkylated with 55 mM iodoacetamide. The in-gel digestion was 
implemented with the trypsin (Promega, Fitchburg, WI) in 50 mM ABC at 37 °C 
overnight. The peptides were extracted with 0.1% formic acid in 50% acetonitrile at 
37 °C for 30 min. Lastly, the peptide extraction was concentrated by speedvac.  
For LC−MS/MS analysis, the digestion product was separated by a 65 min 
gradient elution at a flow rate 0.250 µL/min with the EASY-nLCII integrated nano-
HPLC system (Proxeon, Denmark), which is directly interfaced with the Thermo LTQ-
Orbitrap mass spectrometer. The analytical column was a homemade fused silica 
capillary column (75 µm ID, 150 mm length; Upchurch, Oak Harbor, WA) packed with 
C-18 resin (300 A, 5 µm, Varian, Lexington, MA). Mobile phase A consisted of 0.1% 
formic acid, and mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. 
The LTQ-Orbitrap mass spectrometer was operated in the data-dependent acquisition 
mode using the Xcalibur 2.0.7 software, and there is a single full-scan mass spectrum in 
the Orbitrap (400−1800 m/z, 30 000 resolution) followed by 20 data-dependent MS/MS 
scans in the ion trap at 35% normalized collision energy.  
The Thermo Proteome Discoverer 1.2.0 software was used to search the MS/MS 
data against in ipi.HUMAN.v3.82 database. The searching parameters included peptide 
mass tolerance of 10 ppm, ms/ ms tolerance of 0.8 Da, and two missed cleavages allowed. 
The fixed modification of carbamidomethylation on cysteine and variable modifications 
of oxidation on methionine, deamidated on asparagine and glutamine, and Hey-SAM/Ab-
SAM modified Lys were also used in the database searching. The decoy database search 
was added with the criteria of FDR at 0.01. The criteria used for filtering peptide were the 
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following: 2, 2.75, and 3 for singly charged, doubly charged, and triply or higher charged 
ions, respectively.  
 
Tandem Mass Tagging (TMT) for Quantitative MS Analysis of Proteome-wide 
Substrates of G9a/GLP1  
For quantitative comparison of BPPM-revealed target proteins, samples were 
prepared as described above. Briefly, Hey-SAM incubated HEK293T cell lysates (either 
mock-, Y1211A-, or Y1154A-transfected) were precipitated using methanol. Precipitated 
proteins were redissolved in SDS buffer and subjected to ‘click’ chemistry with azido-
azo-biotin. The ligated proteins were further precipitated using methanol and 
subsequently enriched with streptavidin beads prior to elution with 25 mM Na2S2O4 as 
detailed in the preceding section. Eluted proteins were first resolved by SDS PAGE. The 
gel bands of corresponding molecular weights were excised, reduced with 10 mM of 
DTT and alkylated with 55 mM iodoacetamide. In gel digestion was then carried out with 
the sequence grade modified trypsin (Promega, Fitchburg, WI) in 50 mM ABC at 37 oC 
overnight. The peptides were extracted twice with 1% trifluoroacetic acid in 50% 
acetonitrile aqueous solution for 30 min. The extracts were then centrifuged in a 
Speedvac to reduce the volume. Peptides from different samples were labeled with TMT 
reagents (Thermo, Pierce Biotechnology, Rockford, IL) according to the manufacture’s 
instruction. Briefly, the TMT label reagents were dissolved by anhydrous acetonitrile, 
carefully added to each digestion products (126, 128 and 131 mass tagging were used for 
control vector-, GLP1- and G9a-transfetcted samples, respectively). The reaction 
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mixtures were incubated for 1 hour at ambient temperature (22 oC) and then quenched by 
hydroxylamine. The TMT-labeled peptides were desalted using the stage tips.  
For the subsequent LC-MS/MS analysis, the TMT-labeled peptides were 
separated by a 65 min gradient elution at a flow rate 0.250 µL/min with the EASY-
nLCIITM integrated nano-HPLC system (Proxeon, Denmark), which is directly 
interfaced with the Thermo LTQ-Orbitrap mass spectrometer. The analytical column was 
a home-made fused silica capillary column (75 µm ID, 150 mm length; Upchurch, Oak 
Harbor, WA) packed with C-18 resin (300 A, 5 µm, Varian, Lexington, MA). Mobile 
phase A consisted of 0.1% formic acid, and mobile phase B consisted of 100% 
acetonitrile and 0.1% formic acid. The LTQ-Orbitrap mass spectrometer was operated in 
the data-dependent acquisition mode using the Xcalibur 2.0.7 software and there is a 
single full-scan mass spectrum in the Orbitrap QE (400-1800 m/z, 30,000 resolution) 
followed by 10 MS/MS scans in the quadrupole collision cell using the higher energy 
collision dissociation (HCD). The MS/MS spectra from each LC-MS/MS run were 
searched against the selected database using an in-house Mascot or Proteome Discovery 
(Version 1.3) searching algorithm.  
 
2.3 RESULTS AND DISCUSSION 
Qualitative Determination of Enzyme/Cofactor Pairs for BPPM 
 Initial examination of cofactor/mutant enzyme compatibility was carried out via 
MALDI-MS screening. These efforts primarily focused on β-sp2-hybridized SAM 
analogues, as it had previously been established that β-sp3- and β-sp1-hybridized 
analogues were either unreactive or unstable, respectively.10, 11, 28 Additionally, a library 
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of mutant G9a and GLP1 enzymes containing smaller aliphatic residues in their cofactor 
binding sites was generated and tested. Interestingly, the majority of these mutant 
enzymes demonstrated no observable activity towards any of the SAM analogues 
examined (Figure 2.3).  In fact, mutation of several tyrosine or phenylalanine residues in 
G9a (Y1067, Y1085, F1087, F1138, F1158, and W1159) and GLP1 (Y1124, Y1142, 
F1144, F1195, F1215, and W1216) also resulted in a significant loss of activity towards 
endogenous SAM (Figure 2.3).  Given these two observations, it is likely that mutation of 
these residues results in disruption of the catalytic channel or cofactor-binding pocket.   
 
 
Figure 2.3: Qualitative Assessment of SAM Analogue Compatibility with Engineered G9a or GLP1.  
Extent of modification of H3K9 peptide by SAM or SAM analogues by wild-type or engineered G9a and 
GLP1 as examined by MALDI-MS analysis. Data is represented in heat-map format as % modification of 
peptide substrate. 
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In contrast, a structurally conserved mutant for both GLP1 (F1209A) and G9a 
(F1152A) was identified that maintained enzyme activity towards SAM or several of the 
SAM analogues tested. Compared to wild-type enzymes, these mutants demonstrate 
slightly increased activity towards the bulkier butene-SAM and pentene-SAM (Figure 
2.3).  However, no compatibility for these mutants was observed towards our ‘click’-able 
alkyne- or azide-containing SAM analogues.  Fortunately, mutation of a conserved 
residue for both G9a (Y1154A) and GLP1 (Y1211A) were identified that demonstrate 
excellent compatibility towards a wide variety of SAM analogues tested (Figure 2.3). 
Importantly, these mutant enzymes demonstrated good activity primarily towards the 
alkyne-containing Hey-SAM and the azide-containing Ab-SAM cofactor analogues, 
which are not compatible with wild-type enzymes. Furthermore, these mutants displayed 
very low activity toward SAM, which is ideal for BPPM as it limits competition between 
endogenous SAM and our non-natural SAM analogues. 
 
Kinetic Analysis of Enzyme/Cofactor Pairs 
 In order to further explore the structure-activity relationship between our 
engineered enzymes and cofactor analogues, we performed steady-state kinetics analysis 
for the determination of apparent kcat and KM values with the Y1211A and Y1154A 
mutants using MALDI-MS detection. It had been previously demonstrated that the 
relative ionization efficiencies for the R-modified peptides examined were roughly 
equivalent to that of methylated or unmodified peptides.27 These studies were essential 
for accurate measurement of kinetic parameters, as a difference in ionization efficiency 
would result in an artificial increase or decrease in the observable rate.   
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Figure 2.4:  Steady-state kinetic analysis of wild-type G9a/GLP1 and the Y1154A/Y1211A mutants 
with SAM analogues. (a) Apparent KM and kcat were determined using 25 µM H3K9 (aa 1-21) peptide and 
varied cofactor concentrations.  (b) Rate comparison between wild-type GLP1 with SAM vrs. GLP1 
Y1211A with SAM or Hey-SAM. (c) Rate comparison between wild-type G9a with SAM vrs. G9a 
Y1154A with SAM or Hey-SAM. 
 
 With this foundation established, reaction rates for wild-type GLP1, GLP1 
Y1211A, wild-type G9a, and G9a Y1154A enzymes in the presence of a panel of 
cofactors were determined and fitted to the Michaelis-Menten formula prior to extraction 
of kinetics values (Figure 2.4a).  Interestingly, catalytic efficiencies (kcat/KM) correlated 
nicely with our previous qualitative assessment of cofactor compatibility (Figure 2.3).  
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Both mutants displayed very low catalytic efficiency towards native SAM, which was 
important for their application in cell lysates where native SAM could potentially 
compete with our cofactor analogues.  Furthermore, the G9a Y1154A and GLP1 Y1211A 
mutants displayed highest compatibility towards butane-SAM, pentene-SAM, and Hey-
SAM analogues, with kcat/KM values comparable to those of wild-type enzymes towards 
SAM (Figure 2.4a, b).  Given that Hey-SAM was the only of these three analogues to 
contain a viable chemical handle, it was selected as the primary candidate for BPPM.  
Here, the kinetics of the azide-containing Ab-SAM analogue was not examined.  
However, due to the fact that Ab-SAM is roughly equivalent in size to the Hep-SAM 
analogue (Figure 2.4a), which was shown to be relatively inactive in comparison to Hey-
SAM, it was predicted that Hey-SAM would be an optimal candidate for BPPM analysis.  
Despite this, the Ab-SAM cofactor was also used for comparison during labeling full-
length proteins and proteomic analysis of cell lysates (see below). 
 
Structural Basis for GLP1 Y1211A Compatibility Toward SAM Analogues 
 In order to examine the structural basis for the recognition of bulkier SAM 
analogues by the GLP1 Y1211A and G9a Y1154A mutants, the crystal structure of the 
Y1211A mutant in ternary complex with an H3K9 ε-amino-allyl-lysine-modified peptide 
and SAH was determined through collaboration with the laboratory of Dr. Jinrong Min 
(PDB: 4H4H).  As was predicted, the allyl-modified peptide appeared to nicely occupy a 
cavity created by the Y1211A mutation (Figure 2.5a).  This preexisting cavity appears to 
be composed of the hydrophobic side chains of the H1170, F1209, F1215, and W1216 
residues, as well as the backbone peptides bonds of I1168 and N1169.  Given that the 
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allyl moiety is pointed towards this preexisting hydrophobic cavity and resembles many 
of the SAM analogues previously shown to be enzyme compatible, it is expected that 
other SAM analogues make use of the space created by the Y1211A/Y1154A mutation 
for substrate labeling as well.  
 
 
Figure 2.5: Structural Basis for GLP1 Y1211A Mutant Recognition of SAM Analogues.  (a) Allylated 
histone H3K9 peptide is accommodated by the hydrophobic cavity generated by mutation of Y1211 (PDB 
4H4H).  (b) Superimposed structures of wild-type GLP1 (Teal; PDB 2RFI) and the Y1211A mutant with 
allylated peptide (Green; PDB 4H4H). Both wild-type and mutant GLP1 shared a very high degree of 
structural homology.  
 
Close examination of the overlaid structures of wild-type GLP1 and the Y1211A 
mutant further reveals that the terminal β-sp2-hybridized allyl carbon rests in close 
proximity to the Y1211 side-chain (Figure 2.5b).  This suggests that the Y1211 residue in 
the wild-type enzyme acts to block the bulkier β-sp2-hybridized SAM analogues and 
prevent their interaction with the active site.  In contrast, replacing the Y1211 residue 
with the smaller alanine mutant not only avoids such steric clash, but also allows access 
to and additional interactions with the extended hydrophobic pocket. Given that the 
Y1211/Y1154 residues are generally conserved residues in the hydrophobic channels of 
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most SET domain-containing PKMTS,2 we suspect that corresponding residues in other 
enzymes will likely be important target residues for enzyme engineering efforts as well.  
 
Labeling of Full-Length Histone with SAM Analogues 
In order to further characterize the activities of the GLP1 Y1211A and G9a 
Y1154A mutants with functionalized SAM analogues, we next attempted to label known 
protein substrates for these enzymes.  For these purposes, both full-length histone H3 and 
reconstituted histone octamers were used to confirm engineered enzyme activity and 
specificity.  As seen in Figure 2.6c, labeled H3 was observable by fluorescence imaging 
in samples treated with G9a Y1154A and Hey-SAM, followed by conjugation to a 
fluorescent probe.  In addition, only labeled histone H3 was observed upon treatment 
with the Ab-SAM cofactor analogue, even within the context of a reconstituted histone 
octamer (Figure 2.6a, b).  Importantly, no labeling could be observed in any no-enzyme 
or no-cofactor controls, or on non-substrate histone components.  Lastly, LC-MS/MS 
analysis of G9a/GLP1-modified tryptic histone H3 confirmed transfer of Hey-SAM’s or 
Ab-SAM’s R-groups to lysine 9 of histone H3 (Figure 2.7).  Together, these data suggest 
that both enzyme processivity and specificity are maintained for the mutant enzymes and 
cofactors tested. 
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Figure 2.6:  In-Gel Fluorescence Analysis of Ab-SAM or Hey-SAM Modified Full-Length Histone H3.  
(a) Modification of recombinant H3 by G9a Y1154A and GLP1 Y1211A by Ab-SAM. (b) In a 
reconstituted octomer consisting of histones H2A, H2B, H3, H4, only histone H3 appeared to be modified 
with Ab-SAM by G9a/GLP1 mutants. (c) Hey-SAM demonstrated similar activity towards engineered 




Figure 2.7:  MS/MS Spectrum of Hey-SAM Modified Tryptic Histone H3 Peptide. Full-length H3 was 
reacted with Hey-SAM and G9a Y1154A enzyme prior to trypsinization and LC-MS/MS. 
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Labeling of G9a/GLP1 Substrates in HEK293T Cell Lysates 
 Successful identification of active mutant-cofactor pairs, as was described above, 
allowed for further application of this technology to more complicated biochemical 
mixtures. For this purpose, HEK293T cells were transfected with empty vector, wild-type 
or G9a Y1154A/GLP1 Y1211A enzymes (Figure 2.8a) prior to lysis and treatment with 
our cofactor analogues. Subsequent conjugation with fluorescently labeled chemical 
probes allowed for visualization of engineered enzyme targets in cell lysate.  As shown in 
Figure 2.8b, significant labeling could be observed in G9a Y1154A and GLP1 Y1211A 
transfected cell lysates treated with Ab-SAM, but not in cells transfected with wild-type 
G9a/GLP1 or those treated with empty vector. Furthermore, treatment of cells with Hey-
SAM resulted in similar labeling.  Indeed, G9a Y1154A- and GLP1 Y1211A-transfected 
cells treated with Hey-SAM demonstrated a very similar fluorescent pattern to that of 
Ab-SAM.  In contrast, very little labeling could be observed in mock-transfected 
HEK293T cells (Figure 2.8b).  Together, the observed labeling patterns suggest that the 
Ab-SAM and Hey-SAM cofactors act with transfected G9a and GLP1 mutants to label 
substrates in cell lysate. 
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Figure 2.8: Labeling of G9a/GLP1 Substrates in HEK293T Cell Lysate.  (a) Western blot 
demonstrating transfection and expression of G9a, GLP1 and mutant proteins.  Tubulin was used as a 
loading control.  (b) Cell lysates treated with Ab-SAM followed by conjugation to a fluorescent TAMRA-
DIBO probe. Top panel, increased labeling in mutant-transfected, but not mock-treated or Ab-SAM + SAM 
treated, HEK293T cells by in-gel fluorescence. Bottom panel, coomassie staining of SDS-PAGE resolved 
lysate. (c) Cell lysates treated with Hey-SAM followed by conjugation to a fluorescent TAMRA-azide 
probe. Top panel, increased labeling in mutant-transfected, but not mock-treated, HEK293T cells by in-gel 
fluorescence. Bottom panel, coomassie staining of SDS-PAGE resolved lysate. 
 
Proteomics Analysis of G9a/GLP1 Substrates in HEK293T Cell Lysates 
 Given the apparent success of BPPM-based fluorescent labeling of PKMT targets 
in cell lysates, we next sought to couple substrate labeling with proteomics-based 
identification of G9a/GLP1 candidate substrates.  Initial experiments examined labeling 
of enzyme substrates in HEK293T cell lysates using both Ab-SAM and Hey-SAM for 
comparison (Figure 2.9a).  These experiments were performed using empty vector or 
	   51	  
wild-type enzymes as controls and was achieved through the use of affinity-based biotin-
DIBO or azido-azo-biotin probes for Ab-SAM and Hey-SAM modified proteomes, 
respectively.  
Subsequent proteomic analysis of Ab-SAM treated samples identified a combined 
total of 128 potential substrates for both the G9a and GLP1 enzymes, of which 18 were 
shared (Figure 2.9a).  Despite the relatively low number of putative substrates, several 
previously verified targets of the GLP1/G9a PKMTs were observed in the mutant-
transfected data sets, including histone H3, histone H1.4, Wiz, CDYL, and G9a/GLP1 
(automethylation) suggesting the experiment was behaving correctly. Given our previous 
quantitative assessment of mutant/cofactor compatibility (Figure 2.4), however, we 
suspected that the relatively small size of the data sets derived using the Ab-SAM 
cofactor was likely the result of low catalytic efficiency towards the Y1211A and 
Y1154A mutants. As discussed in the above subsection, Ab-SAM closely resembles the 
Hep-SAM analogue in terms of R-group size, which displayed significantly lower 
catalytic efficiency in comparison to the ‘click’-able Hey-SAM analogue.  Therefore, 
because Hey-SAM had kcat/KM values towards our engineered enzymes that were very 
comparable to those of wild-type enzymes with SAM, it was decided to perform further 
study with this mutant/cofactor pair in order to improve the efficiency of our BPPM 
approach.  Indeed, pull-down and proteomic analysis of HEK293T lysate using the Hey-
SAM analogue resulted in a much larger data set for both G9a and GLP1 after 
comparison to empty-vector controls. By this approach, data sets for GLP1 and G9a 
contained 1,324 and 1,648 potential targets, respectively, with roughly 36% (799 
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proteins) overlap (Figure 2.9a).  This roughly six-fold increase in target identification was 
consistent with the increased compatibility of Hey-SAM towards our engineered enzymes. 
 Following our initial qualitative proteomic studies, additional studies incorporated 
a common quantitative proteomic approach using an isobaric tandem mass tagging 
(TMT) strategy.  Here, tryptic peptides derived from pulled-down PKMT substrates in 
Hey-SAM treated experimental and control samples were reacted with isobaric reagents 
containing different reporter m/z values, mixed, and analyzed LC-MS/MS.  Reporter ions 
distinct to the isobaric TMT reagents used provided quantitative abundance 
measurements for the identified protein sequences, which resulted in a total of 1,145 
potential PMT substrates with >1.5 fold enrichment by TMT analysis (Figure 2.9b).  
Further cross-analysis between TMT-labeled and non-TMT-labeled proteomic data sets 
allowed for the identification of 774 overlaid targets (Figure 2.9c), which were 
designated as ‘high-confidence’ substrates for the G9a and GLP1 PKMTs.  Included in 
this list high confidence substrates was, again, the previously identified substrates 
discussed above, as well as several others including: DNMT1, p53, and HDAC1 (Figure 
2.9d).  Such consistency implies the robustness of the BPPM approach to label, enrich 
and identify the substrates of designated enzymes in complex biochemical settings.  Of 
these high confidence substrates, several commercially available proteins were validated 
as genuine substrates for the G9a and GLP1 PKMTs as is described in the following 
subsection. 
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Figure 2.9: Proteomic Analysis of BPPM-Derived Putative Substrates for the G9a and GLP1 PKMTs.  
(a) Non-quantitative proteomic analysis of GLP1 and G9a substrates in HEK293T cells using either Ab-
SAM or Hey-SAM.  As predicted by kinetics analysis of mutant/cofactor compatibility, Hey-SAM treated 
samples resulted in the identification of a significantly larger number of putative substrates. (b) Correlation 
analysis of high confidence GLP1/G9a targets. Abundance ratios for TMT-analyzed samples were plotted 
against unique target ID. (c) Comparison of data sets between quantitative TMT-proteomic data sets and 
non-TMT data sets.  (d) Previously identified GLP1/G9a proteins that were also identified in our 
mutant/cofactor sample sets but not controls. 
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Validation of Novel Substrates for the G9a/GLP1 PKMTs 
 To validate high-confidence proteomic targets as bona fide substrates of the GLP1 
and G9a PKMTs, a representative panel of commercially available substrates was 
selected from our proteomics lists.  This included proteins such as nucleolin, EEF1A1, 
POLR2A, HAT1, PARP1, PKIM1, HNPRK, TARS, ACLY, PRMT5 and IDH1.  For 
these experiments, wild-type recombinant G9a and GLP1 were incubated with the 
putative substrates in the presence of radioactive 3H-SAM.  Subsequent autoradiographic 
analysis confirmed methylation by either GLP1 or G9a for 11 of the non-histone 
substrates examined (Figure 2.10).  Interestingly, some of the methylated substrates 
appeared to be differentially methylated by both G9a and GLP1, suggesting these 
enzymes may exhibit different substrate preferences despite their high degree of enzyme 
homology. The ready validation of these proteins as substrates for G9a and GLP1 thus 
demonstrates the merit of BPPM technology to identify novel substrates of PKMTs in 
complex biochemical mixtures. 
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Figure 2.10:  Validation of in vitro methylation activities of G9a/GLP1 via autoradiography assay. 
Wild-type G9a/GLP1 were used to examine a panel of commercially available non-histone substrates 
identified by BPPM: TARS, threonyl-tRNA synthetase; ACLY, ATP citrate synthase/lyase; IDH1, soluble 
isocitrate dehydrogenase 1 (NADP+); PRMT5, protein arginine N-methyltransferase 5; EEF1A1, 
eukaryotic translation elongation factor 1 alpha 1; POLR2A, DNA-directed RNA polymerase II subunit 
RPB1 (C-terminal domain); HAT1, histone acetyltransferase 1; PARP1, poly-[ADP-ribose] polymerase 1; 
PKIM1/2, pyruvate kinase isozymes M1/M2; HNRPK, heterogeneous nuclear ribonucleoprotein K. Green 
arrows highlight substrates preferentially methylated by G9a, whereas red arrows highlight substrates 
preferentially methylated by GLP1. 
 
2.4 CONCLUSIONS 
 Based on the research presented herein, we have been able to demonstrate the 
viability of BPPM technology to dissect the substrate profiles of the closely related G9a 
and GLP1 PKMTs.  This was achieved through the establishment of several key pieces of 
information: (i) the identification efficient mutant/cofactor analogue pairs, (ii) use of 
these mutant enzymes for substrate labeling of full length proteins in complex 
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biochemical milieu, and (iii) proteomics analysis of bioorthogonally labeled substrates in 
cell lysate for validation as enzyme substrates.   
 Establishment of mutant/cofactor pairs was initially achieved through the 
screening of recombinant enzyme and cofactor analogue libraries.  After identification of 
promising pairs, catalytic efficiency was then confirmed through steady-state kinetic 
analysis.  By this approach, the GLP1 Y1211A and G9a Y1154A mutants were 
established as having comparable catalytic efficiency to wild-type enzyme when using 
the ‘click’-able Hey-SAM analogue.  As such, this enzyme/cofactor pair was primarily 
used for subsequent application of BPPM, although the azide-containing Ab-SAM also 
demonstrated some merit as well.  After showing that full-length protein substrates could 
be modified selectively, full-length engineered enzymes were expressed in HEK293T 
cells.  Subsequent lysis and supplementation with cofactor analogues allowed for labeling 
of G9a and GLP1 substrates in a complex biochemical setting.  Finally, through 
proteomics analysis, putative targets labeled by our approach were isolated and identified.  
Through this approach, a total of 11 novel substrates for the G9a and GLP1 enzymes 
were validated, along with a large number of putative targets that remain to be examined.   
 All told, these experiments may serve as a roadmap for future application of 
BPPM to various other enzymes.  As discussed above, many SET-domain containing 
PKMTs share key structural features in their catalytic domain.  By focusing engineering 
efforts on these conserved residues in other enzymes, application of BPPM for the 
identification of their substrates may be greatly facilitated.  Indeed, ongoing work by 
other members of our lab has been successful for the application of BPPM to the SET7/9, 
SET8, and SETDB1 enzymes.  Furthermore, our initial application in HEK293T cells 
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also serves as a demonstration of the potential application of BPPM in a more disease 
relevant context.  Future work will likely be focused on determining the biological effects 
associated with the methylation of the identified substrates, as well as application of 
BPPM in cancer cell-lines or disease models, in order to better understand the 
pathological effects associated with aberrant methyltransferase function. 
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CHAPTER 3: DEVELOPMENT OF A SELENIUM-BASED CHEMICAL 
REPORTER FOR WILD-TYPE PROTEIN METHYLTRANSFERASES 
 
3.1 INTRODUCTION 
As with many other posttranslational modifications (PTMs), methylation has been 
shown to be an important means of modulating protein function, activity, and 
localization.1-5 These modifications are catalyzed by SAM-dependent protein 
methyltransferases (PMTs), which transfer the methyl group of SAM to various amino 
acid side-chains, including glutamate/aspartate, cysteine, lysine, arginine, and histidine.3-5 
As discussed in Chapter 1, numerous biological processes are thought to be influenced by 
protein methylation, including: epigenetic regulation through histone modification and 
modulation of chromatin structure, bacterial chemotaxis through the methylation of 
methyl-accepting chemotaxis proteins, and evasion of host immune responses by 
pathogenic bacteria.  Furthermore, other classes of SAM-dependent methyltransferases 
are also essential for their roles in nucleic acid methylation and natural product 
biosynthesis (Chapter 4).  Due to the broad spectrum of substrates and the potential 
impact of SAM-dependent methyltransferases, significant efforts have been made to 
develop tools for the elucidation of their substrates and associated biological effects.6-8  
A powerful approach for the study of PTMs, such as methylation, in biological 
systems has been through the use of chemical reporters containing bioorthogonal 
chemical handles.9 Following incorporation into target molecules, these chemical handles 
can subsequently be coupled to different chemical probes through bioorthogonal ‘click’ 
chemistry in order to analyze PTMs.  This approach has already been reported for the 
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examination of protein glycosylation, acetylation, malonylation, transglutamination, 
lipidation, poly(ADP-ribosyl)ation, and AMPylation.10-18 Given the importance of 
posttranslational methylation, these examples have inspired our group and others to 
develop similar approaches for the study of protein methyltransferases.19, 20 Indeed, we 
have previously reported the use of bulky SAM analogues containing sulfonium-β-sp2-
hybridized alkyne/azide clickable functionalities for the identification of specific PMT 
substrates, termed bioorthogonal profiling of protein methylation (BPPM).7, 21 As 
discussed in chapters 1 and 2, however, application of these analogues generally requires 
the engineering of specific enzymes to achieve efficient substrate labeling due to a 
general incompatibility with wild-type enzymes.   
In light of this limitation, we sought to develop a chemical reporter compatible 
towards wild-type methyltransferases, which would have several potential advantages.  
First, such a cofactor could demonstrate broad-spectrum compatibility across the various 
classes of methyltransferase, including protein, nucleic acid, and natural product 
methyltransferases, making it a potentially useful tool for the study of many biological 
processes.  Secondly, application of a wild-type PMT-compatible SAM mimic would be 
complimentary towards technologies like BPPM for the identification of potential PMT 
substrates, through cross-referencing of proteomic data sets to build confidence in 
potential targets.  Furthermore, implementation of BPPM has thus far only been applied 
to a small group of enzymes, and it is not yet known if all PMTs can be easily engineered 
and introduced back into cellular systems.  A wild-type compatible SAM mimic would 
preclude this issue by eliminating the necessity for enzyme engineering. 
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The optimal candidate for a wild-type PMT compatible SAM mimic was 
originally predicted to be propargyl-SAM (“ProSAM”; Figures 3.1 and 3.10), which had 
been previously reported in the literature.8, 22, 23 This compound was expected to be of 
particular value as a reporter for wild-type methyltransferases, as it contains the smallest 
transferable chemical handle suitable for CuAAC chemistry, and thus should be more 
compatible with the active sites of these enzymes.  While attempting to develop this 
compound for use, however, our attention was caught by several discrepancies 
concerning ProSAM in the literature.  This compound had been previously reported as a 
SAM mimic for both small-molecule methyltransferases (NovO and CouO) and the 
lysine methyltransferase SETDB1.22, 23 However, the same compound had also been 
reported to be unstable at physiological pH.8, 20 Intrigued by these findings, we explored 
the nature of this instability and eventually circumvented it by developing a structurally 
similar, but significantly more stable propargylic Se-adenosyl-L-selenomethionine 
(ProSeAM, Figures 3.2 and 3.10).24 We further demonstrated that ProSeAM is a suitable 
cofactor mimic for multiple wild-type PMTs through its ability to label and identify PMT 
substrates in various biochemical contexts (Figures 3.4, 3.5, 3.8 and 3.9). 
 
3.2 MATERIALS AND METHODS 
General Materials and Methods 
Chemical synthesis of cofactor analogues is detailed in chapter 6, or has been 
reported previously.20, 22 All chemical reagents were purchased from Aldrich Chemical or 
Acros Organics and used without further purification.  Optima grade acetonitrile was 
obtained from Fisher Scientific and degassed under vacuum prior to HPLC analysis.  
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Analytic HPLC was carried out on a Waters 600 Controller HPLC/2998 diode array 
detector using XBridgeTM reversed-phase C18 5 µm 4.6×150 mm column with UV 
detection at 260 nm and with the linear gradient of acetonitrile to 10% in 15 min and then 
to 70% in 5 min in 0.1% aqueous trifluoroacetic acid (flow rate of 1 mL/min).  The 
column was equilibrated with the 0.1% aqueous trifluoroacetic acid solution prior to each 
injection.  CuAAC labeling reagents and azido-conjugated teramethylrhodamine were 
purchased from Aldrich and Invitrogen, respectively.  Proton nuclear magnetic resonance 
spectra (1H NMR) were recorded on Bruker UltrashieldTM Plus 500 or 600 MHz 
instruments at 24 oC. Chemical shifts of 1H NMR spectra are reported as δ in units of 
parts per million (ppm) relative to tetramethylsilane (δ 0.0) or residual deuterium oxide-
d2 (δ 4.80, singlet).   
Histone H3 (aa1-21) peptide (ARTKQTARKSTGGKAPRKQLAGGK), histone 
H4(aa10- 30)-biotin peptide (LGKGGAKRHRKVLRDNIQGITGGK-[Biotin]) and 
RGG-Biotin peptide (GGRGGFGGRGGFGGRGGFGGGK-[Biotin]) were obtained from 
the Proteomics Resource Center of the Rockefeller University and purified by HPLC. 
Recombinant full-length human histone H3.1 was obtained from New England Biolabs. 
Prior to use, the full-length histone solution was subject to Amersham Biosciences PD-10 
desalting columns and eluted with 50 mM Tris HCl (pH = 8.0) containing 1 mM TCEP 
for buffer exchange. 
 
Analysis of Stability of ProSAM and ProSAM by Analytical HPLC and LCMS 
ProSeAM and ProSAM in 0.1% aqueous TFA (pH ~ 2.0) are stable for at least 8 h 
at ambient temperature (conditions of synthesis and HPLC; chapter 6) and for more than 
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three months at -80 °C (storage conditions).  To characterize the stability of these 
compounds, stock solutions of either ProSAM or ProSeAM were prepared in 50 mM Tris 
HCl (pH = 8.0).  Aliquots were removed and analyzed by analytic HLPC or LCMS at 
various time intervals.  Half-life calculations were calculated based on integrated peak 
areas (measured at 260 nm for the adenine moiety) for the various species observed by 
HPLC.  Rapid decomposition of ProSAM was featured by the loss of the expected m/z of 
423.38 and the accumulation of a new hydrated species with the m/z of 441.58 (423.38 + 
18).  The HPLC profile, 1H NMR and ESI-MS of the decomposition product match those 
of KetoSAM, which was synthesized by an independent method (Chapter 6).25   
For the analysis of ProSeAM in the presence of thiol-containing reducing agents, 
stock solutions (200 µL) containing 200 µM ProSeAM, 100 µM Tris HCl (pH = 8.0), and 
increasing concentrations of β-mercaptoethanol (0, 1, and 5 mM) were incubated at 
ambient temperature (22 oC). Aliquots (65 µL) were removed at 0, 35, and 70 minutes 
and monitored by analytical reversed-phase HPLC with UV detection at 260 nm. The % 
ProSeAM remaining was calculated relative to the amount present at t = 0 min. 
 
Protein Expression and Purification 
The expression and purification of recombinant protein lysine methyltransferases 
and protein arginine methyltransferases was described previously or in Chapter 2.20, 26-28 
The GLP1 F1209Y mutant was generated using QuickChange (Stratagene) site-directed 
mutagenesis kits according to manufacturer’s instruction and confirmed via DNA 
sequencing.  PRMT1 and PRMT3 were generously provided by Dr. Rui Wang and Han 
Guo, respectively.  Lysine mono-methyltransferases, SET8 and SET7/9, were expressed 
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and purified as described previously and were provided by Dr. Gil Blum and Dr. Jamie 
McBean, respectively. For the bacterial cysteine methyltransferase NleE, the His×6-
SUMO-NleE plasmid was obtained from Dr. Feng Shao (National Institute of Biological 
Science; Beijing, China) and expressed in BL-21 (DE) cells according to manufacturer’s 
instruction with the exception that 10 µM ZnSO4 was included in the growth medium and 
0.2 mM IPTG was used for induction at OD600 = 0.70 and 22 oC overnight. His×6-
SUMO-NleE was purified with Ni-NTA agarose resin (Qiagen), followed by overnight 
dialysis against 50 mM Tris HCl (pH = 7.5), 150 mM NaCl, 10% glycerol. Protein 
concentrations were determined via Bradford assay kit (Bio-Rad) with BSA as standards. 
All enzymes were stored at -80 °C and thawed on ice prior to use. 
 
MALDI-MS Screening for ProSeAM Compatibility with Wild-Type PMTs 
In general, all reactions (50 µL) were carried out for 2 hours at ambient 
temperature (22 °C). Both biotinylated peptides and nonbiotynylated peptides were used 
as substrates. Nonbiotinylated peptide products were purified over Sep-Pak (Waters) C18 
cartridges according to manufacturer’s protocol, whereas biotinylated peptides were 
enriched by Streptavidin-Sepharose (GE Healthcare) beads after enzymatic reaction. 
These samples were then subjected to MALDI mass spectroscopy as described previously. 
Assay conditions for individual enzymes are described below. For G9a and GLP1, 
reactions contained 2 µM enzyme, 25 µM histone H3 (aa 1-21) peptide and 100 µM 
SAM, ProSAM or ProSeAM in 50 mM Tris HCl (pH = 8.0). The reactions of SUV39H2 
contained 2 µM enzyme, 25 µM histone H3 (aa 1-21) peptide and 100 µM cofactors in 50 
mM Tris HCl (pH = 8.0), 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
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and 2.5 mM MgCl2. The reaction of SET8 contained 5 µM enzyme, 25 µM histone H4 
(aa 10-30) peptide and 100 µM cofactors in 50 mM HEPES (pH = 8.0), 0.005% Tween 
20 and 0.0005% BSA. The reaction of SET7/9 contained 1 µM enzyme, 25 µM histone 
H3 (aa 1-21) peptide and 100 µM cofactor in 50 mM HEPES (pH = 8.0), 0.005% Tween 
20 and 0.0005% BSA. The reaction of PRMT1 contained 2 µM enzyme, 100 µM RGG-
biotin peptide and 100 µM cofactors in 50 mM Tris-HCl (pH = 8.0). The reaction of 
PRMT3 contained 1 µM enzyme, 100 µM RGG-biotin peptide and 100 µM cofactors in 
200 mM HEPES (pH = 8.0). 
 
Kinetics Analysis of ProSeAM as a SAM surrogate Cofactor for GLP1 
Steady-state kinetics was performed to compare ProSeAM and SAM as cofactors 
of GLP1.  For the analysis of GLP1 and SAM, a 10 µL reaction mixture containing 0.5 
µM recombinant GLP1 and 25 µM Histone H3 (aa 1-21) in 50 mM Tris HCl (pH = 8.0) 
was incubated at ambient temperature (22 oC) with increasing concentrations of SAM 
(0.5, 1, 2.5, 5, 7.5, 10, 20, 30, 40, or 50 µM).  For analysis of GLP1 and ProSeAM, a 10 
µL reaction mixture containing 1 µM recombinant GLP1 and 25 µM Histone H3 (aa 1-
21) in 50 mM Tris HCl (pH = 8.0) was incubated at ambient temperature (22 oC) with 
increasing concentrations of ProSeAM (1, 5, 10, 20, 30, 40, 50, 100, 150, or 200 µM).  At 
5, 10, 15, 20, and 25 minute time-points, 1 µL aliquots were removed and the reaction 
quenched by spotting on the top of a MALDI plate pre-arranged with 1.5 µL (10 µg/µL) 
α-cyano-4-hydroxycinnamic acid (CHCA) matrix dissolved in 1:1 H2O:acetonitrile (0.1% 
TFA). An additional 1.5 µL of acetonitrile (0.1% TFA) was added to each spot and 
	   67	  
allowed to dry prior to MALDI-MS analysis as described previously.  MALDI-MS data 
was analyzed based on %modification of peptide and fit to the Michaelis-Menten 
equation to obtain kcat and Km values.  
 
Cell Culture Materials and Procedures 
All cell lines were purchased from American Type Culture Collection (ATCC; 
with the exception of HEK293T and Jurkat cell lines, which were from the laboratory of 
Dr. Stephen Nimer at Memorial Sloan Kettering Cancer Center). These cell lines were 
cultured according to ATCC protocols (Table 3.1).  Prior to collection, the cells were 
treated with 25 µM adenosine-2’, 3’-dialdehyde for 24-48 hrs.  Upon harvesting, the cells 
were washed with PBS three times and pelleted by centrifugation at 1,000 g for 10 min at 
4 oC.   
 
Table 3.1: List of Cell Lines and Corresponding Culture Media Used. 
Cell Line Type Culture Media 
A549 Alveolar Adenocarcinoma F12K with 10% FBS 
HEK293T Embryonic Kidney DMEM with 10% FBS 
HT-29 Colorectal Adenocarcinoma McCoy’s 5A with 10% FBS 
H1299 Non-Small Cell Lung Carcinoma RPMI 1640 with 10% FBS 
Jurkat T-Cell Leukemia RPMI 1640 with 10% FBS 
MCF-7 Breast Adenocarcinoma 1:1 F12K:DMEM with 10% FBS 
MDA-MB-231 Breast Adenocarcinoma 1:1 F12K:DMEM with 10% FBS 
RKO Colon Carcinoma MEM with 10% FBS 
U937 Histiocytic Lymphoma RPMI 1640 with 10% FBS 
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Labeling of Full-Length Proteins with ProSeAM 
For the G9a/GLP1-catalyzed labeling of full-length histone H3.1 with ProSeAM, 
2 µM G9a or GLP1 was incubated with 25 µM recombinant human histone H3.1 (New 
England BioLabs) and 50 µM ProSeAM for 1 hour at 25 °C in 50 mM Tris-HCl (pH = 
8.0).  For NleE- catalyzed labeling of GST-TAB2-NZF with ProSeAM, 3 µM His×6-
SUMO-NleE was incubated with 50 µM GST-TAB2-NZF and 100 µM ProSeAM for 30 
min in the buffer containing 50 mM Tris HCl (pH = 7.5), 150 mM NaCl, 5 mM DTT and 
0.1% NP-40. Alternatively, 3 µM His×6-SUMO-NleE was preincubated with 500 µM 
SAH for 15 min prior to addition of ProSeAM. Upon the completion of the reaction, the 
crude samples were precipitated with 1:2:3 CHCl3/H2O/methanol  (1.2 mL) and washed 
with 1 mL methanol 3 times.  Samples were then subjected to CuAAC as described 
below. 
 
Labeling Cell Lysates with ProSeAM 
Whole cell lysates were prepared fresh from HEK293T cells suspended in buffer 
containing 50 mM Tris HCl (pH = 8.0), 50 mM KCl, 10% glycerol, 1 mM TCEP, 
0.005% Tween 20 and 1× Roche protease inhibitor cocktail and incubated on ice for 20 
min. The suspended cells were then lysed via sonication (Misonix Ultrasonic Liquid 
Processor with a single 15 min pulse at 65% amplitude) and centrifuged at 15,000g for 30 
min.  The supernatants were isolated and their protein concentrations measured via 
Bradford assay (Bio-Rad) with BSA as standards. 
For each 50 µL labeling reaction, 100 µg of total lysate protein was incubated 
with the indicated concentrations of ProSeAM or ProSAM.  Here 0.1 µM 5’-
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methylthioadenosine/SAH nucleosidase (MTAN) was also added into the samples to 
degrade SAH and thus release the potential inhibition of SAH in lysates or from the 
byproduct of methylation reaction.  MTAN treatment was omitted when the samples 
were treated with SAH to inhibit endogenous methyltransferases.  SAH treated samples 
were preincubated for 15 min with 500 µM SAH, 2 µM adenosine-2’,3’-dialdehyde (an 
irreversible inhibitor of SAH hydrolase to block SAH degradation) and 2 µM methylthio-
DADMe-ImmA (an inhibitor of S-methyl-5’-thioadenosine phosphorylase to block SAH 
degradation, a generous gift from the Schramm lab at Albert Einstein College of 
Medicine).  After 2 hour treatment of ProSeAM or ProSAM, the samples were 
precipitated and washed with 1:2:3 CHCl3/H2O/methanol and subjected to CuAAC 
chemistry as described below. 
 
Conjugation of Labeled Substrates to Fluorescent Probe via CuAAC 
After treating full-length histone H3.1 (20 µL reaction mixture of 25 µM histone 
H3.1) or whole cell lysates (100 µg total protein) with ProSeAM or ProSAM as described 
above, samples were precipitated with a mixture containing 600 µL of methanol, 200 µL 
of chloroform and 400 µL of water, and centrifuged at 15,000g for 10 min.  The aqueous 
phase was discarded and the pellets in the interface were washed three times with 1 mL 
methanol, followed by centrifugation at 15,000g.  The supernatants were decanted and 
the protein pellets air-dried for 1 hour. The samples were then dissolved in 20 µL of 
solution containing 50 mM TEA (pH = 7.4), 150 mM NaCl and 4% SDS.  This mixture 
was subjected to CuAAC chemistry by adding 100 µM azido-rhodamine, 2 mM TCEP, 1 
mM CuSO4 and 100 µM Tris[(1- benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) for 
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1 hour at ambient temperature (22 °C) and in the absence of light.  After the CuAAC 
reaction, samples were precipitated with 1.2 mL of 1:2:3 CHCl3/ H2O/methanol mixture 
as described above.  The aqueous phase was discarded and the protein precipitate washed 
three times with 1 mL methanol. The dried samples were dissolved in protein loading 
buffer and heated for 10 min at 100 oC, followed by SDS-PAGE separation.  The 
fluorescent bands were visualized by in-gel fluorescence using an Amersham Biosciences 
Typhoon 9400 fluorescent scanner (excitation at 532 nm, 580 nm filter and 30 nm band-
pass). After the in-gel fluorescence, Coomassie Blue staining was carried out as loading 
control.  
 
Affinity Pull-Down of ProSeAM-Labeled Proteins from HEK293T Cell Lysates 
 ProSeAM (final concentration = 25 µM) was added to a total of 10 mg total 
protein from HEK293T cell lysate (prepared as described above) in 5 mL 50 mM Tris 
HCl (pH = 8.0), 50 mM KCl, 10% glycerol, 1 mM TCEP, 0.005% Tween20, and Roche 
protease inhibitor cocktail.  Non-inhibitor-treated sample buffer was also supplemented 
with 100 nM MTAN in order to release any potential inhibition from SAH present in cell 
lysates.  By contrast, inhibitor treated samples contained 0.5 mM SAH or sinefungin, 2 
µM adenosine-2’-3’dialdehyde, and 2µM methylthio-DADMe-ImmA. 
 After a 1 hour reaction time, the samples were precipitated with 1:2:3 
CHCl3/H2O/methanol (42.5 mL), centrifuged at 3,000 g for 45 minutes and the resultant 
pellets were washed twice with 50 mL of methanol. The protein pellets were then 
suspended in (4.45 mL) 50 mM TEA (pH = 7.4), 150 mM NaCl, 4% (w/v) SDS buffer, 
into which was added 550 µL of CuAAC reaction cocktail containing 100 µL of 5 mM 
	   71	  
azido-azo-biotin29 (100 µM final concentration), 100 µL of 50 mM TCEP (1 mM final 
concentration), 250 µL of TBTA (100 µM final concentration), and 100 µL of 50 mM 
CuSO4 (1 mM final concentration). After a 1.5 h incubation period at ambient 
temperature (22 oC), the proteins were precipitated again by addition of 45 mL of 
methanol at -80 oC, centrifuged at 3,000 g and washed twice with 45 mL of methanol. 
Protein was dried for 15 minutes and then suspended in 1 mL of 50 mM TEA (pH = 7.4), 
150 mM NaCl, 10 mM EDTA, 4% (w/v) SDS buffer, and diluted through addition of 2 
mL of 50 mM TEA (pH = 7.4), 150 mM NaCl, and 1% (w/v) Brij97.  Into these mixtures 
was added 100 µL of Streptavidin-Sepharose beads (GE Healthcare) prewashed 3 times 
with PBS. The samples were incubated for 1 hour with agitation, centrifuged at 3,000 g 
and 4 oC for 2 minutes, and then washed three times with 10 mL of PBS containing 0.2% 
SDS, followed by two additional washes with 10 mL of 250 mM ammonium bicarbonate. 
After removing supernatant and adding 500 µL of 8 M Urea, 25 µL of 200 mM TCEP, 
and 25 µL of 400 mM iodoacetamide, the protein samples were then incubated for 40 
min in the absence of light.  Samples were then washed twice with 10 mL of 250 mM 
ammonium bicarbonate. The bead-immobilized proteins were then liberated by two 
consecutive 30-min incubations with 250 µL of 1% SDS, 250 mM ammonium 
bicarbonate, and 25 mM sodium dithionite. The released proteins were then collected and 
concentrated using Amicon Ultra 3K centrifugal filter units (Millipore), lyophilized and 
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Proteomics Analysis 
Pull-down samples were separated by SDS-PAGE, extracted, and trypsinized as 
described previously.21 The digestion product was then analyzed by LC-MS/MS via 
separation on a 60 min gradient elution at a flow rate of 0.30 µL/min with the UltiMate 
3,000 RSLCnano System (Thermo Scientific), which was directly interfaced with the 
Thermo Q Exactive bench top mass spectrometer. The analytical column was a 
homemade fused silica capillary column (75 µm i.d., 150 mm length; Upchurch, Oak 
Harbor, WA) packed with C-18 resin (300 Å, 5 µm; Varian, Lexington, MA). Mobile 
phase A consisted of 0.1%formic acid, and mobile phase B consisted of 100% 
acetonitrile and 0.1% formic acid. The LTQ-Orbitrap mass spectrophotometer was 
operated in the data-dependent Acquisition mode using Xcalibur 2.2.0 software with a 
single full-scan mass spectrum in the Orbitrap followed by 8 MS/MS scans in the 
quadrupole collision cell using higher energy collision dissociation (HCD). 
The MS/MS data was analyzed using Thermo Proteome discoverer 1.2.0 software 
against the ipi.HUMAN.v3.82 database with the following search parameters: 10 ppm 
peptide mass tolerance, 0.8 Da ms/ms tolerance, and two missed cleavages allowed. In 
addition, modification of carbamidomethylation on cysteine, oxidation of methionine, 
deamidated asparagine and glutamine, and C11H12N4O (ProSeAM + cleaved azido-azo-
biotin linker) or C22H24N8O2 (2× ProSeAM + cleaved azido-azo-biotin linker) were also 
used to search the database. A decoy database search was added with the criteria of FDR 
at 0.01. Peptide filtering criteria were the following: 2, 2.75, and 3 for singly charged, 
doubly charged, and triply or higher charged ions, respectively. 
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3.3 RESULTS AND DISCUSSION 
ProSAM vrs. ProSeAM Stability  
 It had been previously shown that ProSAM underwent rapid degradation at pH 
ranges commonly used for enzymatic reactions (pH = 7-9).20, 26, 30 Through careful time-
dependent HPLC and LCMS analysis, we discovered that ProSAM has an extremely 
short half-life of 1-2 minutes at pH 8.0.  Furthermore, the major byproduct associated 
with ProSAM instability was characterized by its +18 molecular ion peak, which we 
surmised was the result of hydration (+H2O) of the alkyne moiety via a putative allene 
intermediate to yield a ketone containing SAM analogue (KetoSAM; Figures 3.1 and 
3.10).  The formation of this byproduct was later confirmed upon spectral comparison of 
HPLC-purified degradation products with independently synthesized KetoSAM (Chapter 
6).25 
 
Figure 3.1: Analysis of ProSAM Stability.  The ProSAM analogue demonstrated extreme instability at 
physiologically relevant pH ranges.  In Tris HCl (pH = 8) buffer, ProSAM is converted to KetoSAM with 
an estimated half-life of approximately 1-2 minutes.  
  
The stability of ProSeAM was also examined under identical conditions.  
Interestingly, no significant conversion (<5%) of the alkyne moiety to the corresponding 
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ketone could be observed over the course of the experiment.  Rather, ProSeAM 
decomposed primarily to Se-propargyl-5’-selenoadenosine via intramolecular 
lactonization, which is an established decomposition pathway for SAM or SeAM 
(discussed previously in chapter 1; Figures 3.2a and 3.10).  Overall, the half-life of 
ProSeAM was approximately 60-fold longer than that of ProSAM (~60 minutes vrs. < 2 
minutes in Tris HCl pH = 8.0), and conveniently falls within the time range required for 
most methyltransferase-catalyzed reactions.  Furthermore, the stability of ProSeAM was 
also analyzed in the presence of thiol-containing reducing agents.  Despite the expected 
high electrophilicity of the carbons adjacent to the selenonium moiety, ProSeAM was 
found to be stable in the presence of 5 mM β-mercaptoethanol  (<10% decrease in overall 
half-life; Figure 3.2b). 
 
Figure 3.2: Analysis of ProSeAM Stability.  In contrast to ProSAM, the propargyl moiety of the 
selenium-based ProSeAM analogue does not rapidly degrade to the corresponding ketone in Tris HCl (pH 
= 8) buffer. (a) The primary decomposition pathway for ProSeAM was through intramolecular 
lactonization of the α-aminobutyrate moiety to form Se-propargyl-5’-deoxyadenosine rather than loss of the 
propargylic chemical handle. The overall half-life of ProSeAM was found to be roughly 60 fold greater 
than that of ProSAM. (b) Furthermore, ProSeAM was found to be compatible towards the thiol-containing 
reducing agent β-mercaptoethanol, with only a <10% decrease in overall stability. 
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ProSeAM Compatibility of ProSeAM with Wild-Type Methyltransferases 
 The improved stability of ProSeAM enabled us to examine its compatibility 
towards wild-type protein lysine/arginine methyltransferases (PKMTs/PRMTs).  
MALDI-TOF mass spectrometry was applied to monitor the abilities of a panel of 
PKMTs/PRMTs (GLP1, SET7/9, SET8, G9a, SUV39H2, PRMT1 and PRMT3) to 
modify known peptide substrates in the presence of ProSeAM (Figure 3.3a, b). Parallel 
reactions containing SAM or reactions in which enzymes were omitted were also carried 
out as positive and negative controls, respectively.  Of the initial panel of PMTs 
examined, ProSeAM was shown to be compatible toward three PKMTs (GLP1, G9a, and 
SUV39H2) for efficient modification of N-terminal histone H3 peptide.  Interestingly, 
ProSeAM could be processed twice by the GLP1 and SUV39H2 enzymes to generate the 
dipropargylated peptide product, which is consistent with the processive activity of these 
enzymes (both are H3K9 di/tri-methyltransferases).31-33 No modification was observed in 
either the no-enzyme/no-cofactor controls, or in samples treated with the unstable 
ProSAM analogue. Furthermore, no modified peptide products resulting from 
nucleophilic attack at C5’ of ProSeAM’s ribose or the γ-carbon of its α-aminobutyrate 
moiety were observed.  Together, these observations suggest that ProSeAM indeed acts 
as a cofactor surrogate, rather than a nonspecific alkylation reagent. 
 To evaluate catalytic efficiency with ProSeAM, we performed steady-state 
kinetics analysis using the GLP1 PKMT.  Initial rates for GLP1-catalyzed modification 
were determined for ProSeAM and plotted against cofactor concentration using the 
Michaelis-Menten equation, yielding an apparent kcat of 0.375 min-1 and a KM of 45.4 µM.  
Compared to GLP1 with SAM (kcat of 1.97 min-1; KM of 3.1 µM), these kinetic 
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parameters differed by only 5-15 fold and are sufficient for labeling of cell lysates, as is 
demonstrated later in this chapter. 
 
 
Figure 3.3: Compatibility of ProSeAM with Wild-Type PMTs. (a) MALDI-MS analysis of ProSeAM 
compatibility towards GLP1 and SUV39H2 revealed the addition of multiple propargyl groups to histone 
H3 peptide substrate. No modification could be observed when the unstable sulfur-based ProSAM was used. 
(b) List of wild-type arginine and lysine methyltransferases examined.  Of the enzymes tested, only lysine 
di/tri-methyltransferases appeared to be compatible. N.D., not detected (c) Steady state kinetics analysis of 
ProSeAM compatibility towards wild-type GLP1 (1 µM) in comparison to SAM.  KM (ProSeAM) and kcat 
(ProSeAM) were calculated to be 45.4 µM and 0.375 min-1, respectively. 
 
Rationale for ProSeAM’s Preference Towards Lysine Di/Tri-Methyltransferases 
 Of the three PKMTs shown to be compatible with ProSeAM in our initial screen, 
all were di/tri-methyltransferases (both mono-methyltransferases tested appeared to be 
incompatible).  Given this observation, we set out to examine the possible reason for this 
selectivity.  To explore this further, we first generated the F1209Y mutation of GLP1, 
which had previously been shown to act as a di/tri-to-mono-methyltransferase “switch” 
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mutation for SET domain containing PKMTs.  In lysine mono-methyltransferases, such 
as SET8 or SET7/9, this residue is a tyrosine, whereas in di/tri-methyltransferases, this 
residue is typically a phenylalanine.34 As predicted, this mutation altered the processivity 
of GLP1, converting it to a predominantly lysine mono-methyltransferase (Figure 3.4).  
Interestingly, no modification of the peptide substrate could be observed with the GLP1 
F1209Y mutant in the presence of ProSeAM.  This loss-of-function experiment thus 
suggests that the di/tri-PKMTs may utilize a pre-existing vacancy in their active sites to 
accommodate the propargyl group of ProSeAM. 
 
Figure 3.4: Basis for ProSeAM Compatibility Towards Lysine Di/Tri-Methyltransferases.  Mutation 
of phenylalanine 1209 to tyrosine converts GLP1 from a di/tri-methyltransferases to a mono-
methyltransferase.  As a result, GLP1 is no longer compatible towards the ProSeAM analogue. 
 
Enzymatic Labeling of Full-Length Protein Substrates with ProSeAM 
 Compatibility of ProSeAM with wild-type enzymes was further examined via in-
gel fluorescence with full-length recombinant histone H3.1 as a substrate.  As seen in 
Figure 3.5a, multiple labeled bands of H3.1 were observable by fluorescence imaging.  
No labeling was observed in no-enzyme or no-cofactor controls.  Furthermore, the 
striation pattern (0.7 kDa increase per modification after conjugation to the fluorescent 
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probe) correlates well with the degree of alkylation observed by MALDI-MS.  In addition, 
ProSeAM demonstrated compatibility towards the NleE cysteine methyltransferase for 
the labeling of its TAB2-NZF substrate.3 No significant labeling could be observed in no-
enzyme/no-cofactor controls or in samples treated with the PMT inhibitor, SAH (Figure 
3.5b).  Lastly, LC-MS/MS analysis of GLP1-modified tryptic histone H3.1 peptides 
confirmed transfer of ProSeAM’s propargyl group to lysine 9.  No transfer of the 
propargyl group to other residues on H3 could be detected by this method.  Together, 
these data suggest that ProSeAM can be efficiently utilized for the labeling of full-length 
protein substrates. In addition, these data indicate that both enzyme processivity and 
specificity are maintained when utilizing the ProSeAM cofactor mimic.  
 
Figure 3.5: Labeling of Full-Length Protein Substrates using ProSeAM in vitro. (a) In-gel fluorescence 
validation of G9a and GLP1 activity on recombinant histone H3.1 using ProSeAM as a cofactor.  The 
striation pattern is the result of the addition of multiple fluorescent probes to the substrate. (b) In-gel 
fluorescence validation of NleE cysteine PMT activity on the TAB2-NZF substrate. (c) LC-MS/MS 
analysis of tryptic histone H3.1 treated with GLP1 and ProSeAM revealed di-propargylated lysine 9.  
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Endogenous Labeling of Proteins in HEK293T Cell Lysate using ProSeAM 
 To demonstrate the utility of ProSeAM in more complex biochemical systems, 
HEK293T cell lysates were labeled with ProSeAM.  For this purpose, HEK293T cells 
were treated with adenosine-2’,3’-dialdehyde, a SAH hydrolase inhibitor that was 
reported previously to generate hypomethylated proteomes through the accumulation of 
the PMT product inhibitor, SAH.35 These lysates were then treated with ProSeAM, 
conjugated to an azido-rhodamine dye, and visualized by in-gel fluorescence.  Labeled 
proteins were clearly observable in the treated samples, even at low ProSeAM 
concentrations (Figure 3.6).  In contrast, samples treated with the unstable ProSAM 
cofactor showed barely detectable labeling, even at 1 mM cofactor concentration.  
Furthermore, labeling with ProSeAM was proportional to cofactor concentration and 
could be suppressed by treatment with SAH or heat-inactivation (100 oC for 10 minutes). 
Indeed, much of the labeling of substrates that were inhibited by SAH treatment also 
appeared to be inhibited by heat-inactivation.  These data are consistent with labeling by 
endogenous methyltransferases already present in the lysate using ProSeAM as a cofactor 
mimic. 
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Figure 3.6: Labeling of HEK293T Cell Lysates by Endogenous PMTs with ProSeAM. (a) HEK293T 
cell lysates were treated with ProSeAM or ProSAM in the presence or absence of SAH inhibition.  (b) 
HEK293T cell lysates were heated to 100 oC for 10 minutes prior to treatment with increasing 
concentrations of ProSeAM.  Following each labeling reaction, propargylated proteins were conjugated to 
fluorescent probes and resolved by SDS-PAGE prior to fluorescent visualization.  The inhibitor and heat-
sensitive labeling of proteins in lysate suggests that labeling is an enzyme-dependent process. 
 
Proteomic Analysis of Labeled Substrates in HEK293T Cell Lysate  
 Encouraged by ProSeAM’s activity in vitro and apparent ability to label protein 
substrates in cell lysate, we sought to expand its application further through the proteomic 
analysis of labeled substrates in HEK293T cell lysates.  For experimental comparison, 
HEK293T lysates were labeled in the presence of absence of the SAH and sinefungin 
pan-specific PMT inhibitors.36 Propargylated proteins were then conjugated to a 
cleavable azido-azo-biotin affinity probe via CuAAC and enriched over streptavidin 
beads.  Bound proteins were then liberated through treatment with sodium dithionite, 
separated by SDS-PAGE, subjected to trypsin digestion and analyzed by LC/MS-MS 
(Figure 3.7). 
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Figure 3.7: Representation of the Affinity-Based Pull-Down Procedure for ProSeAM Labeled 
Proteins in Cell Lysates.  Wild-type methyltransferases present in cell lysate are treated with ProSeAM to 
label endogenous substrates. These propargylated substrates are then conjugated to a cleavable biotin probe 
(azido-azo-biotin) and isolated through affinity-based enrichment over streptavidin beads.  Enriched protein 
substrates are then eluted by cleavage of the biotin probe through treatment with the sodium dithionite 
reducing agent, trypsinized, and analyzed by LC-MS/MS proteomics. 
 
 Data sets were analyzed through comparison and overlap between no-inhibitor 
and inhibitor-treated samples (Figure 3.8a). Analysis revealed a total of approximately 
300 potential targets by comparison of no-inhibitor to SAH-treated data sets.  In addition, 
roughly 450 potential targets were identified by comparison of no-inhibitor to sinefungin-
treated data sets.  Interestingly, comparison of these potential targets between the two 
data sets treated with different inhibitors indicated that the SAH inhibitor treated samples 
shared approximately 80% identity toward the putative targets identified in the sinefungin 
treated data set (Figure 3.8a).  This may suggest that two different pan-specific PMT 
inhibitors prevent the labeling of many of the same protein substrates, as might be 
expected.  In addition, approximately 30% of the proteins identified in the SAH-treated 
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data sets had also previously been reported as PMT substrates through other methods.37-41 
Several examples of such targets are provided in figure 3.8b. Lastly, of the 11 novel 
substrates validated for the G9a and GLP1 enzymes through application of BPPM 
technology (Chapter 2), 10 were also observed in our ProSeAM-treated data sets.  
Complete lists of identified proteins in our proteomics analysis are provided in the 
Appendix section.   
 
Figure 3.8: Proteomics Analysis of ProSeAM Labeled Proteins in HEK293T Lysates.  (a) Comparison 
of inhibitor-treated proteomic data sets.  Data sets from ProSeAM-treated samples were first compared to 
sinefungin- or SAH-treated data sets.  Identities that did not overlap with inhibitor-treated samples were 
taken as putative PMT substrates and defined as either SAH or sinefungin “Hit Lists”.  Furthermore, 
comparison between SAH and sinefungin hit lists indicated a high degree of identity overlap (~80%). (b) A 
short list of previously reported PMT targets that were detected in HEK293T lysate treated with ProSeAM, 
but not in lysate treated with inhibitor. 
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ProSeAM Labeling in Lysate Across Cancer Cell Lines 
 To further highlight ProSeAM’s potential utility as a chemical reporter for protein 
methylation, we compared fluorescent labeling patterns across eight common cancer cell 
lines (Figure 3.9). Examination of these labeling patterns revealed that, although many 
labeled proteins are shared across all cell lines and could be suppressed by inhibitor 
treatment, a subset of labeling events appeared to be cell-type specific.  For exampled, 
protein c appeared to be strongly labeled in MCF7, HT-29, RKO, A549, and H1299 cells, 
but not in MDA-MB-231, Jurkat, or U937 cells (Figure 3.9).  Similar patterns could also 
be observed for other labeled proteins, such as a, b, c, d, and f.  Interestingly, labeling 
patterns also showed variation between cell lines derived from the same tissue type 
(protein e is labeled in RKO, but not in HT-29 colon cancer cell lines).  As cancer is 
thought to be a complex, biochemically heterogeneous disease and has been linked to 
aberrant protein methylation, these data suggest ProSeAM may be a useful tool for 
determining PMT substrates in complex systems without the need for genetic 
manipulation. 
	   84	  
 
Figure 3.9: In-gel Fluorescence Analysis of ProSeAM Labeling Across Cancer Cell Lines.  Protein 
labeling with ProSeAM as a chemical reporter of endogenous methyltransferases in cancer cell lysates.  
Cells were treated with adenosine-2’, 3’-dialdehyde during growth to generate hypomethylated proteomes 
for more efficient labeling. Cell lysates were then treated with ProSeAM in the presence or absence of the 
SAH inhibitor prior to conjugation to a fluorescent chemical probe and in-gel visualization. 
 
3.4 CONCLUSIONS 
 Motivated by limitations inherent in current technologies for the study of 
biological transmethylation reactions, we set out to develop a chemical reporter for wild-
type protein methyltransferases.  Based on experimental data and literature reports, we 
determined that the initial candidate for this purpose, ProSAM, was unstable at 
biochemically relevant pH ranges (Figure 3.1). Furthermore, we have demonstrated this 
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this compound undergoes rapid hydration of its propargylic chemical handle, likely a 
result of the relative acidity of protons adjacent to the sulfonium moiety, to form the 
KetoSAM byproduct. This instability renders this cofactor impractical for the study of 
methylation for several potential reasons.  First, the short half-life of ProSAM means it is 
unlikely to be efficiently utilized by methyltransferases, which typically require longer 
time periods for efficient substrate modification.  Concomitantly, ProSAM’s instability 
results in the rapid buildup of a potentially competitive species (KetoSAM), which has 
been shown to be a viable cofactor analogue for some methyltransferases. Lastly, 
intermediates formed during ProSAM’s transformation may act as nonspecific alkylating 
reagents, potentially inactivating certain enzymes. 
 
 
Figure 3.10: Stability of ProSAM and ProSeAM Cofactor Analogues.  The sulfur-based cofactor mimic, 
ProSAM, is highly unstable at physiologically relevant pH values and degrades to KetoSAM.  In contrast, 
the selenium-based ProSeAM is significantly more stable under the same conditions. SAH, S-adenosyl-L-


















































t1/2 < 2 min 
at pH 8.0
+
X = S, "SAH"; 

























	   86	  
 
In order to circumvent these limitations, we developed a selenium-based analogue, 
dubbed ProSeAM, with the hypothesis that the presence of a selenonium moiety would 
prevent degradation due to the decreased acidity of protons adjacent to the reactive 
center.42 Indeed, this cofactor analogue displayed significantly increased stability of its 
propargyl chemical handle under identical conditions used to study ProSAM (Figure 3.2).  
Further experimentation confirmed ProSeAM to be a suitable cofactor (Figure 3.3 and 
3.5) for a number of wild-type recombinant PKMTs (G9a, GLP1, and SUV39H2) and the 
NleE cysteine PMT, although it was not compatible with all of the PMTs tested under our 
conditions (SET7/9, SET8, PRMT1, and PRMT3).  In contrast to our findings, Weinhold 
and colleagues have reported compatibility of ProSeAM towards wild-type SET7/9 and 
PRMT1.43 However, the source of this discrepancy may be related to the different 
detection methods used for the two studies.  In their report, the Weinhold group utilized 
antibody-coupled horseradish peroxidase visualization, which is expected to detect even 
extremely weak labeling.  In our work, however, we used MALDI-MS and in-gel 
fluorescence, which, although less sensitive, are expected to better reflect the degree of 
ProSeAM’s compatibility towards wild-type enzymes. Despite this, we cannot rule out 
other possibilities for the discrepancy, such as differences between the enzyme constructs 
and peptide substrates used for each study. 
 We have also gone on to demonstrate ProSeAM’s utility for in-gel fluorescence 
and the proteomic identification of a significant number of potential PMT substrates. 
(Figure 3.6, 3.9, 3.11)  The fact that the labeling of substrates could be inhibited in cell 
lysate, and that many previously identified PMT substrates appeared in our data sets 
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lends confidence to our approach.  In addition, the complementarity of a wild-type PMTs 
reporter towards BPPM was also demonstrated through identification of 10 of the 11 
novel GLP1/G9a substrates reported in Chapter 2.7   
 
Figure 3.11: Application of ProSeAM as a Chemical Reporter for Protein Methylation.  Endogenous 
methyltransferases can utilize ProSeAM to label cellular proteins. These modified proteins can be 
subsequently coupled to chemical probes for analysis through in-gel fluorescence or proteomics. 
 
 In summary, we have successfully overcome a major limitation in the 
development of a wild-type PMT-compatible SAM mimic through the development of 
the selenium-based ProSeAM analogue.  In this chapter, we have demonstrated its utility 
for the study of PMTs and the identification of novel substrates in HEK293T cell lysate 
(Figure 3.11).  Given that nucleic acid, small molecule, and other protein 
methyltransferases have been shown to act on SAM analogues that are structurally 
similar or even bulkier, we expect that additional wild-type enzymes will also 
demonstrate compatibility towards ProSeAM in the future. Research aimed at the 
exploration of ProSeAM’s compatibility towards natural product methyltransferases will 
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CHAPTER 4: ProSeAM COMPATABILITY TOWARDS  
NATURAL PRODUCT METHYLTRANSFERASES 
 
4.1 INTRODUCTION 
As discussed in chapter 1, SAM-dependent methyltransferases are a diverse class 
of enzyme, with examples of target substrates spanning essentially every type of 
biomolecule, from small-molecules and natural products to nucleic acids and proteins.1-4 
Although tremendous efforts are being made towards determining the roles of 
DNA/protein methylation in the regulation epigenetic processes,5 the biological activity 
and function of many nonprotein-methyltransferases unrelated to epigenetics remains a 
fertile area of study.6 In light of the development of chemical biology tools for the study 
of protein methyltransferases,7-12 it was of general interest to expand the application of 
these compounds to the study of natural product methyltransferases (NPMTs). These 
enzymes represent the most diverse class of methyltransferase across species and are 
involved in the biosynthesis of a vast array of metabolites and pharmaceutically relevant 
compounds, where the addition of a methyl group is often essential for altering the 
pharmacological properties of the natural product. The activity of NPMTs can be 
exemplified across every class of small-molecule, with activities ranging from the 
production of essential metabolites to the biosynthesis or more complex natural 
products.13-15 In addition to independently expressed dedicated NPMTs, many 
methyltransferase domains can also be found within larger multifunctional complexes 
responsible for the formation of polyketides and nonribosomal peptides.16  
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Figure 4.1: Structure of Chaetoviridin and Chaetomugilin Azaphilones. 
 
Polyketide natural products, in particular, are a structurally diverse class of 
molecules that provide a rich source of pharmaceutically relevant compounds.17 
Interestingly, these molecules derive their complex structures through the utilization of 
very simple building blocks, such as malonyl-CoA, and repetitive cycles of β-keto 
reduction by polyketides synthases (PKS).18, 19 Besides the enzyme domains responsible 
for the incorporation of the basic building blocks of polyketides, many PKS complexes 
also contain additional tailoring components, such as methyltransferase (MT) domains, 
responsible for the introduction of specific chemical motifs into the final product.16 MT 
domains present in many PKSs catalyze the α-methylation of growing β-keto polyketide 
chains using SAM as a methyl source.  Given the recent development of SAM analogues 
for use with wild-type human protein methyltransferases, it was of interest to explore 
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Figure 4.2: Biosynthesis of Chaetoviridin A. (a) The MT domain of CazF is responsible for the insertion 
of a methyl group early in the biosynthesis of chaetoviridin A. (b) Domain structure of CazF and the 4’-
propargyl-chaetoviridin A analogue of interest for this study. 
 
 In order to explore the cofactor compatibility of PKS MT domains towards SAM 
analogues, we turned our attention to the modification of chaetoviridin A through 
collaboration with the laboratory of Dr. Yi Tang.  In 2012, the Tang and Watanabe labs 
identified the caz gene cluster responsible for the biosynthesis of the chaetoviridin and 
chaetomugilin azaphilones (Figure 4.1).20 Included in this cluster was the highly-reducing 
PKS, CazF, which contains an in-line MT domain.  In vitro experiments using 
reconstituted CazF later confirmed that this MT domain is indeed active in the 
methylation of growing polyketide chains following the first chain-extending 
condensation step.21 As such, CazF represented a good model system for exploring 
whether PKS MT domains are capable of accepting SAM analogues for the 
diversification of natural products (Figure 4.2). Furthermore, as no mutational 
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engineering efforts had been applied to this system previously, we utilized the ProSeAM 
and Keto-SAM analogues. These analogues were predicted to be prime candidates as 
they contain relatively small bioorthogonal chemical handles and had previously been 
shown to be compatible towards wild-type enzymes.10-12, 22 If successful, it was predicted 
that the use of SAM analogues and/or protein engineering might provide a means of 
expanding the structural diversity of additional polyketide natural products, which might 
provide a means of altering their pharmacological properties or exploring their 
mechanism of action. As mentioned previously, this work was performed in collaboration 
with the laboratory of Dr. Yi Tang by Dr. Jaclyn Winter.16 
 
4.2 MATERIALS AND METHODS 
General Methods and Materials 
All solvents and other chemicals used were of analytical grade. Azide-PEG3-5(6)- 
carboxytetramethylrhodamine and click-chemistry protein reaction buffer kit was 
purchased from Click Chemistry Tools (Scottsdale, AZ). Acetoacetyl-S-N-acetyl 
cysteamine (acetoacetyl-SNAC) was a gift from Dr. Kangjian Qiao (UCLA). ProSeAM 
and Keto-SAM were prepared as described in chapter 6. All 1H NMR spectra were 
obtained on a 500 MHz Bruker AV500 spectrometer with a 5 mm dual cryoprobe.  
 
Synthesis of 3-[3-(trimethylsilyl)-2-propyn-1-yl]-2,4-pentanedione.  To a flask 
containing 2,4-pentanedione (18.5 mL, 80.0 mmol, 5.0 equiv) in acetone (32 mL) was 
added 3-bromoprop-1-yn-1-yl-trimethylsilane (3.0 g, 16.0 mmol, 1.0 equiv). Potassium 
carbonate (11.0 g, 80.0 mmol, 5.0 equiv) was then added. The flask was topped with a 
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reflux condenser and the system placed under nitrogen. The reaction mixture was heated 
to reflux for 2 h. After cooling, the reaction was filtered and the filter cake was washed 
with acetone (3 x 20 mL). The filtrate was then concentrated under reduced pressure. The 
resultant oil was purified by flash chromatography (10:1 hexanes:EtOAc) to afford 3-[3-
(trimethylsilyl)-2-propyn-1-yl]-2,4-pentanedione (3.3 g, quantitative yield) as a pale 
yellow oil in a 1:1 mixture of keto:enol tautomers. Rf 0.8 (6:1 hexanes:EtOAc); 1H NMR 
(500 MHz, CDCl3): Enol tautomer: δ ppm 16.52 (s; 1H), 3.14 (s; 2H), 2.21 (s; 6H), 0.14 
(s; 9H); Keto tautomer: δ ppm 3.84 (t; J = 7.65 Hz; 1H), 2.71 (d; J = 7.65 Hz; 2H), 2.40 
(s; 6H), 0.13 (s; 9H). 13C NMR (125 MHz, CDCl3): δ ppm 202.4, 190.9, 106.7, 103.8, 
102.6, 87.6, 85.1, 66.7, 29.5, 23.2, 18.9, 18.8, 0.1, 0.01; IR (film): 2960, 2176, 1703, 
1357, 1249 cm-1. HRMS-ESI: (m/z) calculated for C11H17O2Si: 209.1076. found: 
209.0998.  
 
Synthesis of 4-acetyl-3-oxo-7-(trimethylsilyl)-6-heptynoic acid methyl ester.  To 
a flask containing a solution of 3-[3-(trimethylsilyl)-2-propyn-1-yl]-2,4-pentanedione 
(198.0 mg, 0.942 mmol, 1.0 equiv.) in THF (4.71 mL) at -78 oC was added a freshly 
made 1M solution of NaHMDS in THF (2.82 mL, 2.82 mmol, 3.0 equiv.). After stirring 
at -78 oC for 1 hour, dimethylcarbonate (95 mL, 1.03 mmol, 1.1 equiv.) was added. The 
resulting mixture was removed from the cooling bath and warmed until the internal 
temperature of the reaction reached -10 oC. The reaction was then quenched by the 
addition of 1 M HCl (10 mL). The reaction mixture was transferred to a separatory funnel 
containing EtOAc (20 mL). The layers were separated, and the aqueous layer was 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine 
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(30 mL), dried over MgSO4, and concentrated under reduced pressure. The resultant 
yellow oil was purified by flash chromatography (10:1 hexanes:EtOAc) to afford 4-
acetyl-3-oxo-7-(trimethylsilyl)-6-heptynoic acid methyl ester (120.2 mg, 45% yield) as a 
clear oil. Rf 0.28 (6:1 hexanes:EtOAc); 
1H NMR (500 MHz, DMSO-d6): δ ppm 4.21 (t; 
J = 7.25 Hz; 1H), 3.77 (d; J = 16.9 Hz; 1H), 3.70 (d; J = 16.9; 1H), 3.63 (s; 3H), 2.64 (dd; 
Ja = 7.25, Jb = 1.95; 2H), 2.21 (s; 3H), 0.10 (s; 9H); 13C NMR (125 MHz, DMSO-d6): δ 
ppm 202.5, 198.6, 166.9, 104.0, 86.6, 63.45, 52.0, 48.9, 30.0, 18.1, -0.11); IR (film): 
2958, 2177, 1727, 1707, 1626, 1249 cm-1; HRMS-ESI: (m/z) calculated for C13H21O4Si, 
269.1209. found 269.1201.  
 
Synthesis of 4-hydroxy-6-methyl-5-[3-(trimethylsilyl)-2-propyn-1-yl]-2H-pyran-
2-one. To a vial containing a solution of 4-acetyl-3-oxo-7-(trimethylsilyl)-6-heptynoic 
acid methyl ester (126.2 mg, 0.447 mmol, 1.0 equiv.) in benzene (844 mL) was added 
DBU (134 mL, 0.894 mmol, 2.0 equiv.) in one portion. The resulting solution was stirred 
at 60 oC for 3 h. After cooling, the reaction was quenched with saturated aqueous NH4Cl 
(5 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 
50 mL). The combined organic layers were washed with brine (50 mL), dried over 
MgSO4, and concentrated under reduced pressure. The resultant solid was purified by 
flash chromatography (20:1 CH2Cl2:MeOH) to afford 4-hydroxy-6-methyl-5-[3-
(trimethylsilyl)-2-propyn-1-yl]-2H-pyran-2-one (79.8 mg, 76% yield) as a white solid. 
Mp: 184–186 oC; Rf 0.5 (10:1 CH2Cl2:MeOH); 
1H NMR (500 MHz, CDCl3): δ ppm 5.64 
(s; 1H), 3.36 (s; 2H), 2.34 (s; 3H), 0.13 (s; 9H); 13C NMR (125 MHz, CDCl3): δ ppm 
171.2, 167.2, 161.6, 109.4, 102.2, 90.1, 85.5, 17.8, 14.9, 0.12; IR (film): 2958, 2176, 
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1727, 1645, 1608, 1560, 1248 cm-1; HRMS- ESI: (m/z) [M + H]+ calculated for 
C12H17O3Si, 237.0947. found, 237.0955.  
 
Synthesis of 4-hydroxy-6-methyl-5-(2-propyn-1-yl)-2H-pyran-2-one. To a vial 
containing a solution of 4-hydroxy-6-methyl-5-[3-(trimethylsilyl)-2-propyn-1-yl]-2H-
pyran-2-one (16.6 mg, 0.058 mmol, 1.0 equiv) in THF (588 mL) was added a solution of 
TBAF (1.0M in THF, 88 mL, 0.088 mmol, 1.5 equiv). The reaction mixture was stirred at 
23 oC for 14 hours and then transferred to a separatory funnel containing EtOAc (10 mL) 
and 1 M HCl (25 mL). The layers were separated and the resulting aqueous layer was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine 
(40 mL), dried over MgSO4, and concentrated under reduced pressure to afford the crude 
product. The resultant solid was purified by flash chromatography (2:1 EtOAc:hexanes) 
to afford 4-hydroxy-6-methyl-5-(2-propyn-1-yl)-2H-pyran-2-one (9.2 mg, 97% yield) as 
a white solid. Mp: 209–210 oC; Rf 0.25 (100% EtOAc); 1H NMR (500 MHz, acetone-
d6): δ ppm 10.70 (br s; 1H), 5.37 (s; 1H), 3.33 (d; J = 2.60, 2H), 2.42 (t; J = 2.60, 1H), 
2.28 (s; 3H); 13C NMR (125 MHz, acetone-d6): δ ppm 169.5, 163.6, 161.6, 108.1, 90.0, 
81.6, 69.8, 17.5, 13.9; IR (film): 2959, 2924, 1706, 1674, 1561, 1259 cm-1; HRMS-ESI: 
(m/z) calculated for C9H7O3, 163.0395; found, 163.0395.  
 
CazF in vitro activity assays  
CazF was expressed from S. cerevisiae BJ5464-NpgA21 and purified by gravity-
flow column chromatography as previously described.20 The specificity of CazF’s MT 
domain toward its natural SAM cofactor and unnatural analogs was analyzed by 
	   99	  
incubating 5 µM CazF with 2 mM acetoacetyl-SNAC and 5 µM, 10 µM, 25 µM, 50 µM 
and 1 mM of SAM, ProSeAM, or Keto-SAM in 100 mM phosphate buffer pH = 7.4 in a 
total volume of 10 µL for one hour at room temperature. The reaction was quenched by 
adding 90 µL of MeOH and then centrifuged for ten minutes at room temperature. A 10 
µL aliquot was analyzed on a Shimadzu 2010 EV LC-MS with a Phenomenex Luna 5µ 
2.0 x 100 mM C18 column using a linear gradient of 5-95% MeCN/H2O containing 0.1% 
formic acid over 30 minutes with a flow rate of 0.1 mL/min. The corresponding m/z 
peaks for methyl-acetoacetyl-SNAC and propargyl-acetoacetyl-SNAC were integrated 
and the amount of alkylated-SNAC product was quantified using a standard curve. 
Kinetic constants were calculated by fitting initial velocity data at various concentrations 
of SAM or ProSeAM to Michaelis-Menten parameters using nonlinear least squares 
curve fitting in GraphPad Prism.  
To assess whether the KS domain of CazF would perform another round of 
elongation after the attachment of the propargyl group, 25 mM of protein was incubated 
at room temperature with 2 mM malonyl-CoA and 0.2 mM of SAM or ProSeAM in 100 
mM phosphate buffer pH 7.4 in a total volume of 100 mL. After 1 hour, the reaction was 
treated with base to release the polyketide product by adding 20 mL 1M NaOH, 
incubated at 65 oC for 10 minutes, followed by addition of 40 µL 1N HCl. The reaction 
was then extracted two times with 200 mL of 99% ethyl acetate:1% acetic acid and the 
organic layer was dried using a Speedvac. The extract was resuspended in 20 µL MeOH 
and analyzed by LC-MS as mentioned above. The production of the propargyl-α-pyrone 
in the in vitro assay was confirmed using the synthetic standard 4-hydroxy-6-methyl-5-
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(2-propyn-1-yl)-2H-pyran-2-one. The in vitro production of methyl-α-pyrone was 
previously confirmed.20 
 
In vitro biosynthesis of 4’propargyl-chaetoviridin A using CazF and CazE  
In a 100 µL reaction, 25 µM CazF; 25 µM CazE, which was expressed and 
purified as previously described;20 2 mM NADPH; 2 mM malonyl-CoA; and 2 mM 
cazisochromene were incubated with SAM or ProSeAM in 100 mM phosphate buffer pH 
7.4 for one hour at room temperature. Due to the instability of SAM and ProSeAM at 
neutral conditions and at room temperature, 1 mM of SAM and ProSeAM were added at 
the start of the reaction and after 30 minutes. The final concentration of the cofactors was 
2 mM. The reaction was extracted twice with 300 µL ethyl acetate containing 1% acetic 
acid. The organic layer was dried using a Speedvac and resuspended in 20 µL MeOH. 
The extract was analyzed by LC-MS using the same conditions as in the CazF in vitro 
activity assays. The in vitro biosynthesis of chaetoviridin A using SAM as the alkyl 
donor was confirmed previously.20 The structure of 4’-propargyl-chaetoviridin A, which 
was formed using ProSeAM as the alkyl donor, was proposed based on its retention time, 
UV profile and observed m/z isotopic ratio.  
 
Copper-catalyzed azide-alkyne cycloaddition reaction  
The in vitro reaction for the enzymatic synthesis of 4’-propargyl-chaetoviridin A 
was repeated using the same conditions mentioned above. After incubating at room 
temperature for 1 hour, the reaction was extracted twice with 300 µL ethyl acetate 
containing 1% acetic acid and the organic layer was dried using a Speedvac. The crude 
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extract was then resuspended in 50 µL MeOH. Azide-PEG3-
carboxytetramethylrhodamine-modified product was dissolved in DMSO to a final 
concentration of 2.5 mM and the click labeling reaction was carried out using 2 µL of the 
2.5 mM rhodamine-azide according to the manufacturer’s instructions. After a four-hour 
incubation at room temperature, the reaction was extracted twice with 250 µL ethyl-
acetate containing 1% acetic acid and the organic layer was dried using a Speedvac. The 
extract was resuspended in 20 µL MeOH and analyzed by LC-MS using the same 
conditions as mentioned previously in the CazF in vitro activity assay.  
 
4.3 RESULTS AND DISCUSSION 
Kinetics Analysis of CazF MT domain Towards SAM, Keto-SAM and ProSeAM 
 In order to examine the kinetics of the CazF MT domain towards our SAM 
analogues, recombinant CazF was incubated with Acetoacetyl-S-N-acetyl cysteamine 
(acetoacetyl-SNAC) and SAM, ProSeAM or Keto-SAM.  The products were then 
analyzed by LC-MS and kinetic constants were calculated through fitting initial velocity 
at various concentrations of cofactor to the Michaelis-Menten equation.  Interestingly, no 
product could be observed for reactions using Keto-SAM, suggesting that the MT domain 
of CazF was not able to accommodate this analogue (Figure 4.3a). In contrast, the steady-
state kinetic parameters for methyl-acetoacetyl-SNAC and propargyl-acetoacetyl-SNAC 
were calculated as kcat (SAM) = 0.025 min-1 and KM (SAM) = 15.5 µM, and kcat (ProSeAM) = 
0.036 min-1 and KM (ProSeAM) = 43.6 µM, respectively (Figure 4.3b, c). Although the KM 
towards ProSeAM increased by 3-fold, the overall catalytic efficiency towards this 
cofactor was roughly half that of SAM’s (kcat/KM = 8.25x10-4 µM-1 × min-1 for ProSeAM, 
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kcat/KM = 16.1x10-4 µM-1 × min-1 for SAM), which is quite adequate for further study.  
Furthermore, the slow turnover is likely the result of the acetoacetyl-SNAC substrate 
used instead of the endogenous acyl-carrier (ACP) protein-tethered substrate.   
 
Figure 4.3: Steady-State Kinetics Analysis of Acetoacetyl-SNAC Alkylation by CazF and SAM 
Analogues.  (a) CazF compatibility towards Keto-SAM was tested, although no modification could be 
detected. (b) Analysis of CazF activity towards SAM as a cofactor. Kinetic parameters were measured to be 
kcat (SAM) = 0.025 min-1 and KM (SAM) = 15.5 µM. (c) Analysis of CazF activity towards ProSeAM as a 
cofactor mimic. Kinetic parameters were measured to be kcat (ProSeAM) = 0.036 min-1 and KM (ProSeAM) = 43.6 
µM.  
 
Confirmation of Polyketide Chain Growth Following Propargyl Transfer 
 Following confirmation of CazF MT domain compatibility towards ProSeAM, the 
activity of the β-ketoacyl synthase (KS) domain towards the propargylated diketide 
intermediate was examined in order to establish if subsequent cycles of polyketide chain 
growth could still occur.  Previous work had demonstrated that reconstituted CazF could 
produce 4-hydroxy-6-methyl-α-pyrone when incubated with malonyl-CoA, or the 4-
hydroxy-5,6-dimethyl-α-pyrone when incubated with malonyl-CoA and SAM, followed 
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by treatment with base (Figure 4.4a).20 To examine if the KS domain of CazF could 
accommodate the propargyl diketide, it was therefore incubated with malonyl-CoA and 
ProSeAM, followed by treatment with 1M NaOH. Indeed, LC-MS analysis of the organic 
extract following base hydrolysis revealed the formation of 4-hydroxy-5-propargyl-6-
methyl-α-pyrone, which was confirmed by comparison to a synthetic standard (Figure 
4.4b; materials and methods). However, a significantly higher amount of the 4-hydroxy-
6-methyl-α-pyrone product was also observed in reactions containing ProSeAM, which 
suggests that the KS domain was able to outcompete the MT domain in catalyzing chain 
extension without alkylation.  This is likely related to the slower rate of MT-alkylation 
with ProSeAM in comparison to SAM, as 4-hydroxy-5,6-dimethyl-α-pyrone was found 
to be the predominant product in reactions containing SAM as the cofactor (Figure 4.4b). 
 
Figure 4.4: Propargyl Transfer does not Prevent Polyketide Chain Growth. (a) If, following transfer of 
the propargyl group of ProSeAM, the KS domain is capable of undergoing an additional round of chain-
growth; the triketide product can be transformed to a α-pyrone through base hydrolysis. (b) HPLC analysis 
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In Vitro Enzymatic Synthesis of 4’-Propargyl-Chaetoviridin A 
 
Figure 4.5: Analysis of Enzymatically Synthesized Chaetoviridin A and 4’-Propargyl-chaetoviridin A.  
(a) Reconstituted CazF reactions were treated with the CazE acyltransferase and cazisochromene to 
generate Chaetoviridin A or 4’-Propargyl-chaetoviridin A. Reactions contained malonyl-CoA, NADPH, 
cazisochromene, SAM/ProSeAM, CazF, and CazE. (b) HPLC analysis (360 nm) of chaetoviridins 
synthesized in the presence of ProSeAM or SAM as cofactors. Components were identified by MS. (c) 
HPLC analysis (550 nm) of the CuAAC-conjugated 4’-Propargyl-chaetoviridin A. 
 
 
Previously, in vitro reconstitution of CazF supplied with NADPH, SAM and 
malonyl-CoA was able to produce the requisite triketide product prior to transacylation to 
cazisochromene by the CazE acyltransferase, yielding the chaetoviridin A product.20 In 
order to further establish ProSeAM’s compatibility towards the PKS domains of CazF 
and the CazE acyltransferase, the total enzymatic synthesis of 4’-propargyl-chaetoviridin 
A was performed (Figure 4.5a). For this experiment, equimolar CazF and CazE were 
incubated with malonyl-CoA, SAM/ProSeAM, NADPH, and cazisochromene. LC-MS 
analysis of the products of this reaction indeed revealed the formation of 4’-propargyl-
chaetoviridin A based on m/z (Figure 4.5b). Further confirmation of the presence of the 
propargyl group in the final product was established through CuAAC conjugation to an 
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azide-PEG3-5(6)-carboxytetramethylrhodamine. Formation of the conjugated product 
was confirmed by LCMS and exhibited a characteristic UV absorption λmax at 550 nm, 
which is typical of the rhodamine dye (Figure 4.5c). Together, these data indicated that 
the propargyl group of ProSeAM could indeed be incorporated into the growing 
polyketide and propagated through to the final product.  
 
4.4 CONCLUSIONS 
 In an attempt to explore the cofactor compatibility of PKS MT domains towards 
SAM analogues, we examined their activity towards the CazF HR-PKS MT domain for 
the modification of chaetoviridin A.  In vitro experiments using reconstituted CazF 
confirmed that its MT domain was indeed active in the alkylation of growing polyketide 
chain with ProSeAM (Figure 4.3).  Furthermore, additional cycles of chain growth were 
not inhibited by incorporation of the propargyl group of ProSeAM (Figure 4.4).  Lastly, 
incorporation of the propargyl group could be carried through to the production of 4’-
propargyl-chaetoviridin A through the transacylase activity of CazE towards 
cazisochromene (Figure 4.5). These data suggest that the use of SAM analogues may 
provide a strategy for the diversification of natural products. Although ProSeAM’s 
compatibility towards other PKS systems has not yet been explored, independent 
corroboration by the laboratory of Dr. Jon Thorson has indicated that ProSeAM is 
compatible toward the RebM methyltransferase, which is involved in the biosynthesis of 
rebeccamycin.23 Together, these independent reports provide a foundation for the 
potential use of SAM analogues for the modification of natural products, which may 
provide an alternative strategy for altering their pharmacological properties or exploring 
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their mechanism of action.  Furthermore, these results serve to highlight the broad 
applicability of ProSeAM as a SAM mimic for wild-type methyltransferases. 
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CHAPTER 5: EXAMINATION OF SELENIUM-BASED SAM ANALOGUE 




S-Adenosyl-L-methionine (SAM) is a ubiquitous metabolite utilized in a variety 
of biochemical processes, ranging from the biosynthesis of small molecules to the 
methylation of macromolecules such as nucleic acids and proteins.1 Methylation of DNA, 
RNA, and protein has garnered particular attention in recent years due to implicated 
influence over epigenetic and other essential biological phenomena.2-7 Because of this, 
efforts have been made toward the development of SAM analogues as tools for the study 
of targets and functions of various methyltransferases.8-14 These analogues have generally 
contained specific chemical groups, such as ketones, azides, and terminal alkynes, which 
are compatible with bioorthogonal chemistry and permit the conjugation of a fluorescent 
or affinity-based probe to the labeled substrate for target characterization.  
Amongst the previously reported SAM analogues, a selenium-based Se-adenosyl-
L-selenomethionine (SeAM; Chapter 3) analogue, ProSeAM, has demonstrated potential 
as a chemical reporter of wild-type methyltransferases.12, 13 This SAM mimic is featured 
by its selenonium moiety, which is equivalent to the sulfonium of other SAM analogues.  
In the case of ProSeAM, replacement of the sulfonium group with a selenonium was 
shown to be essential for the suppression of undesired degradation of the propargylic 
chemical handle to a ketone byproduct, as is discussed in chapters 3.  This turned out to 
be critical for the application of ProSeAM as a chemical reporter for various 
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methyltransferases, as the sulfur-based version of this compound was later shown to have 
an extremely short half-life (<2 minutes) at physiologically relevant pH.15-17 
 
 
Figure 5.1: Panel of Selenium- and Sulfur-Based Analogues used in this Study. Selenium and sulfur 
versions of SAM analogues containing the R-groups listed above were synthesized and purified as 
described in chapter 6. Following spectral characterization, these analogues were tested for their 
compatibility towards wild-type and engineered PMTs in order to assess the effect of selenium substitution.  
 
 
Given the apparent success associated with the development of ProSeAM, we 
next focused our efforts to expand the cofactor repertoire of chemical reporters for SAM-
dependent methyltransferases using a similar approach.  As such, we examined the effect 
of substituting selenium into SAM analogues that had otherwise been observed to be 
unreactive towards engineered methyltransferases.  Previous reports had shown that 
bulky S-alkyl SAM analogues lacking sulfonium-β-sp1/sp2-hybridized carbons in their R-
groups are typically inert as cofactor surrogates.8, 11, 18 The proposed rationale for this 
inactivity stems from the notion that conjugative stabilization by β-sp1- or β-sp2-carbons 
in active SAM analogues facilitates the enzyme-catalyzed SN2 transition state.19 However, 
because Se-alkyl SeAM analogues are expected to have weaker carbon-chalcogen bonds 
than their sulfur-based counterparts,20 it was hypothesized that selenium substitution in 
otherwise unreactive β-sp3-hybridized SAM analogues would result in their activation.  If 
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this hypothesis were to prove true, we predicted that it would enable access to a much 
wider variety of β-sp3-hybridized analogues for the study of methyltransferases.  
Additionally, we predicted that selenium substitution may improve the activity of certain 
β-sp1/sp2-hybridized SAM analogues that otherwise have previously only demonstrated 
modest compatibility towards certain enzymes, such as the Enyne-SAM analogue 
(chapter 2).  
In order to test this hypothesis, our efforts utilized the GLP1 Y1211A and G9a 
1154A PKMT mutants described previously (as well as several protein arginine 
methyltransferase [PRMT] mutants reported by other members of the Luo laboratory to 
accommodate bulky SAM analogues)21, 22 in combination with a panel of chemically 
synthesized selenium-based SAM analogues (Figure 5.1). Furthermore, to facilitate the 
development of cofactor libraries of SeAM analogues, we also optimized and scaled up 
the synthesis of their chemical precursor, Se-adenosyl-L-methionine, which is described 
in Chapter 6. Through comparison of SeAM analogues with their equivalent sulfur-based 
counterparts, we herein demonstrate that selenium substitution can enhance the 
compatibility of some cofactors towards specific methyltransferases, favoring otherwise 
less reactive SAM analogues.23   
 
5.2 MATERIALS AND METHODS 
General Methods and Materials 
Chemical synthesis of cofactor analogues is detailed in chapter 6, or has been 
reported previously.18, 23 Chemical reagents were purchased from Aldrich Chemical or 
Acros Organics and used without additional purification.  Histone H3 (aa 1-21) 
	   111	  
(ARTKQTARKSTGGKAPRKQLAGGK) and RGG-biotin (GGRGGFGGRGGFGGRG-
GFGGGK-[Biotin]) peptides were obtained from the Proteomics Resource Center of the 
Rockefeller University and purified by HPLC. MALDI-MS analysis was performed on a 
Voyager-DE STR (Applied Biosystems, Framingham, MA, USA) MALDI-TOF mass 
spectrometer as described previously.  In order to analyze peptide samples, 1 µL of 
reaction mixture was added to 1 µL of a saturated α-cyano-hyrdoxycinnamic acid 
(Protease Biosciences) on a MALDI plate and allowed to dry at ambient temperature (22 
oC). Mass spectra were gathered using delayed extraction in a positive ion mode. 
Desorption was obtained using a 337-nm nitrogen laser with a 3 ns pulse width. 
 
Protein Expression and Purification 
All enzymes were expressed and purified according to previously described 
procedures (chapters 2 and 3).18, 21, 22 Wild-type PRMT3 and PRMT3 M233G were 
generous gifts from Han Guo. Wild-type PRMT1 and PRMT1 Y39FM48G were 
provided as gifts from Dr. Rui Wang.  
 
MALDI-MS Analysis of Methyltransferase-Catalyzed Reactions 
For the assays of wild-type G9a, G9a Y1154A, wild-type GLP1, and GLP1 
Y1211A, 1 µM enzyme and 25 µM H3K9 (aa 1-21) peptide were used. For the assays of 
wild-type PRMT1 and PRMT1 Y39FM48G, 2 µM enzyme and 20 µM RGG-Biotin 
peptide were used. For the assays of wild-type PRMT3 and PRMT3 M233G, 1 µM 
enzyme and 25 µM RGG-biotin peptide were used. The concentration of cofactor 
analogue was 100 µM for all samples. All reactions (10 µL) were carried out in 50 mM 
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Tris HCl (pH = 8.0) for 2 hours at ambient temperature (22 oC). Reactions were quenched 
by the addition of 1 µL H2O containing 10% TFA and processed with C18 ZipTip® 
(Millipore) pipette tips according to manufacturer’s instructions prior to MALDI-MS 
analysis as described above.  Degrees of transalkylation (roughly equivalent to units of 
cofactor consumed) per unit peptide for each analogue were quantified by MALDI-MS 
according to the following formula: 
 
where I represents peak intensities for unmodified (alk0), mono-(alk1), di-(alk2), and 
trialkylated (alk3) products peptides, etc.  Relative transalkylation activities for sulfur and 
selenium analogues with equivalent R-groups were then compared and categorized for 
each examined enzyme. These data are summarized in Table 5.1. 
 
5.3 RESULTS AND DISCUSSION 
Compatibility of Cofactor Analogues Towards Wild-Type and Mutant PMTs 
In order to examine chalcogen-alkyl SAM or SeAM analogues as potential 
cofactor surrogates for PMTs, we selected a panel of wild-type and engineered PMTs 
(wild-type and Y39FM48G PRMT1, wild-type and M233G PRMT3, wild-type and 
Y1154A G9a, wild-type and Y1211A GLP1), which have previously been shown to be 
active toward either native SAM or β-sp1/sp2-carbon-activated SAM analogues as 
cofactors.11, 21, 22 Enzymatic reactions with known peptide substrates were analyzed by 
MALDI-MS in order to assess the relative degrees of transalkylation with the various 
cofactor analogues. These results were then evaluated based on the difference of the 
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efficiency of transalkylation between S-alkyl SAM analogues and their Se-alkyl SeAM 
counterparts (Table 5.1). 
 
Table 5.1: Summary of relative efficiency of transalkylation with SAM analogues versus equivalent 
SeAM analogues. Degree of transalkylation was defined as the equivalents of alkylation (or cofactor 
consumption) per unit peptide substrate according to relative peak intensity of MALDI-MS spectra 
(materials and methods). For instance, if 50% peptide is converted into a mono-alkylated product, the 
degree of the transalkylation will be “0.5”; if all the peptide is converted into a di-alkylated product, the 
degree of the transalkylation will be “2.0”. The relative efficiency between of SeAM and their equivalent 
SAM analogues as cofactors were categorized as “=” for 0~0.1 change of the degree of alkylation; “+” or 
“–” for increase or decrease of 0.1 ~ 0.5 degree of transalkylation, respectively; “+ +” or “–” for increase or 
decrease of >0.5 degree of transalkylation, respectively; NR for no reaction observed for SeAM or SAM 
analogues. These values are shown in parentheses as (S- analogue, Se-analogue). WT G9a, WT GLP1, WT 




Although the bulky, β-sp3-carbon-containing Hexyne-SAM analogue was 
completely inert as a cofactor of the examined PMTs, its equivalent SeAM analogue 
demonstrated activity toward the PRMT3 M233G mutant (Figure 5.2).  Despite modest 
transalkylation efficiency, this reaction was enzyme-dependent, as no modification was 
detected in the presence of native enzyme or in a no-enzyme control. Similarly, the 
Enyne-SAM analogue was only modestly active toward G9a Y1154A and GLP1 Y1211A 
mutants, while the equivalent Enyne-SeAM was shown to be at least 4-fold more reactive 
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under the same conditions (0−20% for the former versus 50−80% conversion for the 
latter; Figure 5.3a). These observations argue that the weaker selenium-carbon bond in 
Se-alkyl SeAM analogues has a positive effect on accelerating transalkylation reactions 
for a subset of PMTs. 
 
Figure 5.2: Examination of Enzyme Compatibility of Hexyne-SAM and -SeAM.  MALDI-MS analysis 
revealed modest activity of the Hexyne-SeAM cofactor towards the PRMT3 M233G mutant. No 
modification of peptide substrate could be observed with the sulfur-based version of the compound or in 
WT or no-enzyme controls. 
 
It was also noted that the effect of selenium substitution to facilitate PMT-
catalyzed transalkylation was context-dependent. For instance, while the Enyne-SeAM 
analogue is more reactive than the Enyne-SAM analogue as a cofactor for G9a Y1154A 
and GLP1 Y1211A mutants, such an effect was not observed for the PRMT3 M233G 
mutant and was even reversed for the PRMT1 Y39FM48G mutant (Figure 5.3b; Table 
5.1). Similarly, SeAM only showed higher reactivity than SAM as a cofactor for wild-
type and G9a Y1154A, wild-type and GLP1 Y1211A, and the PRMT1 Y39FM48G 
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mutant, but not for wild-type PRMT1, wild-type and M233G PRMT3 (Figures 5.4a). In 
addition, the sulfonium-to-selenonium substitution in the Allyl-SAM analogue showed no 
effect on their cofactor reactivity for G9a Y1154A, GLP1 Y1211A, PRMT1 Y39FM48G, 
and PRMT3 M233G mutants (Figure 5.4b).  
 
Figure 5.3: Comparison of Enyne-SAM and -SeAM Compatibility Towards G9a Y1154A and 
PRMT3 M233G Mutants.  (a) In the case of the G9a Y1154A mutant, selenium-substitution appeared to 
activate the Enyne-SeAM cofactor towards enzyme-mediated transalkylation.  Under identical conditions, 
treatment with Enyne-SeAM resulted in 4-fold increased modification of known peptide substrate in 
comparison to its sulfur-based counterpart.  (b) The same effect was not observed for the PRMT3 M233G 
mutant, which displayed roughly equivalent activity between the Enyne-SAM and -SeAM.  
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Figure 5.4: Cofactor Activation by Selenium-Substitution is Context Dependent. (a) SeAM 
demonstrated higher reactivity towards mutant PKMT G9a Y1154A than SAM. (b) In contrast, the Allyl-
SeAM analogue demonstrated no difference in reactivity towards PKMTs including WT G9a. (c) 




Lastly, sulfonium-to-selenonium substitution in Hey-SAM also did not affect its 
cofactor activity toward G9a Y1154A and GLP1 Y1211A variants and even had a 
negative effect on PRMT1 Y39FM48G and PRMT3M233G variants (Figure 5.4c; Table 
5.1). Furthermore, Propyl- and Pentyne-SAM and -SeAM analogues were inert toward all 
PMTs examined (Table 5.1).  According to these data, we observed the general trend that 
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for less reactive SAM derivatives such as Hexyne- and Enyne-SAM analogues, which 
contain a β-sp3-carbon and a rigid bulky alkyl chain, respectively, the replacement of 
sulfonium with selenonium can boost their reactivity as cofactors for certain PMTs. 




 Through examination of a variety of Se-alkyl SeAM analogues and comparison to 
their equivalent S-alkyl SAM analogues, we observed context-dependent reactivity as 
cofactor surrogates for PMTs.  In the case of protein lysine methyltransferases (PKMTs), 
selenium substitution was able to boost the reactivity of otherwise less reactive SAM 
analogues, such as Enyne-SAM. Although the β-unsaturated functionality remained 
essential for cofactor activity of S-alkyl SAM analogues, this functionality appeared to be 
dispensable for certain protein arginine methyltransferases (PRMTs) when Se-alkyl SAM 
analogues are used, as was observed for Hexyne-SeAM and PRMT3 M233G. These 
observations illustrate a complementary role for the weaker selenium-carbon bonds in 
facilitating the SN2 transition state, and the potential application of Se-alkyl SeAM 
analogues as chemical reporters for other methyltransferases.  Although the reported rates 
of the spontaneous cleavage of the chalcogen-carbon bonds can increase by 10-fold from 
SAM to SeAM,24 the efficiency of the PMT-catalyzed transalkylation reactions increases 
by no more than 3-5 fold from S-alkyl SAM analogues to their equivalent Se-alkyl SeAM 
analogues. Such a discrepancy suggests that PMTs also leverage other mechanisms to 
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control the overall catalysis, a process that is currently being explored biochemically in 
our lab through the use of selenium-based and isotopically labeled SAM analogues. 
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CHAPTER 6: SYNTHESIS AND CHARACTERIZATION 
OF CHEMICAL REAGENTS 
 
6.1 INTRODUCTION 
The foundation for much of the work presented in in this dissertation has rested 
heavily upon the chemical synthesis of SAM analogues and related compounds.  
Throughout the course of this research, significant progress was made both in the 
development of new SAM analogues for BPPM technology, as well as the improvement 
of existing methods for the synthesis of selenium-based cofactors.1-4 Furthermore, 
collaborative research projects have prompted synthesis of a variety of other materials, 
including isotopically labeled SAH, cysteine, and L-selenomethionine analogues. 
Although not discussed in previous chapters due to these projects being in very 
preliminary stages, the synthesis of these materials will also be described in this chapter.  
Given its importance in the research herein, synthetic information regarding the 
production of all materials presented throughout this dissertation has been consolidated 
into this chapter. For ease of reference, this chapter’s methods and results section is 
arranged into subheadings according to topics presented previous chapters (i.e. synthesis 
of SAM analogues discussed in chapter 2 will be presented first, followed by selenium-
based analogues and other synthetic materials). Complete spectra for compounds 
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6.2 APPROACH 
Development of SAM Analogues for BPPM 
 Although many of the SAM analogues presented in chapters 2 and 5 had been 
previously reported,5, 6 several presented herein were synthesized and characterized for 
the first time.1, 3, 4 These included the Pentene-SAM, Hep-SAM and azide-containing Ab-
SAM cofactor analogues (Figure 6.1) used in the development and application of BPPM 
technology towards the G9a and GLP1 lysine methyltransferases. Conveniently, 
synthesis of Pentene- and Hep-SAM analogues made use of well-established conditions 
for the alkylation of S-adenosyl-L-methionine in acidic solvent with commercially 
available starting materials.6 The preparation of Ab-SAM, however, first required the 
synthesis of (E)-1-azido-4-bromobut-2-ene, which was obtained through the treatment of 
(E)-1,4-dibromobut-2-ene with sodium azide in a mixture of THF and water (Figure 
6.1).3 Subsequent coupling to SAH and purification by HPLC then yielded the desired 
material for spectral characterization. 
 
Figure 6.1: Synthesis of Previously Unreported SAM Analogues. Hep-SAM and Pentene-SAM were 
synthesized from commercially available materials.  Ab-SAM was synthesized from SAH and (E)-1-azido-
4-bromobut-2-ene, which was generated from (E)-1,4-dibromobutene. 
 
Synthesis of Selenium-Based SAM Analogues 
 Although much of our preliminary research with ProSeAM relied upon a 
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and poorly suited for synthesis of libraries of SeAM analogues at larger scales.  This 
proved to be a significant limitation, especially when examining larger panels of 
selenium-based analogues (chapter 5).  Given this, we set out to develop a convenient 
protection-free strategy to access these materials easily and efficiently.1  
SAM is generated in vivo by S-adenosylmethionine synthetase, which utilizes L-
methionine and ATP as substrates (Figure 6.2).8 Inspired by the biosynthesis of SAM, our 
synthetic strategy also relied upon comparable natural building blocks: L-methionine and 
adenosine, which can be converted into selenohomocystine and 5’-iodo-5’-
deoxyadenosine, respectively.  Subsequent conjugation of these materials would then 
result in the synthesis of Se-adenosyl-L-homocysteine (SeAH), which is the last 
converged precursor in the synthesis of the various Se-alkyl SeAM analogues examined 
in this work. 
 
Figure 6.2: Biosynthesis of SAM and Retrosynthesis of SAM, SeAM and their Chalcogen-Alkyl 
Analogues. 
 
In greater detail, L-methionine was first treated with iodomethane to generate S-
methyl-L-methionine, which then underwent intramolecular displacement to form 
homoserine lactone.9-11 Hydrolysis of this intermediate yielded α-amino-4-hydroxy-
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Treatment of α-amino-4-hydroxybutanoic acid with hydrogen bromide in acetic acid 
yielded α-amino-4-bromobutanoic acid with a yield of 62%.10 This was then treated with 
Na2Se2, generated in situ from selenium powder and NaBH4, to give the key building 
block selenohomocystine in 84% yield.12 Selenohomocystine was readily purified by 
solid-phase extraction with acid-activated Dowex 50WX4 resin. The three-step synthesis 
is featured by its multigram scales, good yields from readily available materials, and 
facile purification (precipitation or solid-phase extraction; Figure 6.3). 
 
Figure 6.3: Chemical Synthesis of SeAH with Yields and Purification Methods Highlighted for Key 
Intermediates. MeI, iodomethane; PPh3, triphenylphosphine.  
 
Another key building block in the synthesis of SeAM analogues is 5’-iodo-5’-
deoxyadenosine, which was readily prepared from adenosine via Appel reaction at gram-
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scale (Figure 6.3).13 SeAH, the last converged precursor in our synthesis of Se-alkyl 
SeAM analogues (Figure 6.2, 6.3), was generated through NaBH4-mediated reduction of 
selenohomocystine to the selenide anion, followed by subsequent coupling with 5’-iodo-
5’-deoxyadenosine with a yield of 58%. Here, a convenient solid-phase extraction 
protocol with Amberlite XAD4 resin was used to purify both 5’-iodo-5’-deoxyadenosine 
and SeAH.14 Although previous syntheses used 5’-chloro-5’-deoxyadenosine15 or 2’,3’-
O-isopropylidene-5’-O-p-toluenesulfonyladenosine7 in similar coupling reactions, we 
found that 5’-iodo-5’-deoxyadenosine can be readily prepared and gave a more robust 
yield under these conditions. We further noted that the efficiency of the last coupling 
reaction would drop significantly if not performed under inert atmosphere, likely due to 
oxidation of the selenide anion and the resultant reformation of the diselenide. 
Collectively, this approach allowed access to SeAH through a protection-free, gram-scale 
synthesis with desired yields and convenient purification.  
Although SeAH is readily subjected to alkylation to generate SeAM and Se-alkyl 
SeAM analogues, their weaker carbon-chalcogen bonds makes these compounds more 
susceptible to decomposition through intramolecular lactonization.16 Thus, more care was 
taken during the purification and storage of these compounds than their sulfonium 
counterparts. We therefore freshly synthesized SeAM and a set of Se-alkyl SeAM 
analogues (Figure 6.4) in milligram scale and examined their reactivity as cofactor 
surrogates for native and engineered methyltransferases (chapter 5). For comparison, the 
equivalent sulfonium-based SAM analogues (Figure 6.4) were also prepared from S-
adenosyl-L-homocysteine (SAH). Here, SeAH and SAH were treated with various alkyl 
halides in the presence of silver perchlorate (or mesolate for Enyne-SAM/Enyne-SeAM) 
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in a 1:1 acetic/formic acid mixture to give the desired products (Table 6.1).5, 17, 18 These 
SAM and SeAM analogues contained either β-sp2or β-sp3 carbons for the purpose of 
comparing their roles on the transition-state stabilization of PMT-catalyzed SN2 
transalkylation reactions (Chapter 5).  
 
 
Figure 6.4: Synthesis of a Panel of SAM and SeAM Analogues. SAM and SeAM analogues were 
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Synthesis of Isotopically Labeled Materials and Selenomethionine Analogues 
 In addition to SAM and SeAM analogues, several other compounds were 
synthesized for various purposes. These compounds included a selenium-based 
methionine analogue (ProSeMet; Figure 6.5a) for use in the in vivo biosynthesis of 
ProSeAM through the action of SAM synthetase, as well as a number of non-radioactive 
34S-labeled amino acids and SAM analogues.  The latter were designed and synthesized 
as part of collaborative efforts with the laboratories of Drs. Steven Gross and Vern 
Schramm (as well as for a former member of the Luo lab: Dr. Joshua Linscott) for use in 
metabolomics and kinetic isotope effect experiments. 
 The synthesis of the selenium-based ProSeMet analogue was initiated from L-
selenohomocystine, which had previously been prepared for use in the synthesis of SeAH 
(see above; Figure 6.5a).1 This transformation was easily carried out in one step through 
NaBH4-mediated reduction of L-selenohomocystine followed by alkylation of the 
selenide anion with propargyl bromide.  Following purification by HPLC, this compound 
could be isolated in reasonable yield (48%) and high purity.  Subsequent work by Dr. Rui 
Wang went on to demonstrate compatibility of this analogue toward wild-type and 
mutant SAM synthetase (unpublished data).  In addition, application of ProSeMet for the 
in situ generation of ProSeAM and enzyme-coupled alkylation of rebeccamycin was 
independently corroborated by the lab of Dr. Jon Thorson.19 
 Incorporation of 34S into labeled compounds was carried out according to 
previously reported methods.20-22 The desired compounds synthesized included: 34S-
methionine, 34S-cysteine and 34S-SAH (Figure 6.5b, c).  For the one pot synthesis of 34S-
methionine, elemental sulfur-34 was first treated with methyl lithium prior to addition of 
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α-amino-4-bromobutanoic acid in order to generate the desired material.20 To generate 
34S-SAH, 34S-methionine was subsequently subjected to Na/NH4(l) reduction conditions 
to generate 34S-homocystine, which was then conjugated to 5′-iodo-5′-deoxyadenosine 
following NaBH4 reduction.21 Lastly, 34S-cysteine was synthesized in a similar fashion to 
that of 34S-methionine, in which elemental sulfur 34 was first treated with 
benzylmagnesium chloride prior to addition of α-amino-3-chloropropanoic acid.22 The 
resultant 34S-benzyl-cysteine was then subjected to Na/NH4(l) reduction conditions to 
afford 34S-cysteine, which was purified by HPLC and characterized by 1H NMR.   
 
Figure 6.5:  Synthesis of 34S and Selenium-Based Amino Acid Analogues. (a) Preparation of ProSeMet 
relies upon alkylation of selenohomocysteine following NaBH4 reduction. (b) 34S-Methionine is derived 
from elemental sulfur-34 treated with methyllithium (MeLi) and α-amino-4-bromo-butanoic acid.  34S-
Methionine may then be converted to 34S-SAH following reductive cleavage by Na(s)/NH3(l). I-Ado, 5’-
iodo-5’-deoxyadenosine. 
 
6.3 SYNTHETIC METHODS AND RESULTS 
GENERAL MATERIALS AND METHODS 
 All chemical reagents were purchased from Aldrich Chemical or Acros Organics 
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acetonitrile was obtained from Fisher Scientific and degassed under vacuum prior to 
HPLC purification. All reactions for the preparation of SAM and SeAM analogues were 
carried out in capped vials (4 mL) stirred with Teflon®-coated magnetic stir bars. 
Reaction solvents were removed by a Büchi rotary evaporator equipped with a dry ice-
acetone condenser. Preparative HPLC purification of SAM and SeAM analogues was 
carried out using a Waters 6000 Controller HPLC/2998 diode array detector with an 
XBridgeTM Prep C18 5 µm OBDTM
 
19x150 mm reverse phase column with UV detection 
at 260 nm. For preparative HPLC purification of SAM analogues, linear gradients of H2O 
containing 0.1% TFA (solvent A) and acetonitrile containing 0.1% TFA (solvent B) were 
used at a flow rate of 10 mL/min (0–70% solvent B in 20 min, then 100% solvent A for 4 
min). Preparative HLPC purification of 34S-labeled amino acids and ProSeMet used 
linear gradients of H2O containing 0.1% TFA (solvent A) and acetonitrile containing 
0.1% TFA (solvent B) were used at a flow rate of 10 mL/min (0–70% solvent B in 11 
min, then 100% solvent A for 4 min). Lyophilization and concentration of aqueous 





Nuclear magnetic resonance and mass spectral data were collected at MSKCC 
Analytical Core Facility. Nuclear magnetic resonance spectra were recorded on Bruker 
UltraShieldTM Plus 500 or 600 MHz instruments. NMR samples were performed in D2O, 
except in the case of SeAH, SAM, and SeAM analogues, which were performed in D2O 
containing 0.1% deuterated trifluoacetic acid to suppress their decomposition. High-
resolution mass spectrometry (HRMS) was conducted using a Waters Acuity SQD LC-
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MS with electrospray ionization (ESI). The concentrations of SAM analogues were 
determined by UV absorption with ε260 = 15400 L mol
-1 cm-1. 
 
SYNTHESIS OF SAM ANALOGUES FOR BPPM 
Synthesis of Pentene-SAM:  Into a solution of S-adenosyl-L-homocysteine (15 
mg, 0.039 mmol) in formic and acetic acids (1:1, 1 mL) was added (E)-1-bromopent-2-
ene (288 mg, 1.95 mmol) and AgClO4 (8 mg, 0.039 mmol) and stirred at ambient 
temperature (22 oC). After 4 hours, an additional batch of AgClO4 and the bromide was 
added to drive the reaction to completion. The reaction was then quenched by distilled 
water containing 0.01% TFA (v/v). The aqueous phase was washed three times with 
diethyl ether (3×15 mL) and then passed through Nalgene 0.2 µM syringe filter. Pentene-
SAM was then purified with preparative reversed-phase HPLC as described above. 
Diastereomeric mixture of the analogue was collected, concentrated and then lyophilized 
overnight. The resultant product (55% yield) was redissolved in water containing 0.01% 
TFA (v/v) and stored at -80 oC before use. 1H-NMR (600 MHz, D2O): δ 8.35 (s, 1H), 
8.34 (s, 0.5H), 8.33 (s, 0.5H), 6.08-6.03 (m, 1.5H), 5.94-5.89 (m, 0.5H), 5.37 (q, 0.5H, J 
= 7.56 Hz), 5.25 (q, 0.5H, J = 7.56 Hz), 4.55 (t, 0.5H, J = 6.18 Hz), 4.51 (t, 0.5H, J = 5.82 
Hz), 4.43-4.40 (m, 1H), 4.0 (d, 1H, J = 7.56 Hz), 3.96 (d, 1H, J = 7.56 Hz), 3.85-3.80 (m, 
1H), 3.77-3.65 (m, 2H), 3.44-3.38 (m, 1H), 3.36-3.28 (m, 1H), 2.02 (q, 1H, J = 7.02 Hz), 
1.93 (q, 1H, J = 6.6 Hz), 0.86 (t, 1.5H, J = 7.44 Hz), 0.78 (t, 1.5H, J = 7.44 Hz). 13C-
NMR (150 MHz, D2O): δ 171.20, 171.14, 150.02, 148.70, 148.66, 147.94, 
147.92,144.54, 144.48, 143.45, 143.41, 117.22, 115.28, 113.35, 112.11, 111.81, 90.02, 
89.99, 78.61, 78.46, 73.0, 72.8, 72.6, 51.81, 51.76, 42.93, 42.23, 40.76, 40.40, 35.20, 
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34.93, 25.23, 25.15, 25.12, 25.03, 20.3, 11.96, 11.83. Total 38 peaks for two 
diastereomers. ESI-MS (m/z): 453.2[M]+, 351.9 [5’-((E)-pent-2-enyl)thio-5’-
deoxyadenosine+H]+, 250.2 [5’-deoxyadenosine]+, 135.8 [adenosine+H]+. HRMS: 
Calculated for C19H29N6O5S: 453.1920; obtained: 453.1913.  
 
Synthesis of Hep-SAM:  Into a solution of S-adenosyl-L-homocystine (15 mg, 
0.039 mmol) in formic and acetic acids (1:1, 1 mL) was added (E)-7-bromohept-5-en-1-
yne (335 mg, 1.95 mmol) and AgClO4 (8 mg, 0.039 mmol) and stirred at ambient 
temperature (22 oC). After 4 hours, an additional batch of AgClO4 and (E)-7-bromohept-
5-en-1-yne was added to drive the reactions to completion. The reaction was then 
quenched by distilled water containing 0.01% TFA (v/v). The aqueous phase was washed 
three times with diethyl ether (3×15 mL) and then passed through Nalgene 0.2 µM 
syringe filter. Hep-SAM was then purified with preparative reversed-phase HPLC as 
described above. Diastereomeric mixture of the SAM analogue was collected, 
concentrated and lyophilized overnight. The resultant product (40% yield) was re-
dissolved in water containing 0.01% TFA (v/v) and stored at -80 oC before use. 1H-NMR 
(600 MHz, D2O): δ 8.37 (s, 0.5H), 8.35 (s, 1H), 8.34 (s, 0.5H), 6.06 (dd, 1H, J = 3.18, 
8.22 Hz), 6.04-6.0 (m, 0.5H), 5.85-5.81 (m, 0.5H), 5.49 (q, 0.5H, J = 7.56 Hz), 5.32 (q, 
0.5H, J = 7.56 Hz), 4.58 (t, 0.5H, J = 6.54 Hz), 4.55 (t, 0.5H, J = 6.12 Hz), 4.44-4.41 (m, 
1H), 4.03 (d, 1H, J = 7.62 Hz), 3.99 (d, 1H, J = 7.92 Hz), 3.81-3.64 (m, 3H), 3.46-3.39 
(m, 1H), 3.35-3.30 (m, 1H), 2.25-2.21 (m, 5H), 2.12-2.09 (m, 2H). 13C-NMR (150 MHz, 
D2O): δ 171.85, 171.75, 150.32, 150.24, 147.97, 147.95, 145.01, 144.84, 144.34, 144.26, 
143.47, 143.38, 117.23, 115.29, 115.0, 114.67, 113.36, 90.08, 90.06, 84.93, 84.77, 78.69, 
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78.34, 72.99, 72.94, 72.66, 70.06, 70.04, 52.32, 52.29, 42.10, 41.34, 40.64, 40.24, 35.23, 
35.02, 30.65, 30.59, 25.30, 25.12, 16.94, 16.76. Total 42 peaks for two diastereomers. 
HRMS: Calculated for C21H29N6O5S: 477.1920; obtained: 477.1903.  
 
Synthesis of (E)-1-azido-4-bromobut-2-ene: (E)-1,4-dibromobut-2-ene (2 g, 9.34 
mmol) was placed in a round-bottom flask and dissolved in THF (10 mL). Sodium azide 
(800 mg, 12.2 mmol) was dissolved in 1 mL water and added to the solution of (E)-1,4-
dibromobut-2-ene. Reaction was stirred overnight at room temperature. Reaction was 
diluted with diethyl ether (100 mL) and successively washed with water (15 mL) and 
saturated NaCl solution (15 mL). The organic layer was dried over anhydrous Na2SO4 
and evaporated under reduced pressure. Crude products were purified by silica gel 
column chromatography using petroleum ether-dichloromethane solvent system affording 
800 mg of (E)- 1-azido-4-bromobut-2-ene (4.6 mmol, 49%) as a colorless liquid. 1H-
NMR (500 MHz, CDCl3): δ 6.03-5.97 (m, 1H), 5.85-5.79 (m, 1H), 3.97 (d, 2H, J=7.45 
Hz), 3.81 (d, 2H, J=5.85 Hz). 13C-NMR (125 MHz, CDCl3): 130.9, 128.1, 51.6, 30.9.  
 
Synthesis of 4-azidobut-2-enyl-SAM (Ab-SAM): S-Adenosyl-L-homocysteine 
(12 mg, 0.031 mmol) was placed in a capped 4 mL glass vial and dissolved into a freshly 
prepared mixture of formic and acetic acids (1:1, 1 mL) and placed in an ice bath. To this 
acidic solution was added (E)-1-azido-4-bromobut-2-ene (269 mg, 1.55 mmol) and 
AgClO4 (5.4 mg, 0.031 mmol). After the mixture was stirred for 5 min, the ice bath was 
removed, and the reaction was allowed to warm to ambient temperature (22 °C). After 5 
hours, the addition of (E)-1-azido-4-bromobut-2-ene (269 mg, 1.55 mmol) and AgClO4 
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(5.4 mg, 0.031 mmol) was repeated to drive the reaction to completion. The resultant 
reaction mixture was quenched by adding 20 mL of distilled water containing 0.01% 
TFA (v/v). The aqueous phase was washed three times with diethyl ether (3 × 15 mL) 
and passed through a Nalgene 0.2 µm syringe filter. Ab-SAM was purified with 
preparative reversed-phase HPLC as described above. Because the stereochemistry at 
sulfonium center could not be assigned unambiguously, a diastereomeric mixture of Ab-
SAM was collected. The mixture was then concentrated by SpeedVac for 2 hours, 
followed by lyophilization overnight. The dried product was then redissolved in water 
containing 0.01% TFA (v/v) and stored at -80 °C before use. The compound was isolated 
in ∼40% yield. 1H NMR (600 MHz, D2O): δ 8.41 (s, 0.5H), 8.39 (s, 1H), 8.38 (s, 0.5H), 
6.1 (t, 1H, J = 3.4 Hz), 6.09−6.06 (m, 0.5H), 5.96−5.91 (m, 0.5H), 5.79− 5.73 (m, 0.5H), 
5.67−5.62 (m, 0.5H), 4.76 (q, 1H, J = 5.22 Hz), 4.6 (t, 0.5H, J = 6.54 Hz), 4.58 (t, 0.5H, J 
= 5.7 Hz), 4.5−4.47 (m, 1H), 4.15 (d, 1H, J = 7.56 Hz), 4.11 (d, 1H, J = 7.56 Hz), 
3.88−3.8 (m, 5H), 3.56−3.38 (m, 2H), 2.3−2.28 (m, 2H). 13C NMR (150 MHz, D2O): δ 
171.59, 171.49, 163.06, 162.83, 150.15, 148, 144.78, 144.72, 143.5, 143.46, 138.23, 
138.06, 119.37, 119.3, 117.92, 117.4, 117.28, 115.35, 90.1, 78.67, 78.41, 73.05 (2C), 
72.88, 72.66, 52.11, 52.08, 51.2, 51.15, 42.03, 41.2, 40.81, 35.84, 35.55, 25.3, 25.16. 
ESI-MS (m/z): 480.1[M]+, 379.09 [5’-(4-azidobut-2-en-1-ynyl)thio-5’-deoxyadeno- 
sine+H]+, 250.2 [5′-deoxyadenosine]+. HRMS: calculated for C18H26N9O5S, 480.1778; 
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SYNTHESIS OF SELENIUM-BASED SAM ANALOGUES 
Synthesis of α-amino-4-hydroxybutanoic acid: L-Methionine (15.0 g, 100 mmol) 
was suspended in a mixture of 140 mL distilled deionized H2O and 200 mL methanol.  
Iodomethane (15 mL, 240 mmol) was then added and the resultant mixture was stirred 
vigorously for 48 hours at ambient temperature (22 oC). Bulk solvent was then removed 
by rotary evaporation to yield a white solid. The reaction product was dissolved in 100 
mL H2O. After adding sodium bicarbonate (8.4 g, 100 mmol), the solution was brought to 
100 oC with reflux for 24 hours. After cooling the reaction mixture to ambient 
temperature (22 oC), the solvent was removed by rotary evaporation, affording the crude 
product as golden oil. This crude product was dissolved in 10 mL H2O and 25 mL 
acetone. Ethanol (200 mL) was then slowly added while stirring the mixture, resulting in 
the precipitation of α-amino-4-hydroxybutanoic acid as a white solid. This product was 
then filtered and dried under high vacuum overnight to give 8.8 g product (74.0 mmol, 
74 % yield). 1H-NMR (600 MHz, D2O): δ ppm 1.87-2.06 (m; 2H; Hβ), 3.62- 3.69 (m; 
2H; Hγ), 3.73 (dd; 1H; Ja = 7.56 Hz, Jb = 4.8 Hz; Hα). 13C- NMR (150 MHz, D2O): δ 
ppm 174.38, 58.57, 53.31, 32.06. 
 
Synthesis of α-amino-4-bromobutanoic acid hydrobromide: In a 75 mL glass 
high-pressure reaction vessel, α-amino-4-hydroxybutanoic acid (5.1 g, 42.9 mmol) was 
suspended in 25 mL hydrobromic acid (33 wt.% in acetic acid). The reaction vessel was 
sealed and heated to 80 oC for 5 hours, and then allowed to cool down overnight to 
ambient temperature (22 oC). The reaction mixture was isolated by vacuum filtration and 
washed with 75 mL diethyl ether. The final product α-amino-4-bromobutanoic acid 
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hydrobromide was obtained by vacuum filtration and dried under high vacuum (7.1 g, 
26.8 mmol, 62 % yield). 1H-NMR (600 MHz, D2O): δ ppm 2.26-2.48 (m; 2H; Hβ), 3.47-
3.56 (m; 2H; Hγ), 4.09 (t; 1H; J = 6.66 Hz; Hα). 13C- NMR (150 MHz, D2O): δ ppm 
173.06, 68.64, 49.83, 29.32. 
 
Synthesis of selenohomocystine: In a 250 mL round bottom flask, 200-mesh 
selenium powder (3.6 g, 46.0 mmol) was suspended in 70 mL ethanol (200 proof). After 
adding sodium borohydride (1.74 g, 46.0 mmol), the mixture was heated to reflux at 80 
oC for 2 hours (the solution became dark maroon in color). Into the reaction vessel was 
added α-amino-4-bromobutanoic acid hydrobromide (6.0 g, 23.0 mmol), resulting in a 
rapid formation of an opaque yellow mixture. The reaction was allowed to proceed under 
reflux at 80 oC overnight and then quenched with 10 mL 2 M HCl. After removing bulk 
solvent by rotary evaporation, the resulting residue was mixed with 25 mL 5% HCl. This 
aqueous solution was then washed three times with 75 mL diethyl ether and subjected to 
vacuum filtration to remove insoluble materials. A yellow solid was obtained after 
removal of aqueous solvent by rotary evaporation. This semi-crude product was then 
dissolved in 15 mL 1 M HCl and purified over Dowex® 50WX8 ion exchange resin 
according to manufacturer’s specifications. In brief, activated resin (5.0 cm x 2.5 cm) was 
washed with 100 mL H2O, followed by the loading of semi-crude product. The resin was 
then washed with an additional 100 mL H2O to remove unbound impurities. Product was 
eluted from the resin using a 5% ammonium hydroxide solution. Fractions containing the 
desired product (bright yellow solution) were combined. After removing bulk solvent by 
rotary evaporation, the resulting yellow solid was placed under high vacuum overnight to 
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afford 3.4 g selenohomocystine 6 (9.5 mmol, 84% yield). 1H-NMR (600 MHz, D2O + 
0.1% TFA-d): δ ppm 2.21-2.34 (m; 2H; Hβ), 2.87-2.92 (m; 2H; Hγ), 3.98 (t; 1H; J = 
6.30 Hz; Hα). 13C- NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 172.25, 52.97, 31.39, 
22.60. HRMS: Calculated for C8H17N2O4Se2: 364.9519; obtained: 364.9518. 
 
Synthesis of 5’-Iodo-5’-deoxyadenosine (I-Ado): Adenosine (10 g, 37.4 mmol) 
was suspended in 25 mL pyridine in a 100 mL round-bottom flask. Triphenylphosphine 
(15 g, 57.2 mmol) was added to the reaction vessel and stirred vigorously. Iodine (15 g, 
59.1 mmol) was then slowly added to the mixture, which rapidly became brown in color. 
The vessel was protected from light and the reaction was allowed to proceed for 18 hours 
at ambient temperature (22 oC). Saturated sodium thiosulfate solution (3 mL) was then 
added to the reaction vessel and allowed to mix for 30 min in order to quench the reaction. 
Bulk solvent was removed by rotary evaporation. The residue was dissolved in 50 mL 
H2O and washed with 75 mL chloroform three times. The aqueous phase was collected 
and the solvent was removed by rotary evaporation. The resulting off-white solid was 
stored at -20 oC as a crude product prior to further purification using Amberlite® XAD4 
resin.  In brief, the crude product was dissolved in 100 mL 0.5 M NaOH and loaded onto 
a 3 x 29 cm column of Amberlite XAD4 resin prewashed with 200 mL H2O. The column 
was then washed with 200 mL 0.2 M ammonium acetate buffer (pH = 5.0) followed by 
300 mL H2O. The desired product was eluted from the resin with 350 mL methanol. 
After removing the solvent by rotary evaporation followed by high vacuum overnight, 5’-
iodo-5’-deoxyadenosine 7 (5.7 g, 15.0 mmol) was obtained with a yield of 40%. 1H-
NMR (600 MHz, D2O): δ ppm 3.46 (ddd; 2H; Ja = 27.54 Hz, Jb = 11.22 Hz, Jc = 4.98 
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Hz; H5’), 4.03 (dt; 1H; Ja = 4.98Hz, Jb = 4.92 Hz; H4’), 4.27 (dd; 1H; Ja = 5.10 Hz, Jb = 
5.04 Hz; H3’), 4.77 (dd; 1H; Ja = 5.28 Hz, Jb = 5.28 Hz; H2’), 5.99 (d; 1H; J = 5.1 Hz; 
H1’), 8.13 (s; 1H; arom. H), 8.28 (s; 1H; arom. H). 13C-NMR (150 MHz, D2O): δ ppm 
155.63, 152.91, 148.96, 140.09, 118.72, 87.26, 82.93, 73.20, 73.11, 5.90. HRMS: 
Calculated for C10H13N5O3I: 378.0063; obtained: 378.0063. 
 
Synthesis of Se-adenosylselenohomocysteine (SeAH): Selenohomocystine (1.4 g, 
3.9 mmol) and sodium borohydride (1.47 g, 38.6 mmol) were suspended in 60 mL 
anhydrous ethanol in a 100 mL round-bottom flask. The mixture was stirred vigorously 
for 15 min under a steady flow of argon (the mixture became opaque white in color). 5’-
Iodo-5’-deoxyadenosine (3.5 g, 9.3 mmol) was then added, the reaction vessel purged, 
and the reaction was allowed to proceed under argon overnight. After removal of bulk 
solvent by rotary evaporation, the residue was dissolved in 30 mL dilute HCl. The 
aqueous phase was washed three times with 50 mL diethyl ether, collected and dried by 
rotary evaporation to afford an off-white solid. This crude product was subject to further 
purification using Amberlite® XAD4 resin. In brief, the crude product was dissolved in 
100 mL 0.5 M NaOH and then loaded onto a 3 x 29 cm column of Amberlite® XAD4 
resin prewashed with 200 mL H2O. The column was washed with 200 mL 0.2 M am- 
monium acetate buffer (pH = 5.0) followed by 300 mL H2O. The desired product was 
eluted from the resin with 200 mL 1:1 H2O:methanol. Fractions (25 mL each) were 
collected and analyzed by LCMS. Fractions containing the desired material were 
combined. Removal of solvent by rotary evaporation and the subsequent high vacuum 
overnight afforded Se-adenosylselenohomocysteine with 58% yield (1.94 g, 4.49 mmol). 
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1H-NMR (600 MHz, D2O + 0.1% TFA-d): δ ppm 2.05- 2.20 (m; 2H; Hβ), 2.60 (t; 2H; J 
= 7.86 Hz; Hγ), 2.95 (ddd; 2H; Ja = 28.86 Hz, Jb = 13.38 Hz, Jc = 5.22 Hz; H5’), 3.92 (t; 
1H; J = 6.42 Hz; Hα), 4.26 (dt; 1H; Ja = 6.78 Hz, Jb = 5.1 Hz; H4’), 4.32 (dd; 1H; Ja = 
5.07 Hz, Jb = 5.04 Hz; H3’), 4.77 (dd; 1H; Ja = 5.07 Hz, Jb = 5.04 Hz; H2’), 6.03 (d; 1H; J 
= 4.86 Hz; H1’), 8.33 (s; 1H; arom. H), 8.41 (s; 1H; arom. H). 13C-NMR (150 MHz, 
D2O + 0.1% TFA-d): δ ppm 171.36, 149.18, 147.50, 143.73, 142.05, 118.11, 87.50, 
83.30, 72.79, 72.07, 52.26, 30.01, 24.52, 17.90. HRMS: Calculated for C14H21N6O5Se: 
433.0739; obtained: 433.0743. 
 
Synthesis of ProSeAM: SeAH (15 mg, 34.8 µmol) was dissolved into a mixture 
of 1:1 formic acid and acetic acid (1 mL) and cooled on ice. Propargyl bromide (50 equiv, 
80% v/v in toluene) was then slowly added. After addition AgClO4 (5.4 mg, 34.8 µmol) 
in 0.5 mL of 1:1 formic and acetic acid mixture, the reaction was continued at ambient 
temperature (22 °C) for another 8 hours then quenched with 5 mL of distilled water 
containing 0.1% TFA (v/v). The aqueous phase was washed three times with diethyl 
ether, centrifuged to remove precipitate, and then passed through a Nalgene 0.2 µM 
syringe filter. ProSeAM was purified by preparative reversed-phase HPLC as described 
in the general methods.  Collected fractions were then concentrated by lyophilization and 
redissolved in water containing 0.1% TFA.  Stock solutions were stored at -80 oC before 
use. The overall yield for this reaction was 15%. 1H NMR for ProSeAM (500 MHz, 
D2O + 0.1% TFA-d): δ = 2.34 (m, 2H), 3.15 (s, 1H), 3.52 (m, 2H), 3.86 (m, 1H), 3.9 
(ddd, 2H; Ja =34.3 Hz, Jb = 12.8 Hz, Jc = 3.2 Hz), 4.14 (m, 2H), 4.49 (m, 1H), 4.56 (t, 1H, 
J = 6.13 Hz), 4.75 (m, 1H), 6.09 (d, 1H, J = 3.85 Hz), 8.37− 8.40 (m, 2H, arom.). ESI-
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MS for ProSeAM (m/z): 471.11 [M]+, 369.99 [5’-(propargyl)-selenoadenosine + H]+, 
249.91 [5′-deoxyadenosine]+, 135.73 [adenine + H]+. HRMS: 471.0871 calculated and 
471.0880 observed for C17H24N6O5Se.  
 
Synthesis and purification of SAM and SeAM analogues: A list of activated 
electrophiles used for the synthesis of SAM and SeAM analogues is presented in Table 
6.1. These electrophiles were either purchased directly from Sigma-Aldrich and used 
without further purification or freshly prepared in house (Table 6.1).1 Briefly, SAH (20 
mg, 51,9 µmol) or SeAH (20 mg, 46.3 µmol) was dissolved in 500 µL 1:1 formic acid 
and acetic acid. Respective electrophiles (Table 6.1, 50 equivalents) and AgClO4 (1 
equivalent dissolved in 250 µL 1:1 formic:acetic acid) were then added to the reaction 
mixture. Reactions were allowed to proceed for 8 hours at ambient temperature (22 oC) 
and then quenched by addition of 3 mL distilled water containing 0.1% TFA. The 
aqueous phases were washed with diethyl ether (3x10 mL). Trace organic solvent in the 
crude sample was removed by rotary evaporation. After passing the sample through a 
Nalgene 0.22 µM syringe filter, the crude product was then purified by preparative 
reversed-phase HPLC as described in General Methods. Desired products were collected, 
lyophilized, dissolved in a small volume of 0.1% TFA and stored at -80 oC. 
Concentrations of SAM and SeAM analogues were determined by their UV absorption as 
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Table 6.1: Electrophiles used in the Preparation of SAM and SeAM Analogues 
 
 
S-Adenosyl-L-methionine (SAM): Purification by HPLC (retention time = 6.0 
min) afforded SAM as a mixture of sulfonium-R,S-epimers with a yield of 50%. 1H-
NMR (600 MHz, D2O + 0.1% TFA-d): δ ppm 2.29-2.41 (m, 2H, Hβ), 2.96/2.93 (s, 3H, 
4:1 S-epimers, 1’’), 3.42-3.68 (m; 2H; Hγ), 3.87-4.00 (m; 3H; H5’, Hα), 4.50- 4.53 (m; 
1H; H4’), 4.57 (dd; 1H; Ja = 5.88 Hz, Jb = 5.73 Hz; H3’), 4.79 (solvent overlap; H2’), 
6.12 (d; 1H; J = 3.90 Hz; H1’), 8.40 (s; 1H; arom. H), 8.41 (s; 1H; arom. H). 13C-NMR 
(150 MHz, D2O + 0.1% TFA-d): δ ppm 170.90, 149.96, 147.94, 144.41, 143.41, 119.32, 
90.00, 78.42, 73.05, 72.60, 51.58, 44.22, 38.48, 24.81, 23.45. HRMS: Calculated for 




Allyl bromide Br Sigma-Aldrich
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Propyl-SAM: Purification by HPLC (retention time = 7.8 min) afforded Propyl-
SAM as a mixture of sulfonium-R,S-epimers as reported previously.6 1H-NMR (600 
MHz, D2O + 0.1% TFA-d): δ ppm 0.84/0.87 (t; 3H; 1:1 epimers; J = 7.32 Hz; H3”), 
1.64-1.74 (m; 2H; H2”), 2.23-2.32 (m; 2H; Hβ), 3.29.3.31 (t; 2H; 1:1 Se-epimers; H1”), 
3.39-3.57 (m; 2H; Hγ), 3.83-3.86 (m; 2H; H5’), 3.88-3.90 (m; 1H; Hα), 4.43- 4.46 (m; 
1H; H4’), 4.50-4.52 (m; 1H; H3’), 4.72-4.77 (m; 1H; solvent overlap; H2’), 6.07 (m; 1H; 
H1’), 8.35 (s; 2H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA- d): δ ppm 171.00, 
149.98, 147.95, 144.47, 143.39, 119.28, 89.99, 78.49, 73.01, 72.71, 51.67, 42.58, 41.84, 
36.26, 25.08, 17.37, 11.79. HRMS: Calculated for C17H27N6O5S: 427.1764; obtained: 
427.1758. 
 
Allyl-SAM: Purification by HPLC yielded Allyl-SAM (retention time = 7.5 min) 
as a mixture of sulfonium-R,S-epimers as reported previously.6 1H-NMR (600 MHz, 
D2O + 0.1% TFA-d): δ ppm 2.18-2.29 (m; 2H; Hβ), 3.31-3.48 (m; 2H; Hγ), 3.75- 3.79 
(m; 2H; H5’), 3.81-3.88 (m; 1H; Hα), 4.00-4.04 (m; 2H; H1”), 4.39-4.43 (m; 1H; H4’), 
4.47-4.50 (m; 1H; H3’), 4.69 (m; 1H; solvent overlap; H2’), 5.52 (d; 1H; J = 17 Hz; 
H3’’), 5.57 (d; 1H; J = 10 Hz; H3’’), 5.74 (ddt; 1H; J = 17 Hz, J = 10 Hz, J = 7.5 Hz; 
H2”), 6.02-6.03 (m; 1H, H1’), 8.30 (s; 2H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% 
TFA-d): δ ppm 170.90, 149.97, 147.93, 144.41, 143.46, 128.83, 122.31, 119.33, 90.03, 
78.58, 73.03, 72.66, 51.53, 42.48, 40.88, 35.25, 25.04. HRMS: Calculated for 
C17H25N6O5S: 425.1607; obtained: 425.1592.  
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Pentyne-SAM: Purification by HPLC (retention time = 8.1 min) afforded 
Pentyne-SAM as sulfonium-S-epimer with a yield of 25%. 1H-NMR (600 MHz, D2O + 
0.1% TFA-d): δ ppm 1.76-1.87 (m; 2H; H3”), 2.08-2.18 (m; 4H; H5”; H2”), 2.21-2.34 
(m; 2H; Hβ), 3.37 (t; 2H; 7.80 Hz; H1”), 3.39-3.51 (m; 2H; Hγ), 3.84-3.89 (m; 3H; H5’; 
Hα), 4.42-4.45 (m; 1H; H4’), 4.49-4.53 (m; 1H; H3’), 4.69-4.76 (m; 1H; solvent overlap; 
H2’), 6.03-6.04 (m; 1H; H1’), 8.34 (m; 2H; arom. H).  13C-NMR (150 MHz, D2O + 
0.1% TFA-d): δ ppm 170.96, 149.99, 147.93, 144.51, 143.54, 119.38, 90.10, 82.0, 78.86, 
72.92, 72.60, 70.94, 51.63, 41.95, 39.98, 36.53, 25.03, 22.43, 16.35. HRMS: Calculated 
for C19H27N6O5S: 451.1764; obtained: 451.1743. 
 
Enyne-SAM: Purification by HPLC (retention time = 8.1 min) afforded Enyne-
SAM as a mixture of sulfonium-R,S-epimers with a yield of 30%.  1H-NMR (600 MHz, 
D2O + 0.1% TFA-d): δ ppm 2.21-2.35 (m; 2H; Hβ), 3.35/3.4 (d; 1H; 40:60 epimers; J = 
2.2 Hz; H5”), 3.37-3.54 (m; 2H; Hγ), 3.71-3.83 (m; 2H; H5’), 3.89- 3.97 (m; 1H; Hα), 
4.07/4.12 (d; 2H; 40:60 epimers; J = 7.7 Hz; H1”), 4.38-4.44 (m; 1H; H4’), 4.53-5.62 (m; 
1H; H3’), 4.67 (m; 1H; solvent overlap; H2’), 5.60/5.80 (dd; 1H; 40:60 epimers; Ja = 15.8 
Hz, Jb = 1.6 Hz; H3”), 5.94/6.04 (dt; 1H; 40:60 epimers; Ja = 15.8 Hz, Jb = 7.8 Hz; H2”), 
6.04 (d; 1H; J = 6.04 Hz; H1’), 8.32-8.34 (m; 2H; arom. H). 13C-NMR (150 MHz, D2O + 
0.1% TFA-d): δ ppm 169.81, 149.12, 147.05, 143.64, 142.99, 127.87, 120.36, 118.65, 
89.68, 81.64, 78.18, 77.70, 72.21, 71.90, 50.49, 41.77, 40.35, 34.93, 24.20. HRMS: 
Calculated for C19H25N6O5S: 449.1607; obtained: 449.1598. 
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Hexyne-SAM: Purification by HPLC (retention time = 9.5 min) afforded Hexyne-
SAM as a mixture of sulfonium-R,S-epimers with a yield of 35%. 1H-NMR (600 MHz, 
D2O + 0.1% TFA-d): δ ppm 1.33-1.46 (m; 2H; H3”), 1.68-1.79 (m; 2H; H2”), 1.96/2.03 
(dt; 2H; 40:60 epimers; Ja = 6.84 Hz, Jb = 2.5 Hz; H4”), 2.17/2.20 (t; 1H; 40:60 epimers; 
J = 2.5 Hz; H6”), 2.24-2.39 (m; 2H; Hβ), 3.31-3.38 (m; 2H H1”), 3.43-3.60 (m; 2H; Hγ), 
3.84-3.87 (m; 2H; H5’), 3.94-4.00 (m; 1H; Hα), 4.43- 4.46 (m; 1H; H4’), 4.50-4.54 (m; 
1H; H3’), 4.72-4.77 (dd; 1H; Ja = 5.46 Hz, Jb = 4.02 Hz; solvent overlap; H2’), 6.06 (d; 
1H; J = 3.36 Hz; H1’), 8.36 (m; 2H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA-
d): δ ppm 170.44, 149.94, 147.92, 144.48, 143.47, 119.26, 90.00, 84.20, 78.24, 72.91, 
72.61, 69.85, 51.22, 41.54, 40.49, 36.18, 25.94, 24.91, 22.56, 16.76. HRMS: Calculated 
for C20H29N6O5S: 465.1920; obtained: 465.1919. 
 
Hey-SAM: Purification by HPLC (retention time = 9.5 min) afforded Hey-SAM 
as a mixture of sulfonium-R,S-epimers with a yield of 35%. 1H-NMR (600 MHz, D2O + 
0.1% TFA-d): δ ppm 2.21-2.33 (m; 2H; Hβ), 2.40/2.44 (t; 1H; J = 2.58 Hz; 30:70 
isomers; H6”), 2.89/2.97 (m; 2H; 30:70 isomers; H4”), 3.32-3.50 (m; 2H; Hγ), 3.69-3.91 
(m; 3H; H5’; Hα), 4.04-4.08 (m; 2H; H1”), 4.43-4.46 (m; 1H; H4’), 4.51-4.53 (m; 1H; 
H3’), 4.72-4.74 (m; 1H; solvent overlap; H2’), 5.62/5.72 (dt; 1H; Ja = 15.3 Hz, Jb = 7.7 
Hz; 30:70 isomers; H2”), 5.86/6.01 (dt; 1H; Ja = 15.3 Hz, Jb = 5.1 Hz; 30:70 isomers; 
H3”), 6.05-6.06 (m; 1H; H1’), 8.34-8.36 (m; 2H; arom. H). 13C-NMR (150 MHz, D2O + 
0.1% TFA-d): δ ppm 170.88, 149.98, 147.89, 144.50, 143.50, 139.15, 119.33 115.64, 
90.08, 80.51, 78.59, 73.00, 72.62, 72.29, 51.60, 42.32, 41.07, 35.46, 25.06, 21.00. 
HRMS: Calculated for C20H27N6O5S: 463.1764; obtained: 463.1745. 
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Se-Adenosyl-L-methionine (SeAM): Purification by HPLC (retention time = 6.0 
min) afforded SeAM as a mixture of sulfonium-R,S-epimers with a yield of 24%. 1H-
NMR (600 MHz, D2O + 0.1% TFA-d): δ ppm 2.22-2.31 (m; 2H; Hβ), 2.72/2.69 (s; 3H; 
45:55 Se-epimers; H1’’), 3.28-3.50 (m; 2H; Hγ), 3.74-3.90 (m; 3H; H5’; Hα), 4.41-4.45 
(m; 1H; H4’), 4.48-4.49 (m; 1H; H3’), 4.72 (solvent overlap; H2’), 6.05 (d; 1H; J = 3.84 
Hz; H1’), 8.34 (s; 2H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 
171.00, 149.96, 147.93, 144.41, 143.38, 119.29, 89.85, 79.05, 73.24, 72.95, 52.17, 41.31, 
35.44, 25.51, 19.44. HRMS: Calculated for C15H23N6O5Se: 447.0895; obtained: 
447.0898. 
 
Propyl-SeAM: Purification by HPLC (retention time = 7.8 min) afforded Propyl-
SeAM as a mixture of sulfonium-R,S-epimers with a yield of 25%. 1H-NMR (600 MHz, 
D2O + 0.1% TFA-d): δ ppm 0.79/0.85 (t; 3H; 55: 45 epimers; J = 7.32 Hz; H3”), 1.62-
1.73 (m; 2H; H2”), 2.22-2.34 (m; 2H; Hβ), 3.24-3.47 (m; 4H; H1”; Hγ), 3.74- 3.81 (m; 
2H; H5’), 3.84-3.94 (m; 1H; Hα), 4.41-4.44 (m; 1H; H4’), 4.47-4.49 (m; 1H; H3’), 4.72-
4.77 (m; 1H; solvent overlap; H2’), 6.04-6.05 (m; 1H; H1’), 8.34- 8.35 (m; 2H; arom. H). 
13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 170.68, 149.94, 147.92, 144.45, 
143.43, 119.24, 89.86, 79.07, 73.34, 73.01, 52.01, 41.91, 39.98, 33.84, 25.78, 18.34, 
12.73. HRMS: Calculated for C17H27N6O5Se: 475.1208; obtained: 475.1199. 
 
Allyl-SeAM: Purification by HPLC (retention time = 7.5 min) afforded Allyl-
SeAM as a mixture of sulfonium-R,S-epimers with a yield of 23%. 1H-NMR (600 MHz, 
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D2O + 0.1% TFA-d): δ ppm 2.21-2.33 (m; 2H; Hβ), 3.23-3.37 (m; 2H; Hγ), 3.67- 3.76 
(m; 2H; H5’), 3.81-3.89 (m; 1H; Hα), 3.96-4.0 (m; 2H; H1”), 4.40-4.43 (m; 1H; H4’), 
4.47-4.51 (m; 1H; H3’), 4.73 (m; 1H; solvent overlap; H2’), 5.45 (d; 1H; J = 17 Hz; 
H3’’), 5.49 (d; 1H; J = 10 Hz; H3’’), 5.79 (ddt; 1H; Ja = 17 Hz, Jb = 10 Hz, Jc = 8 Hz; 
H2”), 6.04 (d; 1H, J = 3.66 Hz; H1’), 8.34 (s; 2H; arom. H). 13C-NMR (150 MHz, D2O + 
0.1% TFA-d): δ ppm 170.86, 149.95, 147.95, 144.44, 143.44, 127.63, 124.42, 119.26, 
89.94, 79.04, 73.38, 72.97, 52.19, 41.17, 39.63, 33.42, 25.70. HRMS: Calculated for 
C17H25N6O5Se: 473.1052; obtained: 473.1068. 
 
Pentyne-SeAM: Purification by HPLC (retention time = 8.2 min) afforded 
Pentyne-SeAM as a mixture of sulfonium-R,S-epimers with a yield of 12%.  1H-NMR 
(600 MHz, D2O + 0.1% TFA-d): δ ppm 1.79-1.87 (m; 2H; 3”), 2.09-2.17 (m; 3H; H5”; 
H2”), 2.22-2.34 (m; 2H; Hβ), 3.33-3.52 (m; 4H; H1”; Hγ), 3.79-3.9 (m; 3H; H5’; Hα), 
4.43-4.46 (m; 1H; H4’), 4.50-4.54 (m; 1H; H3’), 4.72-4.78 (m; 1H; H2’), 6.05- 6.06 (m; 
1H; H1’), 8.37 (s; 2H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA- d): δ ppm 
170.65, 149.96, 147.91, 144.49, 143.59, 119.31, 90.00, 84.43, 78.88, 73.08, 72.89, 71.11, 
51.96, 40.15, 39.03, 34.07, 25.74, 23.39, 17.14. HRMS: Calculated for C19H27N6O5Se: 
499.1208; obtained: 499.1204. 
 
Enyne-SeAM: Purification by HPLC (retention time = 8.2 min) afforded Enyne-
SeAM as a mixture of sulfonium-R,S-epimers with a yield of 34%. 1H-NMR (600 MHz, 
D2O + 0.1% TFA-d): δ ppm 2.26-2.32 (m; 2H; Hβ), 3.28-3.48 (m; 2H; Hγ), 3.36/3.40 
(d; 1H; 30:70 epimers; J = 2.3 Hz; H5”), 3.73-3.87 (m; 3H; H5’; Hα), 4.02/4.06 (d; 2H; 
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30:70 epimers; J = 8.0 Hz; H1”), 4.40-4.44 (m; 1H; H4’), 4.52- 4.59 (m; 1H; H3’), 4.68-
4.72 (m; 1H; solvent overlap; H2’), 5.64/5.79 (dd; 1H; 30:70 epimers; Ja = 1.9 Hz, Jb = 
15.8 Hz; H3”), 5.99-6.14 (m; 1H; H2”), 6.05 (d; 1H; J = 3.6 Hz; H1’), 8.36-8.37 (m; 2H; 
arom. H.). 13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 170.65, 149.96, 147.86, 
143.66, 142.84, 131.08, 119.83, 119.36, 90.10, 82.00, 78.90, 77.95, 72.89, 72.84, 51.92, 
40.84, 39.89, 33.58, 24.71. HRMS: Calculated for C15H25N6O5Se: 497.1052; obtained: 
497.1034.  
 
Hexyne-SeAM: Purification by HPLC (retention time = 9.4 min) afforded 
Hexyne-SeAM as sulfonium-S-epimer with a yield of 16%. 1H-NMR (600 MHz, D2O + 
0.1% TFA-d): δ ppm 1.39 (p; 2H; J = 7.32 Hz; H3”), 1.77 (dp; 2H; Ja = 7.5 Hz, Jb = 3.18 
Hz; H2”), 1.99 (dt; 2H; Ja = 6.96 Hz, Jb = 2.58 Hz; H4”), 2.25 (t; 1H; J = 2.58 Hz; H6”), 
2.35-2.39 (m; 2H; Hβ), 3.34 (t; 2H; J = 8.0 Hz; H1”), 3.45-3.55 (m; 2H; Hγ), 3.80-3.89 
(m; 2H; H5’), 3.98 (t; 1H; J = 6.84 Hz; Hα), 4.49-4.52 (m; 1H; H4’), 4.54-4.57 (m; 1H; 
H3’), 4.85 (dd; 1H; Ja = 5.46 Hz, Jb = 4.77 Hz; H2’), 6.12 (d; 1H; J = 4.02 Hz; H1’), 
8.41-8.45 (2H, arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 171.03, 
150.00, 147.99, 144.61, 143.44, 119.23, 89.59, 84.14, 79.23, 73.15, 73.08, 69.75, 52.17, 
40.23, 39.01, 34.15, 26.78, 25.71, 23.8, 16.63. HRMS: Calculated for C20H29N6O5Se: 
513.1365; obtained: 513.1356. 
 
Hey-SeAM: Purification by HPLC (retention time = 9.4 min) yielded Hey-SAM 
as sulfonium-S-epimer with a yield of 23%. 1H-NMR (600 MHz, D2O + 0.1% TFA-d): 
δ ppm 2.24-2.31 (m; 2H; Hβ), 2.43 (t; 1H; J = 2.64 Hz; H6”), 2.94-2.95 (m; 2H; H4”), 
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3.23-3.37 (m; 2H; Hγ), 3.65-3.76 (m; 2H; H5’), 3.83 (dd; 1H; Ja = 7.62 Hz, Jb = 5.46 Hz; 
Hα), 4.02 (d; 2H; J = 7.92 Hz; H1”), 4.40-4.43 (m; 1H; H4’), 4.50 (dd; 1H; Ja =6.06Hz, Jb 
=3.36Hz;H3’), 4.68 (dd;1H; Ja = 5.58Hz, Jb =3.48 Hz; solvent overlap; H2’), 5.76 (dt; 
1H; Ja = 15.24 Hz, Jb = 8.04 Hz; H3”), 5.96 (dt; 1H; Ja = 15.24 Hz, Jb = 5.22 Hz; H2”), 
6.04 (d; 1H; J = 3.66 Hz; H1’), 8.35 (s; 1H; arom. H), 8.36 (s; 1H, arom. H). 13C-NMR 
(150 MHz, D2O + 0.1% TFA-d): δ ppm 171.00, 149.98, 147.90, 144.46, 143.47, 137.94, 
119.32, 117.89, 90.02, 80.75, 78.98, 73.33, 72.92, 72.14, 52.22, 40.71, 39.46, 33.36, 
25.76,20.92. HRMS: Calculated for C20H27N6O5Se: 511.1208; obtained: 511.1199. 
 
SYNTHESIS OF 34S-LABELED AND SELENOMETHIONINE ANALOGUES 
 Synthesis of α-amino-4-(propargylselanyl)butanoic acid (ProSeMet): 
Selenohomocystine (300 mg, 0.83 mmol) and sodium borohydride (62.3 mg, 1.65 mmol) 
were suspended in 20 mL anhydrous ethanol. The mixture was stirred vigorously for 15 
min under a steady flow of argon (the mixture became opaque white in color). Propargyl 
bromide solution (175 µL, 1.65 mmol) was then added and the reaction was allowed to 
proceed under argon overnight. After removal of bulk solvent by rotary evaporation, the 
residue was dissolved in dilute HCl. The aqueous phase was washed three times with 
diethyl ether, collected and dried by rotary evaporation to afford.  Subsequent preparative 
HPLC purification of the desired compound was performed as described in general 
methods resulting in 174 mg of ProSeMet (48% yield). 1H-NMR (500 MHz, D2O): δ 
ppm 2.22-2.30 (m; 2H;), 2.6 (s; 1H), 2.82 (t; 2H), 3.25 (s; 2H), 3.98 (t; 1H). ESI-MS 
(m/z): 221.76 [M]+, 181.69 [selenohomocysteine]+. 
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Synthesis of 34S-methionine: Elemental sulfur-34 (50 mg, 1.56 mmol) was 
suspended in 7 mL dry THF under argon. To this suspension was added 9.25 mL 
methyllithium solution (1.6 M in diethyl ether) and the reaction allowed to proceed.  
After 10 minutes, α-amino-4-bromobutanoic acid hydrobromide (380 mg, 1.44 mmol) 
dissolved in 6 mL dry ethanol was slowly added to the reaction vessel.  This addition was 
accompanied by the release of a significant amount of gas from the reaction solution. 
Following addition, the vessel was brought to reflex at 60 oC for 2 hours, after which time 
the reaction mixture had become opaque orange in color.  After removal of bulk solvent 
by rotovap, the residue was dissolved in dilute HCl and washed three times with diethyl 
ether prior to purification by prep HPLC as described in the general methods.  The 
calculated yield based on sulfur-34, was 89% (210 mg). 1H-NMR (500 MHz, D2O): δ 
ppm 2.05 (s; 3H), 2.11-2.21 (m; 2H;), 2.61 (t; 2H), 4.05 (t; 1H). ESI-MS (m/z): 151.76 
[M]+, 134.71, 105.73. 
  
Synthesis of 34S-homocystine: 34S-methionine (100 mg, 0.66 mmol) in a dry 
round bottom flask was placed in a -78 oC dry ice/acetone bath.  NH4(l) (~10 mL) was 
condensed in the reaction vessel prior to addition of  ~30 mg sodium metal (~2 
equivalents).  The solution immediately developed a deep blue color, which was 
maintained for 1 hour. The reaction was then quenched through the addition of a minimal 
NH4Cl.  The vessel was then brought to room temperature and left open to air to allow 
NH4 to evaporate.  Residual NH4 was then removed on high vacuum and the residue 
dissolved in water containing 0.1% TFA.  This crude material was then purified by 
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preparative HPLC  (42 mg; 47% yield) and characterized by LCMS prior to use in the 
synthesis of 34S-SAH. ESI-MS (m/z): 272.85 [M]+, 137.69. 
 
Synthesis of 34S-adenosyl-L-methionine (34S-SAH): 34S-homocystine (42 mg, 
0.15 mmol) sodium borohydride (29 mg, 0.75 mmol) were suspended in 10 mL 
anhydrous ethanol. The mixture was stirred vigorously for 30 min under a steady flow of 
argon. 5’-Iodo-5’-deoxyadenosine (174 mg, 0.46 mmol) was then added, the reaction 
vessel purged, and the reaction was allowed to proceed under argon overnight. After 
removal of bulk solvent by rotary evaporation, the residue was dissolved in dilute HCl. 
The aqueous phase was washed three times with diethyl ether prior to purification by 
preparative HPLC as described in the general methods. 1H-NMR (600 MHz, D2O + 
0.1% TFA-d): δ ppm 2.01- 2.15 (m; 2H; Hβ), 2.63 (t; 2H; J = 7.4 Hz; Hγ), 2.95 (m; 2H; 
H5’), 4.04 (t; 1H; J = 6.4 Hz; Hα), 4.22 (m; 1H; H4’), 4.32 (t; 1H; J = 5.16 Hz; H3’), 4.74 
(m; 1H; H2’; solvent overlap), 6.02 (d; 1H; J = 4.8 Hz; H1’), 8.32 (s; 1H; arom. H), 8.40 
(s; 1H; arom. H). 13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 171.57, 149.9, 
148.26, 144.23, 142.84, 118.73, 88.40, 83.58, 72.99, 72.24, 51.54, 33.24, 29.52, 27.21. 
ESI-MS (m/z): 386.86 [M]+, 251.78, 135.61. 
 
Synthesis of 34S-benzylcysteine: Elemental sulfur-34 (50 mg, 1.56 mmol) was 
placed in a dry conical flask flushed with argon. 1.5 mL benzylmagnesium chloride 
solution (1M) in diethyl ether was then added to the vessel and the reaction allowed to 
proceed overnight at room temperature. Following completion of the reaction, bulk 
solvent was first removed under a stream of nitrogen.  The remaining white residue was 
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rinsed 3 times with hexanes and again dried under a stream of nitrogen. NaOH (1mL, 
4M) was then added and the reaction vessel heated to 50 oC. β-chloro-L-alanine 
hydrochloride (250 mg, 1.5 mmol) dissolved in 10 drops H2O was then slowly added to 
the reaction over the course of 5 minutes.  The reaction was allowed to proceed at 50 oC 
for 1 hour prior to quenching with excess glacial acetic acid.  The crude product mixture 
was then washed 3 times with hexanes, and the semicrude aqueous phase further purified 
by preparative HPLC as described in general methods and lyophilized to afford 96 mg 
(0.45 mmol) 34S-benzylcysteine (30 % yield). 1H-NMR (500 MHz, D2O + 0.1% TFA-
d): δ ppm 2.82-2.97 (m; 2H), 3.69 (s; 2H), 3.99 (dd; Ja = 3.4 Hz, Jb = 7.7 Hz; 1H), 7.20-
7.21 (m; 1H; aromatic H), 7.26-7.27 (m; 4H; aromatic H). 13C-NMR (150 MHz, D2O + 
0.1% TFA-d): δ ppm 170.34, 134.47, 128.94, 128.86, 127.56, 117.07, 51.90, 35.24, 
30.35.  ESI-MS (m/z): 213.71 [M]+, 196.63, 131.77. 
 
Synthesis of 34S-cysteine: 34S-benzylcysteine (96 mg, 0.45 mmol) in a dry round 
bottom flask was placed in a -78 oC dry ice/acetone bath. NH4(l) (~10 mL) was condensed 
in the reaction vessel prior to addition of  20 mg sodium metal (~2 equivalents).  The 
solution immediately developed a deep blue color, which was maintained for 45 minutes. 
The reaction was then quenched through the addition of a minimal NH4Cl.  The vessel 
was then brought to room temperature and left open to air to allow NH4 to evaporate. 
Residual NH4 was then removed on high vacuum and the residue dissolved in water 
containing 0.1% TFA.  This crude material was then purified by preparative HPLC and 
characterized (16 mg; 30% yield). 1H-NMR (500 MHz, D2O + 0.1% TFA-d):): δ ppm 
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2.94-3.066 (m; 2H), 3.98 (m; 1H). 13C-NMR (150 MHz, D2O + 0.1% TFA-d): δ ppm 
171.71, 55.32, 24.38. ESI-MS (m/z): 121.75 [M]+. 
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APPENDIX 
Table A1: Proteins identified from GLP1-Y1211A transfected HEK293T cells with 
AbSAM. These proteins were not pulled-down in the control-transfected HEK293T cell. 
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Table S1. Proteins identified from EuHMT1-Y1211A transfected Human Embryonic Kidney 
293T (HEK293T) cells by BPPM approach. These proteins are not pulled-down in the control-
transfected HEK293T cells. 
Serial Accession number Mol. Wt. Score Description      
1 IPI:IPI00946054.2 138.2 243.08 Histone-lysine N-methyltransferase, H3 lysine-9 specific 5      
2 IPI:IPI00023006.1 42.0 121.55 Actin, alpha cardiac muscle 1      
3 IPI:IPI00011253.3 26.7 68.59 40S ribosomal protein S3      
4 IPI:IPI00412492.4 211.9 52.46 Isoform 1 of Plexin-D1      
5 IPI:IPI00414696.1 36.0 38.25 Isoform A2 of Heterogeneous nuclear ribonucleoproteins A2/B1      
6 IPI:IPI00003918.6 47.7 38.18 60S ribosomal protein L4      
7 IPI:IPI00217223.1 49.6 30.01 Multifunctional protein ADE2      
8 IPI:IPI00940148.1 50.6 29.36 Rab GDP dissociation inhibitor beta      
9 IPI:IPI00220301.5 25.0 29.20 Peroxiredoxin-6      
10 IPI:IPI00783097.4 83.1 27.01 Glycyl-tRNA synthetase      
11 IPI:IPI00893580.1 38.2 28.04 HLA-B associated transcript 1      
12 IPI:IPI00216587.9 24.2 27.66 40S ribosomal protein S8      
13 IPI:IPI00011937.1 30.5 26.98 Peroxiredoxin-4      
14 IPI:IPI00640741.1 19.0 25.49 19 kDa protein      
15 IPI:IPI00556485.2 27.4 23.80 RPLP0 protein      
16 IPI:IPI00024279.4 242.2 23.03 HEAT repeat-containing protein 1      
17 IPI:IPI00965459.1 30.1 22.92 30 kDa protein      
18 IPI:IPI00334713.1 30.6 20.90 Isoform 3 of Heterogeneous nuclear ribonucleoprotein A/B      
19 IPI:IPI00947227.3 66.6 20.38 plastin-3 isoform 2      
20 IPI:IPI00332428.5 35.3 19.74 Protein MAK16 homolog      
21 IPI:IPI00016801.1 61.4 19.18 Glutamate dehydrogenase 1, mitochondrial      
22 IPI:IPI00295857.7 138.3 19.16 Isoform 1 of Coatomer subunit alpha      
23 IPI:IPI00024524.4 27.9 18.13 RNA-binding protein PNO1      
24 IPI:IPI00374151.1 25.8 17.93 thioredoxin-dependent peroxide reductase, mitochondrial isoform b      
25 IPI:IPI00291006.2 35.5 17.54 Malate dehydrogenase, mitochondrial      
26 IPI:IPI00884904.1 605.3 17.40 Isoform 3 of Protein AHNAK2      
27 IPI:IPI00297779.7 57.5 17.29 T-complex protein 1 subunit beta      
28 IPI:IPI00220621.1 82.0 17.18 Isoform PDE4B3 of cAMP-specific 3',5'-cyclic phosphodiesterase 4B      
29 IPI:IPI00658013.1 28.4 16.87 nucleophosmin isoform 3      
30 IPI:IPI00453476.2 28.8 16.47 29 kDa protein      
31 IPI:IPI00217467.3 21.9 16.20 Histone H1.4      
32 IPI:IPI00010796.1 57.1 16.02 Protein disulfide-isomerase      
33 IPI:IPI00642716.6 225.7 15.42 myosin-7B      
34 IPI:IPI00795527.1 20.8 15.28 21 kDa protein      
35 IPI:IPI00216318.5 28.1 15.18 Isoform Long of 14-3-3 protein beta/alpha      
36 IPI:IPI00909530.1 12.9 14.94 Histone H3      
37 IPI:IPI00787460.3 134.4 14.65 Ovostatin homolog 1      
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38 IPI:IPI00022977.1 42.6 14.39 Creatine kinase B-type      
39 IPI:IPI00028091.3 47.3 14.33 Actin-related protein 3      
40 IPI:IPI00455599.4 49.1 14.15 Heat shock protein 90Bb      
41 IPI:IPI00965269.1 55.3 13.72 cDNA, FLJ79275, highly similar to T-complex protein 1 subunit epsilon      
42 IPI:IPI00031522.2 82.9 12.91 Trifunctional enzyme subunit alpha, mitochondrial      
43 IPI:IPI00396321.1 34.9 12.68 Leucine-rich repeat-containing protein 59      
44 IPI:IPI00005705.1 37.0 12.56 Isoform Gamma-1 of Serine/threonine-protein phosphatase PP1-gamma catalytic subunit      
45 IPI:IPI00942832.2 437.8 12.38 Isoform 4 of Probable E3 ubiquitin-protein ligase C12orf51      
46 IPI:IPI00305383.1 48.4 12.32 Cytochrome b-c1 complex subunit 2, mitochondrial      
47 IPI:IPI00414101.4 177.4 12.04 Isoform 2 of DNA topoisomerase 2-alpha      
48 IPI:IPI00411592.2 222.7 11.97 Isoform 2 of Chromodomain-helicase-DNA-binding protein 3      
49 IPI:IPI00006196.3 236.4 11.86 Isoform 2 of Nuclear mitotic apparatus protein 1      
50 IPI:IPI00241841.10 57.8 11.59 Keratin, type II cytoskeletal 79      
51 IPI:IPI00413324.6 21.4 11.41 60S ribosomal protein L17      
52 IPI:IPI00307749.2 32.8 11.34 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial      
53 IPI:IPI00922697.2 43.3 11.27 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial      
54 IPI:IPI00030179.3 29.2 11.27 60S ribosomal protein L7      
55 IPI:IPI00009368.4 35.6 11.16 Sideroflexin-1      
56 IPI:IPI00910980.1 120.6 10.83 IARS protein      
57 IPI:IPI00024719.1 49.5 10.76 Histone acetyltransferase type B catalytic subunit      
58 IPI:IPI00552749.5 477.3 10.75 478 kDa protein      
59 IPI:IPI00604431.1 117.8 10.35 Isoform 2 of Cullin-associated NEDD8-dissociated protein 1      
60 IPI:IPI00910113.1 46.9 10.34 cDNA FLJ52902, highly similar to Rab GDP dissociation inhibitor alpha      
61 IPI:IPI00168388.1 70.7 10.31 Isoform 1 of Signal recognition particle 68 kDa protein      
62 IPI:IPI00178475.13 56.5 10.27 Chromodomain Y-like protein 2      
63 IPI:IPI00025239.2 52.5 10.15 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial      
64 IPI:IPI00021435.3 48.6 10.10 26S protease regulatory subunit 7      
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Table A2: Proteins identified from G9a-Y1154A transfected HEK293T cells by with 
AbSAM. These proteins were not pulled-down in the control-transfected HEK293T cell. 
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Table S2. Proteins identified from EuHMT2-Y1154A transfected Human Embryonic Kidney 293T 
(HEK293T) cells by BPPM approach. These proteins are not pulled-down in the control-transfected 
HEK293T  cells. 
Serial Accession number Mol. Wt. Score Description 
1 IPI:IPI00220795.4 128.9 223.37 Isoform 2 of Histone-lysine N-methyltransferase EHMT2 
2 IPI:IPI00382470.3 98.1 106.16 Isoform 2 of Heat shock protein HSP 90-alpha 
3 IPI:IPI00646779.2 50.1 81.85 TUBB6 protein 
4 IPI:IPI00795257.3 31.5 74.07 Glyceraldehyde-3-phosphate dehydrogenase 
5 IPI:IPI00011253.3 26.7 72.88 40S ribosomal protein S3 
6 IPI:IPI00848226.1 35.1 69.91 Guanine nucleotide-binding protein subunit beta-2-like 1 
7 IPI:IPI00644224.2 86.8 49.68 cDNA FLJ54020, highly similar to Heterogeneous nuclear ribonucleoprotein U 
8 IPI:IPI00000816.1 29.2 44.92 Isoform 1 of 14-3-3 protein epsilon 
9 IPI:IPI00003918.6 47.7 44.40 60S ribosomal protein L4 
10 IPI:IPI00420014.2 244.4 39.54 Isoform 1 of U5 small nuclear ribonucleoprotein 200 kDa helicase 
11 IPI:IPI00003865.1 70.9 34.67 Isoform 1 of Heat shock cognate 71 kDa protein 
12 IPI:IPI00165486.11 31.4 33.83 31 kDa protein 
13 IPI:IPI00939492.1 111.4 31.20 HLA-B associated transcript 8 BAT8 isoform a variant 
14 IPI:IPI00030179.3 29.2 30.34 60S ribosomal protein L7 
15 IPI:IPI00453476.2 28.8 29.82 29 kDa protein 
16 IPI:IPI00025273.1 107.7 27.04 Isoform Long of Trifunctional purine biosynthetic protein adenosine-3 
17 IPI:IPI00910980.1 120.6 23.55 IARS protein 
18 IPI:IPI00643644.1 30.9 23.51 HCG1980662 
19 IPI:IPI00396018.1 257.1 22.89 Isoform 3 of Acetyl-CoA carboxylase 1 
20 IPI:IPI00302927.6 57.9 22.09 T-complex protein 1 subunit delta 
21 IPI:IPI00216319.3 28.2 21.90 14-3-3 protein eta 
22 IPI:IPI00397526.3 228.9 21.73 Isoform 1 of Myosin-10 
23 IPI:IPI00797270.4 26.7 21.73 Isoform 1 of Triosephosphate isomerase 
24 IPI:IPI00793177.1 24.2 21.61 24 kDa protein 
25 IPI:IPI00783097.4 83.1 21.48 Glycyl-tRNA synthetase 
26 IPI:IPI00909059.5 57.8 20.63 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A 
27 IPI:IPI00552419.3 75.0 20.34 propionyl-CoA carboxylase alpha chain, mitochondrial isoform c precursor 
28 IPI:IPI00889541.2 80.2 20.20 Isoform 4 of Probable ATP-dependent RNA helicase DDX17 
29 IPI:IPI00218342.10 101.5 19.07 C-1-tetrahydrofolate synthase, cytoplasmic 
30 IPI:IPI00217223.1 49.6 18.82 Multifunctional protein ADE2 
31 IPI:IPI00399170.1 123.0 18.34 Isoform 2 of Regulator of nonsense transcripts 1 
32 IPI:IPI00216308.5 30.8 18.27 Voltage-dependent anion-selective channel protein 1 
33 IPI:IPI00418813.2 25.1 18.11 Pseudogene candidate 
34 IPI:IPI00295857.7 138.3 18.02 Isoform 1 of Coatomer subunit alpha 
35 IPI:IPI00965964.2 129.1 17.59 cDNA FLJ58466, highly similar to Leucyl-tRNA synthetase, cytoplasmic 
36 IPI:IPI00288940.6 867.9 17.40 Isoform 1 of Obscurin 
37 IPI:IPI00376609.1 148.9 17.04 Isoform 2 of Nuclear pore complex protein Nup155 
38 IPI:IPI00012772.8 28.0 17.01 60S ribosomal protein L8 
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39 IPI:IPI00741005.7 315.0 16.95 MAX gene-associated protein isoform 2 
40 IPI:IPI00299214.7 25.5 15.66 Thymidine kinase, cytosolic 
41 IPI:IPI00030578.2 45.9 16.51 Synaptic vesicle membrane protein VAT-1 homolog-like 
42 IPI:IPI00007402.3 119.4 15.56 Importin-7 
43 IPI:IPI01009017.1 50.9 16.55 cDNA FLJ50585, highly similar to T-complex protein 1 subunit beta 
44 IPI:IPI00009329.2 394.2 16.38 Utrophin 
45 IPI:IPI00016801.1 61.4 16.13 Glutamate dehydrogenase 1, mitochondrial 
46 IPI:IPI00925578.1 518.2 15.09 Isoform 4 of Dynein heavy chain 14, axonemal 
47 IPI:IPI00017334.1 29.8 14.75 Prohibitin 
48 IPI:IPI00922165.1 24.6 14.55 Isoform 5 of Adenylate kinase 2, mitochondrial 
49 IPI:IPI00909530.1 12.9 14.36 Histone H3 
50 IPI:IPI00219994.2 107.7 14.36 Isoform 3 of Exportin-2 
51 IPI:IPI00892976.1 99.5 14.33 Euchromatic histone-lysine N-methyltransferase 2 
52 IPI:IPI00922694.1 69.9 14.23 cDNA FLJ51903, highly similar to Stress-70 protein, mitochondrial 
53 IPI:IPI00979136.1 86.4 14.06 Ribonucleoside-diphosphate reductase 
54 IPI:IPI00411592.2 222.7 13.94 Isoform 2 of Chromodomain-helicase-DNA-binding protein 3 
55 IPI:IPI00332428.5 35.3 13.91 Protein MAK16 homolog 
56 IPI:IPI00218408.1 46.0 13.87 Isoform Short of Trifunctional purine biosynthetic protein adenosine-3 
57 IPI:IPI00185146.5 115.9 13.54 Importin-9 
58 IPI:IPI00300371.5 135.5 13.17 Isoform 1 of Splicing factor 3B subunit 3 
59 IPI:IPI00220301.5 25.0 13.17 Peroxiredoxin-6 
60 IPI:IPI00791448.1 29.7 13.18 cDNA FLJ51469, highly similar to 60S acidic ribosomal protein P0 
61 IPI:IPI00217563.4 88.4 12.98 Isoform Beta-1A of Integrin beta-1 
62 IPI:IPI00640741.1 19.0 12.88 19 kDa protein 
63 IPI:IPI00291006.2 35.5 12.46 Malate dehydrogenase, mitochondrial 
64 IPI:IPI00936807.1 138.6 11.87 Isoform 4 of Myosin-VIIa 
65 IPI:IPI00219525.10 53.1 11.77 6-phosphogluconate dehydrogenase, decarboxylating 
66 IPI:IPI00910113.1 46.9 11.74 cDNA FLJ52902, highly similar to Rab GDP dissociation inhibitor alpha 
67 IPI:IPI00413324.6 21.4 11.14 60S ribosomal protein L17 
68 IPI:IPI00010796.1 57.1 10.95 Protein disulfide-isomerase 
69 IPI:IPI00007074.5 59.1 10.87 Tyrosyl-tRNA synthetase, cytoplasmic 
70 IPI:IPI00412579.6 24.8 10.80 60S ribosomal protein L10a 
71 IPI:IPI00032304.2 70.2 10.79 Plastin-1 
72 IPI:IPI00478689.5 180.6 10.71 Protein unc-13 homolog B 
73 IPI:IPI00555744.6 23.8 10.71 Ribosomal protein L14 variant 
74 IPI:IPI00293748.3 55.0 10.68 Isoform 1 of Multiple inositol polyphosphate phosphatase 1 
75 IPI:IPI00797148.1 29.4 10.61 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1 
76 IPI:IPI00291783.4 168.5 10.58 Gem-associated protein 5 
77 IPI:IPI00941747.1 67.5 10.48 Calnexin 
78 IPI:IPI00480077.3 92.7 10.43 Isoform 3 of Polyamine-modulated factor 1-binding protein 1 
79 IPI:IPI00029079.5 76.7 10.24 GMP synthase [glutamine-hydrolyzing] 
80 IPI:IPI00911026.1 31.4 10.20 cDNA FLJ57707, highly similar to Ketosamine-3-kinase 
81 IPI:IPI00910327.1 75.0 10.09 cDNA FLJ54334, highly similar to Origin recognition complex subunit 3 
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Table A3: BPPM-revealed potential nonhistone targets for GLP1-Y1211A in HEK293T 
cells using HeySAM.  These proteins are not present in the control. 
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Table S2. BPPM-revealed potential nonhistone targets of EuHMT1 in HEK293T cells with the 
EuHMT1-Y1211A mutant and Hey-SAM 6 as BPPM reagents. These proteins are not present in 
the control (empty-vector transfected HEK293T cells). 
Serial Accession Description ScoreofEuHMT1
1 IPI00376215.2 Isoform2ofDNAͲdependentproteinkinase cata lyticsubunit 208.3085556
2 IPI00793119.2 cDNAFLJ56274,highlys imi lartoTransketolase 79.90027404
3 IPI00218319.3 Isoform2ofTropomyos inalpha Ͳ3chain 70.50005794
4 IPI00007423.1 Isoform1ofAcidicleucineͲrichnuclearphosphoprotein32fami lymemberB 63.75586653
5 IPI00419373.1 Isoform1ofHeterogeneous nuclearribonucleoproteinA3 56.75522494
6 IPI00640006.1 rabGDPdissociationinhibi torbeta i soform2 53.96958017
7 IPI00965327.1 succinate dehydrogenase complex,subunitA,flavoprotein(Fp) 52.61379075
8 IPI00419880.6 40Sribosomal proteinS3a 48.47704196
9 IPI00513955.1 cDNAFLJ55283,moderatelys imi lartoProteinmagonashi homolog 45.6518743
10 IPI00419258.4 Highmobi l i tygroupproteinB1 43.15532923
11 IPI00219097.4 Highmobi l i tygroupproteinB2 38.17082167
12 IPI00032158.3 Isoform2ofNͲalpha Ͳacetyl transferase 15,NatAauxi l iarysubunit 37.94827914
13 IPI01015565.1 ubiqui tinC 33.89626837
14 IPI00552715.1 TͲcomplexprotein1subunitgamma i soformc 33.83686447
15 IPI00375127.4 eukaryotictrans lationini tiationfactor4H 33.41157961
16 IPI00552190.1 Proteasome (Prosome,macropa in)26Ssubunit,nonͲATPase,10 32.44333482
17 IPI00007797.3 FattyacidͲbindingprotein,epidermal 32.30974603
18 IPI00788942.1 Isoform2ofRuvBͲl i ke 1 28.92567086
19 IPI00414696.1 IsoformA2ofHeterogeneous nuclearribonucleoproteins A2/B1 28.35218573
20 IPI00018534.4 His tone H2Btype 1ͲL 26.84758949
21 IPI00783118.2 5'Ͳnucleotidase domainͲconta iningprotein2i soform1 26.36745024
22 IPI00032140.4 SerpinH1 26.17618561
23 IPI00915869.3 malate dehydrogenase,cytoplasmici soform3 26.06665564
24 IPI01011970.1 phosphogluconate dehydrogenase 25.76162124
25 IPI01015355.1 aconitase 2,mitochondria l 25.55280709
26 IPI00984060.1 glutathione SͲtransferase Mu2i soform2 25.12881255
27 IPI00980749.1 heatshock70kDa protein8 24.39236546
28 IPI00885057.1 Isoform2ofCysteine andhistidineͲrichdomainͲconta iningprotein1 24.32220984
29 IPI00909453.2 heatshock27kDa protein1 24.1226244
30 IPI01011083.1 cDNAFLJ55960,highlys imi lartoProteintransportproteinSec23A 23.34211493
31 IPI00926815.1 ribosomal proteinL37a 23.03368974
32 IPI00293305.4 IsoformBeta Ͳ1BofIntegrinbeta Ͳ1 22.0308578
33 IPI00793677.1 chromosome 21openreadingframe 33 21.87474656
34 IPI00815732.1 Isoform2ofMulti functional proteinADE2 21.49055624
35 IPI00027485.3 Eukaryotictrans lationini tiationfactor4E 21.47505403
36 IPI00937278.2 26Sproteasome nonͲATPase regulatorysubunit8 21.38628244
37 IPI00945233.1 mitochondria l 2Ͳoxoglutarate/malate carrierproteini soform2 21.03095818
38 IPI00916818.1 Phosphoglycerate kinase 20.46259642
39 IPI00023086.3 39Sribosomal proteinL15,mitochondria l 20.1815536
40 IPI00219065.2 Isoform5ofGlycogendebranchingenzyme 19.81091595
41 IPI00294159.3 Tricarboxylate transportprotein,mitochondria l 19.68325853
42 IPI00984887.1 ribosomal proteinS3 19.53965378
43 IPI00470674.5 NADHͲcytochrome b5reductase 1 19.51842237
44 IPI01011090.1 lactate dehydrogenase B 19.31844187
45 IPI00023530.7 Cycl inͲdependentkinase 5 19.30037332
46 IPI00215884.4 IsoformASFͲ1ofSerine/arginineͲrichspl icingfactor1 17.89297962  
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47 IPI00019927.2 26Sproteasome nonͲATPase regulatorysubunit7 17.84248114
48 IPI01015264.1 eukaryotictrans lationini tia tionfactor2B,subunit1alpha,26kDa 17.81041503
49 IPI01013355.1 cDNAFLJ54349,highlys imi lartoVes icleͲfus ingATPase 17.5288763
50 IPI00976247.1 peptidyl Ͳprolyl ci s Ͳtrans i somerase AͲl ike,partia l 17.42233348
51 IPI00386751.2 Isoform2ofHDdomainͲconta iningprotein2 17.40248156
52 IPI00978313.2 cDNAFLJ53638,highlys imi lartoAnnexinA6 17.3944788
53 IPI00719549.2 RBM14ͲRBM4proteini soform1 17.1049633
54 IPI00217168.1 IsoformZKofPlasma membrane ca lciumͲtransportingATPase 4 16.99586105
55 IPI00015905.1 Exosome complexcomponentRRP4 16.95224094
56 IPI00927114.1 ras homologfami lymemberA 16.75960922
57 IPI00291922.2 Proteasome subuni talpha typeͲ5 16.51718521
58 IPI00032955.1 Isoform1ofRINGfingerprotein114 16.17715096
59 IPI00910270.1 PITH(CͲtermina l proteasomeͲinteractingdomainofthioredoxinͲl i ke)domainco 16.03422451
60 IPI00554742.3 Isoform2ofApoptos is inhibitor5 15.79603648
61 IPI00411816.3 39Sribosomal proteinL2,mitochondria l 15.5231719
62 IPI00011274.3 Isoform1ofHeterogeneous nuclearribonucleoproteinDͲl i ke 15.15570092
63 IPI00419802.4 Isoform1of3Ͳhydroxyisobutyryl ͲCoAhydrolase,mitochondria l 15.12682176
64 IPI00748145.2 Isoform1ofGuanine nucleotideͲbindingproteinG(i )subunita lpha Ͳ2 15.10663915
65 IPI00745568.2 Isoform1ofTIP41Ͳl i ke protein 14.99305558
66 IPI00022314.1 Superoxide dismutase [Mn],mitochondria l 14.97399402
67 IPI00026519.1 Peptidyl Ͳprolyl ci s Ͳtrans i somerase F,mitochondria l 14.72927189
68 IPI00974011.1 inos i tol (myo)Ͳ1(or4)Ͳmonophosphatase 1 14.70692635
69 IPI00473085.3 Isoform3ofDynaminͲ1Ͳl i ke protein 14.49450064
70 IPI00013184.1 NͲalpha Ͳacetyl trans ferase 10,NatAcata lyticsubuni t 14.38066006
71 IPI00643459.1 mitochondria l ribosomal proteinS16 14.00365901
72 IPI00830052.9 heatshock70kDa protein1Ͳl ike 13.92066193
73 IPI01012108.1 ubiqui tinͲconjugatingenzyme E2D4(putative) 13.79680896
74 IPI00793137.2 Uncharacterizedprotein 13.71066475
75 IPI00879451.2 cDNAFLJ61051,highlys imi lartoHpaII tinys locus 9cprotein 13.69041753
76 IPI00924536.1 eukaryotictrans lationini tia tionfactor4A2 13.61659217
77 IPI00032823.1 Exosome complexcomponentCSL4 13.57395387
78 IPI00940872.2 Ti tin,i soformCRA_a 13.55056572
79 IPI00791634.5 prohibitin 13.17864013
80 IPI00917733.1 cDNAFLJ10185fi s ,clone HEMBA1004509,highlys imi lartoU4/U6.U5tri ͲsnRNPͲass 13.05751348
81 IPI00797969.1 guanine nucleotide bindingprotein(Gprotein),beta polypeptide 2 12.9626801
82 IPI01011952.1 cDNAFLJ59659,highlys imi lartoVincul in 12.95064139
83 IPI00789842.3 zincphosphodiesterase ELACprotein2i soform3 12.88316751
84 IPI01013371.1 cDNAFLJ58569,highlys imi lartoNucleosome assemblyprotein1Ͳl ike 1 12.66269946
85 IPI00385834.3 Isoform2ofKHdomainͲconta ining,RNAͲbinding,s igna l transductionͲassociated 12.61974573
86 IPI00024662.1 Chromoboxproteinhomolog5 12.54557896
87 IPI00015869.2 Trichohyal in 12.49780846
88 IPI00925126.1 proteinkinase,cAMPͲdependent,regulatory,type I I ,alpha 12.47497773
89 IPI01011589.1 cDNAFLJ10484fi s ,clone NT2RP2000161,highlys imi lartoExosome complexexonu 12.44991589
90 IPI01010049.1 ubiqui tinspeci fi cpeptidase 28 12.18280959
91 IPI00384122.5 cDNAFLJ55034,highlys imi lartoDihydrol ipoyl lys ineͲres idue succinyltransferase 12.10097122
92 IPI00470503.2 Isoform3ofInorganicpyrophosphatase 2,mitochondria l 11.5182457
93 IPI00909437.1 Ribosomal proteinL15 11.42085123
94 IPI00643324.1 Fouranda halfLIMdomains 1 11.34323096  
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95 IPI01011965.1 Ironregulatoryprotein1 11.27859068
96 IPI00892863.1 Isoform2ofCol lagenalpha Ͳ5(VI)cha in 11.220891
97 IPI00978728.1 NADHdehydrogenase (ubiquinone)flavoprotein1,51kDa 11.14177203
98 IPI00059718.3 TRMT61Aprotein(Fragment) 11.04034781
99 IPI00946597.1 acylglycerol kinase 10.86086345
100 IPI01011463.1 cDNAFLJ40890fi s ,clone UTERU2001024,highlys imi lartoSPLICINGFACTOR,ARGIN 10.85630155
101 IPI00186460.7 Isoform1ofCol lagenalpha Ͳ1(II)chain 10.79398465
102 IPI00793985.2 N(a lpha)Ͳacetyl transferase 50,NatEcata lyticsubunit 10.7655735
103 IPI00413214.3 importinsubunitalpha Ͳ6 10.75346398
104 IPI00910176.1 cDNAFLJ57995,moderatelys imi lartoUbiqui tinͲconjugatingenzyme E2Ͳ25kDa 10.74681306
105 IPI00976899.1 ribosomal proteinL8 10.72774029
106 IPI00978608.1 coldshockdomainconta iningE1,RNAͲbinding 10.65494323
107 IPI00915872.2 Trinucleotide repeatconta ining6B(Fragment) 10.33702445
108 IPI00217519.3 Ras ͲrelatedproteinRal ͲA 10.23424554
109 IPI00384061.2 Isoform5ofMethyl transferaseͲl ike protein13 10.20179272
110 IPI00983162.1 poly(A)bindingprotein,cytoplasmic1 10.14514899
111 IPI00879783.1 metastas is associated1fami ly,member3 10.06823587
112 IPI01015038.1 TͲcomplexprotein1subunitdelta 9.967740536
113 IPI00073779.1 Isoform1of28Sribosomal proteinS35,mitochondria l 9.904862165
114 IPI00005707.7 CͲtype mannose receptor2 9.816804647
115 IPI00022316.3 28Sribosomal proteinS18b,mitochondria l 9.807150364
116 IPI00016077.1 ProteinNipSnaphomolog2 9.705330372
117 IPI00165393.1 Acidicleucine Ͳrichnuclearphosphoprotein32fami lymemberE 9.69942975
118 IPI00910437.1 cDNAFLJ52417,highlys imi larto3'(2'),5'Ͳbisphosphate nucleotidase 1 9.686202049
119 IPI01009205.1 RAD23homologB(S.cerevis iae) 9.626133442
120 IPI00643915.1 Peptidyl Ͳprolyl ci s Ͳtrans i somerase 9.595445633
121 IPI00301518.6 Isoform1ofMps one binderkinase activatorͲl i ke 1B 9.466370106
122 IPI01011967.1 cDNAFLJ54535,highlys imi lartoRibosomal proteinS6kinase alpha Ͳ1 9.457336903
123 IPI00910255.1 tRNAͲyWsynthes izingprotein3homolog(S.cerevis iae) 9.457071781
124 IPI00798272.2 branchedͲchainͲaminoͲacidaminotrans ferase,cytosol ici soform2 9.186050892
125 IPI01015230.1 cDNAFLJ53354,highlys imi lartoPuromycinͲsens i tive aminopeptidase 9.174034595
126 IPI01010261.1 cDNAFLJ30173fi s ,clone BRACE2000969,highlys imi larto6Ͳphosphofructokinase, 9.135075808
127 IPI00922039.1 cDNAFLJ57628,highlys imi lartoHomosapiens membraneͲassociatedringfinge 9.084560871
128 IPI00646978.4 lysophosphol ipase I I 9.084253073
129 IPI00027096.2 39Sribosomal proteinL19,mitochondria l 9.016253471
130 IPI00908791.2 LͲlactate dehydrogenase 8.970396996
131 IPI01014610.1 tRNAmethyl transferase 11Ͳ2homolog(S.cerevis iae) 8.936521769
132 IPI00946498.1 stemͲloopbindingprotein 8.920324326
133 IPI00643370.1 Tropomyos in3 8.840212822
134 IPI00926959.1 asparagine synthetase (glutamineͲhydrolyzing) 8.833948374
135 IPI00980330.1 RAP2A,memberofRASoncogene fami ly 8.804337502
136 IPI00304082.8 Isochorismatase domainͲconta iningprotein1 8.798935413
137 IPI00297089.4 AͲkinase anchorprotein6 8.718411922
138 IPI00553138.4 Ves icleͲassociatedmembrane protein2 8.685631752
139 IPI00643317.3 highmobi l i tygroupbox3 8.609049082
140 IPI00399375.2 Isoform2ofThymocyte nuclearprotein1 8.576127291  
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141 IPI01011917.1 prohibitin2 8.569286823
142 IPI00180128.4 Isoform2ofBas icleucine zipperandW2domainͲconta iningprotein1 8.532663822
143 IPI00642864.2 Isoform2ofFADsynthase 8.518769503
144 IPI01015433.1 Glutamate dehydrogenase 8.490028381
145 IPI01015600.1 CIP29protein 8.445426226
146 IPI00893470.2 di ffuse panbronchiol i ti s cri tica l region1 8.3966887
147 IPI00942050.2 Majorhistocompatibi l i tycomplex,class I ,C 8.314289093
148 IPI00383078.5 melanoma antigenfami lyD,1 8.299733639
149 IPI00016346.2 Prol ine synthetase coͲtranscribedhomolog(Bacteria l ),i soformCRA_b 8.297941685
150 IPI00219421.3 Isoform2ofEphrintypeͲBreceptor2 8.289919376
151 IPI00914971.1 farnesyl pyrophosphate synthase i soformb 8.275914669
152 IPI00455457.4 Histone H3 8.2287395
153 IPI00647504.2 Isoform2ofProteinFAM184A 8.141638517
154 IPI00000335.1 Histidine triadnucleotideͲbindingprotein2,mitochondria l 8.135605812
155 IPI00305887.1 Kinetochore proteinNuf2 8.077617884
156 IPI00940685.1 U5smal l nuclearribonucleoprotein40kDa protein 8.068724632
157 IPI00290184.4 tRNA(guanineͲN(7)Ͳ)Ͳmethyl transferase 8.065582037
158 IPI00963822.1 septin11 8.061227322
159 IPI00967259.1 glucosamineͲ6Ͳphosphate deaminase 1 8.058110237
160 IPI00000940.1 Parathyroidhormone 8.038056374
161 IPI00784990.2 Ubiqui tinCspl ice variant 8.036742687
162 IPI00012535.1 DnaJhomologsubfami lyAmember1 8.005677223
163 IPI00219613.6 cDNAFLJ54537,highlys imi lartoHomosapiens pitri lys inmetal lopeptidase 1(PIT 8.003607035
164 IPI00012369.1 Mitoticspindle assemblycheckpointproteinMAD2A 7.727428675
165 IPI00552360.2 Isoform1ofFumarylacetoacetate hydrolase domainͲconta iningprotein1 7.611097336
166 IPI00012491.2 HeatͲs table enterotoxinreceptor 7.599328995
167 IPI00911081.2 glutaryl ͲCoAdehydrogenase 7.570792198
168 IPI00936634.1 Isoform3ofSH2domainͲconta iningprotein2A 7.549822807
169 IPI00302176.5 Isoform1ofH/ACAribonucleoproteincomplexsubunit1 7.544974566
170 IPI00400975.1 Conservedhypothetica l protein 7.460657597
171 IPI00329352.4 Noda l modulator1 7.442754984
172 IPI00935307.2 diaphanous homolog1(Drosophi la) 7.417745352
173 IPI00514944.5 Uroporphyrinogendecarboxylase 7.410956621
174 IPI01014611.1 cDNA,FLJ79139,highlys imi lartoAlkyldihydroxyacetonephosphate synthase,pero 7.407764673
175 IPI01009451.1 MYCͲassociatedzincfingerprotein(purineͲbindingtranscriptionfactor) 7.374407053
176 IPI00908803.1 cDNAFLJ59584,highlys imi lartoMitochondria l Ͳprocess ingpeptidase alpha subu 7.355117321
177 IPI01013039.1 proteasome (prosome,macropain)26Ssubunit,nonͲATPase,9 7.351754189
178 IPI00302673.3 ATPsynthase mitochondria l F1complexassemblyfactor1 7.347349405
179 IPI01008914.1 eukaryoticini tia tionfactor4AͲI i soform2 7.327119589
180 IPI00903226.1 cDNAFLJ46359fi s ,clone TESTI4049786,highlys imi lartoHexokinaseͲ1 7.286429644
181 IPI00749044.2 Simi lartoIQmotifandSec7domain3 7.284358501
182 IPI01011924.1 ubiqui tinspeci fi cpeptidase 7(herpes virus Ͳassociated) 7.239362478
183 IPI00219793.1 Isoform2ofSuppressorofSWI41homolog 7.234596014
184 IPI00001618.2 Ras ͲrelatedproteinRabͲ39A 7.229089737
185 IPI00005573.3 Isoform1of5'(3')Ͳdeoxyribonucleotidase,cytosol i ctype 7.172768831
186 IPI00940894.1 DNApolymerase 7.069058895
187 IPI00556204.1 Eukaryotictrans lationelongationfactor1alpha 2variant(Fragment) 7.016174316  
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188 IPI00552198.1 Phosphoproteinenrichedinastrocytes 15 7.014993906
189 IPI00877618.1 mercaptopyruvate sul furtransferase 7.01315403
190 IPI00177965.5 5'Ͳnucleotidase domainͲconta iningprotein1 7.002598286
191 IPI00019385.4 Trans loconͲassociatedproteinsubuni tdel ta 6.980569601
192 IPI00646415.1 20kDa protein 6.970712662
193 IPI00020771.3 microtubuleͲassociatedprotein7 6.955245972
194 IPI00043678.3 dedicatorofcytokines is 7 6.885029078
195 IPI00646459.1 Nuclearautoantigenicspermprotein 6.882386684
196 IPI00645630.2 enoyl ͲCoAhydratase domainͲconta iningprotein1i soform3 6.879080772
197 IPI01009725.1 cDNAFLJ58302,highlys imi lartoImportinͲ4 6.818561792
198 IPI00789806.2 Isoform2ofCytosol aminopeptidase 6.78508997
199 IPI00910150.1 cDNAFLJ60107,highlys imi lartoDNArepl i cationcomplexGINSproteinPSF1 6.754507303
200 IPI00925176.1 traffi ckingprotein,kines inbinding1 6.746781588
201 IPI00743775.1 Isoform2ofCoi ledͲcoi l domainͲconta iningprotein47 6.72347331
202 IPI00010157.1 SͲadenosylmethionine synthase i soformtypeͲ2 6.712624788
203 IPI00171844.3 COP9s ignalosome complexsubunit4 6.679496765
204 IPI00549307.3 Isoform3ofMOSCdomainͲconta iningprotein1,mitochondria l 6.634622574
205 IPI00157928.2 maleylacetoacetate i somerase i soform2 6.594398022
206 IPI00894205.2 proteinNipSnaphomolog1i soform2 6.587986231
207 IPI00922265.1 Isoform1ofMembrane magnes iumtransporter1 6.58423233
208 IPI00645291.1 Isoform2ofPhosphoribosyl transferase domainͲconta iningprotein1 6.583433151
209 IPI00296999.9 ATPsynthase mitochondria l F1complexassemblyfactor2 6.480558157
210 IPI00292168.3 Histone chaperone ASF1A 6.463583946
211 IPI00291093.3 DNAͲdirectedRNApolymerases I ,I I ,andI I I subunitRPABC1 6.424916029
212 IPI00447177.1 AntigenMLAAͲ23 6.394483566
213 IPI00744932.1 Simi lartoZincfinger,DHHCͲtype conta ining1 6.381577492
214 IPI01013870.1 N(a lpha)Ͳacetyl transferase 40,NatDcata lyticsubunit,homolog(S.cerevis iae) 6.381153107
215 IPI00878669.2 chromoboxhomolog1 6.380673409
216 IPI00007676.3 Es tradiol 17Ͳbeta Ͳdehydrogenase 12(presentinG9a withazido) 6.362389326
217 IPI00797738.1 Cytochrome coxidase subunit6B1 6.351295471
218 IPI00221222.7 ActivatedRNApolymerase I I transcriptional coactivatorp15 6.34903574
219 IPI00908651.1 cDNAFLJ57726,highlys imi lartoHeterogeneous nuclearribonucleoproteinH3 6.290336847
220 IPI00552365.7 EFͲhanddomainfami ly,memberD2 6.279866457
221 IPI00004454.3 Isoform1ofDol ichol Ͳphosphate mannosyl transferase subunit3 6.272236586
222 IPI00936328.2 MARCKSͲrela tedproteinͲl ike,partia l 6.246054411
223 IPI01013456.1 lactate dehydrogenase A 6.22026968
224 IPI00023748.3 NascentpolypeptideͲassociatedcomplexsubunitalpha 6.20839119
225 IPI00964587.1 DTWdomainconta ining2 6.206987619
226 IPI00013946.1 SynaptogyrinͲ2 6.194886208
227 IPI00514049.1 Cytidine monophosphate (UMPͲCMP)kinase 1,cytosol i c 6.14833951
228 IPI00797616.2 Isoform3ofBRCA1ͲassociatedATMactivator1 6.118052006
229 IPI00024524.4 RNAͲbindingproteinPNO1 6.095901728
230 IPI01015706.1 tumorprotein,trans lational lyͲcontrol led1 6.084853888
231 IPI00916572.1 ribosomal proteinL31 6.073718309
232 IPI00644020.1 Sterol OͲacyl transferase 1 6.061112404
233 IPI00513717.3 Isoform2ofChromodomainͲhel icase ͲDNAͲbindingprotein6 6.06077528
234 IPI00031032.1 Muscul in 6.05892539  
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235 IPI00917386.1 Sjogrensyndrome antigenB(autoantigenLa) 6.055042982
236 IPI00908843.1 cDNAFLJ53857,highlys imi lartoInterferonͲinducedproteinwithtetratricopeptid 5.990872145
237 IPI00006408.4 Nitricoxide synthaseͲinteractingprotein 5.941011667
238 IPI00294486.1 Dual speci fi ci typroteinphosphatase 9 5.81464982
239 IPI00063903.5 UpͲregulatedduringskeleta l muscle growthprotein5 5.796951056
240 IPI01011610.1 cDNAFLJ51181,highlys imi larto7Ͳdehydrocholesterol reductase 5.796531439
241 IPI00470515.7 chromosome 1openreadingframe 173 5.771541834
242 IPI01015586.1 glucosamine (NͲacetyl )Ͳ6Ͳsul fatase 5.769265652
243 IPI00889171.1 Isoform2ofJunctionͲmediatingandͲregulatoryprotein 5.738581657
245 IPI00007019.1 Peptidyl Ͳprolyl ci s Ͳtrans i someraseͲl i ke 1 5.570055485
246 IPI00011898.3 Trans lationini tia tionfactoreIFͲ2Bsubuniteps i lon 5.532426834
247 IPI00008437.7 Probable ribosome biogenes is proteinRLP24 5.482391119
248 IPI01011224.1 REX2,RNAexonuclease 2homolog(S.cerevis iae) 5.463126659
249 IPI01015916.1 RNAͲbindingregion(RNP1,RRM)conta ining2,i soformCRA_b 5.447995663
250 IPI00643288.1 Pyrophosphatase (Inorganic)1 5.435631037
251 IPI00980505.1 copperchaperone forsuperoxide dismutase 5.379751444
252 IPI00514094.3 serine/threonine kinase 32C 5.335237026
253 IPI00018691.1 Isoform1of28Sribosomal proteinS18a,mitochondria l 5.301540852
254 IPI00017972.3 Zincfingerprotein703 5.284733772
255 IPI01009339.1 paraspeckle component1 5.243271112
256 IPI00008436.4 DNApolymerase eps i lonsubuni t4 5.213436604
257 IPI00513941.3 SAR1homologA(S.cerevis iae) 5.192499161
258 IPI01010811.1 ATPsynthase,H+transporting,mitochondria l Focomplex,subuni tF2 5.147957802
259 IPI01014702.1 isova leryl ͲCoAdehydrogenase 5.099872589
260 IPI00643597.2 Isoform2ofTransmembrane channel Ͳl i ke protein2 5.091242552
261 IPI00982452.1 sorti l inͲrelatedreceptor,L(DLRclass )Arepeats conta ining 5.085541248
262 IPI00909685.1 cDNAFLJ58965,highlys imi lartoNonspeci fi cl ipidͲtransferprotein 5.044857502
263 IPI00027729.1 Caseinkinase I i soformeps i lon 5.033119917
264 IPI00985162.1 nucleoporin160kDa 4.960441113
265 IPI00926401.1 NͲacylaminoacyl Ͳpeptide hydrolase 4.955853939
266 IPI00645702.1 CTPsynthase 2 4.95538187
267 IPI00646381.1 mitochondria l ribosomal proteinL24 4.934664011
268 IPI00746752.2 IsoformCofBromodomainandWDrepeatͲconta iningprotein1 4.899923325
269 IPI01010215.1 lys ine (K)Ͳspeci fi cdemethylase 2B 4.898071289
270 IPI00640671.3 Isoform2ofProteinfantom 4.881556988
271 IPI00244111.10 Isoform3ofType I I inos i tol Ͳ1,4,5Ͳtri sphosphate 5Ͳphosphatase 4.875109196
272 IPI00967388.1 ribosomal proteinS3A 4.861042738
273 IPI00977873.1 cDNAFLJ61146,highlys imi lartoCel lularnucleicacidͲbindingprotein 4.855553627
274 IPI00014301.3 Oxidase (Cytochrome c)assembly1Ͳl i ke 4.830379963
275 IPI00644993.1 AMTprotein 4.754335403
276 IPI00978059.1 chromosome 11openreadingframe 83 4.688630581
277 IPI00642016.1 crys ta l l in,zeta (quinone reductase) 4.556134224
278 IPI00926007.2 FLJ00144protein(Fragment) 4.520941734
279 IPI00220358.1 Isoform2ofCas scaffoldingproteinfami lymember4 4.520151138
280 IPI01013546.1 Hydroxymethylbi lane synthase 4.499036312
281 IPI00218946.2 Potass ium/sodiumhyperpolari zationͲactivatedcycl icnucleotideͲgatedchannel  4.445723534
282 IPI00902977.1 Isoform6ofOxidationres is tance protein1 4.443925381  
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283 IPI00180408.8 Myos inͲ15 4.442148209
284 IPI00026516.1 Succinyl ͲCoA:3ͲketoacidͲcoenzyme Atrans ferase 1,mitochondria l 4.442061901
285 IPI00983321.1 SOGAfami lymember3 4.439264774
286 IPI01009113.1 polymerase (RNA)I I (DNAdirected)polypeptide A,220kDa 4.437465191
287 IPI00946286.1 col lagenalpha Ͳ3(VI)chaini soform4precursor 4.436850071
288 IPI01015357.1 ATPͲbindingcassette,subͲfami lyB(MDR/TAP),member9 4.430781841
289 IPI00032900.1 BolAͲl i ke protein1 4.410545349
290 IPI01010160.1 UPP1protein 4.40027523
291 IPI00061987.4 uncharacteri zedLOC113230 4.396100521
292 IPI00976931.1 apoptos is Ͳinducingfactor,mitochondrionͲassociated,1 4.378081322
293 IPI00797067.2 U2snRNPͲspeci fi cA'protein 4.372718811
294 IPI00976917.1 hypothetica l proteinLOC144481i soform1 4.371304512
295 IPI00646919.1 transmembrane protein38B 4.367688656
296 IPI00795241.1 Isoform2ofEnolaseͲphosphatase E1 4.339342117
297 IPI00291669.3 Ubiqui tinͲl ike domainͲconta iningCTDphosphatase 1 4.331799507
298 IPI00964697.1 adrenoceptoralpha 2C 4.331721783
299 IPI00926562.1 wingless Ͳtype MMTVintegrations i te fami ly,member10A 4.290638924
300 IPI00929228.1 Isoform2ofTudordomainͲconta iningprotein3 4.273125172
301 IPI00333126.1 LeucineͲrichrepeatͲconta iningprotein56 4.271798134
302 IPI00965978.1 Uncharacterizedprotein 4.250235081
303 IPI00978253.1 indoleamine 2,3Ͳdioxygenase 1 4.244541645
304 IPI00942036.1 centrosomal protein170B 4.241065502
305 IPI00793594.1 mediatorcomplexsubuni t24 4.21948576
306 IPI00300408.3 Copperhomeostas i s proteincutChomolog 4.212116718
307 IPI00909705.1 cDNAFLJ57896,highlys imi lartoArylsul fatase A 4.211012363
308 IPI00978643.1 transmembrane protein41Bi soform2 4.194047928
309 IPI00186395.11 Putative methyl transferaseͲl ike proteinLOC121952 4.174588203
310 IPI01011139.1 golgi transport1B 4.172591209
311 IPI00894231.1 CAPͲGLYdomainconta iningl inkerproteinfami ly,member4 4.172104359
312 IPI00169400.1 Isoform1of28Sribosomal proteinS5,mitochondria l 4.169184685
313 IPI00925074.1 BC1(ubiquinol Ͳcytochrome creductase)synthes is Ͳl i ke 4.164148331
314 IPI00418599.2 Arachidonate 5Ͳl ipoxygenase variant(Fragment) 4.131789207
315 IPI00220716.2 Isoform2ofPutative RNAͲbindingprotein15 4.124369621
316 IPI00973891.1 NudCdomainconta ining2 4.124117374
317 IPI00847423.1 Simi lartoHematopoietics ignal peptideͲconta iningi soform1 4.120315075
318 IPI01012850.1 cDNAFLJ58265,highlys imi lartoUbiquitinͲproteinl i gase BRE1B 4.11916256
319 IPI00976464.1 Sjogrensyndrome/scleroderma autoantigen1 4.115839005
320 IPI00796662.2 cDNAFLJ57580,highlys imi lartoZincfingerprotein485 4.115236282
321 IPI00009111.1 Trophoblastglycoprotein 4.105669975
322 IPI00908950.1 Ribosomal proteinL18 4.073968887
323 IPI01014744.1 microsomal glutathione SͲtransferase 1 4.063024998
324 IPI00942440.2 cDNAFLJ53389,highlys imi lartoHomosapiens RABGTPase activatingprotein1( 4.048054695
325 IPI00017630.6 Nuclearfragi le Xmental retardationͲinteractingprotein1 4.046810627
326 IPI00103471.3 SelenoproteinM 4.043367386
327 IPI00024976.5 Mitochondria l importreceptorsubunitTOM22homolog 4.042171001
328 IPI00917391.1 Uncharacterizedprotein 4.041543961
329 IPI00785127.1 Gm127(Fragment) 4.038759232  
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330 IPI00454905.4 cDNAFLJ42124fi s ,clone TESTI2009477,weaklys imi lartoTRICHOHYALIN 4.021264553
331 IPI00879096.1 SWI/SNFrelated,matrixassociated,actindependentregulatorofchromatin,sub 4.01543808
332 IPI00973955.1 voltageͲdependentanionchannel 3 3.995401144
333 IPI00171123.4 GATAzincfingerdomainͲconta iningprotein1 3.985080719
334 IPI00947213.1 phosphoribosyl pyrophosphate synthetase 2 3.976323605
335 IPI00555927.2 nudix(nucleos ide diphosphate l inkedmoietyX)Ͳtype motif6 3.956722021
336 IPI00910237.1 proteasome subuni tbeta typeͲ5i soform2 3.952091217
337 IPI00976591.1 chromosome 8openreadingframe 82 3.939365864
338 IPI00925558.1 CCR4ͲNOTtranscriptioncomplex,subuni t10 3.932148218
339 IPI00909361.1 solute carrierfami ly35,memberF6 3.895539284
340 IPI00910780.1 cDNAFLJ56706,highlys imi lartoBcl Ͳ2homologous antagonis t/ki l ler 3.895368576
341 IPI00884448.1 Isoform1ofZincfingerprotein862 3.870273113
342 IPI00947310.1 s ingleͲs trandedDNAbindingprotein1,mitochondria l 3.845179558
343 IPI00945908.1 ni tri lase fami ly,member2 3.827937365
344 IPI00925482.1 cleavage andpolyadenylationspeci ficfactor4,30kDa 3.797110558
345 IPI00217949.12 Ubiqui tinͲconjugatingenzyme E2S 3.775313377
346 IPI00647050.1 RNA3'Ͳterminal phosphate cyclase 3.746369123
347 IPI00014539.2 HomeoboxproteinHoxͲB9 3.746046543
348 IPI01015921.1 cDNAFLJ55361,highlys imi lartoNucleolarprotein11 3.741353989
349 IPI00922900.1 cDNAFLJ50656,highlys imi lartoSurfeitlocus protein4 3.731828213
350 IPI00978191.1 catenin(cadherinͲassociatedprotein),alpha 1,102kDa 3.726494074
351 IPI00926978.1 solute carrierfami ly25(carnitine/acylcarni tine trans locase),member20 3.700134039
352 IPI00329742.2 Fumarylacetoacetate hydrolase domainͲconta iningprotein2A 3.688626528
353 IPI00927280.1 Sin3AͲassociatedprotein,18kDa 3.676407814
354 IPI00555624.2 RAB3GAP1protein 3.675404549
355 IPI00449201.2 Isoform2ofUbiqui tinͲl ikeͲconjugatingenzyme ATG3 3.65760088
356 IPI00922359.1 ProteinͲLͲi soaspartate OͲmethyltrans ferase 3.632962704
357 IPI00305423.6 Chargedmultives icularbodyprotein6 3.618782759
358 IPI00909111.1 cDNAFLJ59179,highlys imi larto39Sribosomal proteinL9,mitochondria l 3.615469456
359 IPI00908627.1 cDNAFLJ59271,highlys imi lartoComponentofgems 4 3.610473156
360 IPI00984850.1 ActivationͲinducedcytidine deaminase 3.605342865
361 IPI00031022.2 Heatshockprotein,110kDa 3.593075514
362 IPI00006092.1 Phosphomannomutase 2 3.558265448
363 IPI00640997.1 isopentenyl Ͳdiphosphate del ta i somerase 1 3.542179108
364 IPI00893179.1 XͲrayrepai rcomplementingdefective repairinChinese hamstercel ls 6 3.53842473
365 IPI00983931.1 nonͲSMCcondens inI I complex,subuni tD3 3.53430891
366 IPI00909384.1 cDNAFLJ53505,highlys imi lartoChaperoneͲactivi tyofbc1complexͲl ike,mitochon 3.516098738
367 IPI01012335.1 TatDDNase domainconta ining1 3.515783548
368 IPI00009466.9 coi ledͲcoi l Ͳhel ixͲcoi ledͲcoi l Ͳhel ixdomainͲconta iningprotein2,mitochondria l Ͳl i 3.490503073
369 IPI00926034.1 coi ledͲcoi l domainconta ining12 3.489398479
370 IPI00645836.1 esterase D 3.473929644
371 IPI00792109.1 coi ledͲcoi l domainconta ining43 3.465866327
372 IPI00964365.1 AnnexinA5 3.459147692
373 IPI00909718.1 cDNAFLJ59809,highlys imi lartoBone marrowstromal antigen2 3.450926065
374 IPI00009659.3 Regulationofnuclearpre ͲmRNAdomainͲconta iningprotein1B 3.447496653
375 IPI00028376.1 Mitochondria l importinnermembrane trans locase subuni tTim8A 3.438120604
376 IPI00908328.1 cDNAFLJ51585,moderatelys imi lartoHomosapiens spindle pole bodycompone 3.432426691  
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377 IPI00478062.2 transducinͲl ike enhancerofspl i t2(E(sp1)homolog,Drosophi la) 3.425706387
378 IPI00964581.3 cDNAFLJ53827,highlys imi lartoSpeckleͲtype POZprotein 3.420134544
379 IPI00967045.1 bas ictranscriptionfactor3 3.417832136
380 IPI00001632.4 Isoform2ofUncharacteri zedproteinKIAA1522 3.405859947
381 IPI00396617.1 cDNAFLJ11699fi s ,clone HEMBA1005047,highlys imi lartoRASͲRELATEDPROTEINR 3.378495932
382 IPI00412272.2 SH3domainͲbindingglutamicacidͲri chͲl i ke protein2 3.369605064
383 IPI00384116.3 Isoform2ofPhosphoenolpyruvate carboxykinase [GTP],mitochondria l 3.349629402
384 IPI01011706.1 Superoxide dismutase 1(Fragment) 3.342024565
385 IPI00871391.3 XͲrayrepai rcomplementingdefective repairinChinese hamstercel ls 5(doubleͲ 3.335588455
386 IPI00302674.3 coi ledͲcoi l domainconta ining134 3.335077763
387 IPI00644866.1 cDNAFLJ12775fi s ,clone NT2RP2001677 3.332522869
388 IPI00549413.2 AnnexinA1 3.3319695
389 IPI00304163.5 cDNAFLJ57902,highlys imi lartoProteinMYG1 3.321031094
390 IPI01018329.1 cDNAFLJ57316,highlys imi lartoDNAmismatchrepa irproteinMsh2 3.316637516
391 IPI00385751.6 cDNAFLJ52780,highlys imi lartoTissue alpha ͲLͲfucos idase 3.296418428
392 IPI00965308.1 GTPase activatingprotein(SH3domain)bindingprotein2 3.28204298
393 IPI00161196.3 FͲbox/LRRͲrepeatprotein8 3.275252819
394 IPI00385021.1 ubiquinol Ͳcytochrome creductase complexchaperone 3.269675016
395 IPI01015633.1 ADPͲribosylationfactorͲl i ke 6interactingprotein1 3.264163017
396 IPI00903277.1 cDNAFLJ32474fi s ,clone SKNMC2000593,highlys imi lartoTumornecros is factorre 3.251574993
397 IPI00023939.1 Guanine nucleotide exchange factorMSS4 3.248258591
398 IPI00976381.1 caseinkinase 1,alpha 1 3.242902279
399 IPI01011217.1 Ful l ͲlengthcDNAclone CS0DC001YO07ofNeuroblastoma ofHomosapiens 3.239886045
400 IPI00790053.1 RFT1homolog(S.cerevis iae) 3.237701178
401 IPI00015806.3 Isoform1ofGenera l transcriptionfactor3Cpolypeptide 3 3.234821081
402 IPI01013001.1 GproteinͲcoupledreceptor89C 3.234705448
403 IPI00925720.1 cleavage andpolyadenylationspeci ficfactor4,30kDa 3.232334614
404 IPI00847495.2 cDNAFLJ55640,highlys imi lartoCoi ledͲcoi l domainͲconta iningprotein21 3.232254744
405 IPI00981963.1 FSHDregiongene 1 3.232080936
406 IPI00892665.1 guanine nucleotide bindingproteinͲl i ke 1 3.211884499
407 IPI00903024.1 methyl thioadenos ine phosphorylase 3.206659317
408 IPI00852874.1 SEC13homolog(S.cerevis iae) 3.198170185
409 IPI00640938.1 RNAbindingprotein,autoantigenic 3.198057652
410 IPI00027487.3 Creatine kinase MͲtype 3.193926573
411 IPI00879828.1 Isoform2ofDIS3Ͳl ike exonuclease 1 3.189982891
412 IPI00384120.1 Ful l ͲlengthcDNA5ͲPRIMEendofclone CS0DI052YD12ofPlacenta ofHomosapien 3.184959173
413 IPI00332071.4 Isoform1ofTetherconta iningUBXdomainforGLUT4 3.180494785
414 IPI00940222.2 Isoform3ofAͲkinase anchorprotein12 3.180082798
415 IPI00917463.1 Isoform3ofAncientubiquitous protein1 3.17835784
416 IPI00217465.5 Histone H1.2 3.168960571
417 IPI00911013.1 cDNAFLJ57175,moderatelys imi lartoPituitarytumorͲtransforminggene 1protein 3.165185452
418 IPI00106491.3 mRNAturnoverprotein4homolog 3.163933516
419 IPI00925162.1 trans ferrinreceptor(p90,CD71) 3.161654949
420 IPI00909338.2 lysosome membrane protein2 3.15091753
421 IPI00155466.7 succinateͲCoAl igase,GDPͲforming,beta subunit 3.147031069
422 IPI01014601.1 aminopeptidase puromycinsens itive 3.144531012
423 IPI00878073.1 migrationandinvas ionenhancer1 3.144301653  
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424 IPI00413614.3 Isoform2ofSymplekin 3.137643576
425 IPI00446667.1 cDNAFLJ41384fi s ,clone BRCAN2014602,moderatelys imi lartoDIACYLGLYCEROLKI 3.132920265
426 IPI00183065.6 coi ledͲcoi l andC2domainconta ining1A 3.12879324
427 IPI00894209.1 Isoform8ofInhibi torofgrowthprotein4 3.127731085
428 IPI01018135.1 cDNAFLJ39696fi s ,clone SMINT2011033,highlys imi lartoSortingandassemblym 3.12726903
429 IPI00012313.3 Golgi phosphoprotein3Ͳl ike 3.105096102
430 IPI00916612.1 gamma Ͳglutamylcyclotransferase i soform4 3.096665859
431 IPI00328390.2 Isoform1ofPolycombgroupRINGfingerprotein5 3.09583354
432 IPI00383290.1 leucyl ͲtRNAsynthetase 3.094269037
433 IPI00332157.2 39Sribosomal proteinL54,mitochondria l 3.093358755
434 IPI00966017.1 chromosome 5openreadingframe 24 3.079425335
435 IPI00922210.1 cDNAFLJ52564,moderatelys imi lartoZincfingerprotein346 3.079051018
436 IPI01011569.1 cDNA,FLJ78951,highlys imi lartoCreatine kinase,ubiqui tous mitochondria l 3.063862324
437 IPI00019269.3 WDrepeatͲconta iningprotein61 3.061416388
438 IPI00983408.1 trans forminggrowthfactor,beta receptorI I I 3.056727171
439 IPI00927046.1 epi thel ia l cel l transformingsequence 2oncogene 3.054199457
440 IPI00910126.1 cDNAFLJ59119,highlys imi lartoReceptorexpress ionͲenhancingprotein6 3.046956062
441 IPI00935818.1 adenosylhomocysteinase i soform2 3.045629501
442 IPI00797997.2 5Ͳformyl tetrahydrofolate cycloͲl igase i soformb 3.045045376
443 IPI00980553.1 cDNAFLJ50204,highlys imi larto2,4Ͳdienoyl ͲCoAreductase,mitochondria l 3.035377979
444 IPI00908957.1 cDNAFLJ61419,highlys imi lartoRalAͲbindingprotein1 3.023126841
445 IPI00395401.3 Isoform3ofCdc42Ͳinteractingprotein4 3.016060829
446 IPI00216508.3 Isoform2ofSortingnexinͲ3 3.014677763
447 IPI00019487.3 Probable 7,8ͲdihydroͲ8Ͳoxoguanine triphosphatase NUDT15 3.005639315
448 IPI00927053.2 26Sprotease regulatorysubuni t72 3.003509283
449 IPI00168442.5 FAM75Ͳl ike proteinC9orf79 3.003401756
450 IPI00954159.1 Isoform1ofProteinELYS 2.998862505
451 IPI00970906.1 Isoform1ofTranscriptionelongationfactorANͲtermina l andcentra l domainͲco 2.997951031
452 IPI00644228.1 cDNAFLJ52965,highlys imi lartoUridineͲcytidine kinase 1 2.992982388
453 IPI00878538.1 s ignal transducerandactivatoroftranscription5A 2.991655588
454 IPI00001835.3 ZincfingerandBTBdomainͲconta iningprotein4 2.986486912
455 IPI00030296.6 Eukaryotictrans lationini tia tionfactor4A,i soform2,i soformCRA_b 2.980415583
456 IPI00292393.5 Sodiumchannel proteintype 4subuni talpha 2.980061769
457 IPI01011145.1 OTUdomain,ubiquitinaldehyde binding1 2.975468874
458 IPI00983405.1 l inͲ7homologC(C.elegans) 2.975069761
459 IPI00910998.1 cDNAFLJ51306,highlys imi lartoHomosapiens ci trate lyase beta l ike (CLYBL),tra 2.962366104
460 IPI00397801.4 Fi laggrinͲ2 2.959728479
461 IPI00926172.1 WDrepeatdomain12 2.95571661
462 IPI00298139.5 cDNAFLJ39639fi s ,clone SMINT2003340 2.954498768
463 IPI00748303.3 zincfingerRNAbindingprotein 2.952274323
464 IPI00001830.1 HeterochromatinͲspeci ficnonhis tone protein(Fragment) 2.950314045
465 IPI00908894.1 cDNAFLJ57473,highlys imi lartoRibonuclease Pproteinsubuni tp29 2.948116064
466 IPI01009115.1 NͲacetylglucosamine kinase 2.947503805
467 IPI00556611.1 39Sribosomal proteinL22,mitochondria l i soformb 2.935769081
468 IPI00449669.2 Isoform2ofTrans loconͲassociatedproteinsubunitalpha 2.932744741
469 IPI00967585.1 guanine nucleotide bindingprotein(Gprotein),beta polypeptide 2Ͳl ike 1 2.930656672
470 IPI00791495.2 HLAͲBassociatedtranscript1 2.927881479  
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471 IPI00785036.8 nuclearGTPase,germinal centerassociated 2.927058935
472 IPI00216529.1 IsoformEofPlasma membrane ca lciumͲtransportingATPase 1 2.924975872
473 IPI00219669.5 CarbonicanhydraseͲrelatedprotein 2.921352863
474 IPI00480049.2 IsoformBofInos i tol polyphosphate 5Ͳphosphatase OCRLͲ1 2.917422295
475 IPI00641749.2 Isoform1ofJanus kinase andmicrotubuleͲinteractingprotein3 2.914739132
476 IPI00946474.1 NADHdehydrogenase (ubiquinone)1alpha subcomplex,5,13kDa 2.913308382
477 IPI00977662.1 Parkinsondisease 7domainconta ining1 2.913131475
478 IPI00307665.4 Isoform1ofZincfingerprotein518A 2.90212512
479 IPI00975554.1 proteintyros ine phosphatase type IVA,member2 2.90075922
480 IPI00977503.1 midl ineͲ1i soform5 2.899876595
481 IPI00981929.2 cDNAFLJ33978fi s ,clone DFNES2004354,highlys imi lartoInhibi torofnuclearfact 2.894971848
482 IPI00022426.1 ProteinAMBP 2.892508745
483 IPI00797343.2 coi ledͲcoi l domainconta ining117 2.888273001
484 IPI00296219.4 Glutaminase l i veri soform,mitochondria l 2.885802031
485 IPI00894139.1 golgi toERtrafficprotein4homolog(S.cerevis iae) 2.883171082
486 IPI00910017.1 cDNAFLJ54153,weaklys imi lartoHomosapiens Mof4fami lyassociatedprotein 2.88300252
487 IPI00220147.1 Isoform3ofPantothenate kinase 1 2.88271594
488 IPI00031650.3 Isoform1ofProteinsyndesmos 2.873019934
489 IPI00298409.3 PhosducinͲl i ke protein 2.870197058
490 IPI00910019.2 Majorvaul tprotein 2.869003296
491 IPI01009997.1 cDNAFLJ51981,highlys imi lartoHistone deacetylase 1 2.865437031
492 IPI00985171.1 proteoglycan4 2.86326766
493 IPI00028078.1 IsoformAofPotass iumchannel subfami lyKmember10 2.862164259
494 IPI01013425.1 cDNAFLJ45045fi s ,clone BRAWH3021580,highlys imi lartoRestin 2.858755589
495 IPI00643380.2 chromosome 18openreadingframe 8 2.857409954
496 IPI00893403.1 exportin1(CRM1homolog,yeast) 2.856910229
497 IPI00179408.3 Tetratricopeptide repeatprotein9C 2.856591225
498 IPI00005740.1 NeighborofCOX4 2.854933977
499 IPI00908538.1 arginine andglutamate rich1 2.851033449
500 IPI00922399.1 cDNAFLJ57937,highlys imi lartoDNAͲdirectedRNApolymerase I I 33kDa polypep 2.848650932
501 IPI00384047.1 Isoform1ofTraffi ckingproteinparticle complexsubuni t6B 2.843178988
502 IPI00894369.1 neuroblastoma ampl i fiedsequence 2.830990076
503 IPI00927360.1 nuclearreceptorsubfami ly4,groupA,member2 2.830797911
504 IPI00432753.2 Isoform1ofTors inͲ2A 2.830038071
505 IPI00011865.2 Isoform2ofPlateletͲderivedgrowthfactorD 2.824905634
506 IPI00946064.1 geranylgeranyl diphosphate synthase 1 2.824784279
507 IPI01011129.1 cDNAFLJ38453fi s ,clone FEBRA2019663,highlys imi lartoHomosapiens DEAD(As 2.811005831
508 IPI01012915.1 cDNAFLJ53462,highlys imi lartoTranscriptionintermediaryfactor1Ͳalpha 2.80894351
509 IPI00651702.1 SATB2protein 2.80437851
510 IPI00909427.1 cDNAFLJ59384,highlys imi lartoStriatinͲ4 2.804109097
511 IPI00103004.4 Isoform2ofIntracel lularhyaluronanͲbindingprotein4 2.80377388
512 IPI00307805.5 GrowtharrestandDNAdamage Ͳinducible proteinGADD45beta 2.800504923
513 IPI00219898.1 Isoform2ofNephrin 2.794588804
514 IPI00894394.1 Isoform4ofImmunoglobul inͲl i ke andfibronectintype I I I domainͲconta iningpro 2.789975643
515 IPI00013706.5 39Sribosomal proteinL20,mitochondria l 2.773723125
516 IPI00290764.5 Isoform2ofChronicl ymphocyticleukemia deletionregiongene 6protein 2.770787239
517 IPI00748058.1 Isoform2ofSH3andcys teineͲrichdomainͲconta iningprotein3 2.77041173  
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518 IPI00396551.3 Isoform2ofRAD51Ͳassociatedprotein1 2.768308878
519 IPI00552983.6 ProteinofunknownfunctionDUF634fami lyprotein 2.762229204
520 IPI00002535.2 Peptidyl Ͳprolyl ci s Ͳtrans i somerase FKBP2 2.761423111
521 IPI00554560.4 chromosome 16openreadingframe 88 2.757285118
522 IPI00646520.1 nonͲPOUdomainconta ining,octamerͲbinding 2.753503561
523 IPI00984596.1 leucineͲrichrepeats andIQmoti fconta ining1 2.752708912
524 IPI01011419.1 ATP9Bprotein 2.711783409
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Table A4:  BPPM-revealed potential nonhistone targets of G9a Y1154A in HEK293T 
cells using Hey SAM. These proteins are not present in control samples. 
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a le S3. BP M-revealed potential nonhistone targets of EuHMT2 in HEK293T cells with the 
EuHMT21-Y1154A mutant and Hey-SAM 6 as BPPM reagents. These proteins are not present 
in the control (empty-vector transfected HEK293T cells). 
Serial Accession Description ScoreofEuHMT2
1 IPI00296337.2 Isoform1ofDNAͲdependentproteinkinase cata lyticsubunit 683.7383871
2 IPI00220795.4 Isoform2ofHistoneͲl ys ine NͲmethyl transferase EHMT2 466.1512184
3 IPI00302592.2 Isoform2ofFi laminͲA 207.2757595
4 IPI00909140.9 cDNAFLJ56903,highlys imi lartoTubul inbeta Ͳ7chain 134.9918664
5 IPI00024279.4 HEATrepeatͲconta iningprotein1 120.841238
6 IPI00883857.2 IsoformLongofHeterogeneous nuclearribonucleoproteinU 118.6945181
7 IPI00006482.1 IsoformLongofSodium/potass iumͲtransportingATPase subunitalpha Ͳ1 108.9071741
8 IPI00414482.3 Isoform1ofGenera l transcriptionfactor3Cpolypeptide 1 108.9063585
9 IPI00893062.1 XͲrayrepa ircomplementingdefective repa irinChinese hamstercel l s 6 98.84765005
10 IPI00790636.1 HLAͲBassociatedtranscript1 91.60756612
11 IPI01018179.1 Isoform4ofInterleukinenhancerͲbindingfactor3 91.36282182
12 IPI00216049.1 Isoform1ofHeterogeneous nuclearribonucleoproteinK 88.98906755
13 IPI00293464.5 DNAdamageͲbindingprotein1 81.18342185
14 IPI00402182.2 Isoform2ofHeterogeneous nuclearribonucleoproteinQ 74.11966062
15 IPI00026202.1 60Sribosomal proteinL18a 70.69340944
16 IPI00010204.1 Serine/arginineͲrichspl icingfactor3 66.33425546
17 IPI00894141.2 DNAͲdirectedRNApolymerase 65.24241805
18 IPI00030275.5 Heatshockprotein75kDa,mitochondria l 59.69980907
19 IPI01015236.1 cDNAFLJ52378,highlys imi lartoTubul inbeta Ͳ7chain 58.46184039
20 IPI01014074.1 cDNAFLJ53296,highlys imi lartoSerine/threonineͲproteinphosphatase 2A65kDa r 58.19350886
21 IPI00745272.3 Isoform2ofGlyoxa lase domainͲconta iningprotein4 57.74798656
22 IPI00646899.2 ribosomal proteinL10 57.57459235
23 IPI00892976.1 Euchromatichis toneͲl ys ine NͲmethyl transferase 2 57.4455924
24 IPI00550451.1 Serine/threonineͲproteinphosphatase PP1Ͳalpha cata lyticsubunit 56.66304755
25 IPI00301109.4 Isoform1ofInorganicpyrophosphatase 2,mitochondria l 54.79612994
26 IPI00026625.1 Isoform1ofNuclearpore complexproteinNup155 53.59179616
27 IPI00299608.3 Isoform1of26Sproteasome nonͲATPase regulatorysubunit1 52.03631973
28 IPI00017617.1 Probable ATPͲdependentRNAhel icase DDX5 51.95726752
29 IPI00003348.3 Guanine nucleotideͲbindingproteinG(I)/G(S)/G(T)subunitbeta Ͳ2 50.74977994
30 IPI00939492.2 HLAͲBassociatedtranscript8BAT8i soforma variant(Fragment) 50.66032219
31 IPI00003964.4 Isoform2ofProbable ubiqui tincarboxyl Ͳtermina l hydrolase FAFͲX 50.29524088
32 IPI00291755.6 Isoform1ofNuclearpore membrane glycoprotein210 49.22668934
33 IPI01015522.1 cDNAFLJ55253,highlys imi lartoActin,cytoplasmic1 47.32136416
34 IPI00784332.4 Simi lartoTubul inalpha Ͳ3C/Dchain 47.26412559
35 IPI00064328.3 proteinarginine NͲmethyl transferase 5i soformb 46.35761309
36 IPI00647102.4 cDNAFLJ42590fi s ,clone BRACE3009708,highlys imi lartoSodium/potass iumͲtransp 45.72382426
37 IPI00604620.3 Nucleol in 45.58505511
38 IPI00216530.1 IsoformKofPlasma membrane ca lciumͲtransportingATPase 1 45.45633245
39 IPI00940257.2 cDNAFLJ52362,highlys imi lartoTͲcomplexprotein1subuniteps i lon 45.03963923
40 IPI00793930.1 TUBA1Bprotein 44.1114819
41 IPI00642042.3 Putative uncharacterizedproteinDKFZp686J1372 43.91723847
42 IPI00965271.1 smal l subunitprocessome component20homolog 42.85621881
43 IPI00983023.1 phosphoglycerate mutase 1Ͳl i ke 42.1787138
44 IPI00964983.1 ribosomal proteinS3A 41.65900421
45 IPI00796337.1 poly(rC)Ͳbindingprotein2i soforma 41.27402925
46 IPI01013547.1 cystathionineͲbeta Ͳsynthase 40.56543255  
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47 IPI00472939.3 Signal peptidase complexsubunit2 40.41459775
48 IPI00171438.2 ThioredoxindomainͲconta iningprotein5 39.3563168
49 IPI00456429.3 UbiquitinͲ60Sribosomal proteinL40 38.90302277
50 IPI00013891.1 IsoformLongofTransformerͲ2proteinhomologalpha 37.85644484
51 IPI00903323.1 cDNAFLJ38640fi s ,clone HHDPC2003472,highlys imi lartoCHLORIDEINTRACELLULAR 35.82258964
52 IPI00646721.1 Ubiquitincarboxyl Ͳterminal hydrolase 35.46411991
53 IPI00787827.1 Isoform2ofPresequence protease,mitochondria l 33.91579771
54 IPI00446235.2 Isoform2ofNADHͲcytochrome b5reductase 3 33.31059861
55 IPI00166293.5 His tone H2Btype 3ͲB 32.30172586
56 IPI00304417.7 Isoci trate dehydrogenase [NAD]subunitbeta,mitochondria l precursor 32.26378059
57 IPI01014975.1 Tal in1 31.65581322
58 IPI01018004.1 3'(2'),5'Ͳbisphosphate nucleotidase 1 31.31366825
59 IPI00099986.5 KetosamineͲ3Ͳkinase 31.07059574
60 IPI00005719.1 Isoform1ofRas ͲrelatedproteinRabͲ1A 30.42552304
61 IPI00306048.5 Isoform1ofATPase fami lyAAAdomainͲconta iningprotein3B 30.22437739
62 IPI00220487.4 Isoform1ofATPsynthase subunitd,mitochondria l 29.69207406
63 IPI00294701.1 CDKͲactivatingkinase assemblyfactorMAT1 28.72710562
64 IPI00297492.2 Dol ichyl Ͳdiphosphool igosaccharideͲͲproteinglycosyl transferase subunitSTT3A 28.56105924
65 IPI00154473.5 Isoform1ofElongationfactorG,mitochondria l 28.23124099
66 IPI00031627.4 DNAͲdirectedRNApolymerase II subunitRPB1 27.87834454
67 IPI00908647.1 cDNAFLJ59942,highlys imi lartoProstaglandinEsynthase 3 27.80573511
68 IPI00011307.4 Bi functional methylenetetrahydrofolate dehydrogenase/cyclohydrolase,mitochon 27.65156341
69 IPI00008485.1 Cytoplasmicaconitate hydratase 27.61344528
70 IPI00328985.1 Isoform1ofTHOcomplexsubunit6homolog 27.59589958
71 IPI00384456.4 IsoformGTBPͲNofDNAmismatchrepairproteinMsh6 27.50466967
72 IPI00032304.2 PlastinͲ1 27.36275649
73 IPI00335130.5 mitochondria l ribosomal proteinL37 27.21831703
74 IPI00018288.1 DNAͲdirectedRNApolymerase II subunitRPB3 26.89926624
75 IPI01010848.1 Methionine aminopeptidase 26.41838145
76 IPI00946054.3 Isoform3ofHistoneͲl ys ine NͲmethyl transferase EHMT1 25.92109776
77 IPI00472054.2 IsoformAofConsti tutive coactivatorofPPARͲgamma Ͳl i ke protein1 25.78061318
78 IPI00924935.1 cDNAFLJ57106,highlys imi lartoTransferrinreceptorprotein1 24.9913497
79 IPI00168209.3 DTWdomainͲconta iningprotein2 24.76762366
80 IPI00032849.2 Nucleolarprotein16 24.5403409
81 IPI00983716.1 ubiqui tinproteinl igase E3componentnͲrecognin5 24.53851151
82 IPI00418202.2 pyridoxa l (pyridoxine,vi taminB6)kinase 24.44453502
83 IPI00305978.4 AflatoxinB1aldehyde reductase member2 24.39702511
84 IPI00217975.4 LaminͲB1 24.35361624
85 IPI00010845.3 NADHdehydrogenase [ubiquinone]i ronͲsul furprotein8,mitochondria l 24.22619653
86 IPI00926412.1 Transformation/transcriptiondomainͲassociatedproteinvariant 23.87043071
87 IPI00032872.3 28Sribosomal proteinS16,mitochondria l 23.81681204
88 IPI00843975.1 Ezrin 23.72064447
89 IPI00915022.2 Isoform1ofTHOcomplexsubunit2 23.37501526
90 IPI00909083.1 eukaryoticpeptide chainrelease factorGTPͲbindingsubunitERF3Ai soform2 23.2077117
91 IPI00927876.1 polymerase (RNA)I I (DNAdirected)polypeptide H 23.01699042
92 IPI00926706.1 actinrelatedprotein2/3complex,subunit1A,41kDa 22.53975105
93 IPI00975963.1 eukaryotictrans lationelongationfactor1delta (guanine nucleotide exchange pro 22.28946233  
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94 IPI00975850.1 ribosomal proteinL8 22.23127723
95 IPI00641040.1 esterase D 22.21193528
96 IPI00000792.1 Quinone oxidoreductase 22.15558577
97 IPI00009607.1 Ras ͲrelatedproteinRapͲ2c 22.08097172
98 IPI00410017.1 Isoform2ofPolyadenylateͲbindingprotein1 21.9293642
99 IPI00217992.1 Isoform3ofDystonin 21.92004824
100 IPI00339385.1 Isoform2ofRetinol dehydrogenase 11 21.70267034
101 IPI00333985.2 Isoform2ofNodal modulator2 21.68538427
102 IPI00465022.9 Isoform2ofStructura l maintenance ofchromosomes flexible hinge domainͲconta 21.6378448
103 IPI00037070.3 heatshock70kDa protein8 21.34835196
104 IPI00414860.6 60Sribosomal proteinL37a 21.27662992
105 IPI01016026.1 cDNAFLJ53202,highlys imi lartoExportinͲ2 21.27041531
106 IPI00305258.4 Isoform1ofMOSCdomainͲcontainingprotein1,mitochondria l 21.26810241
107 IPI01014700.1 cDNAFLJ51193,highlys imi lartoDNAmismatchrepairproteinMsh2 21.0701077
108 IPI01010578.1 cytoplasmicFMR1interactingprotein2 21.02910089
109 IPI00295992.4 Isoform2ofATPase fami lyAAAdomainͲconta iningprotein3A 20.9871881
110 IPI00301204.2 Isoform1ofRetinol dehydrogenase 13 20.79895854
111 IPI01013219.1 prohibi tin2 20.71885967
112 IPI00328815.4 Isoform1ofUbiquitincarboxyl Ͳterminal hydrolase 48 20.68755722
113 IPI00056494.5 60Sribosomal proteinL36a Ͳl i ke 19.84472513
114 IPI00182757.10 Isoform1ofProteinKIAA1967 19.83158898
115 IPI00967041.1 Ubiquitincarrierprotein 19.72968006
116 IPI00293260.5 Isoform1ofDnaJhomologsubfami lyCmember10 19.13160372
117 IPI01011635.1 CDC10proteinvariant(Fragment) 19.08216
118 IPI00748807.2 Isoform1ofNuclearpore complexproteinNup160 19.02867842
119 IPI01014189.1 MYCbindingprotein2 18.75863028
120 IPI00157908.4 Isoform3ofApoptos is Ͳinducingfactor1,mitochondria l 18.59455872
121 IPI00844172.1 Myos in 18.58733106
122 IPI00295889.2 Signal recognitionparticle 19kDa protein 18.56547809
123 IPI00980391.2 cDNAFLJ54047,highlys imi lartoAlpha Ͳ1catenin 18.41666961
124 IPI00014213.1 Probable leucyl ͲtRNAsynthetase,mitochondria l 18.35570359
125 IPI00027699.2 Proteasome (Prosome,macropain)26Ssubunit,nonͲATPase,10 18.28348708
126 IPI00885106.1 Simi lartoTransmembrane 9superfami lymember4precursor 18.13494015
127 IPI00420108.6 Dihydrol ipoyl lys ineͲres idue succinyl transferase componentof2Ͳoxoglutarate dehy 18.09095812
128 IPI00514701.1 Isoform2ofMitoticcheckpointproteinBUB3 17.8680315
129 IPI00903112.1 cDNAFLJ36533fi s ,clone TRACH2004428,highlys imi lartoLactotransferrin(Fragmen 17.33468866
130 IPI00890827.1 Isoform2ofSerine/threonineͲproteinphosphatase 6cata lyticsubunit 17.32423234
131 IPI00215888.4 Signal recognitionparticle 72kDa protein 17.1121819
132 IPI00619903.3 Isoform2ofUDPͲglucose:glycoproteinglucosyl transferase 1 16.92570233
133 IPI00902914.2 transmembrane 9superfami lymember2 16.88384128
134 IPI00299254.4 Eukaryotictrans lationini tiationfactor5B 16.79346323
135 IPI01012145.1 Hydroxymethylbi lane synthase 16.78157663
136 IPI00908696.2 ADPͲribosylationͲl i ke factor6interactingprotein5 16.75019765
137 IPI00788781.1 fattyacidbindingprotein5(psorias is Ͳassociated) 16.7113061
138 IPI01014596.1 ubiquitinC 16.70653343
139 IPI00019329.1 Dyneinl ightchain1,cytoplasmic 16.70442867
140 IPI00884904.1 Isoform3ofProteinAHNAK2 16.68552947  
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141 IPI00295427.5 Isoform1of39Sribosomal proteinL39,mitochondria l 16.68056345
142 IPI00946099.1 sorcin 16.52582979
143 IPI00640401.1 ATPase,Na+/K+transporting,alpha 2(+)polypeptide 16.52371335
144 IPI00645329.1 Isoform3ofHistoneͲbindingproteinRBBP4 16.43619323
145 IPI00020557.2 ProlowͲdens i tyl ipoproteinreceptorͲrelatedprotein1 16.39069438
146 IPI00006252.3 Aminoacyl tRNAsynthase complexͲinteractingmulti functional protein1 16.3434124
147 IPI00658000.3 Isoform1ofInsul inͲl i ke growthfactor2mRNAͲbindingprotein3 16.23186374
148 IPI00024913.2 IsoformLongofES1proteinhomolog,mitochondria l 16.21972036
149 IPI00816106.3 Isoform4ofDedicatorofcytokines is protein7 16.0455668
150 IPI00792218.1 proteasome subunitalpha typeͲ4i soform2 16.04161143
151 IPI00647678.2 cDNAFLJ52703,highlys imi lartoAsparaginyl ͲtRNAsynthetase,cytoplasmic 15.62722707
152 IPI00554701.2 Cytochrome bͲc1complexsubunit9 15.61058617
153 IPI00305289.2 Kines inͲl i ke proteinKIF11 15.60377216
154 IPI00103732.1 Thymidylate synthetase,i soformCRA_a 15.59636855
155 IPI00642326.1 zincfinger,MYMͲtype 3 15.44959974
156 IPI00396203.7 Isoform1ofTubul inͲspeci ficchaperone D 15.43279815
157 IPI00645518.1 Isoform1ofCDPͲdiacylglycerol ͲͲinos i tol 3Ͳphosphatidyl transferase 15.31668091
158 IPI00024719.1 IsoformAofHistone acetyl transferase type Bcata lyticsubunit 15.30857706
159 IPI00293735.2 Elongatorcomplexprotein1 15.27497411
160 IPI00929313.1 coi ledͲcoi l domainconta ining168 15.07390261
161 IPI01011651.1 nucleoporin98kDa 15.02397823
162 IPI01012847.1 RAB35,memberRASoncogene fami ly 14.94564271
163 IPI00398727.3 Isoform2ofAcyl Ͳproteinthioesterase 1 14.82557869
164 IPI00981725.1 peptidylprolyl i somerase H(cyclophi l inH) 14.69265079
165 IPI01013095.1 cDNA,FLJ79243,highlys imi lartoEukaryotictrans lationini tiationfactor3subunit1 14.58456922
166 IPI00743813.3 Isoform1ofAbnormal spindleͲl i ke microcephalyͲassociatedprotein 14.49706197
167 IPI00011619.4 Bi functional 3'Ͳphosphoadenosine 5'Ͳphosphosul fate synthase 1 14.39087629
168 IPI00328361.7 Seryl ͲtRNAsynthetase,mitochondria l 14.34127712
169 IPI00374272.3 chromosome 5openreadingframe 51 14.28932667
170 IPI00034159.1 VͲtype protonATPase subunitd1 14.14081883
171 IPI00032387.1 DNArepl icationcomplexGINSproteinPSF1 14.1289773
172 IPI00216770.1 Isoform2of26Sprotease regulatorysubunit6B 14.11542821
173 IPI00383500.3 Isoform2ofFermitinfami lyhomolog2 14.09937
174 IPI00414384.1 Isoform1ofHydroxysteroiddehydrogenaseͲl i ke protein2 13.95179152
175 IPI00607577.2 superoxide dismutase [Mn],mitochondria l i soformBprecursor 13.84640741
176 IPI00910755.1 cDNAFLJ51707,highlys imi lartoHeatͲshockprotein105kDa 13.83009171
177 IPI00041325.1 H/ACAribonucleoproteincomplexsubunit2 13.82135797
178 IPI00177498.16 Isoform3ofLIMandca lponinhomologydomains Ͳconta iningprotein1 13.80416584
179 IPI00552913.4 Isoform2ofSyntaxinͲ7 13.76695967
180 IPI00028005.1 Nuclearpore complexproteinNup107 13.68241692
181 IPI00019407.1 Sterol Ͳ4Ͳalpha Ͳcarboxylate 3Ͳdehydrogenase,decarboxylating 13.59610152
182 IPI00852917.1 Copine I 13.57617283
183 IPI00300078.6 Periodictryptophanprotein2homolog 13.56396508
184 IPI00744711.2 Polyribonucleotide nucleotidyl transferase 1,mitochondria l 13.42098427
185 IPI00790334.1 Polymerase (DNAdirected),eps i lon,i soformCRA_a 13.40018821
186 IPI00166749.3 Mitochondria l Ͳprocess ingpeptidase subunitalpha 13.38723707
187 IPI00952964.1 LͲlactate dehydrogenase Achaini soform4 13.30574989  
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188 IPI00966693.1 glutathione SͲtransferase,CͲterminal domainconta ining 13.25156164
189 IPI00939526.1 Uncharacterizedprotein 13.2412262
190 IPI00965290.1 Isoform3ofCul l inͲ4B 13.20198965
191 IPI00983406.1 branchedͲchainͲaminoͲacidaminotransferase,cytosol ici soform5 13.14481378
192 IPI00477424.4 DHX57proteinvariant(Fragment) 13.1199398
193 IPI00790937.3 60Sribosomal exportproteinNMD3 13.08651328
194 IPI00979853.1 eukaryotictrans lationini tiationfactor3,subunitM 13.01624179
195 IPI00798401.2 cDNAFLJ50992,highlys imi lartoCoroninͲ1C 12.9656148
196 IPI00742682.2 NucleoproteinTPR 12.95771432
197 IPI01015254.1 cDNAFLJ53681,highlys imi lartoGlycogen(s tarch)synthase,muscle 12.92818904
198 IPI00910697.1 cDNAFLJ53703,highlys imi lartoHistidyl ͲtRNAsynthetase 12.88820577
199 IPI00658145.3 Isoform1ofBRCA1ͲassociatedATMactivator1 12.84551978
200 IPI00328911.3 E3ubiquitinͲproteinl igase HECTD1 12.81816292
201 IPI00789281.2 Isoform3ofProteinvi ri l i zerhomolog 12.78548574
202 IPI01012511.1 cDNAFLJ50223,highlys imi lartoSterol OͲacyl transferase 1 12.65474391
203 IPI00382699.2 Isoform5ofFi laminͲB 12.55565691
204 IPI00878236.3 fibrous sheathͲinteractingprotein2 12.4965713
205 IPI00944623.1 Isoform3ofGolginsubfami lyAmember3 12.46515846
206 IPI01011723.1 cDNAFLJ51704,highlys imi lartoADPͲribosylationfactorͲl i ke protein1 12.1291225
207 IPI01009186.1 cDNAFLJ58476,highlys imi lartoPoly(rC)Ͳbindingprotein2 12.12248826
208 IPI00640096.2 cDNAFLJ57101,highlys imi lartoSACdomainͲconta iningprotein3 12.09884024
209 IPI00182180.2 OTUdomainͲconta iningprotein6B 11.93218946
210 IPI00871617.1 Isoform1ofLys Ͳ63Ͳspeci ficdeubiqui tinase BRCC36 11.8933475
211 IPI00893923.1 Isoform2ofGolgi toERtrafficprotein4homolog 11.80594444
212 IPI00003455.3 Isoform4ofNucleoporinNDC1 11.69121122
213 IPI00966935.1 methionyl aminopeptidase 1 11.54681015
214 IPI00976647.1 staufen,RNAbindingprotein,homolog2(Drosophi la ) 11.51790977
215 IPI00552886.1 Exosomal core proteinCSL4 11.51610184
216 IPI00552920.2 Exosome complexcomponentRRP43 11.48156738
217 IPI00218106.3 Isoform2ofTranscriptionelongationfactorAprotein1 11.38789392
218 IPI01011408.1 cDNAFLJ16235fi s ,clone FEBRA2028516 11.30251765
219 IPI00646415.1 RAB14,memberRASoncogene fami ly 11.29374671
220 IPI00743994.2 lamininsubunitalpha Ͳ3i soform3 11.21005273
221 IPI00002335.1 huntingtin 11.17695832
222 IPI00797126.2 nascentpolypeptideͲassociatedcomplexsubunitalpha i soforma 11.11984396
223 IPI00921912.2 rodcGMPͲspeci fic3',5'Ͳcycl icphosphodiesterase subunitbeta i soform3 10.99007988
224 IPI00297084.7 Dol ichyl Ͳdiphosphool igosaccharideͲͲproteinglycosyl transferase 48kDa subunit 10.89367771
225 IPI00294879.1 RanGTPaseͲactivatingprotein1 10.86647868
226 IPI00917001.2 cDNA,FLJ79439,highlys imi lartoNEDD8Ͳactivatingenzyme E1cata lyticsubunit 10.85314226
227 IPI00291175.7 Isoform1ofVincul in 10.82610989
228 IPI00171459.4 Inactive hydroxysteroiddehydrogenaseͲl i ke protein1 10.82172179
229 IPI00939530.1 cDNAFLJ34106fi s ,clone FCBBF3008073,highlys imi lartoSPLICINGFACTOR,ARGININ 10.78457308
230 IPI00033907.1 AnaphaseͲpromotingcomplexsubunit1 10.73571968
231 IPI00220665.6 Isoform3ofHexokinaseͲ1 10.71835494
232 IPI00329719.1 Myos inͲId 10.68723392
233 IPI00910514.1 xaa ͲProdipeptidase i soform2 10.65641642
234 IPI00014253.4 Ribosome biogenes is regulatoryproteinhomolog 10.64323997  
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235 IPI00181135.4 BranchedͲchainͲaminoͲacidaminotransferase 10.63430691
236 IPI00900328.3 transcriptionactivatorBRG1i soformF 10.62978029
237 IPI00384745.4 guanine nucleotide bindingproteinͲl i ke 1 10.53790355
238 IPI00791573.1 Isoform2ofSuppressorofG2al lele ofSKP1homolog 10.52630734
239 IPI00877948.1 Minichromosome maintenance complexcomponent5 10.50127697
240 IPI00394699.3 Uncharacterizedprotein 10.49009347
241 IPI00169168.1 Isoform3ofFͲboxonlyprotein22 10.43747807
242 IPI00396218.2 SCY1Ͳl i ke protein2 10.42661786
243 IPI00786874.1 Putative Golgi pHregulatorC 10.37785602
244 IPI00908668.1 apoptos is inhibi tor5i soformc 10.30549598
245 IPI00218922.5 Trans locationproteinSEC63homolog 10.23215318
246 IPI00414980.2 Isoform2ofMyos inͲIb 10.22754383
247 IPI00910169.1 cDNAFLJ54122,highlys imi lartoCytosol aminopeptidase 10.0674417
248 IPI00946283.1 transportin3 10.05775833
249 IPI00968174.1 IQmoti fconta iningGTPase activatingprotein2 9.929574966
250 IPI00002557.1 Coatomersubunitgamma Ͳ2 9.908848047
251 IPI00843789.2 Glycine dehydrogenase [decarboxylating],mitochondria l 9.883997917
252 IPI00909961.1 cDNAFLJ50720,highlys imi lartoHomosapiens tropomyos in3(TPM3),transcriptvar 9.837865829
253 IPI00910728.1 cDNAFLJ57599,moderatelys imi lartoEukaryotictrans lationini tiationfactor3subu 9.831304789
254 IPI00470922.2 Isoform2ofNͲalpha Ͳacetyl transferase 50,NatEcata lyticsubunit 9.777771473
255 IPI00219526.6 Isoform1ofPhosphoglucomutaseͲ1 9.775624275
256 IPI00239415.4 Polytrophin 9.697652102
257 IPI00925016.1 NͲacylaminoacyl Ͳpeptide hydrolase 9.694558859
258 IPI00215764.1 IsoformShortofMetastas is ͲassociatedproteinMTA1 9.636773586
259 IPI00216999.2 Pumi l iodomainͲconta iningproteinC14orf21 9.629089594
260 IPI00074489.1 NDUFB10protein 9.616615295
261 IPI00856038.2 cDNAFLJ53358,highlys imi lartoHeterogeneous nuclearribonucleoproteinR 9.535647154
262 IPI00646889.1 Uncharacterizedprotein 9.468101025
263 IPI00061245.4 28Sribosomal proteinS10,mitochondria l 9.452897549
264 IPI00922035.1 cDNAFLJ52950 9.363273859
265 IPI00106847.3 IsoformGTBPͲal tofDNAmismatchrepairproteinMsh6 9.361681223
266 IPI00000846.2 Isoform1ofChromodomainͲhel icaseͲDNAͲbindingprotein4 9.30049777
267 IPI00976265.2 dipeptidyl Ͳpeptidase 3 9.297903538
268 IPI00945912.1 cDNAFLJ59963,highlys imi lartoHomosapiens multiple substrate l ipidkinase (MU 9.279073238
269 IPI00025710.1 chromosome 21openreadingframe 59 9.151694775
270 IPI00410069.4 zincfingerCCCHͲtype,antivi ra l 1 9.137892008
271 IPI00180681.6 coi ledͲcoi l domainͲconta iningprotein41 9.098641634
272 IPI00647528.1 Exosome component2,i soformCRA_b 9.083474636
273 IPI00920991.1 Simi lartoCycl ink 8.956657887
274 IPI00294501.1 7Ͳdehydrocholesterol reductase 8.902279615
275 IPI00022542.1 RhoͲassociatedproteinkinase 1 8.890659809
276 IPI00642838.3 Isoform2ofLysophosphol ipaseͲl i ke protein1 8.841372252
277 IPI00966031.1 Eukaryotictrans lationini tiationfactor4E 8.82912755
278 IPI00922492.1 cDNAFLJ53090,moderatelys imi lartoRNAͲbindingmoti f,s ingleͲs trandedͲinteracti 8.820865154
279 IPI01013010.1 eukaryotictrans lationini tiationfactor2B,subunit1alpha,26kDa 8.683921099
280 IPI00024317.1 IsoformLongofGlutaryl ͲCoAdehydrogenase,mitochondria l 8.629867792
281 IPI01015267.1 phosphoglucomutase 2 8.614906311  
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282 IPI00477355.3 KIF1Ͳbindingprotein 8.612172127
283 IPI00065486.3 Isoform2ofATPͲbindingcassette subͲfami lyBmember6,mitochondria l 8.608422995
284 IPI00910254.2 cDNAFLJ50983,highlys imi lartoHomosapiens l ysocardiol ipinacyl transferase (LYC 8.607723951
285 IPI00470870.1 Putative uncharacterizedproteinDKFZp686J22257 8.564293146
286 IPI00184311.4 Ectonucleotide pyrophosphatase/phosphodiesterase fami lymember1 8.496405363
287 IPI00926796.1 procol lagenͲl ys ine,2Ͳoxoglutarate 5Ͳdioxygenase 3 8.487639189
288 IPI00797314.1 COP9consti tutive photomorphogenichomologsubunit3(Arabidops is ) 8.480714321
289 IPI00017921.7 Isoform2ofProteinbicaudal Chomolog1 8.418764591
290 IPI00853417.1 SCO2cytochrome coxidase assemblyprotein 8.412479877
291 IPI00005492.2 WDrepeatͲconta iningprotein5 8.403086901
292 IPI00947201.1 GLISfami lyzincfinger3transcriptvariantTS5 8.397313356
293 IPI00917299.1 gamma Ͳglutamylcyclotransferase 8.375939608
294 IPI00878484.1 Ewingsarcoma breakpointregion1 8.321173191
295 IPI00983652.2 cDNAFLJ61021,highlys imi lartoFarupstreamelementͲbindingprotein1 8.286056519
296 IPI01009061.1 TruncatedtumorsuppressorproteinP16 8.27630496
297 IPI00927188.1 Solute carrierfami ly4sodiumbicarbonate cotransportermember7type 2variant 8.248812914
298 IPI00981773.1 cDNAFLJ53377,highlys imi lartoProcol lagenͲl ys ine,2Ͳoxoglutarate 5Ͳdioxygenase 1 8.229576111
299 IPI00018236.2 Gangl ios ide GM2activator 8.210482597
300 IPI00903257.1 cDNAFLJ39170fi s ,clone OCBBF2003028,highlys imi lartoRattus norvegicus bas icle 8.172838449
301 IPI00024802.1 TATAͲbindingproteinͲassociatedfactor172 8.127103567
302 IPI00974096.1 fami lywithsequence s imi lari ty184,memberA 8.075909615
303 IPI00398625.5 Hornerin 8.045919418
304 IPI00977865.1 nonͲspeci ficl ipidͲtransferproteini soform8proprotein 8.02077508
305 IPI00008511.2 NADHdehydrogenase subunit5 8.004798412
306 IPI00984992.1 nonͲSMCcondens inI I complex,subunitD3 7.977009058
307 IPI00216659.1 Isoform2ofRNAͲbindingprotein8A 7.946021318
308 IPI00878524.1 ribosomal proteinL3 7.911752939
309 IPI00853207.1 Proteinphosphatase 2Aactivator,regulatorysubunit4 7.889402628
310 IPI00219833.2 Mitochondria l importinnermembrane trans locase subunitTim17ͲB 7.879449368
311 IPI00983620.1 peptidyl Ͳprolyl cis Ͳtrans i somerase AͲl i ke 7.864541054
312 IPI00098902.4 2Ͳoxoglutarate dehydrogenase,mitochondria l 7.815811157
313 IPI00514769.3 Isoform1ofSerine/threonineͲproteinphosphatase 6regulatoryankyrinrepeatsu 7.812160254
314 IPI00946670.1 NADHdehydrogenase (ubiquinone)1alpha subcomplex,5,13kDa 7.799548864
315 IPI00885004.1 Isoform2ofXinactinͲbindingrepeatͲconta iningprotein2 7.798505783
316 IPI00980681.1 chloride channel ,nucleotideͲsens i tive,1A 7.791601181
317 IPI00977524.1 Isoform1of39Sribosomal proteinL22,mitochondria l 7.686861992
318 IPI00941385.2 Isoform3ofUbiquitincarboxyl Ͳterminal hydrolase 10 7.675077915
319 IPI00908755.1 cDNAFLJ53392,highlys imi lartoUbiquitinͲactivatingenzyme E1 7.640746355
320 IPI00974217.2 inos i tol (myo)Ͳ1(or4)Ͳmonophosphatase 1 7.634245396
321 IPI00012837.1 Kines inͲ1heavychain 7.632534742
322 IPI00968146.1 ribosomal proteinS3A 7.612484217
323 IPI00657704.4 tumorproteinp53bindingprotein1 7.589646816
324 IPI00914601.2 Ubiquitincarboxyl Ͳterminal hydrolase 7.572229862
325 IPI00797590.4 NOP2protein 7.556642294
326 IPI00878316.2 intraflagel lartransportprotein27homologi soform3 7.49800539
327 IPI00237446.7 Isoform2ofProbable phosphol ipidͲtransportingATPase IG 7.497519016
328 IPI00873472.1 Isoform1ofProteintransportproteinSec24A 7.455308676  




Islam K. et al.  Supporting Information   
 
 S53
329 IPI00938044.2 3Ͳhydroxyacyl ͲCoAdehydratase 3Ͳl i ke i soform1 7.423033476
330 IPI00011522.3 cDNA,FLJ79450,highlys imi larto3Ͳketoacyl ͲCoAthiolase,peroxisomal 7.394384146
331 IPI00853634.3 Isoform6ofTrinucleotide repeatͲconta ininggene 6Aprotein 7.388463974
332 IPI00747876.2 Isoform4ofProteinCASC5 7.37757659
333 IPI01010425.1 angiopoietinͲl i ke 4 7.372381449
334 IPI00032137.2 Alpha ͲactininͲ3 7.364738464
335 IPI00983323.1 Parkinsondisease 7domainconta ining1 7.361906528
336 IPI00293242.1 Isoform2ofGenera l transcriptionfactorI IͲI 7.329498291
337 IPI00385645.1 Isoform2ofFibroblastgrowthfactor17 7.319234848
338 IPI00854642.1 Isoform1ofSis terchromatidcohes ionproteinPDS5homologA 7.312296152
339 IPI00477489.1 Isoform1ofRas ͲrelatedproteinRabͲ4B 7.309978485
340 IPI00847558.1 Simi lartoNonͲPOUdomainͲconta iningoctamerͲbindingprotein 7.268417597
341 IPI00218465.10 Phosphol ipase AͲ2Ͳactivatingprotein 7.261775017
342 IPI00926241.1 Isoform2ofTBC1domainfami lymember4 7.246945143
343 IPI00917410.1 proteinkinase,interferonͲinducible double s trandedRNAdependentactivator 7.241206408
344 IPI00883900.2 cDNAFLJ61360,highlys imi lartoCrumbs homolog1 7.2365973
345 IPI01009317.1 cDNAFLJ50426,highlys imi lartoUbiquitincarboxyl Ͳterminal hydrolase 7 7.222208738
346 IPI00168262.2 Procol lagengalactosyl transferase 1 7.221436024
347 IPI00295502.6 Isoform1ofProteinWiz 7.207459211
348 IPI00555893.3 Isoform3ofVacuolarproteinsortingͲassociatedprotein54 7.203310013
349 IPI01015580.1 adaptorͲrelatedproteincomplex2,beta 1subunit 7.122530222
350 IPI00876931.1 Integratorcomplexsubunit1 7.115786314
351 IPI00103560.1 Isoform1ofDual speci fici typroteinphosphatase CDC14B 7.115598679
352 IPI00910144.2 chromosome 22openreadingframe 28 7.101982832
353 IPI00908746.1 cDNAFLJ51535,highlys imi lartoPhosphatidylethanolamineͲbindingprotein1 7.098308086
354 IPI00013949.1 Smal l glutamineͲrichtetratricopeptide repeatͲconta iningproteinalpha 7.046792269
355 IPI01011241.1 eukaryotictrans lationini tiationfactor3,subunitH 7.026051283
356 IPI00945735.1 RAB7A,memberRASoncogene fami ly 7.024266958
357 IPI00984284.1 heterogeneous nuclearribonucleoproteinH1(H) 7.018344879
358 IPI00977201.1 FERMdomainconta ining8 6.955527067
359 IPI00301434.4 BolAͲl i ke protein2 6.94065237
360 IPI00514321.1 Chromosome 20openreadingframe 72 6.917865992
361 IPI00867688.2 Simi lartoDEAH(AspͲGluͲAla ͲHis )boxpolypeptide 40 6.862523794
362 IPI00642443.3 Genera l transcriptionfactorI I IC,polypeptide 5,63kDa 6.845027924
363 IPI01010581.1 cDNAFLJ51337,highlys imi lartoSignal transducerandactivatoroftranscription4 6.833633184
364 IPI00644425.1 Ras homologgene fami ly,memberC 6.826744556
365 IPI00747534.3 Pyrrol ineͲ5Ͳcarboxylate reductase 6.82123065
366 IPI00894206.2 tetratricopeptide repeatprotein27i soform2 6.798231125
367 IPI01014476.1 Aspartate aminotransferase 6.768373966
368 IPI00167806.3 Isoform2ofRNAͲbindingproteinMusashi homolog2 6.729918718
369 IPI00894059.1 exportin1(CRM1homolog,yeast) 6.72880125
370 IPI00444454.3 Isoform2ofPutative hel icase MOVͲ10 6.72008872
371 IPI00984387.1 cDNAFLJ53166,highlys imi lartoDihydropyrimidinaseͲrelatedprotein2 6.719806194
372 IPI00607548.4 Isoform5ofInaDͲl i ke protein 6.709991217
373 IPI00940377.1 glutathione SͲtransferase mu2(muscle) 6.697089434
374 IPI00642422.2 Isoform2ofProbable his toneͲl ys ine NͲmethyl transferase ASH1L 6.681286812
375 IPI00977554.1 endoribonuclease Diceri soform2 6.647475004  
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376 IPI00903191.1 Eukaryotictrans lationini tiationfactor3,subunitD 6.604324341
377 IPI00964248.1 transmembrane protein165 6.596060276
378 IPI01010257.1 Simi lartoYLPmoti fconta ining1 6.589266539
379 IPI00967340.1 LPSͲrespons ive ves icle trafficking,beachandanchorconta ining 6.580407143
380 IPI00930380.1 Serine/threonineͲproteinphosphatase 6.571713686
381 IPI00937974.2 Delta Ͳaminolevul inicaciddehydratase 6.566494703
382 IPI00007358.1 ZincfingerHITdomainͲconta iningprotein1 6.555282831
383 IPI00217143.3 succinate dehydrogenase complex,subunitA,flavoprotein(Fp) 6.536279202
384 IPI00791794.1 Isoform6ofProteindiaphanous homolog3 6.527878284
385 IPI00909721.1 cDNAFLJ51562,highlys imi lartoProhibi tin 6.50565052
386 IPI00556601.1 Solute carrierfami ly25member4variant(Fragment) 6.498196125
387 IPI00387088.1 Isoform4ofFADsynthase 6.477309942
388 IPI00978171.1 proteasome (prosome,macropain)26Ssubunit,ATPase,3 6.422775984
389 IPI00549343.3 Ves icleͲassociatedmembrane protein3 6.397579193
390 IPI00947130.1 coi ledͲcoi l domainconta ining14 6.365230799
391 IPI00787306.1 regulatorofchromosome condensationi soformb 6.311150789
392 IPI00639828.1 Fouranda hal fLIMdomains 1 6.293713331
393 IPI00024129.1 Peptidyl Ͳprolyl cis Ͳtrans i somerase C 6.268741608
394 IPI00984541.1 ectonucleotide pyrophosphatase/phosphodiesterase fami lymember7Ͳl i ke 6.262800455
395 IPI00658186.1 cDNAFLJ59463,highlys imi lartoGeranylgeranyl pyrophosphate synthetase 6.249212265
396 IPI00789033.2 5'Ͳnucleotidase,cytosol icI I IͲl i ke 6.247641563
397 IPI00412742.1 Isoform2ofCalciumͲbindingmitochondria l carrierproteinSCaMCͲ1 6.234661579
398 IPI00029744.1 SingleͲs trandedDNAͲbindingprotein,mitochondria l 6.233521223
399 IPI00556429.3 cDNAFLJ51423,highlys imi lartoSerine/threonineͲproteinkinase PLK1 6.232278109
400 IPI00645206.2 Isoform1ofProtocadherinͲ17 6.215114594
401 IPI00966157.1 SAR1homologB(S.cerevis iae) 6.206763029
402 IPI00176637.5 Eukaryotictrans lationini tiationfactor2subunit2Ͳl i ke protein 6.189522028
403 IPI00788837.2 cDNAFLJ54752,highlys imi lartoPoly(rC)Ͳbindingprotein2 6.184121609
404 IPI00641815.1 Isoform2ofTIP41Ͳl i ke protein 6.180614471
405 IPI00297121.6 repl icationterminationfactor2domainconta ining1 6.179140091
406 IPI01015730.1 DNAͲdirectedRNApolymerase 6.136565924
407 IPI01013345.1 testis expressed10 6.110919952
408 IPI00873716.1 Lamina Ͳassociatedpolypeptide 2,i soforms beta/gamma variant(Fragment) 6.102148771
409 IPI00657768.1 phosphoribosylglycinamide formyltransferase,phosphoribosylglycinamide synthe 6.102040291
410 IPI00027180.1 CAAXprenyl protease 1homolog 6.094688416
411 IPI00916797.1 nonͲSMCcondens inI I complex,subunitG2 6.076131105
412 IPI00927458.1 ribosomal proteinL32 6.071841955
413 IPI01011969.1 cDNAFLJ58372,highlys imi lartoNuclearpore complexproteinNup88 6.059197664
414 IPI00743576.1 Isoform2ofVͲtype protonATPase 116kDa subunita i soform1 6.02908659
415 IPI00004506.3 BTB/POZdomainͲconta iningproteinKCTD5 5.988526583
416 IPI00741107.3 Isoform3ofMelanoma inhibi toryactivi typrotein3 5.979962349
417 IPI00642510.3 testis Ͳexpressedsequence 10proteini soform2 5.925148249
418 IPI00892532.1 glypican1 5.92497921
419 IPI00647751.2 Isoform2ofCalmodul inͲregulatedspectrinͲassociatedprotein1 5.924484491
420 IPI00909684.1 cDNAFLJ57602,highlys imi lartoCreatine kinase MͲtype 5.888777733
421 IPI00410091.3 chromosome 11openreadingframe 73 5.875143051
422 IPI00789008.1 Floti l l inͲ2 5.873680592  
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423 IPI01013230.1 cDNAFLJ51319,highlys imi lartotRNA(adenineͲN(1)Ͳ)Ͳmethyl transferase nonͲcata l 5.834569693
424 IPI00964795.1 cDNAFLJ58215,highlys imi lartoHomosapiens leucine zippertranscriptionfactorͲl 5.817508936
425 IPI00740909.1 Isoform3ofAlstromsyndrome protein1 5.813872099
426 IPI00056496.1 Ras ͲrelatedproteinRabͲ24 5.811949492
427 IPI00790673.2 Isoform3ofCytoplasmicFMR1Ͳinteractingprotein1 5.76056695
428 IPI00007731.1 Isoform1ofBAGfami lymolecularchaperone regulator5 5.752711296
429 IPI00045939.4 2Ͳaminoethanethiol dioxygenase 5.743136883
430 IPI01011531.2 cDNAFLJ54191,highlys imi lartoAnnexinA7 5.737822056
431 IPI00909122.1 poly(A)Ͳspeci ficribonuclease PARNi soform2 5.656954288
432 IPI01010584.1 KIAA0586 5.6519382
433 IPI00645341.1 BCL6corepressor 5.629693508
434 IPI00022430.1 Glycera ldehydeͲ3Ͳphosphate dehydrogenase,testi s Ͳspeci fic 5.616788387
435 IPI00011077.4 39Sribosomal proteinL32,mitochondria l precursor 5.58299017
436 IPI00000156.3 IsoformBeta ofDNAl igase 3 5.463475227
437 IPI00965501.2 cDNAFLJ54242,highlys imi lartoCalnexin 5.423078299
438 IPI00654820.2 ATPsynthase subunita 5.402955532
439 IPI00929107.1 Seipini soform1 5.297815084
440 IPI00186139.8 Simi lartoProteinKRI1homolog 5.294789791
441 IPI01010750.1 DNAl igase (Fragment) 5.294677258
442 IPI00872952.1 Ubiquinol Ͳcytochrome creductase hinge protein,i soformCRA_c 5.278233051
443 IPI00640947.2 Isoform2oftRNAͲdihydrouridine synthase 3Ͳl i ke 5.276941299
444 IPI00514530.5 actin,alpha 1,skeleta l muscle 5.267291546
445 IPI00550234.4 Isoform1ofActinͲrelatedprotein2/3complexsubunit5 5.248762608
446 IPI00738216.3 KIAA0947 5.246402979
447 IPI00926196.2 cDNAFLJ56396,highlys imi lartoHuntingtinͲinteractingprotein1 5.238226891
448 IPI00893074.1 Fami lywithsequence s imi lari ty118,memberA 5.206407547
449 IPI00413144.6 Isoform2ofTres l in 5.174490452
450 IPI00852843.1 Isoform2ofNͲalpha Ͳacetyl transferase 25,NatBauxi l iarysubunit 5.157077789
451 IPI00477093.3 Isoform3ofIntegratorcomplexsubunit3 5.132245064
452 IPI00927271.1 transformer2beta homolog(Drosophi la ) 5.12930584
453 IPI00878795.1 RANbindingprotein1 5.125430346
454 IPI00980781.1 NͲacetyl transferase 10(GCN5Ͳrelated) 5.037157536
455 IPI00982254.1 cDNAFLJ60573,highlys imi lartoTNFreceptorͲassociatedfactor5 4.956015348
456 IPI01010224.1 zincfingerprotein844 4.917386532
457 IPI00647044.1 Microsomal glutathione SͲtransferase 3 4.916156292
458 IPI00953689.1 Alpha Ͳ2ͲHSͲglycoprotein 4.895540237
459 IPI00019046.4 Isoform1ofPreͲmRNAͲspl icingfactorRBM22 4.87909627
460 IPI00982734.1 Conservedhypothetica l protein 4.849043846
461 IPI00980903.1 phosphatidyl inos i tol 4Ͳkinase,cata lytic,beta 4.841104031
462 IPI00172648.1 Isoform5ofRibosomeͲreleas ingfactor2,mitochondria l 4.790606499
463 IPI00456965.5 Isoform1of2ͲmethoxyͲ6Ͳpolyprenyl Ͳ1,4Ͳbenzoquinol methylase,mitochondria l 4.789173126
464 IPI00167818.3 SPANXA2overlappingtranscript1(nonͲproteincoding) 4.770785332
465 IPI00792538.1 APEXnuclease (multi functional DNArepairenzyme)1 4.667920589
466 IPI00394874.3 Isoform2ofEctonucleos ide triphosphate diphosphohydrolase 8 4.656054974
467 IPI00446850.1 chromosome 1openreadingframe 186 4.620590687
468 IPI00031047.2 IQmoti fconta iningG 4.586830616
469 IPI00915457.1 Isoform1ofPOTEankyrindomainfami lymemberC 4.578995228  
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470 IPI00922577.1 cDNAFLJ53768,highlys imi lartoHepatocyte growthfactorͲl i ke protein 4.565380573
471 IPI00967531.1 peroxisomal biogenes is factor10 4.541862965
472 IPI00791071.2 Isoform2ofProteinPIEZO2 4.518009663
473 IPI00885017.1 cDNA,FLJ79527,moderatelys imi lartoUroporphyrinogendecarboxylase 4.502159119
474 IPI00977526.1 fami lywithsequence s imi lari ty126,memberB 4.491538048
475 IPI00941345.1 tenascinXB 4.478475571
476 IPI00385955.1 Bra inmy037protein 4.467207432
477 IPI00878764.1 l (3)mbtͲl i ke 2(Drosophi la ) 4.463213921
478 IPI00879449.1 spermantigenwithca lponinhomologyandcoi ledͲcoi l domains 1Ͳl i ke 4.461359024
479 IPI00470766.14 Isoform1ofOlfactomedinͲl i ke protein2B 4.452666759
480 IPI00945820.1 Uncharacterizedprotein 4.451300144
481 IPI00219478.3 Isoform2ofPhosphoserine aminotransferase 4.419585705
482 IPI00985082.1 Receptortype proteintyros ine phosphatase gamma (Fragment) 4.407513142
483 IPI00220381.2 Isoform2ofTranscriptionfactor20 4.401259422
484 IPI01012170.1 atlastinGTPase 3 4.385352135
485 IPI00293288.2 Isoform1ofGlutamate receptor,ionotropicka inate 5 4.378353119
486 IPI00790281.2 cDNAFLJ51777,highlys imi lartoSquamous cel l carcinoma antigenrecognizedbyTͲc 4.369580746
487 IPI01011431.1 cDNAFLJ60167,highlys imi lartoCytosol icacyl coenzyme Athioesterhydrolase 4.365740776
488 IPI00909251.1 cDNAFLJ51165,highlys imi lartoDNAdamageͲbindingprotein1 4.331735611
489 IPI00008527.3 60Sacidicribosomal proteinP1 4.300535679
490 IPI00171540.2 Chromosome transmiss ionfidel i typrotein8homologi soform2 4.280999184
491 IPI00015580.3 Isoform3ofForminͲbindingprotein1Ͳl i ke 4.280753613
492 IPI00939219.1 Equi l ibrative nucleos ide transporter1 4.262634277
493 IPI00945125.1 superki l lervi ra l icidicactivi ty2Ͳl i ke (S.cerevis iae) 4.259326458
494 IPI00978544.1 ATPase,H+transporting,l ysosomal 50/57kDa,V1subunitH 4.258832932
495 IPI00292787.6 ActinͲrelatedprotein5 4.229960442
496 IPI00873684.1 Isoform2ofCol lagenalpha Ͳ1(IV)chain 4.200462341
497 IPI01010893.1 late endosomal/lysosomal adaptor,MAPKandMTORactivator1 4.200406551
498 IPI00980323.2 cDNAFLJ51919,highlys imi lartoHomosapiens abhydrolase domainconta ining8( 4.197277546
499 IPI00171856.1 Deoxyhypus ine hydroxylase 4.190542221
500 IPI00386885.1 cDNAFLJ14414fi s ,clone HEMBA1004847,highlys imi lartoSIGNALRECOGNITIONPAR 4.186115265
501 IPI00017533.2 Cytochrome coxidase subunit3 4.178531647
502 IPI01014582.1 lactate dehydrogenase A 4.168670654
503 IPI00745311.2 Ki l lercel l immunoglobul inͲl i ke receptor3DS1 4.165480137
504 IPI00945805.1 ribonuclease P/MRP40kDa subunit 4.165179729
505 IPI00397498.1 Isoform2ofCarbamoyl Ͳphosphate synthase [ammonia],mitochondria l 4.142326355
506 IPI00006934.1 Hydroxyacidoxidase 1 4.140348434
507 IPI01009009.1 RBM14ͲRBM4proteini soform2 4.1335392
508 IPI00440719.2 N(a lpha)Ͳacetyl transferase 10,NatAcata lyticsubunit 4.089213848
509 IPI00976088.1 ribonucleotide reductase M1 4.08574295
510 IPI00411545.3 Isoform3ofThrombopoietin 4.053452492
511 IPI00477605.6 Isoform1ofAcyl Ͳcoenzyme Asynthetase ACSM5,mitochondria l 4.029726028
512 IPI00172656.6 FASͲassociatedfactor2 4.014418125
513 IPI00471914.6 Isoform2ofFYVE,RhoGEFandPHdomainͲconta iningprotein6 3.978642225
514 IPI01010503.1 stress ͲinducedͲphosphoprotein1 3.972180367
515 IPI00909754.1 cDNAFLJ61500,highlys imi lartoNNPͲ1protein 3.964648247
516 IPI00967973.1 Calnexin 3.95118475  
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517 IPI00549761.3 Chitobiosyldiphosphodol ichol beta Ͳmannosyl transferase 3.946815252
518 IPI00853224.1 StARͲrelatedl ipidtransferprotein7,mitochondria l 3.938904047
519 IPI00656111.1 IsoformEofProteoglycan4 3.934770823
520 IPI00167841.2 Isoform2ofActivatingtranscriptionfactor7Ͳinteractingprotein2 3.929155827
521 IPI00924758.1 cDNAFLJ32188fi s ,clone PLACE6002056,highlys imi lartoGuanine nucleotideͲbindin 3.922733784
522 IPI00016074.2 MͲphase phosphoprotein6 3.912299156
523 IPI00916247.2 exonuclease 3'Ͳ5'domaincontaining2 3.891948462
524 IPI00914539.1 Isoform2ofAnkyrinrepeatandFYVEdomainͲconta iningprotein1 3.890255928
525 IPI00219090.1 Isoform2ofProteinarginine NͲmethyl transferase 7 3.8867414
526 IPI00911085.1 cDNAFLJ53754,highlys imi lartoTransmembrane emp24domainͲconta iningprotein 3.886036158
527 IPI00893200.1 19kDa protein 3.873499632
528 IPI00968217.1 NOP14nucleolarprotein 3.843609095
529 IPI00903259.2 cDNAFLJ54005,highlys imi lartoTranscriptionelongationfactorSPT5 3.842230082
530 IPI00981682.1 prol ine synthetase coͲtranscribedhomolog(bacteria l ) 3.840254068
531 IPI00011201.1 NADͲdependentmal icenzyme,mitochondria l 3.814752579
532 IPI00947372.2 structura l maintenance ofchromosomes 4 3.812386274
533 IPI00879643.1 mitochondria l fi s s ionprocess 1 3.807324171
534 IPI00980448.1 NADHdehydrogenase (ubiquinone)1beta subcomplex,4,15kDa 3.787592173
535 IPI00916763.1 heatshock10kDa protein1(chaperonin10) 3.747044325
536 IPI00745182.1 phosphol ipase C,gamma 1 3.731425047
537 IPI00185398.4 methionyl ͲtRNAsynthetase 3.730978489
538 IPI01012564.1 cDNAFLJ52405,highlys imi lartoMyos inIc 3.730549574
539 IPI00966206.1 programmedcel l death6 3.729136467
540 IPI00031424.1 Isoform2ofPhosphatidyl inos i tol 4Ͳkinase alpha 3.728237629
541 IPI00607610.1 Isoform1ofProteinFAM36A 3.727309227
542 IPI00642862.1 Peptidyl Ͳprolyl cis Ͳtrans i someraseͲl i ke 4 3.714351177
543 IPI01014635.1 solute carrierfami ly3(activators ofdibas icandneutra l aminoacidtransport),me 3.713633299
544 IPI00007814.3 VͲtype protonATPase subunitC1 3.700995922
545 IPI00555788.2 Isoform3ofGlycerophosphodiesterphosphodiesterase domainͲconta iningprotei 3.698200703
546 IPI01015537.1 genera l transcriptionfactorI IH,polypeptide 3,34kDa 3.69206953
547 IPI00472003.1 Isoform4ofBH3Ͳinteractingdomaindeathagonis t 3.677544594
548 IPI00981108.1 cDNAFLJ35898fi s ,clone TESTI2009520,highlys imi lartoRattus norvegicus endoplas 3.676934004
549 IPI00941876.2 Isoform5ofPARP1Ͳbindingprotein 3.670991421
550 IPI00329025.1 Proteinjagunal homolog1 3.655322552
551 IPI00964370.1 cDNAFLJ60877,highlys imi lartoZincfingerprotein346 3.633505821
552 IPI00980509.1 nucleosome assemblyprotein1Ͳl i ke 4 3.629339695
553 IPI00977571.1 hypothetica l proteinLOC100508996 3.625877142
554 IPI00910915.1 cDNAFLJ54756,moderatelys imi lartoHomosapiens nitricoxide synthase interacti 3.624631166
555 IPI00001141.4 Mitochondria l importinnermembrane trans locase subunitTim22 3.610780239
556 IPI00005045.1 ATPͲbindingcassette subͲfami lyFmember2 3.604427099
557 IPI00418277.3 Chondroi tinsul fate synthase 3 3.575285912
558 IPI00645653.1 trans locase ofinnermitochondria l membrane 23homologB(yeast) 3.567307472
559 IPI00740019.3 Isoform1ofProteinDaple 3.561594009
560 IPI00791914.2 BMͲ010variant(Fragment) 3.551699877
561 IPI00975639.1 dynamin3 3.546967268
562 IPI00291417.2 Isoform1ofDephosphoͲCoAkinase domainͲconta iningprotein 3.539319515
563 IPI00027705.2 Isoform1ofDNAprimase large subunit 3.534766436  
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564 IPI00382858.2 IsoformBofTrimethyl lys ine dioxygenase,mitochondria l 3.529125452
565 IPI00386667.2 Isoform2ofCarboxypeptidase A6 3.528172255
566 IPI00844404.2 Isoform2ofTRMT1Ͳl i ke protein 3.524603367
567 IPI00059242.3 SynapseͲassociatedprotein1 3.520887136
568 IPI00145593.7 NucleolarMIF4GdomainͲconta iningprotein1 3.505145788
569 IPI00010120.4 Isoform1ofCͲterminal Ͳbindingprotein2 3.504005671
570 IPI01012217.1 Ful l ͲlengthcDNAclone CS0DI035YL21ofPlacenta ofHomosapiens 3.502397299
571 IPI00908319.1 cDNAFLJ51570,highlys imi lartoThioredoxindomainͲconta iningprotein1 3.500628233
572 IPI00910984.1 cDNAFLJ57468 3.495084524
573 IPI00843886.1 apol ipoproteinO 3.490085602
574 IPI00976697.1 fami lywithsequence s imi lari ty76,memberA 3.488691807
575 IPI01012747.1 a ldehyde dehydrogenase 5fami ly,memberA1 3.485749245
576 IPI00942336.1 l i s terinE3ubiquitinproteinl igase 1 3.485023975
577 IPI00916551.1 malate dehydrogenase 1,NAD(soluble) 3.479502916
578 IPI00604702.1 Isoform2ofPhosphopantothenoylcysteine decarboxylase 3.47889924
579 IPI00924999.1 IMP(inos ine 5'Ͳmonophosphate)dehydrogenase 2 3.474856853
580 IPI00888266.3 nͲacetylserotoninOͲmethyl transferaseͲl i ke proteinͲl i ke 3.474449635
581 IPI00829629.1 Isoform3ofProteasome activatorcomplexsubunit4 3.460556269
582 IPI00297455.6 AͲkinase anchorprotein8Ͳl i ke 3.456336975
583 IPI00982043.1 KIAA1967 3.451563597
584 IPI01010009.1 diablo,IAPͲbindingmitochondria l protein 3.451171875
585 IPI00964195.1 coproporphyrinogenoxidase 3.444897652
586 IPI00981208.1 cysteine andhis tidineͲrichdomain(CHORD)conta ining1 3.443861723
587 IPI00965708.1 pleiotropicregulator1 3.441361666
588 IPI00909062.2 CoAsynthase 3.432289839
589 IPI00975884.1 solute carrierfami ly39(zinctransporter),member14 3.430989265
590 IPI00032995.1 LanCͲl i ke protein2 3.424777269
591 IPI00257933.8 ProteinBEX5 3.423010588
592 IPI00025344.1 NADHdehydrogenase [ubiquinone]i ronͲsul furprotein6,mitochondria l 3.41641736
593 IPI00384224.4 Simi lartodual speci fici typhosphatase 9 3.416248798
594 IPI00888802.1 coi ledͲcoi l domainconta ining74A 3.416227818
595 IPI00985284.1 La ribonucleoproteindomainfami ly,member1 3.413938761
596 IPI00298353.4 GuanylateͲbindingprotein7 3.412475348
597 IPI00966636.1 matrin3 3.411032677
598 IPI00419792.3 Simi lartoDual speci fici tymitogenͲactivatedproteinkinase kinase 2 3.410777092
599 IPI00640296.1 Heterogeneous nuclearribonucleoproteinK 3.410216331
600 IPI00954996.1 chromosome Xopenreadingframe 56 3.409793377
601 IPI01014588.1 cDNAFLJ58155,highlys imi lartoCohes insubunitSAͲ2 3.409322023
602 IPI00647752.2 cDNAFLJ61735,highlys imi lartoZincfingerA20domainͲconta iningprotein1 3.407420635
603 IPI00217386.1 Isoform2ofDNAͲdirectedRNApolymerases I andI I I subunitRPAC1 3.404648304
604 IPI00007049.1 28Sribosomal proteinS18c,mitochondria l 3.401761532
605 IPI01013137.1 cDNAFLJ58497,highlys imi lartoUncͲ13homologC 3.401104927
606 IPI01013452.1 proteasome (prosome,macropain)26Ssubunit,nonͲATPase,9 3.400309563
607 IPI01014223.1 cDNAFLJ50851,highlys imi lartoTyros ineͲproteinphosphatase nonͲreceptortype1 3.39807415
608 IPI01015742.1 serine/threonine kinase 38l i ke 3.397047043
609 IPI00878166.1 Isoform2ofNHLrepeatͲconta iningprotein2 3.393936634
610 IPI00879999.1 Isoform1ofATPͲdependentRNAhel icase DDX54 3.385189056  
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611 IPI01009407.1 cDNAFLJ45137fi s ,clone BRAWH3038827,highlys imi lartoHomosapiens leucineͲzi 3.38276577
612 IPI00009771.6 LaminͲB2 3.380929232
613 IPI00306661.3 E3ubiquitinͲproteinl igase KCMF1 3.376299381
614 IPI00909658.1 cDNAFLJ52759,highlys imi lartoPlastinͲ2 3.375437975
615 IPI00902957.1 cDNAFLJ90012fi s ,clone HEMBA1000462,highlys imi lartoCCR4ͲNOTtranscriptionco 3.371630907
616 IPI00867515.1 uncͲ51Ͳl i ke kinase 4(C.elegans) 3.366783857
617 IPI00945024.1 staphylococca l nuclease andtudordomainconta ining1 3.366449118
618 IPI00654793.2 NADkinase domainconta ining1 3.358320475
619 IPI00007979.4 NADHͲubiquinone oxidoreductase chain2 3.349155188
620 IPI00916446.1 dis ta l Ͳless homeobox1 3.343543053
621 IPI00375701.2 Isoform2ofVIPpeptides 3.336665392
622 IPI00395507.4 Isoform2ofELAVͲl i ke protein4 3.335440874
623 IPI00943071.2 cDNAFLJ57184,highlys imi lartoBromodomainandWDrepeatdomainͲconta ining 3.335140228
624 IPI01015469.1 2Ͳoxoglutarate andi ronͲdependentoxygenase domainconta ining1 3.333026171
625 IPI00645320.1 Isoform3ofBeta ͲcateninͲl i ke protein1 3.329285145
626 IPI00925850.2 cDNAFLJ54572,highlys imi lartoLysosomal alpha Ͳmannos idase 3.327897787
627 IPI00902543.3 NOP2/Sundomainfami ly,member5 3.326188326
628 IPI00853433.1 ATPase,H+transporting,l ysosomal 31kDa,V1subunitE1 3.324478149
629 IPI00215687.1 Isoform3ofGlutaminase kidneyi soform,mitochondria l 3.323078871
630 IPI00032406.1 DnaJhomologsubfami lyAmember2 3.321737766
631 IPI00328938.4 Isoform1ofE3ubiquitinͲproteinl igase RNF138 3.315677643
632 IPI00307325.2 Zincfingerprotein161homolog 3.315529585
633 IPI00000105.4 Majorvaultprotein 3.314646006
634 IPI00856004.1 ras ͲrelatedproteinRͲRas2i soformb 3.313657522
635 IPI00797490.2 cDNAFLJ53588,highlys imi lartoTrans locationͲassociatedmembrane protein1 3.311407328
636 IPI00887254.2 Putative ferri tinheavypolypeptideͲl i ke 19 3.30765748
637 IPI00930396.1 cDNAFLJ35812fi s ,clone TESTI2006051,highlys imi lartoAcyl Ͳcoenzyme Athioestera 3.304494143
638 IPI01018260.1 cDNAFLJ11747fi s ,clone HEMBA1005530,highlys imi lartoAnaphaseͲpromotingcom 3.300151587
639 IPI00376394.4 Sul fhydryl oxidase 2 3.298935175
640 IPI00019976.2 Coi ledͲcoi l domainͲconta iningprotein85B 3.298585892
641 IPI00788816.1 Simi lartoSubmaxi l laryglandandrogenͲregulatedprotein3homologBprecursor 3.295587301
642 IPI00915874.1 partnerofNOB1homolog(S.cerevis iae) 3.287039042
643 IPI00926620.1 cytochrome P450,fami ly51,subfami lyA,polypeptide 1 3.286698818
644 IPI00646692.2 RAB31,memberRASoncogene fami ly 3.285127401
645 IPI00640585.2 transmembrane protein161A 3.283124447
646 IPI00909562.1 cDNAFLJ52462,moderatelys imi lartoMus musculus proteasome (prosome,macrop 3.279426575
647 IPI00402109.4 Isoform2ofPhosphatidyl inos i tol glycananchorbiosynthes is class Uprotein 3.278314352
648 IPI00795109.1 cDNA,FLJ79092,highlys imi lartoGTPͲbindingnuclearproteinRan 3.278274775
649 IPI00470629.4 Isoform1ofCalmodul inͲl ys ine NͲmethyl transferase 3.274087906
650 IPI00152196.3 NͲacylneuraminateͲ9Ͳphosphatase 3.271921158
651 IPI00065521.5 Putative tRNApseudouridine synthase Pus10 3.271898031
652 IPI00964345.1 caseinalpha s1 3.271681547
653 IPI00927704.1 transmembrane protein237 3.267240047
654 IPI00916096.1 Conservedhypothetica l protein 3.264837265
655 IPI00922126.1 cDNAFLJ57759,moderatelys imi lartoTransgel inͲ2 3.261574507
656 IPI00847400.1 chromosome 19openreadingframe 47 3.252752066
657 IPI00855846.1 ABRACͲterminal l i ke 3.250239372  
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658 IPI00759537.1 Isoform2ofMitochondria l RhoGTPase 2 3.247343302
659 IPI00909746.1 cDNAFLJ51502,highlys imi larto60Sribosomal proteinL18a 3.246116638
660 IPI01009730.1 Putative uncharacterizedproteinDKFZp547A1913 3.245847225
661 IPI00641449.2 Isoform2ofEnhancerofmRNAͲdecappingprotein4 3.244997263
662 IPI00927183.1 Wi l l iams Beurensyndrome chromosome region22 3.241432905
663 IPI01015062.1 cDNAFLJ45314fi s ,clone BRHIP3005142,highlys imi lartoProteasomeͲassociatedpr 3.237799644
664 IPI00215905.1 IsoformI IC4ofLowaffini tyimmunoglobul ingamma FcregionreceptorI IͲc 3.235785246
665 IPI00031115.5 Golginsubfami lyAmember1 3.234233856
666 IPI00965557.1 methyl transferase l i ke 14 3.230890036
667 IPI00854630.2 prol ine rich12 3.229253292
668 IPI00643530.1 cytochrome b5reductase 1 3.228613853
669 IPI00792017.1 schlafenfami lymember12 3.222703695
670 IPI00217430.1 Isoform2ofNLRfami lyCARDdomainͲconta iningprotein4 3.215734959
671 IPI00478620.2 triparti te moti fͲconta iningprotein48 3.211925507
672 IPI00795573.1 NECAPendocytos is associated1 3.210455894
673 IPI00514986.1 5'Ͳnucleotidase domainconta ining1 3.204140425
674 IPI01015523.1 coi ledͲcoi l serineͲrichprotein2 3.202517986
675 IPI00556297.1 Arginine/serineͲrichspl icingfactor6variant(Fragment) 3.202192783
676 IPI00917916.1 DIS3mitoticcontrol homolog(S.cerevis iae)Ͳl i ke 2 3.201835394
677 IPI00301163.1 ProteinOͲglucosyl transferase 1 3.19927907
678 IPI00173901.1 Isoform2ofHistoneͲl ys ine NͲmethyl transferase,H3l ys ineͲ36andH4l ys ineͲ20spe 3.195893049
679 IPI01010263.1 ubiquitinproteinl igase E3componentnͲrecognin7(putative) 3.194836617
680 IPI00984362.1 tissue speci fictransplantationantigenP35B 3.194470167
681 IPI00807384.2 cleavage andpolyadenylationspeci ficfactor3,73kDa 3.189180136
682 IPI00976712.1 zincfinger,CCHCdomainconta ining11 3.18565011
683 IPI00100245.1 DNAͲdirectedRNApolymerase II I subunitRPC6 3.185195923
684 IPI00639912.2 nuclearautoantigenicspermprotein(his toneͲbinding) 3.1851542
685 IPI00644568.1 buddinguninhibi tedbybenzimidazoles 3homolog(yeast) 3.181827784
686 IPI00983570.1 HLAclass I his tocompatibi l i tyantigen,AͲ69alpha chainͲl i ke i soform17 3.178947449
687 IPI00220542.1 Isoform2ofSerine protease HTRA2,mitochondria l 3.178910494
688 IPI00927837.1 zincfingerCCCHͲtype conta ining15 3.177031517
689 IPI00552426.2 serine/threonine kinase 24 3.176285744
690 IPI01013073.1 mutShomolog6(E.col i ) 3.175209284
691 IPI00160506.1 ADAMmetal lopeptidase withthrombospondintype 1moti f,13 3.172572374
692 IPI00184433.2 SupportedbyHumanESTs AA017424.1(NID:g1479799),H85906.1 3.16696763
693 IPI00642657.1 Isoform3ofChol ine transporterͲl i ke protein1 3.166265965
694 IPI01010643.1 cDNAFLJ38844fi s ,clone MESAN2003662,highlys imi lartoCul l inͲ1 3.162334442
695 IPI00013296.3 40Sribosomal proteinS18 3.146720648
696 IPI00916394.2 RAD54Ͳl i ke 2(S.cerevis iae) 3.143470049
697 IPI00043262.1 SATB2antisense RNA1 3.139975071
698 IPI01014549.1 heme bindingprotein1 3.139760256
699 IPI00514271.1 Phosphodiesterase 4B,cAMPͲspeci fic 3.136208773
700 IPI00178714.2 Isoform2ofSerine/threonineͲproteinkinase PAK4 3.135077715
701 IPI00939864.2 cDNAFLJ31273fi s ,clone KIDNE2006299,weaklys imi lartoBOB1PROTEIN 3.133990526
702 IPI00976489.1 ribosomal proteinS2 3.132829905
703 IPI00644349.4 cDNAFLJ60449,highlys imi lartoHomosapiens prionproteininteractingprotein(P 3.130381584
704 IPI00910594.2 DDB1andCUL4associatedfactor7 3.127041578  
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705 IPI00759768.1 Isoform2ofElongationfactorTuGTPͲbindingdomainͲconta iningprotein1 3.126696348
706 IPI00556344.2 Isoform2ofLysophosphatidicacidphosphatase type 6 3.12577486
707 IPI00061282.2 Proteinkinase,AMPͲactivated,alpha 1cata lyticsubunit,i soformCRA_b 3.125466108
708 IPI00847729.2 thyroidhormone receptorinteractor13 3.121195316
709 IPI00795983.1 Coi ledͲcoi l alpha Ͳhel ica l rodprotein1 3.11758256
710 IPI00291525.1 Dimethyladenos ine transferase 1,mitochondria l 3.115568638
711 IPI00413611.1 DNAtopoisomerase 1 3.113761425
712 IPI00217005.7 AnkyrinrepeatdomainͲconta iningprotein18A 3.111149788
713 IPI00909015.2 cDNAFLJ58500,highlys imi lartoCytoplasmicdynein1l ightintermediate chain1 3.10572052
714 IPI00302309.6 tetratricopeptide repeatdomain17 3.10140872
715 IPI00947454.1 plastin3 3.097033262
716 IPI00922127.1 cDNAFLJ54708,highlys imi larto150kDa oxygenͲregulatedprotein 3.096722126
717 IPI00658002.1 Isoform3ofTyros ineͲproteinphosphatase nonͲreceptortype 11 3.094691753
718 IPI00976000.1 integratorcomplexsubunit9 3.094225883
719 IPI00965867.1 importin11 3.087956667
720 IPI01018192.1 cDNAFLJ30950fi s ,clone HCASM1000061 3.086732626
721 IPI00450783.1 Isoform2ofERlumenproteinreta iningreceptor2 3.081044197
722 IPI00295394.2 Cytochrome coxidase assemblyproteinCOX11,mitochondria l 3.077878475
723 IPI00922333.1 cDNAFLJ50250,highlys imi lartoStructura l maintenance ofchromosome 1Ͳl i ke 1pro 3.076677799
724 IPI00333634.4 chromosome 20openreadingframe 194 3.076010942
725 IPI00921944.1 cDNAFLJ54863,highlys imi lartoCTPsynthase 1 3.073092699
726 IPI00945851.1 ribophorinI 3.064904928
727 IPI00910541.2 cDNAFLJ58838,highlys imi lartoHomosapiens radica l SͲadenosyl methionine and 3.061270952
728 IPI00218266.1 IsoformLongofVasoactive intestina l polypeptide receptor1 3.060194254
729 IPI00943678.1 anaphaseͲpromotingcomplexsubunit1Ͳl i ke 3.059614897
730 IPI00795180.3 cDNAFLJ59673,highlys imi lartoHomosapiens growthandtransformationͲdepend 3.055035353
731 IPI00329321.3 LYRmoti fͲconta iningprotein7 3.053508282
732 IPI01013650.1 GproteinͲcoupledreceptor126 3.051602125
733 IPI00977213.1 succinate dehydrogenase complex,subunitD,integra l membrane protein 3.050844431
734 IPI00964658.1 septin11 3.049089909
735 IPI00553172.1 caspase 3,apoptos is Ͳrelatedcysteine peptidase 3.046720266
736 IPI00414005.2 IsoformShortofSodium/potass iumͲtransportingATPase subunitalpha Ͳ1 3.046513557
737 IPI00984321.2 excis ionrepaircross Ͳcomplementingrodentrepairdeficiency,complementationg 3.034834385
738 IPI00976594.1 cDNAFLJ55046,highlys imi lartoMethionyl ͲtRNAsynthetase 3.033221245
739 IPI00303335.3 Nebul in 3.027050972
740 IPI00910598.1 Isoform2ofNucleos ide diphosphate kinase 6 3.023873806
741 IPI00045456.1 chromosome 10openreadingframe 113 3.021387339
742 IPI00983309.1 STT3,subunitofthe ol igosaccharyl transferase complex,homologA(S.cerevis iae) 3.021257162
743 IPI00217240.1 WDrepeatͲconta iningprotein75 3.019135952
744 IPI00297626.4 SyntaxinͲbindingprotein3 3.017946482
745 IPI00217541.3 ATPͲdependentRNAhel icase DDX51 3.017280817
746 IPI00917443.2 dedicatorofcytokines is 5 3.015888929
747 IPI00855962.1 Isoform2ofFK506Ͳbindingprotein15 3.014819384
748 IPI00983774.1 proteinphosphatase 2,cata lyticsubunit,beta i sozyme 3.01027441
749 IPI00184707.1 Isoform2ofFERMdomainͲcontainingprotein6 3.009544134
750 IPI00002424.1 PleckstrinhomologydomainͲconta iningfami lyFmember2 3.005003214
751 IPI00853068.2 Hemoglobinalpha Ͳ2 3.003887415  
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752 IPI00945467.1 phosphatidyl inos i tol Ͳspeci ficphosphol ipase C,Xdomainconta ining2 2.996738434
753 IPI01012689.1 IsoformE1SofG1/SͲspeci ficcycl inͲE1 2.995843649
754 IPI00909081.2 proteintyros ine phosphatase type IVA2i soform4 2.990827322
755 IPI00922246.1 cDNAFLJ58698,highlys imi lartocAMPͲdependentproteinkinase,alpha Ͳcata lyticsu 2.987887621
756 IPI00965994.1 glucosamineͲ6Ͳphosphate deaminase 1 2.97500205
757 IPI01010778.1 cDNAFLJ55806,highlys imi lartoGolgi phosphoprotein3 2.972642422
758 IPI00398129.6 Simi larto3Ͳhydroxybutyrate dehydrogenase type 2 2.972138405
759 IPI00329369.8 ALS2CͲterminal Ͳl i ke proteini soform3 2.967597723
760 IPI00963825.1 ATPsynthase,H+transporting,mitochondria l Focomplex,subunitC1(subunit9) 2.964182854
761 IPI00386679.1 ZNF607protein 2.962964296
762 IPI00384478.3 fami lywithsequence s imi lari ty227,memberB 2.959823608
763 IPI00386908.3 Isoform2ofAlpha Ͳparvin 2.959525824
764 IPI00785125.2 Putative uncharacterizedproteinFLJ00310 2.958783627
765 IPI01015780.1 cDNAFLJ57449,highlys imi lartoNotchless homolog1 2.957838058
766 IPI00792035.2 Isoform3ofGlyoxa lase domainͲconta iningprotein4 2.955942154
767 IPI00909237.1 cDNAFLJ55703,highlys imi lartoSolute carrierfami ly2,faci l i tatedglucose transpo 2.955162048
768 IPI00966573.1 enolaseͲphosphatase 1 2.954790831
769 IPI01010550.1 cDNAFLJ55457,highlys imi lartoATPͲdependentRNAhel icase DHX8 2.953880548
770 IPI00830092.1 Isoform2ofTwistedgastrulationproteinhomolog1 2.953283787
771 IPI00952785.3 Ca++Ͳdependentsecretionactivator2 2.952512264
772 IPI00024464.1 PRO0843 2.951581955
773 IPI00926887.1 gl ioblastoma ampl i fiedsequence 2.949511766
774 IPI00300631.3 ScaffoldattachmentfactorB1 2.948192596
775 IPI00927766.1 NCKinteractingproteinwithSH3domain 2.946702719
776 IPI00946316.1 karyopherinalpha 4(importinalpha 3) 2.943986416
777 IPI00102918.1 Isoform2ofATRͲinteractingprotein 2.94173336
778 IPI01009299.1 cDNAFLJ60635,highlys imi lartoAngiotens inͲconvertingenzyme,somatici soform 2.940118551
779 IPI00795577.3 Isoform7ofMucinͲ4 2.939316511
780 IPI00982125.1 FCF1protein 2.937950373
781 IPI00888999.1 Isoform2ofPNMAͲl i ke protein2 2.937551737
782 IPI00945513.1 TRAF3interactingprotein3 2.932587147
783 IPI00980492.1 Conservedhypothetica l protein 2.932492495
784 IPI00916535.1 prolyl 4Ͳhydroxylase subunitalpha Ͳ1i soform3precursor 2.931104183
785 IPI01010177.1 cDNAFLJ51879,highlys imi lartoPrenylcysteine oxidase 2.928237677
786 IPI00941117.2 cDNAFLJ50310,highlys imi lartoZincfingerprotein198 2.926929235
787 IPI00984730.1 Simi lartoDnaJ(Hsp40)homolog,subfami lyB,member1 2.926818609
788 IPI00940357.2 RNAͲdirectedDNApolymerase (reverse transcriptase)domainconta iningprotein 2.926532984
789 IPI00893883.1 NME/NM23nucleos ide diphosphate kinase 4 2.924023867
790 IPI00917184.1 coi ledͲcoi l domainconta ining150 2.923926115
791 IPI00879333.1 guanine nucleotide bindingprotein(Gprotein),beta polypeptide 1Ͳl i ke 2.922519684
792 IPI00902652.1 cDNAFLJ37148fi s ,clone BRACE2025333,highlys imi lartoHomosapiens Na+/H+exc 2.919394493
793 IPI01009695.1 Bromodomainadjacenttozincfingerdomain,1Ai soformbvariant 2.913550615
794 IPI00975761.1 process ingofprecursor1,ribonuclease P/MRPsubunit(S.cerevis iae) 2.907921314
795 IPI00984399.1 laminͲB1i soform2 2.905791283
796 IPI00979313.1 fami lywithsequence s imi lari ty118,memberB 2.902616739
797 IPI00640929.1 Ribosomal proteinS6 2.901382685
798 IPI00979873.1 ribosomal RNAͲprocess ingprotein7homologAͲl i ke,partia l 2.89830637  
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799 IPI00028937.1 Ornithine decarboxylase antizyme 2 2.892297268
800 IPI00967823.1 ELMO/CEDͲ12domainconta ining2 2.891439676
801 IPI00966960.1 acyl ͲCoAsynthetase fami lymember2 2.886399746
802 IPI00291457.2 Serine/threonineͲproteinkinase 35 2.885710239
803 IPI00395967.2 TMEM97protein 2.880130768
804 IPI00798339.4 Isoform4ofE1AͲbindingproteinp400 2.879770756
805 IPI00215907.2 serine/arginineͲri chspl icingfactor7 2.876781464
806 IPI00479058.2 40Sribosomal proteinS15 2.875518322
807 IPI00792050.1 ribosomal proteinL8 2.873644114
808 IPI00442921.1 CDNAFLJ26213fi s ,clone ADG07906 2.872962952
809 IPI00514217.6 SuccinateͲCoAl i gase,ADPͲforming,beta subuni t 2.869974375
810 IPI00552303.3 annexinA11 2.869552851
811 IPI00910936.1 cDNAFLJ61101,highlys imi lartoEukaryotictrans lationini tiationfactor5 2.865088701
812 IPI00410547.1 uncharacterizedLOC400940 2.860070944
813 IPI00917435.1 Isoform4ofThyroidadenoma Ͳassociatedprotein 2.85930419
814 IPI00967837.1 multimerin1 2.855486393
815 IPI00019400.1 Thiopurine SͲmethyltrans ferase 2.852811098
816 IPI01013172.1 cDNAFLJ58642,highlys imi lartoHomosapiens elongationprotein3homolog(ELP3 2.850491285
817 IPI00981200.1 SID1transmembrane fami ly,member2 2.846666098
818 IPI00514742.3 Uncharacteri zedprotein 2.842525959
819 IPI00514385.2 Isoleucyl ͲtRNAsynthetase 2.841986895
820 IPI00917171.1 integrinͲl inkedkinaseͲassociatedserine/threonine phosphatase 2.833169699
821 IPI01012107.1 defenderagainstcel l death1 2.83266139
822 IPI00002225.6 LAG1longevi tyassurance homolog4 2.831745625
823 IPI00747361.3 aladini soform2 2.829845905
824 IPI00028083.1 Trans lationini tia tionfactoreIFͲ2Bsubunitbeta 2.825948238
825 IPI00385079.1 MSTP151 2.825237274
826 IPI00902967.1 cDNAFLJ44468fi s ,clone UTERU2026025,moderatelys imi lartoSPLICINGFACTOR,AR 2.824178696
827 IPI00072541.4 Isoform3ofPCI domainͲconta iningprotein2 2.824063301
828 IPI00383562.1 Isoform4ofFermitinfami lyhomolog1 2.820923328
829 IPI00099463.2 Sphingos ineͲ1Ͳphosphate lyase 1 2.815997601
830 IPI00942583.1 Uncharacteri zedprotein 2.814167023
831 IPI01009798.1 mitochondria l ribosomal proteinS28 2.801440001
832 IPI00291643.4 SPRYdomainͲconta iningprotein4 2.797506809
833 IPI01011878.1 cDNAPSEC0228fi s ,clone HEMBA1006099,weaklys imi lartoCOPͲCOATEDVESICLEMEM 2.790140152
834 IPI00329826.4 cDNAFLJ46853fi s ,clone UTERU3009775,moderatelys imi lartoRattus norvegicus PA 2.78877306
835 IPI00219484.1 Isoform3ofU1smal l nuclearribonucleoprotein70kDa 2.782621145
836 IPI00908503.1 cDNAFLJ50605,moderatelys imi lartoPlastinͲ3 2.78034997
837 IPI00007234.1 Zincfingerprotein510 2.770253658
838 IPI00643715.1 DnaJ(Hsp40)homolog,subfami lyC,member14 2.766234398
839 IPI00383182.1 PP3895 2.7661376
840 IPI01010916.1 majorhistocompatibi l i tycomplex,class I I ,DQbeta 1 2.765980482
841 IPI00936836.2 myomes in3 2.750969172
842 IPI00964379.1 THOcomplex3 2.744432688
843 IPI00001539.8 3Ͳketoacyl ͲCoAthiolase,mitochondria l 2.741857767
844 IPI00219866.2 Isoform2ofZincfingerRanͲbindingdomainͲconta iningprotein2 2.718465805
845 IPI00218848.5 ATPsynthase,H+transporting,mitochondria l F0complex,subuni tE 2.712542772
846 IPI00382790.3 Isoform2ofSharpin 2.6983459
847 IPI00982409.1 RINGfingerproteinC14orf164Ͳl ike 2.66461277
848 IPI00028003.1 Cytochrome coxidase subuni t7B,mitochondria l 2.619421244
849 IPI00945220.1 golgi integra l membrane protein4 2.604919434  
	   186	  
Table A5: BPPM-revealed common nonhistone targets of GLP1 and G9a in HEK293T 
cells using HeySAM. The proteins are no found in control. 
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Table S4. BPP -revealed common nonhistone targets of EuHMT1 and 2 in HEK293T cells 
with the EuHMT21-Y1154A mutant and Hey-SAM 6 as BPPM reagents. These proteins are not 
present in the control (empty-vector transfected HEK293T cells). 
Serial Accession Description ScoreofEuHMT1 scoreofEuHMt2
1 IPI00942420.2 Isoform1ofHistoneͲl ys ine NͲmethyl transferase EHMT1 729.0146117 51.76659226
2 IPI00026781.3 Fattyacidsynthase 391.2522674 759.7647235
3 IPI00304925.5 Heatshock70kDa protein1A/1B 235.7833066 321.283962
4 IPI00220644.8 IsoformM1ofPyruvate kinase i sozymes M1/M2 166.911351 149.4408383
5 IPI00449049.5 Poly[ADPͲribose]polymerase 1 160.6497989 260.0815408
6 IPI00645078.1 Ubiqui tinͲl i ke modifierͲactivatingenzyme 1 148.5826547 212.3655384
7 IPI00420014.2 Isoform1ofU5smal l nuclearribonucleoprotein200kDa hel icase 121.9588175 366.528441
8 IPI00893035.1 carbamoyl Ͳphosphate synthetase 2,aspartate transcarbamylase,an 121.9285016 238.1053216
9 IPI00645452.1 Tubul in,beta 118.182215 50.23914671
10 IPI00643041.3 GTPͲbindingnuclearproteinRan 116.9542315 70.04592967
11 IPI00019502.3 Isoform1ofMyos inͲ9 115.9260545 237.2038248
12 IPI00000874.1 Peroxi redoxinͲ1 113.6827171 177.3387182
13 IPI00013452.11 Bi functiona l aminoacyl ͲtRNAsynthetase 106.737942 172.1725242
14 IPI00017726.1 Isoform1of3Ͳhydroxyacyl ͲCoAdehydrogenase typeͲ2 104.8656714 61.59832907
15 IPI00018146.1 14Ͳ3Ͳ3proteintheta 103.0258706 77.91386127
16 IPI00219018.7 Glycera ldehydeͲ3Ͳphosphate dehydrogenase 101.2805254 256.5314114
17 IPI00007928.4 PreͲmRNAͲprocess ingͲspl icingfactor8 100.3890626 291.0308721
18 IPI00021263.3 14Ͳ3Ͳ3proteinzeta/del ta 99.24341798 64.90589786
19 IPI00456969.1 Cytoplasmicdynein1heavychain1 99.18983865 391.7522783
20 IPI00394838.3 cDNAFLJ56442,highlys imi lartoATPͲci trate synthase 96.82186866 149.8845675
21 IPI00216587.9 40Sribosomal proteinS8 94.91858125 49.05260539
22 IPI00218200.8 BͲcel l receptorͲassociatedprotein31 94.08164167 40.01049781
23 IPI00383581.4 cDNAFLJ61290,highlys imi lartoNeutra l alpha Ͳglucos idase AB 92.65108037 164.5848365
24 IPI00297779.7 TͲcomplexprotein1subunitbeta 85.41790318 19.29311204
25 IPI00030179.3 60Sribosomal proteinL7 84.80247474 51.23387122
26 IPI00967971.1 ubiqui tincarboxyl Ͳtermina l esterase L1(ubiqui tinthiolesterase) 84.78158069 46.09521461
27 IPI00217223.1 Multi functiona l proteinADE2 82.60718107 96.83288717
28 IPI00807545.1 Isoform3ofHeterogeneous nuclearribonucleoproteinK 82.27658319 65.32964873
29 IPI00008240.2 Methionyl ͲtRNAsynthetase,cytoplasmic 80.92234015 117.8301554
30 IPI00793443.2 Isoform1ofImportinͲ5 80.01624537 106.7574532
31 IPI00007188.6 ADP/ATPtrans locase 2 79.9827168 56.53837276
32 IPI00783097.4 Glycyl ͲtRNAsynthetase 78.70939565 120.6101208
33 IPI00329801.12 AnnexinA5 78.23380566 55.84255219
34 IPI00979136.1 Ribonucleos ideͲdiphosphate reductase 77.46082282 108.3014402
35 IPI00329633.5 Threonyl ͲtRNAsynthetase,cytoplasmic 77.27365184 120.9481163
36 IPI00025091.3 40Sribosomal proteinS11 77.253052 71.76152396
37 IPI00889541.2 Isoform4ofProbable ATPͲdependentRNAhel icase DDX17 76.96171999 94.11570525
38 IPI00412579.6 60Sribosomal proteinL10a 74.75596213 47.42085719
39 IPI00294911.1 Succinate dehydrogenase [ubiquinone]i ronͲsul fursubunit,mitocho 74.74311042 42.59361458
40 IPI00220301.5 Peroxi redoxinͲ6 74.10010314 49.33346581
41 IPI00217030.10 40Sribosomal proteinS4,Xi soform 74.05303216 50.09114695
42 IPI01012026.1 chromodomainhel icase DNAbindingprotein4 74.04750729 151.010915
43 IPI00024175.3 Isoform1ofProteasome subunitalpha typeͲ7 73.91543031 27.6172812
44 IPI00022774.3 Trans i tiona l endoplasmicreticulumATPase 73.26129746 149.5695152
45 IPI00644224.2 cDNAFLJ54020,highlys imi lartoHeterogeneous nuclearribonucleop 72.63242865 145.3232844
46 IPI00978796.1 cofi l in1(nonͲmuscle) 71.99949503 85.76440644  
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47 IPI01014604.1 TͲcomplexprotein1subuni tdelta 69.65310025 78.14010024
48 IPI00140420.4 Staphylococca l nuclease domainͲconta iningprotein1 69.51705146 89.10199308
49 IPI00029133.4 ATPsynthase subunitb,mitochondria l 69.10584235 49.95107341
50 IPI00018465.1 TͲcomplexprotein1subuni teta 69.01046848 84.1580894
51 IPI00465365.4 IsoformA1ͲAofHeterogeneous nuclearribonucleoproteinA1 66.49793029 212.3037598
52 IPI00291467.7 ADP/ATPtrans locase 3 65.61314964 51.63087511
53 IPI00012268.3 26Sproteasome nonͲATPase regulatorysubunit2 64.83733439 127.3789473
54 IPI00878075.1 RANbindingprotein1 64.83252692 38.07210541
55 IPI00917777.1 116kDa U5smal l nuclearribonucleoproteincomponenti soformb 64.2363987 102.9461691
56 IPI00549248.4 Isoform1ofNucleophosmin 61.72652674 131.7312021
57 IPI00419585.9 Peptidyl Ͳprolyl cis Ͳtrans i somerase A 61.64404869 70.94191241
58 IPI00867533.1 60Sribosomal proteinL6 61.51985025 110.2808673
59 IPI00002966.2 Heatshock70kDa protein4 61.04511046 85.93793941
60 IPI00027230.3 Endoplasmin 61.04120731 125.1475878
61 IPI00795292.1 Isoform3ofNucleos ide diphosphate kinase B 60.4085772 53.31095743
62 IPI00215917.3 ADPͲribosylationfactor3 59.20805001 62.3566103
63 IPI00217966.9 Isoform1ofLͲl actate dehydrogenase Achain 58.67067504 178.4921441
64 IPI00029623.1 Proteasome subunitalpha typeͲ6 57.18178296 28.82169819
65 IPI00020127.1 Repl icationproteinA70kDa DNAͲbindingsubunit 56.42424345 110.0033898
66 IPI00015018.1 Inorganicpyrophosphatase 56.11794639 170.3900266
67 IPI00027350.3 Peroxi redoxinͲ2 55.92931271 63.50261545
68 IPI00397526.3 Isoform1ofMyos inͲ10 55.7543714 119.0089898
69 IPI00218988.4 Isoform2ofAdenylate kinase 2,mitochondria l 55.4243381 44.54196548
70 IPI00465361.4 60Sribosomal proteinL13 54.99939442 20.32618785
71 IPI00374151.1 thioredoxinͲdependentperoxide reductase,mitochondria l i soformb 54.59023404 89.67426276
72 IPI00022891.3 ADP/ATPtrans locase 1 54.13334846 39.65227294
73 IPI00300371.5 Isoform1ofSpl i cingfactor3Bsubunit3 53.94768524 97.95910382
74 IPI00219306.1 Proteinmagonashi homolog 53.76058745 40.29925013
75 IPI00783781.2 Nuclearpore complexproteinNup205 53.75590611 136.3286684
76 IPI00783378.3 UbiquitinͲconjugatingenzyme E2O 52.98222733 57.0727365
77 IPI00020075.4 Abhydrolase domainͲconta iningprotein10,mitochondria l 52.12625527 25.16440916
78 IPI00941747.1 Calnexin 52.08898282 108.939739
79 IPI00895852.1 cel lularnucleicacidͲbindingproteini soform5 52.00794601 85.08035088
80 IPI00925853.1 cDNAFLJ60586,highlys imi lartoNADHͲubiquinone oxidoreductase 7 51.66277575 3.832695961
81 IPI00013214.2 cDNAFLJ55599,highlys imi lartoDNArepl icationl i cens ingfactorMCM 51.3785069 91.51911545
82 IPI00644127.2 Isoleucyl ͲtRNAsynthetase,cytoplasmic 50.39426541 136.8429933
83 IPI00003886.3 Isoform2ofGuanine nucleotideͲbindingproteinͲl i ke 3 50.23450446 84.67073178
84 IPI00216308.5 VoltageͲdependentanionͲselective channel protein1 49.92797661 30.21461153
85 IPI00216691.5 Profi l inͲ1 49.36589336 39.42420149
86 IPI00642936.2 glutathione SͲtrans ferase omega Ͳ1i soform3 49.1392777 30.95730042
87 IPI00012048.1 Isoform1ofNucleos ide diphosphate kinase A 48.40361905 43.98702502
88 IPI00170924.2 Histidine triadnucleotideͲbindingprotein3 48.3692143 64.2205677
89 IPI00739915.3 Putative tubul inbeta cha inͲl ike proteinENSP00000290377 47.63914037 52.74071693
90 IPI00016832.1 IsoformShortofProteasome subuni talpha typeͲ1 47.40951896 19.06253815
91 IPI00848298.1 Isoform2ofApol ipoproteinAͲIͲbindingprotein 47.40377808 20.14720654
92 IPI00015920.2 Isoform1ofMitochondria l dicarboxylate carrier 47.16355371 28.72216034
93 IPI00927606.1 Glutathione peroxidase 1 46.70900249 70.61924076  
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94 IPI00411680.11 Isoform1ofProteinͲLͲi soaspartate(DͲaspartate)OͲmethyl trans feras 46.48782468 32.04926777
95 IPI00219217.3 LͲlactate dehydrogenase Bcha in 46.39972949 175.9723818
96 IPI00555744.6 Ribosomal proteinL14variant 45.61308312 19.45099711
97 IPI00010896.3 Chloride intracel lularchannel protein1 44.61412549 22.36223078
98 IPI00218606.7 40Sribosomal proteinS23 44.01858759 41.93586826
99 IPI00789370.3 serine hydroxymethyl transferase,mitochondria l i soform3 43.69448233 62.71231842
100 IPI00411592.2 Isoform2ofChromodomainͲhel icaseͲDNAͲbindingprotein3 42.26829982 54.09346461
101 IPI00221088.5 40Sribosomal proteinS9 41.80261087 55.15500164
102 IPI00025329.1 60Sribosomal proteinL19 41.73298621 33.53769732
103 IPI00289819.5 CationͲindependentmannoseͲ6Ͳphosphate receptor 41.57298326 194.5548613
104 IPI00004968.1 PreͲmRNAͲprocess ingfactor19 41.54854751 23.14249349
105 IPI00216298.6 Thioredoxin 40.90045071 24.13620567
106 IPI00246975.8 Glutathione SͲtrans ferase Mu3 40.52072382 16.22876978
107 IPI00219078.5 Isoform1ofSarcoplasmic/endoplasmicreticulumca lciumATPase 2 40.1899116 105.0190744
108 IPI01017942.1 cycl inͲdependentkinase 1 40.14090967 20.30771685
109 IPI00965314.1 ATPͲbindingcassette,subͲfami lyE(OABP),member1 40.0531795 3.533854246
110 IPI00981739.1 tubul infoldingcofactorA 39.8813827 26.229635
111 IPI00006980.1 chromosome 14openreadingframe 166 39.82267761 26.09525371
112 IPI00016342.1 Ras ͲrelatedproteinRabͲ7a 39.55969405 56.70726061
113 IPI00221093.7 40Sribosomal proteinS17 38.01497412 25.90276027
114 IPI00015833.1 Coi ledͲcoi l Ͳhel ixͲcoi ledͲcoi l Ͳhel ixdomainͲconta iningprotein3,mito 37.96621513 28.57314563
115 IPI00396321.1 LeucineͲri chrepeatͲconta iningprotein59 37.65153241 95.53281498
116 IPI00215911.3 DNAͲ(apurinicorapyrimidinics i te)l yase 37.33648491 152.2553763
117 IPI00953417.1 tubul in,beta class I 36.98217416 21.46094656
118 IPI00008998.3 3Ͳhydroxyacyl ͲCoAdehydratase 3 36.8838954 73.19380951
119 IPI00002824.7 Cysteine andglycineͲri chprotein2 36.07404995 55.03849053
120 IPI00515040.1 Isoform2ofAlpha NͲtermina l proteinmethyltrans ferase 1A 35.88850784 27.32974958
121 IPI00025273.1 IsoformLongofTri functiona l purine biosyntheticproteinadenos ine 35.88418746 74.20943737
122 IPI00643368.1 Ras homologgene fami ly,memberC 35.85121965 3.590638876
123 IPI00807491.2 Isoform2ofGenera l transcriptionfactor3Cpolypeptide 1 35.73834395 7.998302937
124 IPI00179330.6 UbiquitinͲ40Sribosomal proteinS27a 35.43276453 19.45930576
125 IPI00641437.1 HEATrepeatconta ining1 35.142452 17.69447613
126 IPI00008530.1 60Sacidicribosomal proteinP0 34.72628856 111.2969279
127 IPI00646304.4 Peptidyl Ͳprolyl cis Ͳtrans i somerase B 34.28955984 48.38023973
128 IPI00220834.8 XͲrayrepaircross Ͳcomplementingprotein5 33.88251209 107.6939523
129 IPI00910113.1 cDNAFLJ52902,highlys imi lartoRabGDPdissociationinhibi tora lph 33.65728259 51.53565001
130 IPI00024911.1 Endoplasmicreticulumres identprotein29 33.55024695 7.204618931
131 IPI00295098.3 Signal recognitionparticle receptorsubuni tbeta 33.44176197 25.10525703
132 IPI00413324.6 60Sribosomal proteinL17 33.39969826 55.80420852
133 IPI00908896.2 heterogeneous nuclearribonucleoproteinH1(H) 33.32276654 30.50481462
134 IPI00156374.6 Isoform1ofImportinͲ4 33.15105653 60.80217481
135 IPI00032903.3 Peptidyl ͲtRNAhydrolase 2,mitochondria l 33.08517528 37.90535879
136 IPI00012074.3 Isoform1ofHeterogeneous nuclearribonucleoproteinR 32.83499622 55.09549785
137 IPI00908754.1 cDNAFLJ50714,moderatelys imi lartoRas ͲrelatedproteinRapͲ1b 32.82168961 53.55689955
138 IPI00980410.1 mitochondria l carrier2 32.69967675 34.56406307
139 IPI00375513.3 IsoformSoluble ofCatechol OͲmethyl transferase 32.68832779 27.21326852
140 IPI00917575.2 cDNAFLJ51046,highlys imi larto60kDa heatshockprotein,mitochon 32.64225578 28.52809048  
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141 IPI00001159.11 Trans lational activatorGCN1 32.41869712 85.26480722
142 IPI00759663.1 IsoformCytoplasmic+peroxisomal ofPeroxiredoxinͲ5,mitochondria l 32.32378983 30.06219959
143 IPI00017672.4 cDNAFLJ25678fi s ,clone TST04067,highlys imi lartoPURINENUCLEOSI 32.2683475 15.28783107
144 IPI00005024.3 Isoform1ofMybͲbindingprotein1A 31.99996924 77.87896466
145 IPI00003870.1 Putative ATPͲdependentClpprotease proteolyticsubuni t,mitochond 31.84814167 14.99601603
146 IPI00018931.6 VacuolarproteinsortingͲassociatedprotein35 31.56291461 47.37325096
147 IPI00013180.2 ProteinBUD31homolog 31.43726826 39.22823119
148 IPI00219678.3 Eukaryotictrans lationini tiationfactor2subunit1 31.36786199 38.0262506
149 IPI00073602.1 Exosome complexcomponentMTR3 31.27500772 15.42575288
150 IPI00003815.3 RhoGDPͲdissociationinhibi tor1 31.23469472 24.02476215
151 IPI00296913.1 ADPͲsugarpyrophosphatase 30.79156375 17.39159036
152 IPI01014863.1 Acetyl ͲCoAacetyl transferase,cytosol ic 30.49259949 22.96209049
153 IPI00893541.1 proteindisul fide i somerase fami lyA,member3 30.36398935 31.07933569
154 IPI00297579.4 Chromoboxproteinhomolog3 30.30350041 33.87606478
155 IPI00292020.3 Spermidine synthase 30.29854989 14.65871668
156 IPI00031691.1 60Sribosomal proteinL9 29.98712397 36.02842021
157 IPI00021347.1 UbiquitinͲconjugatingenzyme E2L3 29.80865288 21.37869477
158 IPI00028055.4 Transmembrane emp24domainͲconta iningprotein10 29.61652017 48.22544694
159 IPI00293331.3 Ribonucleases P/MRPproteinsubunitPOP1 29.48490858 33.2104609
160 IPI00219153.4 60Sribosomal proteinL22 29.35732174 18.14248013
161 IPI00413641.7 Aldose reductase 29.30551267 78.07148504
162 IPI00063242.6 Isoform2ofSerine/threonineͲproteinphosphatase PGAM5,mitocho 29.15536594 2.969429731
163 IPI00007611.1 ATPsynthase subunitO,mitochondria l 28.96623611 56.21613884
164 IPI00792330.2 ADPͲribosylationfactor4 28.81387091 39.91422415
165 IPI00647400.1 arginyl aminopeptidase (aminopeptidase B) 28.38294697 52.35423279
166 IPI00296370.2 leucine carboxyl methyltrans ferase 1 28.13103223 32.68146014
167 IPI00219622.3 Proteasome subunitalpha typeͲ2 28.01113796 6.670053482
168 IPI00984405.1 DEAD(AspͲGluͲAla ͲAsp)boxhel icase 5 27.97559333 9.441040039
169 IPI00182533.5 60Sribosomal proteinL28 27.8903029 20.32191014
170 IPI00221091.9 40Sribosomal proteinS15a 27.87808824 26.42860079
171 IPI00171199.5 Isoform2ofProteasome subuni ta lpha typeͲ3 27.87724471 13.3510921
172 IPI00010414.4 PDZandLIMdomainprotein1 27.65128565 92.54963565
173 IPI00003217.3 Proteasome subunitbeta typeͲ7 27.62663984 14.19120789
174 IPI00411706.1 SͲformylglutathione hydrolase 27.4816606 31.72799945
175 IPI00306280.4 Dens ityͲregulatedprotein 26.47071457 23.68208313
176 IPI00218693.8 Adenine phosphoribosyl transferase 26.11487603 40.49584842
177 IPI00169413.1 28Sribosomal proteinS34,mitochondria l 25.91457605 19.98661828
178 IPI00607799.5 Isoform1of3Ͳhydroxybutyrate dehydrogenase type 2 25.69540119 15.34840512
179 IPI00878876.1 cDNAFLJ51872,highlys imi lartoSmal l nuclearribonucleoproteinSm 25.57746196 15.92051387
180 IPI00456940.5 60Sribosomal proteinL7Ͳl ike 1 25.47294021 14.533535
181 IPI00030877.2 15kDa selenoproteini soform1precursor 25.47280741 22.05384469
182 IPI00218493.7 HypoxanthineͲguanine phosphoribosyltrans ferase 25.37085819 12.59149814
183 IPI00003386.3 E3ubiquitinͲproteinl i gase RBX1 25.28809643 20.6283741
184 IPI00438229.2 Isoform1ofTranscriptionintermediaryfactor1Ͳbeta 25.18329024 65.05789638
185 IPI00260318.3 cycl inͲdependentkinase 2i soform2 25.16826892 10.64922738
186 IPI00946221.1 ribosomal proteinL24 25.13393474 57.49180627
187 IPI00003588.1 Eukaryotictrans lationelongationfactor1eps i lonͲ1 25.08676624 28.65892458  
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188 IPI00926851.1 TRAMadaptorwithGOLDdomaini soform2 25.0576334 12.12693405
189 IPI00895865.1 electrontrans ferflavoproteinsubunitalpha ,mitochondria l i soform 25.02187204 20.30047679
190 IPI00304612.9 60Sribosomal proteinL13a 24.99991417 26.87083387
191 IPI00219155.5 60Sribosomal proteinL27 24.93350792 12.54528141
192 IPI00300096.4 Ras ͲrelatedproteinRabͲ35 24.8862865 18.3901031
193 IPI00940393.3 EEF1A1protein 24.6656723 81.66274333
194 IPI00655650.2 40Sribosomal proteinS26 24.61743641 23.73561382
195 IPI00025874.2 Dol ichyl Ͳdiphosphool igosaccharideͲͲproteinglycosyltrans ferase sub 24.13459992 72.23646331
196 IPI00013917.3 40Sribosomal proteinS12 24.00824642 11.29956412
197 IPI00007402.3 ImportinͲ7 23.74324346 48.00437307
198 IPI00555749.1 Proteasome 26SATPase subuni t5variant(Fragment) 23.71801162 43.66379905
199 IPI01018104.1 cDNAFLJ52561,highlys imi lartoFouranda halfLIMdomains protein 23.61455297 15.67550874
200 IPI01014503.1 Uncharacterizedprotein 23.49908495 25.88044834
201 IPI00007811.1 Cycl inͲdependentkinase 4 23.48174167 15.09010434
202 IPI00873286.2 cDNAFLJ55750,highlys imi lartoEukaryotictrans lationini tia tionfact 23.45419812 11.49638867
203 IPI00303722.5 ProteinFAM136A 23.30880928 36.111835
204 IPI00644674.1 Cytosol icFeͲSclusterassemblyfactorNUBP2 22.99330688 11.04510665
205 IPI00021828.1 CystatinͲB 22.94549203 24.37318659
206 IPI00006211.4 Isoform1ofVes icleͲassociatedmembrane proteinͲassociatedprote 22.8651557 14.96650648
207 IPI01013843.1 cDNAFLJ59776,highlys imi lartoPrefoldinsubuni t3 22.77480769 11.55967331
208 IPI00027270.1 60Sribosomal proteinL26 22.55340433 23.58366847
209 IPI00011876.3 cDNAFLJ59758,highlys imi lartoSͲmethyl Ͳ5Ͳthioadenos ine phosphor 22.38703632 16.71141124
210 IPI00334907.3 Isoform1ofPhosphatidyl inos i tol trans ferproteinbeta i soform 22.3500936 65.49831676
211 IPI01010050.1 cDNA,FLJ78818,highlys imi lartoVoltage ͲdependentanionͲselective 22.23621225 5.225667953
212 IPI00794911.3 Coatomersubunitgamma 22.19975686 17.72200608
213 IPI00215719.6 60Sribosomal proteinL18 22.1474607 27.57744861
214 IPI00105598.3 Proteasome 26SnonͲATPase subunit11variant(Fragment) 22.03928852 6.919309378
215 IPI00453473.6 Histone H4 21.98193645 11.90534139
216 IPI00643504.1 ringfingerprotein2 21.96214581 7.100060463
217 IPI00456758.4 60Sribosomal proteinL27a 21.87804031 19.38668346
218 IPI00746438.2 Isoform2of60Sribosomal proteinL11 21.80755496 29.98282504
219 IPI01011782.1 cDNAFLJ61430,highlys imi lartoATPͲdependentRNAhel icase DDX50 21.78792763 23.28930044
220 IPI00017297.1 MatrinͲ3 21.75937772 42.7282083
221 IPI00220667.3 Isoform4ofHexokinaseͲ1 21.74832654 58.12198567
222 IPI01012526.1 glucos idase,a lpha;neutra l AB 21.72934151 9.832138062
223 IPI00026824.2 Heme oxygenase 2 21.72010708 72.25547433
224 IPI00221325.3 E3SUMOͲproteinl i gase RanBP2 21.49732208 30.0734508
225 IPI00908723.1 cDNAFLJ61039,highlys imi lartoStomatinͲl i ke protein2 21.48810863 18.12077689
226 IPI00081836.3 Histone H2Atype 1ͲH 21.4817996 25.64582062
227 IPI00167941.1 Midas in 21.46257401 114.3588099
228 IPI00429689.3 Serine/threonineͲproteinphosphatase 2Acata lyticsubuni tbeta i so 21.41615653 101.8603373
229 IPI00008380.1 Serine/threonineͲproteinphosphatase 2Acata lyticsubuni talpha i s 21.40297103 101.5836127
230 IPI00294398.2 Isoform1ofHydroxyacyl Ͳcoenzyme Adehydrogenase,mitochondria l 21.36481214 6.69530654
231 IPI00006907.1 Probable fructoseͲ2,6Ͳbisphosphatase TIGAR 21.32082558 10.89680028
232 IPI00016458.3 Isoform1ofLͲ2Ͳhydroxyglutarate dehydrogenase,mitochondria l 21.23870134 15.10022569
233 IPI00029079.5 GMPsynthase [glutamineͲhydrolyzing] 21.20630789 37.17861724
234 IPI00028004.2 Proteasome subunitbeta typeͲ3 21.16501713 29.57798219  
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235 IPI00795892.1 profi l in2 21.044034 18.24080682
236 IPI00171611.7 Histone H3.2 20.88544345 28.79178953
237 IPI00645138.2 cDNAFLJ55652,highlys imi lartoNucleolarGTPͲbindingprotein1 20.81382537 48.12162352
238 IPI00295485.4 Heatshock70kDa protein4L 20.73207259 50.60684347
239 IPI00022018.1 Dol ichol Ͳphosphate mannosyltrans ferase 20.72329092 19.41536641
240 IPI00009342.1 Ras GTPaseͲactivatingͲl i ke proteinIQGAP1 20.70216203 43.39088202
241 IPI00220993.1 IsoformCNPI of2',3'Ͳcycl i cͲnucleotide 3'Ͳphosphodiesterase 20.66739511 24.2182169
242 IPI00427330.3 Ribosome maturationproteinSBDS 20.5949223 2.973943233
243 IPI00215790.6 60Sribosomal proteinL38 20.52120352 11.53737783
244 IPI00549885.4 Isoform2ofPyruvate dehydrogenase E1componentsubuni tbeta ,m 20.50771928 63.37418199
245 IPI00010153.5 60Sribosomal proteinL23 20.50240135 12.92345476
246 IPI01015295.1 cDNAFLJ30049fi s ,clone ADRGL1000033,highlys imi larto26Sproteas 20.48267412 10.43838573
247 IPI00010271.3 IsoformAofRas ͲrelatedC3botul inumtoxinsubstrate 1 20.18120885 35.11968374
248 IPI00178440.3 Elongationfactor1Ͳbeta 19.93448758 11.65764499
249 IPI00445401.4 Isoform2ofE3ubiquitinͲproteinl igase HUWE1 19.93258858 129.8415353
250 IPI00016513.5 Ras ͲrelatedproteinRabͲ10 19.7488091 37.5575211
251 IPI00219358.7 Isoform1ofMannoseͲ6Ͳphosphate i somerase 19.56478715 13.99072981
252 IPI00472633.7 Isoform3ofTransformerͲ2proteinhomologbeta 19.54099369 34.55797982
253 IPI00170692.4 Isoform1ofVes icleͲassociatedmembrane proteinͲassociatedprote 19.54041743 10.09439015
254 IPI00012795.3 Eukaryotictrans lationini tiationfactor3subunitI 19.50349522 62.16252136
255 IPI00019196.3 Ribonuclease Pproteinsubunitp30 19.37051654 13.54499817
256 IPI00029631.1 Enhancerofrudimentaryhomolog 19.35223317 10.10195589
257 IPI00414168.1 E3ubiquitinͲproteinl i gase MARCH5 19.35148454 10.86114836
258 IPI00642046.1 ribosomal L1domainconta ining1 19.30265665 42.51666975
259 IPI00218728.4 Isoform1ofPlateletͲactivatingfactoracetylhydrolase IBsubunita lp 19.30063415 6.796374559
260 IPI00978910.1 Gl ia maturationfactorbeta 19.29461503 6.928934574
261 IPI00020599.1 Cal reticul in 19.22097254 58.32678366
262 IPI00411937.4 Nucleolarprotein56 19.08992338 55.92416358
263 IPI00789582.2 cDNAFLJ51552,highlys imi lartoEukaryotictrans lationini tia tionfact 19.07729435 21.82286453
264 IPI00395887.4 ThioredoxinͲrelatedtransmembrane protein1 19.07211781 11.23121548
265 IPI00916060.1 DNAͲdirectedRNApolymerase 19.04974222 38.15083671
266 IPI00644531.1 transgel in2 18.88507462 29.70350599
267 IPI00003766.4 ProteinETHE1,mitochondria l 18.88325882 3.126749754
268 IPI01010461.1 hypoxia upͲregulated1 18.87546682 17.63665271
269 IPI00026970.4 FACTcomplexsubunitSPT16 18.70021462 33.64892483
270 IPI01010797.1 cDNA,FLJ96158,highlys imi lartoHomosapiens calpa in2,(m/II)la rg 18.66959786 30.85051012
271 IPI00219757.13 Glutathione SͲtrans ferase P 18.60493469 12.1351583
272 IPI00971018.1 Isoform1ofTARDNAͲbindingprotein43 18.56664896 19.22315741
273 IPI01012383.1 OTUdomain,ubiquitina ldehyde binding1 18.31986809 64.10212636
274 IPI00000821.2 39Sribosomal proteinL16,mitochondria l 18.28165388 6.928866386
275 IPI00012750.3 40Sribosomal proteinS25 18.24493194 7.302073002
276 IPI00025347.4 Ribosomal RNAsmal l subunitmethyl transferase NEP1 17.93830657 6.505105972
277 IPI01014133.1 cDNAFLJ32936fi s ,clone TESTI2007533,highlys imi lartoRuvBͲl ike 2 17.87639046 30.22881627
278 IPI00910754.1 LͲlactate dehydrogenase Acha ini soform2 17.84153605 9.799121618
279 IPI00017469.1 Sepiapterinreductase 17.78612185 8.42458725
280 IPI00032808.1 Ras ͲrelatedproteinRabͲ3D 17.76695919 12.4209168
281 IPI00016786.1 Isoform2ofCel l divis ioncontrol protein42homolog 17.71056509 50.16028833  
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282 IPI00031169.1 Ras ͲrelatedproteinRabͲ2A 17.69229293 30.06599617
283 IPI00917181.1 Ribosomal proteinL36a 17.68854117 26.74609089
284 IPI00003927.5 Peptidyl Ͳprolyl cis Ͳtrans i somerase D 17.65873814 11.56363511
285 IPI00219077.4 Isoform1ofLeukotriene AͲ4hydrolase 17.58453393 26.63442516
286 IPI00556107.1 DNAͲ3Ͳmethyladenine glycosylase i soformc 17.57844281 34.92022943
287 IPI00029046.1 Malectin 17.57364154 13.42012191
288 IPI00219861.3 Isoform1ofLowmolecularweightphosphotyros ine proteinphosph 17.48403931 13.03783321
289 IPI00794545.1 deoxyuridine 5'Ͳtriphosphate nucleotidohydrolase,mitochondria l i s 17.41640306 20.93088627
290 IPI00185374.4 26Sproteasome nonͲATPase regulatorysubunit12 17.37279034 18.54274511
291 IPI00018783.1 Inos ine triphosphate pyrophosphatase 17.35806489 23.23776221
292 IPI00023542.6 Transmembrane emp24domainͲconta iningprotein9 17.34732461 12.5365169
293 IPI00014053.3 Isoform1ofMitochondria l importreceptorsubuni tTOM40homolog 17.29182148 51.52494693
294 IPI00025084.3 Calpa insmal l subunit1 17.26847553 11.42881656
295 IPI00303954.3 cytochrome b5type Bprecursor 17.2508781 32.84485555
296 IPI00868999.1 Simi lartoAcidicribosomal phosphoproteinP0 17.19005585 6.193804741
297 IPI00942944.1 proteinDEKi soform2 17.0475266 18.61816978
298 IPI00005692.1 28Sribosomal proteinS12,mitochondria l 16.97285175 8.977897167
299 IPI00013167.1 28Sribosomal proteinS25,mitochondria l 16.91688275 26.91265559
300 IPI00023406.1 Cytochrome cͲtype heme lyase 16.86869431 6.956211329
301 IPI00396329.1 Ribosome productionfactor2homolog 16.69620633 50.31776333
302 IPI00023647.4 Isoform1ofUbiqui tinͲl i ke modifierͲactivatingenzyme 6 16.67186379 36.5750742
303 IPI00062866.4 Isoform1ofZincfingerCCCHͲtype antivi ra l protein1Ͳl i ke 16.60305166 32.87110829
304 IPI00925601.1 5Ͳaminoimidazole Ͳ4Ͳcarboxamide ribonucleotide formyl trans ferase 16.5197804 27.30317044
305 IPI00024821.1 26Sproteasome nonͲATPase regulatorysubunit14 16.49425149 46.22907114
306 IPI00410324.2 Isoform1ofProteinLSM12homolog 16.34122086 7.410131693
307 IPI00879638.2 cDNAFLJ58652,highlys imi lartoProbable ATPͲdependentRNAhel ica 16.28180313 8.521591902
308 IPI00005107.2 NiemannͲPickC1protein 16.24896646 37.4597559
309 IPI00219365.3 Moes in 16.2058394 30.11094594
310 IPI01011282.1 23kDa protein 16.15997243 13.28340149
311 IPI00168184.8 cDNAFLJ56053,highlys imi lartoSerine/threonineͲproteinphosphata 16.04391837 5.994200945
312 IPI01011132.1 Isoform1ofDNAtopoisomerase 2Ͳalpha 16.02649283 47.97874737
313 IPI00023064.1 NADHdehydrogenase [ubiquinone]1alpha subcomplexassemblyfa 16.00889349 19.44897747
314 IPI00916802.1 Sjogrensyndrome antigenB(autoantigenLa) 15.84578443 21.62210894
315 IPI00017283.2 Isoleucyl ͲtRNAsynthetase,mitochondria l 15.54805946 79.32804489
316 IPI00021095.1 ProteinMis18Ͳalpha 15.43418527 11.97754002
317 IPI00216057.6 Sorbi tol dehydrogenase 15.38418078 16.8930974
318 IPI00640037.2 cDNAFLJ38496fi s ,clone FELIV1000137,highlys imi larto60SRIBOSOM 15.3722167 7.36440134
319 IPI00297241.4 NucleolarpreͲribosomal Ͳassociatedprotein1 15.26629472 64.38480663
320 IPI00383680.3 dol i chyl Ͳdiphosphool igosaccharide ͲͲproteinglycosyl trans ferase sub 15.2184515 21.20480132
321 IPI00060031.3 ADPͲribosylationfactorͲl i ke protein8A 15.20935559 36.73852849
322 IPI00398774.3 Isoform2ofMps one binderkinase activatorͲl i ke 3 15.13529372 12.17595506
323 IPI00909577.1 cDNAFLJ52894,highlys imi lartoIsoci trate dehydrogenase 15.11244202 20.18908143
324 IPI00185503.4 Isoform2ofATPͲbindingcassette subͲfami lyDmember3 14.98766041 30.74609566
325 IPI00411765.3 Isoform2of14Ͳ3Ͳ3proteins igma 14.98706102 9.002167463
326 IPI00640703.3 ExportinͲ5 14.95011711 25.50934196
327 IPI00239077.5 Histidine triadnucleotideͲbindingprotein1 14.87256193 6.230341673
328 IPI00219575.5 Bleomycinhydrolase 14.86099052 4.411576271  
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329 IPI00924816.1 Myotrophin 14.80269027 25.96178555
330 IPI01013052.1 caspase 12(gene/pseudogene) 14.80241656 20.2420795
331 IPI00910164.1 cDNAFLJ53381,highlys imi lartoMonocarboxylate transporter1 14.7109592 40.8945055
332 IPI00760588.2 Isoform5ofDoubleͲs trandedRNAͲspeci fi cadenos ine deaminase 14.69395542 33.06698012
333 IPI00740142.2 u5smal l nuclearribonucleoprotein200kDa hel icaseͲl ike,partia l 14.67643595 13.38677335
334 IPI00304932.2 Ribosomal RNAͲprocess ingprotein8 14.64496183 28.81081104
335 IPI00029629.4 E3ubiquitin/ISG15l igase TRIM25 14.55224824 41.33140135
336 IPI00021785.2 Cytochrome coxidase subunit5B,mitochondria l 14.54167295 11.38466263
337 IPI00737530.1 actinͲrelatedprotein2/3complexsubunit1BͲl ike 14.47739291 17.5527246
338 IPI00218568.7 PterinͲ4Ͳalpha Ͳcarbinolamine dehydratase 14.44081759 15.21335578
339 IPI00479722.2 Proteasome activatorcomplexsubunit1 14.4245286 8.93192625
340 IPI00646605.3 Isoform3ofE3ubiquitinͲproteinl igase UBR4 14.39617968 55.55451703
341 IPI00953109.2 Isoform6ofFi laminͲB 14.38293767 103.4262052
342 IPI00012315.2 Nucleos ide diphosphate kinase 3 14.35925961 7.999052525
343 IPI01009435.1 THOcomplexsubunit2 14.33485222 37.97984362
344 IPI00853337.1 ADPͲribosylationfactor5 14.32359123 26.4231627
345 IPI00022597.1 NEDD8Ͳconjugatingenzyme Ubc12 14.31094575 18.13961244
346 IPI00984586.1 tryps inͲ3i soform4preproprotein 14.28379822 2.935996056
347 IPI00246058.10 Programmedcel l death6Ͳinteractingprotein 14.27806425 29.39755034
348 IPI00099996.2 Mitochondria l ribonuclease Pprotein1 14.25307441 11.43853045
349 IPI00059764.4 Isoform1ofZincfingerprotein428 14.14135289 3.339945316
350 IPI00658013.1 nucleophosmini soform3 14.14046288 23.19569707
351 IPI00017381.1 Repl icationfactorCsubuni t4 14.09888244 13.64978266
352 IPI00017799.5 cDNAFLJ55158,highlys imi lartoThioredoxin,mitochondria l 14.06674433 3.320490599
353 IPI01015100.1 MembraneͲassociatedprogesterone receptorcomponent2 14.04842472 12.71248055
354 IPI00220648.5 Phosphomeva lonate kinase 13.97088099 8.992396593
355 IPI00947020.2 Ras homologenrichedinbrain 13.71872401 11.95468044
356 IPI00024157.1 Peptidyl Ͳprolyl cis Ͳtrans i somerase FKBP3 13.6936903 3.0353055
357 IPI00604652.1 NEDD8Ͳactivatingenzyme E1regulatorysubuni ti soformc 13.66355371 18.91427255
358 IPI00329301.3 Isoform1ofNADHdehydrogenase [ubiquinone]1alpha subcomple 13.64425278 16.18613505
359 IPI00893703.1 ribosomal proteinS7 13.64069605 17.02438021
360 IPI00152695.2 WDrepeatͲconta iningprotein82 13.63987303 20.23001885
361 IPI00290543.5 Isoform1ofNuclearproteinloca l i zationprotein4homolog 13.63589573 27.5719955
362 IPI00909694.2 a lpha Ͳaminoadipicsemia ldehyde dehydrogenase i soform3 13.55945539 6.823871851
363 IPI00940720.2 PARP1protein(Fragment) 13.53916049 12.79487371
364 IPI00004165.1 Fos39347_1 13.52875137 3.22106123
365 IPI00550852.4 Isoform1ofDynactinsubuni t4 13.52199078 29.76708961
366 IPI00017510.3 Cytochrome coxidase subunit2 13.47459793 16.73841619
367 IPI00927715.1 Ribosomal proteinL15 13.45742917 15.7077837
368 IPI00927892.1 Mitochondria l Ͳprocess ingpeptidase subuni tbeta 13.39058852 23.17147756
369 IPI00976817.1 polyͲUbindingspl icingfactor60KDa 13.3136878 5.053713322
370 IPI00011694.1 Tryps inͲ1 13.29701853 25.8478961
371 IPI00916474.2 mannosyl Ͳol igosaccharide glucos idase i soform2 13.23869753 27.74307871
372 IPI00031647.2 Programmedcel l deathprotein2Ͳl i ke 13.20120621 12.38316584
373 IPI00443909.1 Isoform1ofProteincanopyhomolog2 13.19260883 15.38165808
374 IPI01010565.1 cDNAFLJ51063,highlys imi lartoDihydrol ipoyl lys ineͲres idue acetyl tr 13.17704034 3.651170254
375 IPI01015427.1 cDNAFLJ58247,highlys imi larto26Sprotease regulatorysubunit4 13.14909625 7.447316885  
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376 IPI00011916.1 Aminoacyl tRNAsynthase complexͲinteractingmulti functional prote 13.07555175 26.68466663
377 IPI00007694.5 Isoform1ofProteinphosphatase methylesterase 1 13.06180024 12.27838659
378 IPI00005161.3 ActinͲrelatedprotein2/3complexsubunit2 13.05300403 13.93984199
379 IPI00793205.1 cDNAFLJ56571,highlys imi lartoSpl icingfactor,arginine/serineͲri ch 13.04667401 2.993952513
380 IPI01013544.1 cDNAFLJ54328,highlys imi lartoHeatshock70kDa protein1 13.04402208 75.04023147
381 IPI00014577.1 Ras ͲrelatedproteinRabͲ18 12.96826291 18.26451421
382 IPI00795257.3 Glycera ldehydeͲ3Ͳphosphate dehydrogenase 12.95435119 42.29723239
383 IPI00917605.1 cytochrome c,somatic 12.88886666 11.01686788
384 IPI00216293.6 Thiosul fate sul furtrans ferase 12.8551867 2.791210413
385 IPI00019326.1 Adrenodoxin,mitochondria l 12.77173233 8.928052902
386 IPI00009253.2 Alpha Ͳsoluble NSFattachmentprotein 12.71969557 2.872599125
387 IPI00018671.1 Dual speci fici typroteinphosphatase 3 12.64930868 18.46640468
388 IPI00973816.1 proteasome (prosome,macropa in)26Ssubuni t,nonͲATPase,13 12.64352679 27.08849835
389 IPI01013402.1 cDNAFLJ46429fi s ,clone THYMU3014372,highlys imi lartoDNArepl ica 12.61844373 40.9428072
390 IPI00643876.2 cDNAFLJ50466,highlys imi lartoDNA(cytos ineͲ5)Ͳmethyl transferaseͲ 12.58668089 15.16066217
391 IPI00025156.4 Isoform1ofE3ubiquitinͲproteinl igase CHIP 12.58575606 8.156795502
392 IPI00745893.2 smal l ubiqui tinͲrelatedmodifier2i soformbprecursor 12.5713799 6.090990543
393 IPI00005050.1 28Sribosomal proteinS14,mitochondria l 12.56365681 8.25626111
394 IPI00292135.1 LaminͲBreceptor 12.54350257 22.18463612
395 IPI00645869.1 Isoform2ofProteinLAS1homolog 12.4950614 15.71039009
396 IPI00554521.2 Ferri tinheavychain 12.49393749 31.01583433
397 IPI00645898.3 XͲprolyl aminopeptidase (Aminopeptidase P)1,soluble 12.43623996 21.54259062
398 IPI00011997.4 chromosome 8openreadingframe 33 12.41482973 3.802040815
399 IPI00029266.1 Smal l nuclearribonucleoproteinE 12.33372808 12.59852314
400 IPI00794746.1 Uncharacterizedprotein 12.33148813 6.071681738
401 IPI00945960.1 s ignal sequence receptor,gamma (trans loconͲassociatedproteinga 12.29565358 12.55513477
402 IPI00005705.1 IsoformGamma Ͳ1ofSerine/threonineͲproteinphosphatase PP1Ͳgam 12.20368648 62.51254654
403 IPI00966877.1 tRNA(cytos ineͲ5Ͳ)Ͳmethyl trans ferase NSUN2i soform2 12.2026782 27.62003875
404 IPI00025340.3 Pyridoxal phosphate phosphatase 12.19011784 6.942385197
405 IPI01014044.1 Isoform1ofNADHdehydrogenase [ubiquinone]1beta subcomplex 12.06624794 12.12593031
406 IPI00020510.1 CDGSHi ronͲsul furdomainͲconta iningprotein1 12.0614717 8.634587288
407 IPI00965541.1 CCHCͲtype zincfinger,nucleicacidbindingprotein 11.95422387 13.28625417
408 IPI00480093.6 ERO1Ͳl i ke beta 11.92051363 6.071348906
409 IPI00927582.2 Isoform5ofSerrate RNAeffectormolecule homolog 11.88848162 30.37669873
410 IPI00979721.1 Isoform3ofMini Ͳchromosome maintenance complexͲbindingprote 11.88371491 12.42308044
411 IPI00218054.2 SelenoproteinH 11.86993909 5.228617668
412 IPI00788938.1 LͲlactate dehydrogenase 11.76095319 35.13553357
413 IPI00028481.1 Ras ͲrelatedproteinRabͲ8A 11.74769545 19.31895494
414 IPI00154590.6 MKI67FHAdomainͲinteractingnucleolarphosphoprotein 11.72099137 55.91034389
415 IPI00001655.1 chromosome 16openreadingframe 80 11.67676139 15.90857196
416 IPI00166483.2 transmembrane protein256 11.63630533 6.518399239
417 IPI00798211.1 tubul infoldingcofactorB 11.49359608 11.63812995
418 IPI00930694.1 insul inͲl ike growthfactor2mRNAͲbindingprotein1i soform2 11.47464442 9.614244461
419 IPI00028277.8 Isoform1ofAlpha ͲketoglutarateͲdependentdioxygenase FTO 11.45226812 10.07923675
420 IPI00219512.2 Isoform2ofUbiqui tincarboxyl Ͳtermina l hydrolase i sozyme L5 11.39187741 20.55851364
421 IPI00298961.3 ExportinͲ1 11.3826592 52.11610389
422 IPI01013273.1 cDNA,FLJ79129,highlys imi lartoTͲcomplexprotein1subuni tzeta 11.35524893 7.006772041  
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423 IPI00793102.1 ribosomal proteinL35a 11.35146785 12.99345636
424 IPI00016597.3 CeroidͲl ipofuscinos is neurona l protein6 11.30901694 7.689606667
425 IPI01015738.1 Alpha actinin4shorti soform 11.29110169 6.77367425
426 IPI00759659.1 Isoform2ofGolgi membrane protein1 11.22557688 6.926651716
427 IPI00909691.1 cDNAFLJ50174,highlys imi lartoHomosapiens SNAREproteinYkt6(Y 11.2249918 6.76971817
428 IPI00910422.2 cDNAFLJ52802,highlys imi lartoEukaryotictrans lationini tia tionfact 11.21058941 17.07328272
429 IPI01011335.1 cDNAFLJ60435,highlys imi lartoHeterogeneous nuclearribonucleop 11.08753657 17.91938734
430 IPI00217413.3 ATPͲdependentRNAhel icase DHX29 11.08337402 18.55859256
431 IPI00910455.1 cDNAFLJ60259,highlys imi lartoElongationfactorTs ,mitochondria l 11.05444479 6.411585569
432 IPI00100460.2 Aspartyl ͲtRNAsynthetase,mitochondria l 11.03229046 27.18651175
433 IPI00250297.3 LͲaminoadipate Ͳsemialdehyde dehydrogenaseͲphosphopantethein 11.0196867 31.70700741
434 IPI00290416.3 Isoform1ofObgͲl ike ATPase 1 11.0009377 15.52790523
435 IPI00414347.2 Isoform2ofAnkyrinrepeatandSOCSboxprotein18 10.96737456 2.774348736
436 IPI00171665.1 NucleoporinNup37 10.9279871 10.40621829
437 IPI00984414.2 Elongationfactor1Ͳa lpha 10.92542124 18.99169207
438 IPI00908662.2 ribosomal proteinL4 10.87329102 3.33714366
439 IPI00003949.1 UbiquitinͲconjugatingenzyme E2N 10.85238695 7.103901386
440 IPI00215920.8 ADPͲribosylationfactor6 10.78922439 8.970561504
441 IPI00002902.5 Polynucleotide 5'Ͳhydroxyl Ͳkinase NOL9 10.75507736 23.95106339
442 IPI00910298.1 cDNAFLJ56236,highlys imi lartoExportinͲ2 10.71265221 14.08889389
443 IPI01009326.1 cDNAFLJ53379,highlys imi lartoTͲcomplexprotein1subunittheta 10.65254021 9.490504503
444 IPI00100656.3 Isoform1ofTrans Ͳ2,3Ͳenoyl ͲCoAreductase 10.63536382 10.27974463
445 IPI00178431.12 ATPͲdependentDNAhel icase Q1 10.52583528 25.62801909
446 IPI00011250.3 Ubiquitincarboxyl Ͳterminal hydrolase i sozyme L3 10.51327205 2.848175764
447 IPI00003968.1 NADHdehydrogenase [ubiquinone]1alpha subcomplexsubunit9,m 10.48416424 22.29064155
448 IPI00792023.2 Ariadne homolog2variant(Fragment) 10.43514371 8.87221384
449 IPI00788612.2 LIMandsenescentcel l antigenͲl i keͲconta iningdomainprotein1 10.40838933 54.09051752
450 IPI01015006.1 cDNAFLJ14416fi s ,clone HEMBA1005202,highlys imi lartoSIGNALREC 10.32061744 26.9031744
451 IPI00984941.1 lysophosphol ipase I 10.24244213 12.11687398
452 IPI01010794.1 THOcomplexsubunit4 10.18708611 7.619431019
453 IPI00167549.3 ADPͲribosylationfactorͲl i ke 14effectorprotein 10.16257095 2.859004498
454 IPI00299084.1 Transmembrane protein33 10.13495803 16.83365798
455 IPI00980668.1 heterogeneous nuclearribonucleoproteinH1(H) 10.12468576 11.15116978
456 IPI00555878.1 Probable DNAdCͲ>dUͲeditingenzyme APOBECͲ3C 10.09930563 12.15285873
457 IPI00741996.9 KMͲPAͲ2protein 10.09748459 51.81624365
458 IPI00000006.1 GTPase HRas 10.09243774 15.75251102
459 IPI00744692.1 Transaldolase 10.09027243 24.16368175
460 IPI00015956.3 Exosome complexcomponentRRP40 10.0793612 6.181510687
461 IPI00373882.2 repl icationfactorCsubunit3i soform2 10.07904959 6.745334148
462 IPI00645646.1 17kDa protein 9.952640533 15.1362884
463 IPI00793232.1 cDNAFLJ59109,highlys imi lartoPyridoxine Ͳ5'Ͳphosphate oxidase 9.920525074 3.588242531
464 IPI00218857.1 Isoform1ofDual speci fi ci tymitogenͲactivatedproteinkinase kinas 9.890594721 3.283116579
465 IPI00294943.1 ProteinariadneͲ1homolog 9.876232147 18.67661929
466 IPI00926585.1 eukaryotictrans lationelongationfactor1beta 2 9.847770691 3.480661154
467 IPI00021266.1 60Sribosomal proteinL23a 9.834607363 17.05376267
468 IPI00909181.1 GrpEproteinhomolog 9.780870676 6.555705309
469 IPI00020602.1 Caseinkinase I I subuni talpha' 9.737714052 5.432087421  
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470 IPI00927255.1 LanClantibioticsynthetase componentCͲl i ke 1(bacteria l ) 9.692457914 16.40298176
471 IPI01012426.1 RAP1B,memberofRASoncogene fami ly 9.666450977 2.987706423
472 IPI00759596.1 Isoform4ofHeterogeneous nuclearribonucleoproteins C1/C2 9.631971359 8.547278166
473 IPI00184525.2 Isoform2ofMethyl thioriboseͲ1Ͳphosphate i somerase 9.610852718 3.093814373
474 IPI00019912.3 Peroxisomal multi functional enzyme type 2 9.566012144 22.61170793
475 IPI00847986.1 Isoform2of40Sribosomal proteinS24 9.536608696 15.47692728
476 IPI00939558.2 cDNAFLJ38696fi s ,clone KIDNE2001931,highlys imi lartoHETEROGENE 9.513035297 12.05787754
477 IPI00397904.6 Nuclearpore complexproteinNup93 9.509429932 32.65908766
478 IPI00006113.1 DNAͲdirectedRNApolymerase I I subuni tRPB9 9.481889009 9.967593908
479 IPI00641665.1 interleukinenhancerbindingfactor2,45kDa 9.44649291 10.82668447
480 IPI00329600.3 Probable saccharopine dehydrogenase 9.4371171 9.199316978
481 IPI00100984.4 Isoform1ofHEATrepeatͲconta iningprotein3 9.334487915 10.81985712
482 IPI00967562.1 heterogeneous nuclearribonucleoproteinD(AUͲrichelementRNAb 9.321878672 5.888921976
483 IPI00939491.1 Isoform2ofCysteinyl ͲtRNAsynthetase,cytoplasmic 9.261469126 46.16977072
484 IPI00963816.1 phosphoribosylaminoimidazole carboxylase,phosphoribosylamino 9.248252392 7.062841654
485 IPI00012353.1 39Sribosomal proteinL3,mitochondria l 9.221636057 23.34996629
486 IPI00215974.2 Queuine tRNAͲribosyltrans ferase 9.1964674 15.76839066
487 IPI00556157.1 Polypyrimidine tractͲbindingprotein1i soformcvariant(Fragment) 9.12130475 5.903226376
488 IPI00910419.1 cDNAFLJ52929,highlys imi lartoDol ichyl Ͳdiphosphool igosaccharide 9.084523201 6.170256138
489 IPI00983417.1 CD59molecule,complementregulatoryprotein 9.036623478 9.638309956
490 IPI00152912.1 IsoformBofEctodysplas inͲAreceptorͲassociatedadapterprotein 9.005042553 4.228182316
491 IPI00893580.1 HLAͲBassociatedtranscript1 8.983823538 17.40922332
492 IPI00921560.2 Isoform2ofPolycombgroupRINGfingerprotein1 8.963470936 3.294580221
493 IPI00155601.1 MACROdomainͲconta iningprotein1 8.959338903 3.539744139
494 IPI01011575.1 cDNAFLJ60080,highlys imi larto130kDa leucineͲri chprotein(Fragme 8.913601875 12.86030412
495 IPI00924895.1 SNRPGprotein 8.880480289 8.205285788
496 IPI00514956.1 Rabgeranylgeranyltrans ferase,beta subunit 8.827101946 10.16696143
497 IPI00016746.1 Isoform1ofCoreͲbindingfactorsubunitbeta 8.752801418 4.835932732
498 IPI00398131.4 Isoform1ofProteinl inͲ28homologB 8.721138 40.98487496
499 IPI00382459.1 Isoform3ofCul l inͲ3 8.651211977 7.626033545
500 IPI00642213.1 RNAbindingprotein,autoantigenic 8.526372194 18.50947499
501 IPI00184884.6 NonͲs tructura l maintenance ofchromosomes element1homolog 8.472459793 3.866527081
502 IPI00037448.3 Glyoxylate reductase/hydroxypyruvate reductase 8.332123518 37.4287343
503 IPI00334282.2 ProteinFAM3C 8.316915274 6.036994934
504 IPI00847896.1 Simi lartoGlutamateͲri chWDrepeatͲconta iningprotein1 8.295090675 10.13525772
505 IPI00025086.4 Cytochrome coxidase subunit5A,mitochondria l 8.239332438 6.078767776
506 IPI00031106.1 Proteasome assemblychaperone 3 8.186425209 4.018624306
507 IPI00910980.1 IARSprotein 8.16508317 13.75889993
508 IPI00927674.1 cDNAFLJ51867,highlys imi lartoRas ͲrelatedproteinRabͲ5A 8.127687931 4.493696213
509 IPI00783302.1 Isoform1ofPentatricopeptide repeatͲconta iningprotein3,mitocho 8.112862825 11.22996235
510 IPI00747810.3 fascinhomolog1,actinͲbundl ingprotein(Strongylocentrotus purpur 8.111647129 11.07534266
511 IPI00514399.1 ribosomal proteinS27 8.091253519 18.15767574
512 IPI00007175.3 Isoform1of60Sribosome subuni tbiogenes is proteinNIP7homolog 8.060260534 15.19271469
513 IPI00954146.2 cDNAFLJ31682fi s ,clone NT2RI2005335,highlys imi lartoMMS19Ͳl ike  7.972952843 14.81135249
514 IPI00943181.1 proteasome (prosome,macropa in)activatorsubuni t2(PA28beta) 7.944501638 6.811487913
515 IPI00336094.5 Isoform2of3Ͳhydroxyacyl ͲCoAdehydrogenase typeͲ2 7.888287306 8.275798321
516 IPI00008438.1 40Sribosomal proteinS10 7.886199474 11.52813387  
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517 IPI00014198.3 Exosome complexcomponentRRP42 7.845750332 23.2186923
518 IPI00170972.2 UPF0553proteinC9orf64 7.828207016 19.82426786
519 IPI00965022.1 ringfingerandCHYzincfingerdomainconta ining1,E3ubiqui tinpro 7.766227722 2.837225437
520 IPI00394982.1 DEAD(AspͲGluͲAla ͲAsp)boxpolypeptide 52 7.727472305 24.68902898
521 IPI01011073.1 cDNAFLJ55446,highlys imi lartoSuperki l lervi ra l i cidicactivi ty2Ͳl i ke  7.663134575 18.66403675
522 IPI00011770.1 NADHdehydrogenase [ubiquinone]1alpha subcomplexsubunit4 7.633547544 11.51311016
523 IPI00784161.1 Isoform1ofTranscriptionelongationfactorSPT6 7.614886999 15.28077078
524 IPI00009471.1 WDrepeatͲconta iningprotein3 7.614540577 35.85176802
525 IPI00016372.1 Ras ͲrelatedproteinRabͲ9A 7.587427855 7.753925085
526 IPI00412714.3 Isoform4ofPlasminogenactivatorinhibi tor1RNAͲbindingprotein 7.568902731 13.90614605
527 IPI00908317.2 ringfingerprotein114 7.559832811 2.772971153
528 IPI00973067.1 P450(cytochrome)oxidoreductase 7.506262779 11.68334246
529 IPI00977430.1 cDNA,FLJ79286,highlys imi lartoTͲcomplexprotein1subuni tgamma 7.426075459 67.55640221
530 IPI00220919.1 Isoform3ofDNA(cytos ineͲ5)Ͳmethyl trans ferase 1 7.415436745 29.40709066
531 IPI00025178.3 PreͲmRNAͲspl i cingfactorSPF27 7.403060198 8.553205252
532 IPI00010218.1 Cytochrome P450monooxygenase 7.382110596 8.127945662
533 IPI00413958.5 Isoform2ofFi laminͲC 7.362661839 6.055697441
534 IPI00646783.2 TRMT1Ͳl i ke proteini soform2 7.26845789 11.58942533
535 IPI00979604.1 ribosomal proteinS3 7.249117374 10.05483961
536 IPI00010418.6 Isoform2ofMyos inͲIc 7.232308149 5.530830622
537 IPI00927400.1 leucineͲrichrepeats andcalponinhomology(CH)domainconta ining 7.231191158 10.10188627
538 IPI00642982.1 LONP1protein 7.214317322 22.44947171
539 IPI00220114.1 Isoform3ofSl i thomolog2protein 7.173071146 7.331262827
540 IPI00910979.1 pyruvate kinase i sozymes M1/M2i soforme 7.110543251 16.17550302
541 IPI00967721.1 matrin3 7.101774693 22.11561322
542 IPI00219840.4 Isoform1ofAPͲ2complexsubuni ts igma 7.097867489 2.949874163
543 IPI00967490.1 cDNAFLJ56719,highlys imi lartoProbable dimethyladenos ine transf 7.090898037 14.38364577
544 IPI01015385.1 Isoci trate dehydrogenase 7.07719636 15.28122592
545 IPI00909939.1 cDNAFLJ52195,highlys imi lartoLIMandSH3domainprotein1 7.049134731 18.06489325
546 IPI00145260.3 Putative trans ferase CAF17,mitochondria l 6.990388155 17.54720378
547 IPI00029264.4 Cytochrome c1,heme protein,mitochondria l 6.984880447 6.802279472
548 IPI00790752.1 NADHdehydrogenase (ubiquinone)1beta subcomplex,9,22kDa 6.95763278 4.443318844
549 IPI00008164.2 Prolyl endopeptidase 6.91545105 21.66241336
550 IPI00641719.1 Surfei t4 6.90372467 10.94220948
551 IPI00178047.7 prol ine,glutamate andleucine richprotein1 6.89819169 9.530154705
552 IPI00395777.6 CCR4ͲNOTtranscriptioncomplexsubunit7i soform2 6.879837036 3.427024841
553 IPI00964815.1 hexosaminidase B(beta polypeptide) 6.878056526 3.192093849
554 IPI00419263.4 enoyl ͲCoAdelta i somerase 2,mitochondria l i soform1 6.834798098 12.46290755
555 IPI00514078.1 Isoform5ofPogotransposable elementwithZNFdomain 6.818772078 22.88752937
556 IPI00005154.1 FACTcomplexsubunitSSRP1 6.817866087 22.53734565
557 IPI00979883.1 phosphatidylserine synthase 1 6.789215803 7.925734043
558 IPI00017704.3 Coactos inͲl i ke protein 6.788805962 3.505471468
559 IPI00915421.1 vi taminKͲdependentgamma Ͳcarboxylase i soform2 6.780940533 11.76735616
560 IPI00033770.5 Isoform1ofProbable alpha ͲketoglutarateͲdependentdioxygenase  6.766112328 18.29696798
561 IPI00400922.5 ProteinRRP5homolog 6.764267206 92.87314916
562 IPI00976971.1 cDNAFLJ51637,highlys imi lartoMetastas is ͲassociatedproteinMTA 6.759697199 9.131706953
563 IPI00854687.2 Isoform2ofSis terchromatidcohes ionproteinPDS5homologA 6.751713753 7.598765135  
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564 IPI00644653.1 cDNAFLJ56337,highlys imi lartoHighmobi l i tygroupproteinB1 6.738008976 33.20047784
565 IPI00969375.1 Hydroxyacyl ͲCoenzyme Adehydrogenase/3Ͳketoacyl ͲCoenzyme Athio 6.722335577 5.969776154
566 IPI01010659.1 ATPͲbindingcassette,subͲfami lyC(CFTR/MRP),member1 6.717027664 9.024774551
567 IPI00219504.1 Isoform2ofUbiqui tincarboxyl Ͳtermina l hydrolase 15 6.623579979 6.502687693
568 IPI00061531.4 39Sribosomal proteinL53,mitochondria l 6.616873503 4.070573807
569 IPI00879792.1 Cytochrome b5reductase 3 6.559267282 2.853048086
570 IPI00871956.1 Simi lartoRibosomal proteinS2 6.558877945 5.107149363
571 IPI00061525.3 Glucosamine 6Ͳphosphate NͲacetyl trans ferase 6.554480791 15.9050281
572 IPI00922694.1 cDNAFLJ51903,highlys imi lartoStress Ͳ70protein,mitochondria l 6.526292324 6.769001722
573 IPI00872800.3 cDNAFLJ13369fi s ,clone PLACE1000610,weaklys imi lartoMSN5PROTE 6.474249125 7.574740648
574 IPI00645201.1 Ribosomal proteinS8 6.465322495 10.60897493
575 IPI00300299.6 Signal peptidase complexsubuni t3 6.444749594 9.801193237
576 IPI00375145.1 IsoformShortofUbiquitincarboxyl Ͳterminal hydrolase 5 6.440598011 22.03447986
577 IPI00925437.1 proteasome (prosome,macropa in)26Ssubuni t,nonͲATPase,2 6.434225321 3.400685072
578 IPI00328885.3 immunoglobul inͲl ike andfibronectintype I I I domainͲconta iningpro 6.432921171 9.719846487
579 IPI00746351.2 Isoform1ofExosome complexexonuclease RRP44 6.390559196 77.7708149
580 IPI00003327.1 ADPͲribosylationfactorͲl i ke protein3 6.376639128 15.37890005
581 IPI00908881.2 GlucoseͲ6Ͳphosphate i somerase 6.348568916 48.91212177
582 IPI00908776.2 actinin,alpha 4 6.348047733 11.78577113
583 IPI00964684.1 heatshock70kDa protein4Ͳl ike 6.31890583 14.87951994
584 IPI00301364.3 Isoform1ofSͲphase kinaseͲassociatedprotein1 6.236357689 15.45435095
585 IPI00006970.2 Mitochondria l 28Sribosomal proteinS2 6.224236012 5.738352776
586 IPI00984288.1 Conservedhypothetica l protein 6.20807004 3.053001404
587 IPI00018364.2 Ras ͲrelatedproteinRapͲ2b 6.203061819 15.88207364
588 IPI00940901.1 Isoform2ofRRP12Ͳl ike protein 6.19925189 26.62055063
589 IPI00854677.1 fusedinsarcoma 6.19677496 16.18292904
590 IPI00152998.3 LeucineͲri chrepeatͲconta iningprotein40 6.18484354 10.00075197
591 IPI00917086.1 cDNAFLJ53711,highlys imi lartoTRFͲproximal proteinhomolog 6.171779394 6.913748503
592 IPI00022832.1 Brainprotein44 6.114253283 5.5035429
593 IPI00293276.10 Macrophage migrationinhibi toryfactor 6.095655203 5.905552149
594 IPI00032957.1 SUMOͲconjugatingenzyme UBC9 6.089789629 11.05720043
595 IPI00556640.1 PSAPprotein 6.067298651 5.829153061
596 IPI00985413.1 e3SUMOͲproteinl igase RanBP2Ͳl ike 6.020735264 10.58321714
597 IPI00464999.2 HEATrepeatͲconta iningprotein6 5.959110975 12.2603209
598 IPI00000181.2 mitochondria l ribosomal proteinS24 5.954578161 8.018149137
599 IPI00604431.1 Isoform2ofCul l inͲassociatedNEDD8Ͳdissociatedprotein1 5.931916714 31.62165904
600 IPI00869040.2 Isoform2ofCytosol icFeͲSclusterassemblyfactorNUBP1 5.930080414 24.11399269
601 IPI00419531.2 Cleavage andpolyadenylationspeci fici tyfactorsubunit2 5.919741869 9.586447239
602 IPI00430472.2 Activatings ignal cointegrator1complexsubuni t3 5.897911072 15.47793245
603 IPI00031615.3 ProteinLLPhomolog 5.780694723 3.592237473
604 IPI00292894.5 Pre ͲrRNAͲprocess ingproteinTSR1homolog 5.77294302 36.7349472
605 IPI00795212.1 Isoform2ofProbable Xaa ͲProaminopeptidase 3 5.72518611 5.582162619
606 IPI00152240.3 ProteinkishͲA 5.718772411 2.775909185
607 IPI00877999.1 ribosomal proteinL3 5.71636343 5.576543808
608 IPI00640892.1 Glyceronephosphate OͲacyltrans ferase 5.714292765 5.636987925
609 IPI00982721.1 transcriptionelongationfactorB(SII I),polypeptide 1(15kDa,elongi 5.694688559 3.263932943
610 IPI00182289.6 40Sribosomal proteinS29 5.664246559 2.92510581  
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611 IPI00301609.8 Serine/threonineͲproteinkinase Nek9 5.65256834 11.85293865
612 IPI00394987.3 Isoform2ofFͲbox/LRRͲrepeatprotein12 5.642956734 8.256112576
613 IPI00974544.1 IsoformSVof14Ͳ3Ͳ3proteineps i lon 5.52858901 5.959573984
614 IPI00943258.1 Uncharacterizedprotein 5.526394844 7.282265425
615 IPI00058192.1 Isoform1ofGDPͲfucose proteinOͲfucosyltrans ferase 1 5.434002638 26.76087356
616 IPI00743142.2 Isoform1of6Ͳphosphofructokinase,muscle type 5.428494692 22.03418517
617 IPI00472887.3 Isoform2ofCytoskeletonͲassociatedprotein5 5.417030573 27.95958161
618 IPI00009597.1 IsoformSMNͲdelta7ofSurviva l motorneuronprotein 5.387907982 35.93483925
619 IPI00059809.3 secretorycarriermembrane protein1 5.379752636 7.605496883
620 IPI00910384.1 fami lywithsequence s imi lari ty76,memberA 5.370937824 4.471651554
621 IPI00917676.1 leucine Ͳrichpentatricopeptide repeatcontaining 5.370515347 6.448785067
622 IPI00307259.12 DnaJhomologsubfami lyCmember13 5.362244606 17.96756458
623 IPI00419919.6 Ribosomal proteinL29 5.254568815 5.944256783
624 IPI00023728.1 Gamma Ͳglutamyl hydrolase 5.247240782 13.57725263
625 IPI00021812.2 Neuroblas tdifferentiationͲassociatedproteinAHNAK 5.227503061 8.485305548
626 IPI00795318.2 cDNAFLJ54365,highlys imi lartoDNArepl icationl i cens ingfactorMCM 5.194228888 30.22742081
627 IPI00294495.5 UbiquitinͲfoldmodifierͲconjugatingenzyme 1 5.176022768 26.05916619
628 IPI00797850.2 Isoform2ofDual speci fi ci tymitogenͲactivatedproteinkinase kinas 5.119152308 3.745077372
629 IPI00300074.4 Phenyla lanyl ͲtRNAsynthetase beta chain 5.111426592 20.55725718
630 IPI00412741.1 Isoform1ofSideroflexinͲ4 5.057983398 7.226323843
631 IPI00917430.1 spl icingfactor3b,subuni t1,155kDa 5.043381691 8.899055958
632 IPI00744575.3 IsoformShortofProbable ubiquitincarboxyl Ͳterminal hydrolase FAF 4.988269329 9.697586775
633 IPI00306383.2 Isoform2ofSecretorycarrierͲassociatedmembrane protein3 4.843749523 10.43175745
634 IPI00747530.3 Isoform3ofTax1Ͳbindingprotein1 4.822367668 9.279594421
635 IPI00004839.1 CrkͲl i ke protein 4.729190826 7.640843868
636 IPI01012475.1 proteindisul fide i somerase fami lyA,member3 4.72342968 3.185017109
637 IPI00020729.1 Insul inreceptorsubstrate 4 4.552227974 8.339183807
638 IPI00644082.1 Isoform3oftRNAguanos ineͲ2'ͲOͲmethyltrans ferase TRM11homolog 4.451956272 4.14463377
639 IPI00977506.2 prohibitin 4.449507236 48.61954975
640 IPI00304409.3 CalciumͲregulatedheats table protein1 4.354152679 7.878768682
641 IPI00922290.1 cDNAFLJ53094,highlys imi lartoReceptorexpress ionͲenhancingprot 4.316569328 3.844114304
642 IPI00439944.1 ARCN1protein 4.308863163 6.997230768
643 IPI00022640.1 Neurogranin 4.29251194 3.468683958
644 IPI00013860.3 3Ͳhydroxyisobutyrate dehydrogenase,mitochondria l 4.278584957 3.140899181
645 IPI00010463.5 GTPͲbindingprotein1 4.245082378 9.582326889
646 IPI00235412.7 dynamin1Ͳl i ke 4.143373489 18.62033153
647 IPI00924593.1 cDNAFLJ52880,highlys imi lartoMalate dehydrogenase,mitochondr 4.139891624 4.061082363
648 IPI00332511.5 Serine/threonineͲproteinphosphatase 2A55kDa regulatorysubunit 4.128800392 10.31970835
649 IPI00894559.1 NDUFA10protein 4.117241383 4.028757572
650 IPI00947406.1 chromosome 7openreadingframe 50 4.103247643 8.806075096
651 IPI00026328.3 ThioredoxindomainͲconta iningprotein12 4.094028473 6.261412382
652 IPI00552646.1 chromosome Xopenreadingframe 38 4.068939209 2.786943197
653 IPI00218050.2 Isoform2ofDNAmismatchrepai rproteinMlh3 4.058671951 4.380568504
654 IPI00917166.1 dynactin1 3.930629492 8.637899637
655 IPI00909432.1 Isoform4ofGlutathione SͲtransferase kappa 1 3.926178217 3.271624804
656 IPI00925058.1 Ribosomal proteinL15 3.923327684 3.402714968
657 IPI00293078.1 Probable ATPͲdependentRNAhel icase DDX27 3.905130386 10.28052139  
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658 IPI00032851.1 Coatomersubunitzeta Ͳ1 3.897438288 15.62135386
659 IPI00015891.1 Prefoldinsubunit4 3.881435871 3.21504283
660 IPI00749054.2 Isoform3oftRNA(uraci l Ͳ5Ͳ)Ͳmethyltransferase homolog 3.856481314 8.432951927
661 IPI00847768.1 DEADͲboxproteinp72 3.846444368 3.573546648
662 IPI00217405.1 Isoform1ofE3ubiquitinͲproteinl igase UBR1 3.834622383 8.006597757
663 IPI00056357.3 UPF0556proteinC19orf10 3.834048986 5.605211735
664 IPI00106698.2 Proteinpelota homolog 3.829904079 3.965002298
665 IPI00642454.1 Ribosomal proteinL7a 3.825775385 2.914595127
666 IPI00026358.3 Gamma ͲaminobutyricacidreceptorͲassociatedproteinͲl i ke 2 3.812661886 6.262497902
667 IPI00789134.5 Glycera ldehydeͲ3Ͳphosphate dehydrogenase 3.793359756 20.75409532
668 IPI01015636.1 pogotransposable elementwithZNFdomain 3.788869143 3.18219471
669 IPI00005218.1 Molybdopterinsynthase cata lyticsubunit 3.785743475 4.095580101
670 IPI00788157.1 Isoform2of5'Ͳ3'exoribonuclease 2 3.778432369 31.18069959
671 IPI00930594.1 acyl Ͳcoenzyme Athioesterase 13i soform2 3.753232479 3.017426491
672 IPI00103599.1 BRI3Ͳbindingprotein 3.745472908 7.51076436
673 IPI01010993.1 19kDa protein 3.739369869 2.845736027
674 IPI00916188.1 Nucleol in 3.739291668 19.88579917
675 IPI00797533.2 mitochondria l ribosomal proteinL46 3.728572607 2.894883871
676 IPI00965481.1 ribosomal proteinS3A 3.728090525 3.205724955
677 IPI00219025.3 GlutaredoxinͲ1 3.71999979 3.495915413
678 IPI00456702.3 Isoform2ofCOMMdomainͲconta iningprotein4 3.700555325 3.986202955
679 IPI00647001.1 Acidic(LeucineͲrich)nuclearphosphoprotein32fami ly,memberB 3.680024862 4.003193855
680 IPI00554617.2 cDNAFLJ57277,highlys imi lartoTripeptidyl Ͳpeptidase 1 3.667347193 7.41711092
681 IPI00031982.1 Isoform1ofNckͲassociatedprotein1 3.667258739 22.90902853
682 IPI00893242.1 aminoacyl tRNAsynthetase complexͲinteractingmulti functional pro 3.666265249 5.994104862
683 IPI00925990.1 DEAD(AspͲGluͲAla ͲAsp)boxhel icase 56 3.663386106 3.793273449
684 IPI00026167.5 NHP2Ͳl ike protein1 3.65789938 16.38205147
685 IPI00299506.9 Isoform2ofGlucosamine ͲͲfructoseͲ6Ͳphosphate aminotrans ferase  3.639338017 19.81249595
686 IPI00983028.1 prol ine synthetase coͲtranscribedhomolog(bacteria l ) 3.639157534 2.893331528
687 IPI00003004.1 Mitochondria l glutamate carrier1 3.633758783 3.708626747
688 IPI00794773.1 cDNAFLJ51912,highlys imi lartoFumarylacetoacetase 3.633337021 3.022817612
689 IPI00642816.2 Isoform1ofSignal recogni tionparticle 9kDa protein 3.61745286 3.627454281
690 IPI00106642.4 DihydropyrimidinaseͲl i ke 2 3.612304211 4.149096012
691 IPI01018285.1 FADͲdependentoxidoreductase domainconta ining1 3.607123137 2.839509249
692 IPI00032911.3 TATAboxͲbindingproteinͲl ike protein1 3.604743958 7.538852692
693 IPI00333763.7 GlutaredoxinͲrelatedprotein5,mitochondria l 3.548946619 4.103365421
694 IPI00743342.2 Fouranda hal fLIMdomains protein2 3.543523312 8.178222895
695 IPI00009148.1 Diphosphoinos itol polyphosphate phosphohydrolase 1 3.536843538 4.002020359
696 IPI00032827.1 Pre ͲmRNAbranchs i te proteinp14 3.524932384 8.709682941
697 IPI00306642.3 DDB1ͲandCUL4Ͳassociatedfactor13 3.523300171 3.617166281
698 IPI00980440.1 aminopeptidase puromycinsens itive 3.513344288 3.441233397
699 IPI00926546.2 TIA1cytotoxicgranuleͲassociatedRNAbindingprotein 3.510085106 3.830174446
700 IPI01015488.1 estrogenͲrelatedreceptora lpha 3.497158766 3.681059122
701 IPI00015609.1 DDB1ͲandCUL4Ͳassociatedfactor16 3.492106438 3.067657709
702 IPI00658162.2 cDNAFLJ36570fi s ,clone TRACH2011302,highlys imi lartoSELENIDE,W 3.480367899 4.516431808
703 IPI00980890.2 cDNAFLJ58780,highlys imi lartoHomosapiens lysosomal Ͳassociate 3.47510457 6.85842371
704 IPI00642486.1 ubiqui tinrelatedmodifier1 3.474912643 3.344897985  
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705 IPI00917594.1 proteasome (prosome,macropa in)26Ssubuni t,nonͲATPase,1 3.442355156 8.706087828
706 IPI00170596.1 Pai redamphipathichel ixproteinSin3a 3.438802481 5.449266911
707 IPI00927538.1 transducin(beta)Ͳl ike 2 3.418755531 7.273132324
708 IPI00902463.1 cDNAFLJ46898fi s ,clone UTERU3022168,highlys imi lartoProteinFAM 3.396526098 21.77505827
709 IPI00783250.1 TRIP12protein 3.389698505 9.825669765
710 IPI00412713.4 Sortingandassemblymachinerycomponent50homolog 3.37523222 7.850270987
711 IPI00909956.1 cDNAFLJ59103,highlys imi lartoTͲcomplexprotein1subuniteps i lon 3.369731665 4.03897047
712 IPI00797802.1 mitochondria l 2Ͳoxoglutarate/malate carrierproteini soform3 3.350028038 6.823238134
713 IPI00643263.1 Vps20Ͳassociated1homolog 3.347207785 11.76907969
714 IPI00384155.1 Ful l ͲlengthcDNAclone CS0DI002YH20ofPlacenta ofHomosapiens 3.333331585 4.626288414
715 IPI00031526.3 chromosome 19openreadingframe 43 3.332810879 9.43253684
716 IPI00748354.1 Isoform1ofMitochondria l intermembrane space importandassem 3.330058098 12.85658073
717 IPI00642244.2 ERmembrane proteincomplexsubunit1 3.329001665 6.481980085
718 IPI00816513.2 mutShomolog2,coloncancer,nonpolypos is type 1(E.col i ) 3.318204403 3.714787483
719 IPI00646750.2 cytochrome coxidase assemblyfactor6homolog(S.cerevis iae) 3.313561916 3.490073919
720 IPI00220373.5 Insul inͲdegradingenzyme 3.309896469 14.45638919
721 IPI00978986.1 nucleoporin160kDa 3.309469938 31.80257511
722 IPI01009290.1 cDNAFLJ52916,highlys imi lartoribosomal RNAmethyltrans ferase 1 3.304074526 2.816954136
723 IPI00396056.6 Isoformp18of7,8ͲdihydroͲ8Ͳoxoguanine triphosphatase 3.296686649 3.553375483
724 IPI00646767.1 nucleardistributionChomolog(A.nidulans ) 3.292669296 7.126162052
725 IPI01015765.1 cDNAFLJ57240,highlys imi lartoMitochondria l proteins importrecep 3.291688919 14.81278539
726 IPI00927379.1 LUC7Ͳl ike 3.282767773 3.292594433
727 IPI00013396.3 U1smal l nuclearribonucleoproteinC 3.261357307 7.142628908
728 IPI00169325.1 WDrepeatͲconta iningprotein36 3.25672245 25.42709994
729 IPI00384571.3 MRPL43protein(Fragment) 3.250708818 3.587357759
730 IPI00978302.1 cofi l in1(nonͲmuscle) 3.245178699 9.820427179
731 IPI00218895.6 DNAͲdirectedRNApolymerase I I subuni tRPB7 3.242640018 8.362938881
732 IPI00791782.2 Isoform3ofTransmembrane protein85 3.238839149 3.189184427
733 IPI00877664.1 HNRPCprotein 3.229525328 6.038960695
734 IPI00218838.1 Isoform2ofGlomul in 3.226986408 3.44948864
735 IPI00019380.1 NuclearcapͲbindingproteinsubunit1 3.226590872 38.25334501
736 IPI00294211.2 PreͲmRNAͲspl i cingfactorATPͲdependentRNAhel icase PRP16 3.224330187 3.504382849
737 IPI00946754.1 Protease serine 1 3.217814922 9.725289345
738 IPI00640188.1 PRA1domainfami ly,member2 3.215258598 3.194475889
739 IPI00006574.1 fami lywithsequence s imi lari ty49,memberA 3.203294277 6.060539007
740 IPI00787239.1 Isoform2ofTransmembrane protein70,mitochondria l 3.190694809 3.062651634
741 IPI00927631.1 nuclearcapbindingproteinsubunit2,20kDa 3.180920124 3.165471554
742 IPI00796478.1 Synaptogyrin1 3.178820372 3.604151011
743 IPI00974419.1 minichromosome maintenance complexcomponent4 3.172092199 10.73406553
744 IPI00965753.1 neurolys in(metal lopeptidase M3fami ly) 3.166867971 7.52709794
745 IPI01013815.1 cDNAFLJ54736,highlys imi lartoScaffoldattachmentfactorB 3.160569906 6.301415205
746 IPI00908568.1 repl icationfactorCsubunit5i soform3 3.156708956 10.77553797
747 IPI00552972.3 ribophorinI I 3.154435635 3.805977583
748 IPI00105068.2 mannoseͲPͲdol ichol uti l i zationdefect1 3.145113468 7.013731241
749 IPI00894025.1 ribosomal proteinL10 3.142888308 3.099099159
750 IPI00966408.1 hydroxysteroid(17Ͳbeta)dehydrogenase 11 3.126099825 5.856959581
751 IPI00647467.1 Isoform2ofProteinͲtyros ine phosphatase mitochondria l 1 3.116794348 6.496219635  
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752 IPI00399195.1 Isoform2ofCirhin 3.110436678 3.85973525
753 IPI00983399.1 RAB15,memberRASoncogene fami ly 3.108854532 3.227412224
754 IPI00030847.3 Transmembrane 9superfami lymember3 3.108247519 6.353409529
755 IPI00908532.1 cDNAFLJ57633,highlys imi lartoLysosomeͲassociatedmembrane gly 3.107279062 4.186969757
756 IPI00377084.1 ribonuclease P/MRPproteinsubuni tPOP5i soformc 3.103389263 2.764899731
757 IPI00063130.2 Transmembrane protein205 3.094141006 3.628275633
758 IPI00027704.5 DNAprimase smal l subunit 3.088574886 10.48273039
759 IPI00940786.2 cDNAFLJ50873,highlys imi lartoDNArepl icationl i cens ingfactorMCM 3.08483696 5.70458436
760 IPI00872761.2 fragi le Xmental retardation1proteini soformISO12 3.077638626 3.697481632
761 IPI00916398.1 IMP4,U3smal l nucleolarribonucleoprotein,homolog(yeast) 3.07574439 10.13596678
762 IPI00152377.1 Dol ichyl Ͳdiphosphool igosaccharideͲͲproteinglycosyltrans ferase sub 3.0711689 8.360854387
763 IPI00410157.4 Isoform4ofCCR4ͲNOTtranscriptioncomplexsubuni t1 3.069497108 3.153642654
764 IPI00513841.1 Nicastrin 3.068019867 10.66344333
765 IPI00396331.4 Zincfingerprotein224 3.063132048 3.123922348
766 IPI00796102.1 actinrelatedprotein2/3complex,subuni t3,21kDa 3.056749344 3.016141176
767 IPI01011483.1 Fanconi anemia,complementationgroupI 3.054372311 7.051631212
768 IPI00655681.1 succinate dehydrogenase cytochrome b560subuni t,mitochondria l i s 3.052879572 3.373564482
769 IPI00006442.1 Coi l in 3.052608252 8.148685455
770 IPI00007052.6 Mitochondria l fi s s ion1protein 3.050519466 3.074013233
771 IPI00166013.1 AAR2spl icingfactorhomolog(S.cerevis iae) 3.047001362 6.960672855
772 IPI00884370.1 DFNA5proteinfami lyprotein 3.045160055 2.985293627
773 IPI00879437.1 prolyl 4Ͳhydroxylase,beta polypeptide 3.028154373 2.977276087
774 IPI00328089.16 Isoform2ofTranscriptionfactorHIVEP3 3.015028477 3.170693398
775 IPI00329332.1 SyntaxinͲ12 3.009957552 28.30562234
776 IPI00639819.1 TARDNAbindingprotein 3.003374338 25.38175821
777 IPI00983093.1 poly(A)bindingprotein,cytoplasmic1 2.986663818 2.845418215
778 IPI00982362.1 Uncharacterizedprotein 2.985399246 5.20803833
779 IPI00418523.1 Simi lartoNucleolarcomplexprotein2homolog 2.976199865 3.104102135
780 IPI00008753.1 Meta l lothioneinͲ1X 2.968417406 2.829637289
781 IPI00001146.1 U6snRNAͲassociatedSmͲl i ke proteinLSm6 2.96451807 5.99358058
782 IPI00892695.1 brainandreproductive organͲexpressed(TNFRSF1Amodulator) 2.953055382 3.993766069
783 IPI00977024.1 ringfingerprotein170 2.939703226 5.906941414
784 IPI00401264.5 Endoplasmicreticulumres identprotein44 2.93690753 6.655044317
785 IPI00024775.1 Ras ͲrelatedproteinRabͲ7L1 2.936436415 5.391480207
786 IPI00304935.6 ProteinSAAL1 2.925481319 2.954362869
787 IPI00797749.1 cDNAFLJ34514fi s ,clone HLUNG2006599,highlys imi lartoSyntaxinͲ4 2.903419971 3.420435667
788 IPI00916988.1 Isoform2ofRNApseudouridylate synthase domainͲconta iningprote 2.897808552 8.946968317
789 IPI00221232.9 Guanine nucleotideͲbindingproteinG(I)/G(S)/G(O)subuni tgamma Ͳ 2.892389297 2.927713156
790 IPI00556364.1 Interleukinenhancerbindingfactor3i soformcvariant(Fragment) 2.874989986 7.323945999
791 IPI00916648.1 WDrepeatandFYVEdomainconta ining1 2.858377695 7.127812862
792 IPI00477181.2 ringfingerprotein220 2.857547522 3.856014013
793 IPI00026119.6 UbiquitinͲactivatingenzyme E1 2.853475094 4.151154995
794 IPI00978325.1 catheps inC 2.779670954 3.754447222
795 IPI00945551.1 cms1ribosomal smal l subuni thomolog(yeast) 2.775691748 7.515066147
796 IPI00643908.3 cDNAFLJ53700,highlys imi lartoHepatoma Ͳderivedgrowthfactor 2.774966478 6.971341133
797 IPI00477012.1 Isoform2ofDoubleͲs trandedRNAͲspeci fi ceditase 1 2.773857355 6.595125914
798 IPI00019488.1 U3smal l nucleolarribonucleoproteinproteinIMP3 2.759111643 3.54423666
799 IPI00514669.1 SH3domainbindingglutamicacidͲri chproteinl i ke 3 2.708771467 2.784610033  
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G9a and GLP1 in HEK293T cells with HeySAM.   
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Table S5. BPPM-revealed nonhistone targets of EuHMT1 and 2 in HEK293T cells using tandem 
mass tagging (TMT).  
 
Serial Accession Description EuHMT1/Control EuHMT2/control EuHMT2/EuHMT1
1 IPI00942420.2 Isoform1ofHis toneͲl ys ine NͲmethyltrans ferase EHMT1 11.339 2.382 0.177
2 IPI00186290.6 Elongationfactor2 2.165 2.251 1.068
3 IPI00220795.4 Isoform2ofHis toneͲl ys ine NͲmethyltrans ferase EHMT2 3.336 8.583 2.815
4 IPI00792677.1 cDNAFLJ60097,highlys imi lartoTubul ina lpha Ͳubiquitous 3.235 2.486 0.974
5 IPI00218343.4 Tubul ina lpha Ͳ1Cchain 2.023 1.946 0.988
6 IPI00909140.9 cDNAFLJ56903,highlys imi lartoTubul inbeta Ͳ7cha in 1.940 1.987 1.135
7 IPI00007752.1 Tubul inbeta Ͳ2Ccha in 1.973 1.748 0.805
8 IPI00984352.1 proteinarginine methyl transferase 1 2.422 2.021 0.829
9 IPI00031370.3 Tubul inbeta Ͳ2Bchain 1.870 1.780 0.964
10 IPI00396485.3 Elongationfactor1Ͳa lpha 1 2.624 2.212 0.906
11 IPI00021439.1 Actin,cytoplasmic1 2.832 2.426 0.761
12 IPI00219018.7 GlyceraldehydeͲ3Ͳphosphate dehydrogenase 2.653 2.468 0.964
13 IPI00414676.6 HeatshockproteinHSP90Ͳbeta 2.646 1.937 0.874
14 IPI00022977.1 Creatine kinase BͲtype 2.975 2.219 0.698
15 IPI00784295.2 Isoform1ofHeatshockproteinHSP90Ͳa lpha 3.106 2.186 0.803
16 IPI00455383.4 Isoform2ofClathrinheavycha in1 3.055 2.569 0.858
17 IPI00922693.1 cDNAFLJ53662,highlys imi lartoActin,alpha skeleta l musc 3.362 2.119 0.630
18 IPI00304925.5 Heatshock70kDa protein1A/1B 2.487 1.846 0.756
19 IPI00465248.5 Isoforma lpha Ͳenolase ofAlpha Ͳenolase 1.863 1.812 0.945
20 IPI00925572.1 asparagine synthetase [glutamineͲhydrolyzing]i soformb 2.863 2.544 0.843
21 IPI00014424.1 Elongationfactor1Ͳa lpha 2 2.509 2.783 1.109
22 IPI00911039.1 cDNAFLJ54408,highlys imi lartoHeatshock70kDa protein 2.594 1.448 0.558
23 IPI00807545.1 Isoform3ofHeterogeneous nuclearribonucleoproteinK 2.952 2.073 0.699
24 IPI00465439.5 Fructose Ͳbisphosphate aldolase A 2.469 2.025 0.825
25 IPI00784154.1 60kDa heatshockprotein,mitochondria l 2.529 1.899 0.719
26 IPI00000874.1 Peroxi redoxinͲ1 2.765 2.032 0.763
27 IPI00658109.1 Isoform1ofCreatine kinase UͲtype,mitochondria l 3.039 2.232 0.709
28 IPI00644224.2 cDNAFLJ54020,highlys imi lartoHeterogeneous nuclearrib 2.624 1.702 0.683
29 IPI00219217.3 LͲlactate dehydrogenase Bchain 2.764 2.605 1.007
30 IPI00644079.4 cDNAFLJ44920fi s ,clone BRAMY3011501,highlys imi lartoH 2.731 1.798 0.658
31 IPI00026781.3 Fattyacidsynthase 2.964 2.663 0.869
32 IPI00011200.5 DͲ3Ͳphosphoglycerate dehydrogenase 2.619 1.963 0.741
33 IPI00219446.5 PhosphatidylethanolamineͲbindingprotein1 2.175 1.704 0.759
34 IPI00012011.6 Cofi l inͲ1 3.308 2.653 0.824
35 IPI00784090.2 TͲcomplexprotein1subuni ttheta 2.631 2.103 0.802
36 IPI00003865.1 Isoform1ofHeatshockcognate 71kDa protein 2.102 1.703 0.773
37 IPI00011253.3 40Sribosomal proteinS3 3.011 2.497 0.818
38 IPI01011191.1 cDNAFLJ59681,highlys imi lartoPlastinͲ3 3.086 1.659 0.470
39 IPI00220327.4 Keratin,type I I cytoskeleta l 1 2.287 1.729 0.774
40 IPI00021290.5 ATPͲci trate synthase 2.196 2.134 0.894
41 IPI00479186.7 IsoformM2ofPyruvate kinase i sozymes M1/M2 2.648 2.020 0.754
42 IPI00220740.1 Isoform2ofNucleophosmin 2.539 1.996 0.753
43 IPI00216691.5 Profi l inͲ1 4.000 2.225 0.589
44 IPI00419585.9 Peptidyl Ͳprolyl cis Ͳtrans i somerase A 2.683 1.953 0.661  
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45 IPI00418471.6 Vimentin 1.785 1.825 1.011
46 IPI00797270.4 Isoform1ofTriosephosphate i somerase 2.634 1.881 0.729
47 IPI00291006.2 Malate dehydrogenase,mitochondria l 2.107 2.238 1.075
48 IPI01015565.1 ubiqui tinC 3.479 2.517 0.582
49 IPI00643041.3 GTPͲbindingnuclearproteinRan 2.540 1.998 0.793
50 IPI00645078.1 UbiquitinͲl ike modi fierͲactivatingenzyme 1 2.139 2.097 0.918
51 IPI00909207.1 cDNAFLJ60461,highlys imi lartoPeroxi redoxinͲ2 2.018 1.734 0.840
52 IPI01011912.1 Phosphoglycerate kinase 2.799 2.184 0.814
53 IPI00299524.2 Condens incomplexsubunit1 3.358 2.968 0.859
54 IPI00795292.1 Isoform3ofNucleos ide diphosphate kinase B 3.114 2.009 0.644
55 IPI00217966.9 Isoform1ofLͲl actate dehydrogenase Acha in 2.646 2.818 1.050
56 IPI00855957.3 Isoform2ofFarupstreamelementͲbindingprotein2 2.656 2.098 0.821
57 IPI00003362.3 78kDa glucoseͲregulatedprotein 2.163 1.669 0.794
58 IPI00010796.1 Proteindisul fideͲi somerase 2.409 1.888 0.778
59 IPI00554786.5 Isoform5ofThioredoxinreductase 1,cytoplasmic 2.733 2.238 0.792
60 IPI00937615.2 Elongationfactor1Ͳgamma 2.291 2.167 0.991
61 IPI00414696.1 IsoformA2ofHeterogeneous nuclearribonucleoproteins  2.808 2.370 0.877
62 IPI00297779.7 TͲcomplexprotein1subuni tbeta 1.750 1.661 0.948
63 IPI00012048.1 Isoform1ofNucleos ide diphosphate kinase A 2.553 1.936 0.802
64 IPI00793443.2 Isoform1ofImportinͲ5 2.190 2.055 0.830
65 IPI00966238.2 cDNAFLJ51907,highlys imi lartoStress Ͳ70protein,mitocho 2.193 1.918 0.863
66 IPI00019755.3 Glutathione SͲtransferase omega Ͳ1 2.420 2.095 0.818
67 IPI00013881.6 Heterogeneous nuclearribonucleoproteinH 1.974 2.192 1.090
68 IPI00013452.11 Bi functiona l aminoacyl ͲtRNAsynthetase 2.831 2.270 0.795
69 IPI00604620.3 Nucleol in 2.230 1.946 0.881
70 IPI00024145.2 Isoform2ofVoltageͲdependentanionͲselective channel p 2.874 2.206 0.733
71 IPI00216298.6 Thioredoxin 3.674 2.068 0.536
72 IPI00001639.2 Importinsubunitbeta Ͳ1 2.224 1.761 0.821
73 IPI00008530.1 60Sacidicribosomal proteinP0 2.829 2.782 0.962
74 IPI00016610.2 Poly(rC)Ͳbindingprotein1 3.121 2.617 0.862
75 IPI00554723.5 60Sribosomal proteinL10 2.698 1.944 0.785
76 IPI00815732.1 Isoform2ofMulti functional proteinADE2 2.572 1.956 0.769
77 IPI00021304.1 Keratin,type I I cytoskeleta l 2epidermal 2.336 3.532 1.906
78 IPI00411704.9 Isoform1ofEukaryotictrans lationini tia tionfactor5AͲ1 2.761 1.999 0.668
79 IPI00021263.3 14Ͳ3Ͳ3proteinzeta/del ta 2.606 2.007 0.801
80 IPI00000816.1 Isoform1of14Ͳ3Ͳ3proteineps i lon 2.601 1.814 0.760
81 IPI00449049.5 Poly[ADPͲribose]polymerase 1 2.248 1.965 0.893
82 IPI00303568.3 ProstaglandinEsynthase 2 2.252 2.005 0.855
83 IPI00025273.1 IsoformLongofTri functiona l purine biosyntheticproteina 2.376 2.243 0.935
84 IPI00027230.3 Endoplasmin 1.765 1.717 0.973
85 IPI00844578.1 ATPͲdependentRNAhel icase A 2.631 2.390 0.936
86 IPI01012004.1 cDNAPSEC0175fi s ,clone OVARC1000169,highlys imi lartoP 2.518 2.258 0.807
87 IPI00003881.5 Heterogeneous nuclearribonucleoproteinF 2.285 2.199 0.900
88 IPI00413324.6 60Sribosomal proteinL17 2.389 1.800 0.737
89 IPI00759596.1 Isoform4ofHeterogeneous nuclearribonucleoproteins C1 2.809 2.386 0.685
90 IPI01014604.1 TͲcomplexprotein1subuni tdelta 2.465 1.999 0.819
91 IPI00027107.5 elongationfactorTu,mitochondria l precursor 2.899 1.277 0.435  
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92 IPI00011937.1 Peroxi redoxinͲ4 2.623 2.223 0.792
93 IPI00009865.4 Keratin,type I cytoskeleta l 10 1.774 1.649 0.878
94 IPI00003918.6 60Sribosomal proteinL4 2.463 2.400 0.971
95 IPI00010720.1 TͲcomplexprotein1subuni teps i lon 2.437 2.078 0.835
96 IPI00900327.2 cDNAFLJ58339,highlys imi lartoPoly(rC)Ͳbindingprotein2 2.898 2.771 0.909
97 IPI00027442.4 Alanyl ͲtRNAsynthetase,cytoplasmic 1.977 1.806 0.924
98 IPI00848161.1 Isoform1ofSpl iceosome RNAhel icase DDX39B 2.135 2.056 0.926
99 IPI00002966.2 Heatshock70kDa protein4 2.014 2.007 0.935
100 IPI00646304.4 Peptidyl Ͳprolyl cis Ͳtrans i somerase B 2.587 2.063 0.810
101 IPI00018146.1 14Ͳ3Ͳ3proteintheta 3.096 2.403 0.743
102 IPI00551024.5 Bi functiona l ATPͲdependentdihydroxyacetone kinase/FAD 2.701 1.988 0.714
103 IPI00438230.3 Isoform2ofTranscriptionintermediaryfactor1Ͳbeta 2.593 2.159 0.832
104 IPI00216492.1 Isoform2ofHeterogeneous nuclearribonucleoproteinH3 2.698 2.502 0.938
105 IPI00922367.1 nonͲPOUdomainͲconta iningoctamerͲbindingproteini sof 2.443 2.058 0.789
106 IPI00018206.4 Aspartate aminotransferase,mitochondria l 2.269 1.801 0.826
107 IPI00022774.3 Trans i tiona l endoplasmicreticulumATPase 1.894 1.957 0.947
108 IPI00952607.1 TͲcomplexprotein1subuni teta i soformd 2.592 2.064 0.803
109 IPI00024933.3 Isoform1of60Sribosomal proteinL12 3.286 2.632 0.784
110 IPI00005198.2 InterleukinenhancerͲbindingfactor2 2.264 1.786 0.848
111 IPI00465365.4 IsoformA1ͲAofHeterogeneous nuclearribonucleoprotein 2.983 2.679 1.093
112 IPI00218606.7 40Sribosomal proteinS23 3.860 2.426 0.633
113 IPI00179964.5 Isoform1ofPolypyrimidine tractͲbindingprotein1 2.330 2.018 0.866
114 IPI00220684.1 Isoform3ofHeterogeneous nuclearribonucleoproteinD0 2.759 2.111 0.709
115 IPI00789370.3 serine hydroxymethyltransferase,mitochondria l i soform3 1.993 2.084 1.076
116 IPI00009904.1 Proteindisul fideͲi somerase A4 2.055 1.763 0.871
117 IPI00003935.6 Histone H2Btype 2ͲE 2.516 1.883 0.799
118 IPI00290566.1 TͲcomplexprotein1subuni ta lpha 2.716 2.105 0.737
119 IPI00909530.1 Histone H3 3.197 2.420 0.726
120 IPI00220642.7 14Ͳ3Ͳ3proteingamma 2.460 2.071 0.771
121 IPI00413344.3 Cofi l inͲ2 2.917 1.744 0.598
122 IPI00218342.10 CͲ1Ͳtetrahydrofolate synthase,cytoplasmic 2.043 1.994 0.892
123 IPI00552590.1 TͲcomplexprotein1subuni tzeta i soformb 2.699 1.851 0.731
124 IPI00374151.1 thioredoxinͲdependentperoxide reductase,mitochondria 2.175 1.811 0.894
125 IPI00012007.6 Adenosylhomocysteinase 2.106 1.733 0.779
126 IPI00004534.5 Phosphoribosyl formylglycinamidine synthase 3.384 2.866 0.958
127 IPI00941747.1 Calnexin 2.364 2.007 0.816
128 IPI00031804.1 Isoform1ofVoltageͲdependentanionͲselective channel p 2.744 1.955 0.764
129 IPI00219160.3 60Sribosomal proteinL34 4.626 2.366 0.741
130 IPI00218547.1 IsoformShortofDelta Ͳ1Ͳpyrrol ineͲ5Ͳcarboxylate synthase 2.585 2.431 0.903
131 IPI00025091.3 40Sribosomal proteinS11 3.019 2.648 0.816
132 IPI00383296.5 Isoform2ofHeterogeneous nuclearribonucleoproteinM 1.904 1.946 1.121
133 IPI00013917.3 40Sribosomal proteinS12 3.238 2.003 0.602
134 IPI00008433.4 40Sribosomal proteinS5 2.118 1.858 0.909
135 IPI00470498.1 Isoform3ofPlasminogenactivatorinhibi tor1RNAͲbindin 2.108 1.729 0.731
136 IPI00549389.3 Conservedhypothetica l protein 2.651 2.138 0.806
137 IPI00017334.1 Prohibitin 2.330 1.929 0.765
138 IPI00001734.3 Phosphoserine aminotransferase 3.067 2.378 0.777  
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139 IPI00298547.3 ProteinDJͲ1 1.960 1.566 0.778
140 IPI00746438.2 Isoform2of60Sribosomal proteinL11 2.442 1.992 0.816
141 IPI00299000.5 Prol i ferationͲassociatedprotein2G4 1.805 1.927 1.096
142 IPI00218993.1 IsoformBeta ofHeatshockprotein105kDa 2.411 2.322 0.836
143 IPI00908543.1 cDNAFLJ56133,highlys imi lartoSerine/threonineͲprotein 2.493 1.876 0.727
144 IPI00783097.4 Glycyl ͲtRNAsynthetase 2.289 2.009 0.894
145 IPI00220766.5 Lactoylglutathione l yase 2.323 2.021 0.826
146 IPI01013559.1 cDNAFLJ58502,highlys imi lartoProteindisul fide Ͳi somera 1.772 1.750 0.977
147 IPI00013485.3 40Sribosomal proteinS2 2.800 2.408 0.831
148 IPI00216319.3 14Ͳ3Ͳ3proteineta 2.527 2.068 0.818
149 IPI00783271.1 LeucineͲri chPPRmoti fͲconta iningprotein,mitochondria l 2.427 2.464 1.086
150 IPI00219330.2 Isoform5ofInterleukinenhancerͲbindingfactor3 2.334 2.255 0.934
151 IPI00219616.7 RiboseͲphosphate pyrophosphokinase 1 2.620 2.537 0.958
152 IPI00385834.3 Isoform2ofKHdomainͲconta ining,RNAͲbinding,s ignal tr 3.117 2.534 0.847
153 IPI00917777.1 116kDa U5smal l nuclearribonucleoproteincomponenti s 1.919 1.816 0.959
154 IPI00744692.1 Transaldolase 2.543 2.313 0.896
155 IPI00178440.3 Elongationfactor1Ͳbeta 2.598 2.042 0.763
156 IPI00026202.1 60Sribosomal proteinL18a 2.840 1.865 0.699
157 IPI00759832.1 IsoformShortof14Ͳ3Ͳ3proteinbeta/a lpha 2.380 1.672 0.702
158 IPI00794545.1 deoxyuridine 5'Ͳtriphosphate nucleotidohydrolase,mitoch 2.982 2.176 0.735
159 IPI00215914.5 ADPͲribosylationfactor1 3.212 2.464 0.767
160 IPI00025491.1 Eukaryoticini tiationfactor4AͲI 1.982 2.041 1.041
161 IPI01012872.1 58kDa protein 2.907 1.608 0.569
162 IPI00982539.1 Dha kinase/FMNcyclase spl ice variant 2.604 1.808 0.694
163 IPI00553169.5 fi laminA,a lpha 3.595 2.753 0.769
164 IPI00952778.2 Isoform1ofProbable ATPͲdependentRNAhel icase DDX17 2.188 2.166 0.998
165 IPI00479306.1 Isoform1ofProteasome subunitbeta typeͲ5 2.075 1.847 0.890
166 IPI00335168.9 IsoformNonͲmuscle ofMyosinl i ghtpolypeptide 6 3.051 2.311 0.757
167 IPI00383539.5 Citrate synthase 2.626 2.139 0.840
168 IPI00015018.1 Inorganicpyrophosphatase 2.877 3.493 1.068
169 IPI00291467.7 ADP/ATPtrans locase 3 1.906 1.540 0.808
170 IPI00007188.6 ADP/ATPtrans locase 2 2.710 2.043 0.754
171 IPI00455457.4 Histone H3 3.622 2.653 0.670
172 IPI00867533.1 60Sribosomal proteinL6 4.121 3.937 0.954
173 IPI00940237.1 ATPͲdependentRNAhel icase DDX39A 2.267 2.190 0.966
174 IPI00908881.2 GlucoseͲ6Ͳphosphate i somerase 1.526 1.871 0.995
175 IPI00019502.3 Isoform1ofMyosinͲ9 3.147 2.392 0.799
176 IPI00303722.5 ProteinFAM136A 2.845 2.172 0.760
177 IPI00853337.1 ADPͲribosylationfactor5 2.486 1.525 0.613
178 IPI00011454.1 Isoform2ofNeutra l a lpha Ͳglucos idase AB 1.920 1.740 0.923
179 IPI00642042.3 Putative uncharacterizedproteinDKFZp686J1372 2.689 2.093 0.735
180 IPI00413641.7 Aldose reductase 2.471 2.503 1.050
181 IPI00893035.1 carbamoyl Ͳphosphate synthetase 2,aspartate transcarbam 3.780 2.951 0.803
182 IPI00909975.1 Ubiquitincarrierprotein 3.120 2.066 0.677
183 IPI00979136.1 Ribonucleos ideͲdiphosphate reductase 3.118 2.590 0.857
184 IPI00646055.2 cDNAFLJ58608,highlys imi lartoHeatshockprotein75kDa 2.115 1.816 0.968
185 IPI00307524.7 Arseni te methyl transferase 2.513 1.947 0.782  
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186 IPI00221092.8 40Sribosomal proteinS16 2.986 1.775 0.548
187 IPI00553185.2 TͲcomplexprotein1subuni tgamma 2.158 1.318 0.666
188 IPI00909336.1 cDNAFLJ59092 2.392 2.960 1.100
189 IPI00550689.3 tRNAͲspl i cingl i gase RtcBhomolog 2.903 2.518 0.807
190 IPI00219306.1 Proteinmagonashi homolog 3.163 2.403 0.724
191 IPI01012504.1 6Ͳphosphogluconate dehydrogenase,decarboxylating 2.080 1.981 0.983
192 IPI00218988.4 Isoform2ofAdenylate kinase 2,mitochondria l 2.317 1.885 0.808
193 IPI00925196.2 IMPdehydrogenase 2 2.465 2.711 1.194
194 IPI00008964.3 Ras ͲrelatedproteinRabͲ1B 2.501 1.906 0.769
195 IPI00977640.1 sodium/potass iumͲtransportingATPase subuni ta lpha Ͳ1i 3.750 2.818 0.748
196 IPI00878876.1 cDNAFLJ51872,highlys imi lartoSmal l nuclearribonucleop 4.885 2.883 0.658
197 IPI00012750.3 40Sribosomal proteinS25 2.879 2.375 0.703
198 IPI00418262.5 Fructose Ͳbisphosphate aldolase 0.701
199 IPI00943894.1 glycogenphosphorylase,l i verformi soform2 1.981 1.804 0.910
200 IPI00845388.1 destrini soformb 3.043 2.164 0.711
201 IPI00550363.3 Transgel inͲ2 2.331 2.020 0.854
202 IPI00419880.6 40Sribosomal proteinS3a 2.572 1.882 0.704
203 IPI00216613.1 IsoformShortofSpl icingfactor,prol ineͲandglutamineͲri c 2.088 1.825 0.874
204 IPI00045498.4 Isoform3ofHeterogeneous nuclearribonucleoproteinDͲl 2.142 2.281 1.053
205 IPI00219617.5 Isoform1ofRiboseͲphosphate pyrophosphokinase 2 3.052 3.192 1.046
206 IPI00944455.2 NCAPD2protein(Fragment) 3.607 2.731 0.757
207 IPI01015230.1 cDNAFLJ53354,highlys imi lartoPuromycinͲsens i tive amin 2.147 2.138 0.946
208 IPI00221093.7 40Sribosomal proteinS17 3.664 2.495 0.679
209 IPI00009328.4 Eukaryoticini tiationfactor4AͲI I I 2.328 2.164 0.892
210 IPI00300371.5 Isoform1ofSpl icingfactor3Bsubuni t3 3.437 2.744 0.861
211 IPI00021828.1 CystatinͲB 3.225 1.946 0.556
212 IPI00003949.1 UbiquitinͲconjugatingenzyme E2N 3.313 1.931 0.777
213 IPI00182533.5 60Sribosomal proteinL28 3.884 2.581 0.662
214 IPI00013214.2 cDNAFLJ55599,highlys imi lartoDNArepl i cationl i cens ing 2.176 1.988 0.848
215 IPI00982482.2 isoleucyl ͲtRNAsynthetase 3.378 2.595 0.872
216 IPI00022597.1 NEDD8Ͳconjugatingenzyme Ubc12 2.581 1.817 0.774
217 IPI00010153.5 60Sribosomal proteinL23 3.639 2.198 0.614
218 IPI00220301.5 Peroxi redoxinͲ6 2.928 2.133 0.782
219 IPI00402182.2 Isoform2ofHeterogeneous nuclearribonucleoproteinQ 2.531 1.013 0.400
220 IPI00005719.1 Isoform1ofRas ͲrelatedproteinRabͲ1A 1.923 1.450 0.754
221 IPI00981739.1 tubul infoldingcofactorA 3.239 1.791 0.609
222 IPI00102128.1 Isoform1ofProteinarginine NͲmethyltrans ferase 6 2.516 1.250 0.508
223 IPI00022239.7 Methionine aminopeptidase 1 2.676 2.228 0.813
224 IPI00217030.10 40Sribosomal proteinS4,Xi soform 2.486 1.903 0.772
225 IPI01013843.1 cDNAFLJ59776,highlys imi lartoPrefoldinsubunit3 2.072 1.488 0.718
226 IPI00220834.8 XͲrayrepa ircross Ͳcomplementingprotein5 2.113 1.852 0.879
227 IPI00221088.5 40Sribosomal proteinS9 2.907 2.537 0.976
228 IPI00008240.2 Methionyl ͲtRNAsynthetase,cytoplasmic 1.964 2.173 0.995
229 IPI00740142.2 u5smal l nuclearribonucleoprotein200kDa hel icaseͲl ike, 3.199 2.812 0.858
230 IPI00021840.1 40Sribosomal proteinS6 3.472 2.882 0.813
231 IPI00908512.2 cys tathionine gamma Ͳlyase i soform3 2.494 2.115 0.808
232 IPI00798375.2 cDNAFLJ59357,highlys imi lartoProbable ATPͲdependentR 2.658 0.980 0.369  
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233 IPI00004860.2 IsoformComplexedofArginyl ͲtRNAsynthetase,cytoplasmi 2.576 1.219 0.473
234 IPI00477179.1 Isoform2ofNucleolarRNAhel icase 2 2.271 1.707 0.847
235 IPI00465044.2 ProteinRCC2 2.981 2.172 0.727
236 IPI00856038.2 cDNAFLJ53358,highlys imi lartoHeterogeneous nuclearrib 2.205 1.740 0.804
237 IPI00514399.1 ribosomal proteinS27 1.900 1.000 0.559
238 IPI00940673.1 cDNAFLJ53217,highlys imi lartoTransketolase 2.582 3.725 1.362
239 IPI00021187.4 Isoform1ofRuvBͲl ike 1 1.819 1.867 1.022
240 IPI00604431.1 Isoform2ofCul l inͲassociatedNEDD8Ͳdissociatedprotein 2.267 2.225 0.949
241 IPI00007611.1 ATPsynthase subunitO,mitochondria l 1.998 1.504 0.705
242 IPI00013894.1 Stress ͲinducedͲphosphoprotein1 2.512 1.696 0.706
243 IPI00646689.1 ThioredoxindomainͲcontainingprotein17 3.272 2.008 0.568
244 IPI00965913.1 albumin 2.578 1.305 0.508
245 IPI00219156.7 60Sribosomal proteinL30 4.698 2.475 0.686
246 IPI00924816.1 Myotrophin 1.810 1.083 0.608
247 IPI00915869.3 malate dehydrogenase,cytoplasmici soform3 2.573 2.287 0.927
248 IPI00643915.1 Peptidyl Ͳprolyl cis Ͳtrans i somerase 2.714 2.379 0.696
249 IPI00395887.4 ThioredoxinͲrelatedtransmembrane protein1 2.699 2.919 1.099
250 IPI00296370.2 leucine carboxyl methyltransferase 1 2.590 2.312 0.966
251 IPI00304612.9 60Sribosomal proteinL13a 3.102 2.334 0.772
252 IPI00031517.1 DNArepl i cationl i cens ingfactorMCM6 2.099 1.930 0.867
253 IPI00299904.3 Isoform1ofDNArepl icationl i cens ingfactorMCM7 2.430 1.976 0.877
254 IPI00745335.7 IsoformCytoplasmicofPhosphol ipidhydroperoxide glutat 2.756 2.100 0.748
255 IPI00908754.1 cDNAFLJ50714,moderatelys imi lartoRas ͲrelatedproteinR 1.763 1.468 0.807
256 IPI00967721.1 matrin3 2.682 2.000 0.763
257 IPI00472176.1 Isoform2oftRNA(uraci l Ͳ5Ͳ)Ͳmethyl transferase homologA 2.569 2.333 0.875
258 IPI00008438.1 40Sribosomal proteinS10 2.798 2.803 0.869
259 IPI00329633.5 Threonyl ͲtRNAsynthetase,cytoplasmic 2.395 1.897 0.802
260 IPI00893541.1 proteindisul fide i somerase fami lyA,member3 2.220 1.366 0.615
261 IPI00293655.3 ATPͲdependentRNAhel icase DDX1 2.810 2.056 0.758
262 IPI00550746.4 NuclearmigrationproteinnudC 2.717 1.852 0.658
263 IPI00301434.4 BolAͲl ike protein2 2.338 1.446 0.631
264 IPI00651660.1 60Sribosomal proteinL3i soformb 2.433 2.268 0.862
265 IPI00009032.1 Lupus La protein 1.876 1.758 0.898
266 IPI00456747.1 ATPsynthase,H+transporting,mitochondria l F0complex,s 1.850 1.564 0.759
267 IPI00030363.1 Acetyl ͲCoAacetyl transferase,mitochondria l 2.532 1.857 0.787
268 IPI00843996.1 cDNAFLJ52832,highlys imi lartoSpl icingfactor,arginine/s 2.677 1.839 0.649
269 IPI00026824.2 Heme oxygenase 2 2.245 2.627 1.105
270 IPI00395674.1 IsoformSMͲBofSmal l nuclearribonucleoproteinͲassociat 2.976 2.256 0.716
271 IPI00010157.1 SͲadenosylmethionine synthase i soformtypeͲ2 2.363 2.295 0.978
272 IPI00555749.1 Proteasome 26SATPase subuni t5variant(Fragment) 2.682 1.170 0.435
273 IPI00027834.3 Heterogeneous nuclearribonucleoproteinL 2.854 1.555 0.545
274 IPI00020599.1 Cal reticul in 2.525 1.775 0.697
275 IPI00977964.1 ribosomal proteinL27a 3.685 2.431 0.638
276 IPI00019359.4 Keratin,type I cytoskeleta l 9 2.577 1.511 0.652
277 IPI00795892.1 profi l in2 3.048 1.752 0.665
278 IPI00471928.6 ATPsynthase subunita lpha 1.604 1.740 1.180
279 IPI00012493.1 40Sribosomal proteinS20 3.104 1.922 0.824  
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280 IPI00220637.5 Seryl ͲtRNAsynthetase,cytoplasmic 2.726 1.918 0.693
281 IPI00297579.4 Chromoboxproteinhomolog3 2.491 1.767 0.726
282 IPI00908647.1 cDNAFLJ59942,highlys imi lartoProstaglandinEsynthase  2.397 1.828 0.751
283 IPI00910830.1 cDNAFLJ57715,highlys imi lartoVoltageͲdependentanion 3.417 3.018 0.883
284 IPI00021700.3 Prol i feratingcel l nuclearantigen 2.613 3.443 1.242
285 IPI00305383.1 Cytochrome bͲc1complexsubunit2,mitochondria l 2.426 1.724 0.714
286 IPI00247583.5 60Sribosomal proteinL21 2.955 2.268 0.785
287 IPI00219905.1 IsoformBoftRNA(cytos ine(38)ͲC(5))Ͳmethyl transferase 2.473 1.993 0.806
288 IPI00009104.7 RuvBͲl i ke 2 1.944 1.952 0.971
289 IPI01009538.1 Putative uncharacterizedproteinDKFZp781B11202 1.822 2.116 1.069
290 IPI00019329.1 Dyneinl i ghtchain1,cytoplasmic 2.437 1.197 0.490
291 IPI00026268.3 Guanine nucleotideͲbindingproteinG(I)/G(S)/G(T)subuni 2.580 2.206 0.960
292 IPI00642457.1 adenine phosphoribosyl transferase i soformb 1.561 1.470 0.926
293 IPI00000811.2 Proteasome subunitbeta typeͲ6 2.219 1.643 0.737
294 IPI00396321.1 LeucineͲri chrepeatͲcontainingprotein59 2.733 2.549 1.010
295 IPI00470610.4 Pyrrol ineͲ5Ͳcarboxylate reductase 2 2.730 2.912 1.064
296 IPI00024993.4 Enoyl ͲCoAhydratase,mitochondria l 2.291 1.794 0.768
297 IPI00643876.2 cDNAFLJ50466,highlys imi lartoDNA(cytos ineͲ5)Ͳmethyl tra 2.055 2.223 1.082
298 IPI00759663.1 IsoformCytoplasmic+peroxisomal ofPeroxi redoxinͲ5,mito 2.772 2.273 0.738
299 IPI00412579.6 60Sribosomal proteinL10a 2.883 2.014 0.655
300 IPI00983652.2 cDNAFLJ61021,highlys imi lartoFarupstreamelementͲbin 2.515 1.037 0.412
301 IPI00299177.4 Isoform1ofCateye syndrome cri tica l regionprotein5 2.661 2.257 0.907
302 IPI00792330.2 ADPͲribosylationfactor4 2.831 1.794 0.634
303 IPI00640006.1 rabGDPdissociationinhibi torbeta i soform2 2.195 1.889 0.898
304 IPI00003168.1 Phosphoribosyl pyrophosphate synthaseͲassociatedprote 2.765 3.034 1.025
305 IPI00794610.2 dnaJhomologsubfami lyCmember7i soform2 3.180 2.308 0.787
306 IPI00760588.2 Isoform5ofDoubleͲs trandedRNAͲspeci ficadenos ine dea 2.359 2.056 0.954
307 IPI00655650.2 40Sribosomal proteinS26 3.956 2.386 0.575
308 IPI00927101.1 Uncharacterizedprotein 2.348 2.029 0.762
309 IPI00016572.1 Smal l nuclearribonucleoproteinG 2.693 1.639 0.603
310 IPI00298961.3 ExportinͲ1 2.290 2.011 0.807
311 IPI00179953.2 Isoform1ofNuclearautoantigenicspermprotein 4.306 2.624 0.660
312 IPI00026271.5 40Sribosomal proteinS14 3.324 2.093 0.618
313 IPI00332511.5 Serine/threonineͲproteinphosphatase 2A55kDa regulato 2.089 2.177 0.998
314 IPI00219757.13 Glutathione SͲtransferase P 2.255 1.558 0.746
315 IPI00453473.6 Histone H4 3.666 1.977 0.580
316 IPI00644653.1 cDNAFLJ56337,highlys imi lartoHighmobi l i tygroupprotei 2.632 2.074 0.774
317 IPI00946221.1 ribosomal proteinL24 3.166 2.986 0.959
318 IPI00430813.3 Isoform2ofCel lularnucleicacidͲbindingprotein 3.452 2.328 0.743
319 IPI01012383.1 OTUdomain,ubiquitina ldehyde binding1 2.543 2.404 1.055
320 IPI00927892.1 Mitochondria l Ͳprocess ingpeptidase subunitbeta 1.884 2.027 1.006
321 IPI00964409.3 heatshock70kDa protein4Ͳl i ke 1.898 1.798 0.896
322 IPI00023344.2 Isoform1ofSymplekin 2.770 2.882 0.969
323 IPI00009901.1 Nucleartransportfactor2 1.866 1.086 0.528
324 IPI00029266.1 Smal l nuclearribonucleoproteinE 5.050 2.859 0.671
325 IPI00964686.1 heterogeneous nuclearribonucleoproteinA/B 2.133 2.047 0.923
326 IPI00016513.5 Ras ͲrelatedproteinRabͲ10 2.019 1.484 0.735  
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327 IPI01014727.1 cDNAFLJ51983,highlys imi lartoPhosphoglycerate mutase 2.442 2.157 0.830
328 IPI00299573.12 60Sribosomal proteinL7a 3.146 2.365 0.761
329 IPI00926977.1 26Sprotease regulatorysubuni t10B 2.729 2.219 0.763
330 IPI00792916.2 glucos idase 2subuni tbeta i soform2 3.032 3.188 1.019
331 IPI00027223.2 Isoci trate dehydrogenase [NADP]cytoplasmic 2.772 2.171 0.708
332 IPI00218829.9 Eukaryoticpeptide chainrelease factorGTPͲbindingsubun 2.355 2.137 0.924
333 IPI00336094.5 Isoform2of3Ͳhydroxyacyl ͲCoAdehydrogenase typeͲ2 2.776 2.180 0.829
334 IPI00156374.6 Isoform1ofImportinͲ4 3.711 3.138 0.955
335 IPI00081836.3 Histone H2Atype 1ͲH 2.610 1.777 0.614
336 IPI00926258.1 proteasome (prosome,macropain)26Ssubunit,nonͲATPas 1.455 1.847 1.170
337 IPI00215780.5 40Sribosomal proteinS19 3.179 1.974 0.706
338 IPI00290416.3 Isoform1ofObgͲl ike ATPase 1 2.705 1.428 0.566
339 IPI00019927.2 26Sproteasome nonͲATPase regulatorysubuni t7 2.663 2.910 1.093
340 IPI00984839.1 ATPͲdependentRNAhel icase DDX3Xi soform2 2.773 2.187 0.789
341 IPI01015454.1 PPM1Gprotein 2.933 2.651 0.882
342 IPI00644712.4 XͲrayrepa ircross Ͳcomplementingprotein6 1.530 1.665 1.054
343 IPI00031522.2 Tri functional enzyme subunita lpha,mitochondria l 2.241 1.706 0.807
344 IPI00964635.1 annexinA5 2.091 1.914 0.908
345 IPI00479877.4 4Ͳtrimethylaminobutyraldehyde dehydrogenase 2.028 2.119 0.944
346 IPI00640037.2 cDNAFLJ38496fi s ,clone FELIV1000137,highlys imi larto60S 2.537 2.810 1.121
347 IPI00030706.1 Activatorof90kDa heatshockproteinATPase homolog1 2.822 2.150 0.767
348 IPI00927606.1 Glutathione peroxidase 1 2.790 2.052 0.766
349 IPI00940851.1 ELAVͲl ike protein1 2.616 1.754 0.702
350 IPI00001159.11 Trans lationa l activatorGCN1 3.908 2.981 0.757
351 IPI00170924.2 Histidine triadnucleotideͲbindingprotein3 1.997 1.849 0.977
352 IPI00029631.1 Enhancerofrudimentaryhomolog 2.223 1.190 0.535
353 IPI00382699.2 Isoform5ofFi laminͲB 3.789 3.114 0.822
354 IPI00010882.3 IsoformDFF45ofDNAfragmentationfactorsubunita lpha  2.698 2.386 0.856
355 IPI00300074.4 Phenyla lanyl ͲtRNAsynthetase beta cha in 2.935 3.910 1.007
356 IPI00759824.2 Isoform2ofAcidicleucineͲri chnuclearphosphoprotein32 2.556 2.023 0.840
357 IPI00032872.3 28Sribosomal proteinS16,mitochondria l 3.591 2.262 0.645
358 IPI00910697.1 cDNAFLJ53703,highlys imi lartoHistidyl ͲtRNAsynthetase 1.774 1.922 1.084
359 IPI00293276.10 Macrophage migrationinhibi toryfactor 2.049 1.409 0.788
360 IPI00012772.8 60Sribosomal proteinL8 3.265 2.461 0.698
361 IPI00888475.2 Isoform6ofMicrotubuleͲassociatedprotein4 3.971 3.064 0.814
362 IPI01011421.1 Dihydrol ipoyl dehydrogenase 2.756 2.171 0.763
363 IPI00005511.1 PHDfingerͲl ike domainͲconta iningprotein5A 4.239 2.264 0.616
364 IPI00003588.1 Eukaryotictrans lationelongationfactor1eps i lonͲ1 2.903 2.165 0.801
365 IPI00910438.1 cDNAFLJ54574,highlys imi lartoStaphylococca l nuclease d 2.253 2.024 0.894
366 IPI00291783.4 GemͲassociatedprotein5 3.627 3.024 0.839
367 IPI00026167.5 NHP2Ͳl ike protein1 2.445 1.411 0.607
368 IPI01009775.1 cDNAFLJ52574,highlys imi lartoSeptinͲ7 2.080 1.889 0.920
369 IPI00006865.4 Ves icleͲtra ffickingproteinSEC22b 2.504 1.632 0.660
370 IPI00216425.1 Isoform2ofTestin 2.406 2.635 1.085
371 IPI00011913.1 Heterogeneous nuclearribonucleoproteinA0 2.423 3.772 1.167
372 IPI00177817.4 Isoform2ofSarcoplasmic/endoplasmicreticulumcalcium 3.494 2.739 0.799  
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373 IPI00219994.2 Isoform3ofExportinͲ2 2.087 2.078 0.893
374 IPI00376503.2 pyrrol ineͲ5Ͳcarboxylate reductase 1,mitochondria l i soform 2.419 1.740 0.719
375 IPI00335069.2 26Sproteasome nonͲATPase regulatorysubuni t12i soform 2.009 1.933 0.938
376 IPI00026519.1 Peptidyl Ͳprolyl cis Ͳtrans i somerase F,mitochondria l 2.359 1.834 0.706
377 IPI00964515.1 guanine nucleotide bindingprotein(Gprotein),beta poly 2.204 1.897 0.878
378 IPI00218493.7 HypoxanthineͲguanine phosphoribosyl transferase 2.658 2.172 0.824
379 IPI00304417.7 Isoci trate dehydrogenase [NAD]subunitbeta,mitochondr 2.485 1.925 0.786
380 IPI00945620.1 guanine monphosphate synthetase 2.460 2.106 0.944
381 IPI00456695.1 Isoform2of26Sproteasome nonͲATPase regulatorysubun 1.743 2.146 1.023
382 IPI00479934.1 nonͲspeci fi cl ipidͲtransferproteini soform4proprotein 3.317 1.981 0.611
383 IPI00011916.1 Aminoacyl tRNAsynthase complexͲinteractingmulti functio 2.563 3.257 1.235
384 IPI00215911.3 DNAͲ(apurinicorapyrimidinics i te)l yase 2.407 2.613 1.078
385 IPI00005024.3 Isoform1ofMybͲbindingprotein1A 4.018 3.097 0.797
386 IPI00877948.1 Minichromosome maintenance complexcomponent5 1.991 2.491 1.079
387 IPI00953696.1 glutathione reductase,mitochondria l i soform4precursor 1.697 1.817 1.064
388 IPI01012867.1 ubiqui tinͲconjugatingenzyme E2variant2 2.900 2.056 0.709
389 IPI00867679.2 cDNAFLJ51729,highlys imi lartoProteasome subunitalpha 2.355 1.934 0.762
390 IPI00879160.1 RANbindingprotein1 2.349 1.866 0.735
391 IPI00291646.3 Methylenetetrahydrofolate dehydrogenase (NADP+depen 2.101 1.845 0.820
392 IPI00306960.3 Asparaginyl ͲtRNAsynthetase,cytoplasmic 2.708 1.922 0.698
393 IPI00922359.1 ProteinͲLͲi soaspartate OͲmethyltransferase 2.136 1.790 0.743
394 IPI00012795.3 Eukaryotictrans lationini tiationfactor3subuni tI 2.873 2.932 1.077
395 IPI00020127.1 Repl icationproteinA70kDa DNAͲbindingsubuni t 2.588 0.928 0.421
396 IPI00644668.3 Fouranda halfLIMdomains 1 3.269 2.602 0.797
397 IPI00025874.2 Dol ichyl Ͳdiphosphool igosaccharide ͲͲproteinglycosyl trans 3.456 2.953 1.200
398 IPI00645201.1 Ribosomal proteinS8 3.017 2.595 0.804
399 IPI00218830.1 IsoformShortofGlycylpeptide NͲtetradecanoyltransferase 2.927 2.990 0.837
400 IPI01014177.1 ST13protein 2.168 2.041 0.934
401 IPI00023647.4 Isoform1ofUbiqui tinͲl i ke modifierͲactivatingenzyme 6 2.251 2.148 0.902
402 IPI00026833.4 Adenylosuccinate synthetase i sozyme 2 2.565 2.145 1.243
403 IPI00306708.5 LymphokineͲactivatedki l lerTͲcel l Ͳoriginatedproteinkina 3.457 2.599 0.826
404 IPI00607884.2 cDNA,FLJ79413,highlys imi lartoHematologica l andneuro 1.929 1.460 0.765
405 IPI00414384.1 Isoform1ofHydroxysteroiddehydrogenaseͲl i ke protein2 2.073 2.103 1.015
406 IPI00026328.3 ThioredoxindomainͲcontainingprotein12 2.484 2.130 0.871
407 IPI00291175.7 Isoform1ofVincul in 2.028 1.556 0.818
408 IPI00549885.4 Isoform2ofPyruvate dehydrogenase E1componentsubun 2.172 2.300 1.117
409 IPI00983098.1 lysophosphol ipase I 1.953 1.515 0.842
410 IPI00978288.1 proteasome subunitbeta typeͲ2i soform2 2.723 2.445 0.776
411 IPI00783982.1 Coatomersubunitgamma 2.143 2.359 1.145
412 IPI00062037.1 Dyneinl i ghtchain2,cytoplasmic 2.072 1.349 0.651
413 IPI00008552.6 GlutaredoxinͲ3 2.738 2.448 0.902
414 IPI00028055.4 Transmembrane emp24domainͲconta iningprotein10 2.436 1.852 0.801
415 IPI00917605.1 cytochrome c,somatic 3.302 2.253 0.632
416 IPI00788836.1 dihydrol ipoamide SͲacetyl transferase 2.669 2.481 0.899
417 IPI00003886.3 Isoform2ofGuanine nucleotideͲbindingproteinͲl ike 3 2.995 1.429 0.410
418 IPI00939560.1 thioredoxindomainͲconta iningprotein5i soform3 1.876 1.944 1.036
419 IPI00783378.3 UbiquitinͲconjugatingenzyme E2O 3.249 2.757 0.879
420 IPI00646415.1 RAB14,memberRASoncogene fami ly 2.291 1.569 0.679  
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421 IPI01013402.1 cDNAFLJ46429fi s ,clone THYMU3014372,highlys imi lartoD 2.748 3.522 0.980
422 IPI00792135.2 ATP5Hprotein(Fragment) 2.015 1.670 0.823
423 IPI00397526.3 Isoform1ofMyosinͲ10 1.916 1.825 0.953
424 IPI00963825.1 ATPsynthase,H+transporting,mitochondria l Focomplex, 2.567 2.802 0.735
425 IPI00001757.1 Isoform1ofRNAͲbindingprotein8A 1.852 1.550 0.819
426 IPI00004839.1 CrkͲl i ke protein 3.577 3.226 0.874
427 IPI00026089.4 Spl icingfactor3Bsubuni t1 3.141 2.627 0.814
428 IPI00006980.1 chromosome 14openreadingframe 166 2.526 1.296 0.550
429 IPI00554521.2 Ferri tinheavychain 1.796 1.404 0.788
430 IPI00786995.1 DNAͲdependentproteinkinase cata lyticsubunitͲl ike 3.054 2.815 0.887
431 IPI00456969.1 Cytoplasmicdynein1heavycha in1 3.743 2.938 0.818
432 IPI00946636.2 cDNAFLJ51804,highlys imi lartoVacuolarATPsynthase cat 2.456 2.394 0.955
433 IPI00302850.4 Smal l nuclearribonucleoproteinSmD1 2.722 1.543 0.577
434 IPI00645329.1 Isoform3ofHis toneͲbindingproteinRBBP4 1.841 1.664 0.934
435 IPI00465361.4 60Sribosomal proteinL13 2.926 2.482 0.736
436 IPI00977156.1 eukaryotictrans lationini tia tionfactor3,subunitE 2.152 1.995 0.975
437 IPI00218414.5 Carbonicanhydrase 2 3.112 2.365 0.760
438 IPI00291939.1 Structural maintenance ofchromosomes protein1A 3.833 2.920 0.790
439 IPI00514724.1 UbiquitinͲconjugatingenzyme E2variant1 2.424 1.697 0.700
440 IPI00294911.1 Succinate dehydrogenase [ubiquinone]i ronͲsul fursubuni 2.630 2.067 0.795
441 IPI00031570.1 CancerͲrelatednucleos ideͲtriphosphatase 2.373 1.870 0.786
442 IPI00982721.1 transcriptionelongationfactorB(SIII),polypeptide 1(15kD 3.939 2.470 0.627
443 IPI00294955.3 U6snRNAͲassociatedSmͲl ike proteinLSm4 3.270 2.080 0.603
444 IPI01009339.1 paraspeckle component1 2.809 1.405 0.500
445 IPI00017963.1 Smal l nuclearribonucleoproteinSmD2 3.255 1.929 0.589
446 IPI01014812.1 cDNAFLJ52595,highlys imi lartoMediumͲcha inspeci fi cacy 2.609 2.024 0.737
447 IPI00642213.1 RNAbindingprotein,autoantigenic 2.319 2.608 1.074
448 IPI00221091.9 40Sribosomal proteinS15a 4.289 2.330 0.565
449 IPI00063245.2 farupstreamelement(FUSE)bindingprotein3 2.680 2.252 0.840
450 IPI00387130.1 Isoform1ofAnamors in 3.692 3.417 0.892
451 IPI00943173.1 CoroninͲ1C 3.450 2.288 0.723
452 IPI00220667.3 Isoform4ofHexokinaseͲ1 1.491 1.603 0.919
453 IPI00105598.3 Proteasome 26SnonͲATPase subuni t11variant(Fragment) 1.822 2.353 1.232
454 IPI00103467.5 Aldehyde dehydrogenase X,mitochondria l 1.766 1.931 1.153
455 IPI00005613.3 Spl icingfactorU2AF35kDa subunit 2.546 2.539 0.988
456 IPI01015738.1 Alpha actinin4shorti soform 1.959 1.818 0.928
457 IPI00031836.3 Developmental lyͲregulatedGTPͲbindingprotein1 2.864 2.459 0.859
458 IPI00019640.1 Serine/threonineͲproteinkinase VRK1 2.123 2.207 1.040
459 IPI00979610.1 SͲphase kinaseͲassociatedprotein1 3.144 2.327 0.726
460 IPI00927677.1 heterogeneous nuclearribonucleoproteinA3 2.817 2.211 0.895
461 IPI00021435.3 26Sprotease regulatorysubuni t7 1.684 1.884 1.093
462 IPI00219025.3 GlutaredoxinͲ1 1.888 0.717 0.380
463 IPI00218568.7 PterinͲ4Ͳalpha Ͳcarbinolamine dehydratase 1.621 1.205 0.743
464 IPI00014151.3 26Sproteasome nonͲATPase regulatorysubuni t6 2.766 2.422 0.864
465 IPI00009922.3 SRAstemͲloopͲinteractingRNAͲbindingprotein,mitochond 2.769 1.678 0.597
466 IPI00297982.7 Eukaryotictrans lationini tiationfactor2subuni t3 1.987 1.966 0.985
467 IPI01010654.1 cDNAFLJ57899,highlys imi lartoMitoticcheckpointprotein 2.735 2.133 0.776  
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468 IPI01009456.1 cDNAFLJ40884fi s ,clone UTERU2000607,highlys imi lartoA 1.505 1.721 1.143
469 IPI01015965.1 eukaryotictrans lationelongationfactor1del ta (guanine n 2.301 2.462 1.070
470 IPI00925601.1 5Ͳaminoimidazole Ͳ4Ͳcarboxamide ribonucleotide formyltra 3.186 2.035 0.683
471 IPI01012099.1 PRP6preͲmRNAprocess ingfactor6homolog(S.cerevis iae) 2.339 2.021 0.867
472 IPI00304409.3 CalciumͲregulatedheats table protein1 2.495 2.039 0.702
473 IPI00644813.1 Smal l nuclearribonucleoproteinpolypeptide C 2.109 1.495 0.677
474 IPI00745893.2 smal l ubiqui tinͲrelatedmodifier2i soformbprecursor 4.159 2.626 0.631
475 IPI00295857.7 Isoform1ofCoatomersubuni ta lpha 2.980 2.520 0.789
476 IPI00334907.3 Isoform1ofPhosphatidyl inos i tol transferproteinbeta i so 2.168 2.397 1.108
477 IPI00983658.1 adenos ine kinase i soformd 2.747 1.499 0.542
478 IPI00008527.3 60Sacidicribosomal proteinP1 5.131 3.303 0.644
479 IPI00942408.1 Isoform1ofCycl inͲdependentkinase inhibi tor2A,i soform 4.106 2.614 0.637
480 IPI00909229.1 cDNAFLJ51308 1.955 1.410 0.623
481 IPI00921820.1 cDNA,FLJ78950,highlys imi lartoIsoci trate dehydrogenase 2.266 1.847 0.815
482 IPI00945574.1 RAB7A,memberRASoncogene fami ly 3.152 2.130 0.702
483 IPI00023234.3 SUMOͲactivatingenzyme subunit2 2.170 1.908 0.938
484 IPI00219153.4 60Sribosomal proteinL22 2.934 1.647 0.530
485 IPI00815843.1 RPL14protein(Fragment) 3.465 2.728 0.597
486 IPI00977658.1 Eukaryotictrans lationini tiationfactor3subuni tH 3.359 2.620 0.767
487 IPI00029557.3 GrpEproteinhomolog1,mitochondria l 2.130 1.665 0.797
488 IPI01009361.1 N(a lpha)Ͳacetyl transferase 15,NatAauxi l iarysubuni t 1.890 2.033 1.050
489 IPI00012369.1 Mitoticspindle assemblycheckpointproteinMAD2A 1.973 1.541 0.727
490 IPI00334627.3 Putative annexinA2Ͳl i ke protein 2.364 2.662 1.126
491 IPI00878484.1 Ewingsarcoma breakpointregion1 2.594 2.068 1.092
492 IPI00977915.3 HYOU1protein 3.330 2.779 0.812
493 IPI00170972.2 UPF0553proteinC9orf64 2.533 2.287 1.054
494 IPI00020451.4 Isoform1ofProteinIMPACT 2.729 2.233 0.836
495 IPI00013847.4 Cytochrome bͲc1complexsubunit1,mitochondria l 2.240 1.852 0.827
496 IPI00965680.1 nucleoporin155kDa 3.192 2.828 0.746
497 IPI00218372.1 Isoform2ofProteasome subunita lpha typeͲ7 2.593 1.693 0.701
498 IPI01015591.1 cDNAFLJ55635,highlys imi lartopreͲmRNAͲspl i cingfactorA 2.664 2.080 0.781
499 IPI00955815.2 pyruvate dehydrogenase E1componentsubuni talpha,som 1.993 1.311 0.641
500 IPI00926495.1 ribosomal proteinL35a 4.530 2.216 0.524
501 IPI00177008.1 Phosphoglycolate phosphatase 2.790 2.764 1.067
502 IPI00016736.1 Isoform1of1Ͳphosphatidyl inos i tol Ͳ4,5Ͳbisphosphate pho 4.052 2.856 0.603
503 IPI00789792.1 dynactin2(p50) 1.916 1.992 0.968
504 IPI00020602.1 Caseinkinase I I subuni ta lpha' 4.707 4.464 0.948
505 IPI01012417.1 NOP2/SunRNAmethyl transferase fami ly,member2 2.007 2.081 0.938
506 IPI00945855.1 profi l in2 4.255 2.485 0.584
507 IPI01014975.1 Tal in1 4.295 3.187 0.767
508 IPI00011698.4 his tone deacetylase complexsubunitSAP18 3.101 2.225 0.711
509 IPI00909657.1 cDNAFLJ50378,highlys imi lartoPhenyla lanyl ͲtRNAsynthet 2.464 1.903 0.735
510 IPI00787559.1 thymidylate kinase i soform2 2.353 2.289 0.895
511 IPI00299147.8 Smal l ubiqui tinͲrelatedmodifier3 3.508 1.968 0.561
512 IPI00983602.1 mitochondria l carrier2 4.026 4.743 1.093
513 IPI00789806.2 Isoform2ofCytosol aminopeptidase 2.420 2.435 1.044
514 IPI00514607.2 Isoform2ofHis toneͲarginine methyl transferase CARM1 3.223 2.208 0.733  
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515 IPI00647813.1 Isoform2ofInos ineͲ5'Ͳmonophosphate dehydrogenase 1 1.494 1.900 1.272
516 IPI00895865.1 electrontransferflavoproteinsubuni talpha,mitochondria 2.323 1.938 0.934
517 IPI00982162.1 ras homologfami lymemberC 2.886 2.151 0.648
518 IPI00215790.6 60Sribosomal proteinL38 2.347 1.232 0.544
519 IPI00000643.1 BAGfami lymolecularchaperone regulator2 2.173 1.462 0.682
520 IPI01012205.1 cDNAFLJ53863,highlys imi lartoCystathionine beta Ͳsyntha 2.590 2.268 0.866
521 IPI00513775.1 Isoform2of14kDa phosphohis tidine phosphatase 3.013 1.668 0.572
522 IPI00908582.1 cDNAFLJ50164,highlys imi lartoProteinfl i ghtless Ͳ1homol 3.886 2.917 0.736
523 IPI00428288.1 Isoform4of39Sribosomal proteinL43,mitochondria l 2.883 2.170 0.747
524 IPI00295386.7 Carbonyl reductase [NADPH]1 2.657 1.919 0.722
525 IPI00022334.1 Ornithine aminotrans ferase,mitochondria l 2.702 0.991 0.413
526 IPI00022442.2 Acyl carrierprotein,mitochondria l 2.275 1.668 0.768
527 IPI00973884.1 SͲphase kinaseͲassociatedprotein1 2.482 2.757 1.111
528 IPI00759715.1 IsoformCytoplasmicofFumarate hydratase,mitochondria 2.456 2.400 1.000
529 IPI01012065.1 proteasome (prosome,macropain)subunit,a lpha type,1 2.530 2.068 0.831
530 IPI00003327.1 ADPͲribosylationfactorͲl i ke protein3 2.868 2.050 0.770
531 IPI00797249.1 LͲxylulose reductase i soform2 2.302 2.227 0.831
532 IPI01012026.1 chromodomainhel icase DNAbindingprotein4 3.096 2.470 0.830
533 IPI00012202.1 Methylosome protein50 3.172 2.043 0.644
534 IPI01009016.1 Isoform4ofCel lulartumorantigenp53 1.880 1.768 0.932
535 IPI00746004.2 40Sribosomal proteinS27Ͳl i ke 2.465 1.973 0.800
536 IPI01014044.1 Isoform1ofNADHdehydrogenase [ubiquinone]1beta su 2.259 1.868 0.752
537 IPI00873286.2 cDNAFLJ55750,highlys imi lartoEukaryotictrans lationini t 2.191 1.650 0.841
538 IPI00171798.1 Metastas is ͲassociatedproteinMTA2 2.589 2.486 0.956
539 IPI00016786.1 Isoform2ofCel l divis ioncontrol protein42homolog 2.143 1.797 0.838
540 IPI00908889.1 cDNAFLJ54065,moderatelys imi lartoMus musculus pi tri l y 1.954 1.726 0.912
541 IPI00925237.1 nonͲSMCcondens inI complex,subunitH 2.001 2.088 0.960
542 IPI00980919.1 Serine/threonineͲproteinphosphatase 6.424 6.094 0.991
543 IPI00006052.3 Prefoldinsubunit2 3.667 2.536 0.622
544 IPI00794581.1 tropomodul in2(neuronal ) 1.697 1.011 0.596
545 IPI00025039.1 rRNA2'ͲOͲmethyltransferase fibri l larin 2.536 2.446 0.906
546 IPI00853093.3 Isoform1ofMethyl transferaseͲl i ke protein2B 3.197 3.015 0.971
547 IPI00550234.4 Isoform1ofActinͲrelatedprotein2/3complexsubunit5 2.465 1.953 0.674
548 IPI00010130.3 Glutamine synthetase 2.410 2.237 0.845
549 IPI00219077.4 Isoform1ofLeukotriene AͲ4hydrolase 2.484 1.213 0.447
550 IPI00384016.1 Ful l ͲlengthcDNA5ͲPRIMEendofclone CS0DJ009YL13ofTce 1.767 1.653 0.943
551 IPI00873948.3 DNAͲdirectedRNApolymerase 3.095 2.516 0.773
552 IPI00184284.6 Isoform2ofVacuolarproteinsortingͲassociatedprotein2 2.456 2.214 0.901
553 IPI00419919.6 Ribosomal proteinL29 2.336 2.074 0.848
554 IPI01018329.1 cDNAFLJ57316,highlys imi lartoDNAmismatchrepai rprot 1.984 1.851 1.110
555 IPI00029534.1 Amidophosphoribosyltransferase 2.647 1.966 0.743
556 IPI00008454.1 DnaJhomologsubfami lyBmember11 2.522 2.099 0.834
557 IPI00332371.9 Isoform1of6Ͳphosphofructokinase,l ivertype 1.713 2.082 1.216
558 IPI00216508.3 Isoform2ofSortingnexinͲ3 2.738 1.960 0.670
559 IPI00386755.2 ERO1Ͳl ike proteina lpha 2.784 1.933 0.709
560 IPI00743142.2 Isoform1of6Ͳphosphofructokinase,muscle type 2.405 1.901 0.790
561 IPI01010195.1 cDNAFLJ55629,highlys imi lartoTranscriptionelongationf 3.271 3.311 0.997  
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562 IPI00021785.2 Cytochrome coxidase subunit5B,mitochondria l 2.684 1.725 0.609
563 IPI01014174.1 PRP19/PSO4preͲmRNAprocess ingfactor19homolog(S.cer 2.372 2.729 0.945
564 IPI00977749.1 cys teine andhistidine Ͳri chdomain(CHORD)conta ining1 3.123 3.882 1.184
565 IPI00026546.1 PlateletͲactivatingfactoracetylhydrolase IBsubunitbeta 2.268 1.640 0.724
566 IPI00946039.1 tRNAmethyltrans ferase 10homologC(S.cerevis iae) 2.603 2.502 0.922
567 IPI00005087.1 Tropomodul inͲ3 2.132 1.826 0.857
568 IPI00250297.3 LͲaminoadipate Ͳsemialdehyde dehydrogenaseͲphosphop 4.238 3.259 0.987
569 IPI00910113.1 cDNAFLJ52902,highlys imi lartoRabGDPdissociationinhi 4.334 3.106 0.717
570 IPI00106495.1 Condens incomplexsubunit3 2.017 2.265 1.013
571 IPI00007402.3 ImportinͲ7 2.615 1.822 0.697
572 IPI00641924.2 28Sribosomal proteinS9,mitochondria l 2.408 1.907 0.817
573 IPI00982694.1 serumamyloidAͲl i ke 1 3.281 2.116 0.627
574 IPI00644349.4 cDNAFLJ60449,highlys imi lartoHomosapiens prionprote 2.901 2.318 0.801
575 IPI00556021.3 DNApolymerase (Fragment) 3.485 3.511 1.007
576 IPI00028946.2 Isoform3ofReticulonͲ3 2.345 2.115 0.855
577 IPI00215719.6 60Sribosomal proteinL18 10.555 6.181 0.577
578 IPI00219678.3 Eukaryotictrans lationini tiationfactor2subuni t1 2.674 2.529 1.043
579 IPI00013122.1 Hsp90coͲchaperone Cdc37 1.887 2.117 1.122
580 IPI00411937.4 Nucleolarprotein56 2.125 2.111 0.993
581 IPI01015342.1 cDNA,FLJ79540,highlys imi lartoSerineͲthreonine kinase r 3.143 2.997 0.985
582 IPI00433833.1 THOC3protein 2.658 2.099 0.813
583 IPI00001589.1 Mitochondria l importinnermembrane trans locase subun 1.973 1.296 0.657
584 IPI00375145.1 IsoformShortofUbiqui tincarboxyl Ͳtermina l hydrolase 5 2.251 2.200 0.977
585 IPI00184821.1 Isoform1ofBifunctional coenzyme Asynthase 3.020 1.866 0.681
586 IPI01010004.1 cDNAFLJ50858,highlys imi lartoHomosapiens abhydrolas 1.905 1.037 0.789
587 IPI00039626.3 IsoformDofConsti tutive coactivatorofPPARͲgamma Ͳl ike p 4.051 3.011 0.747
588 IPI00644724.1 HIVͲ1Tatspeci fi cfactor1 2.112 1.905 0.905
589 IPI00937278.2 26Sproteasome nonͲATPase regulatorysubuni t8 2.900 2.160 0.725
590 IPI00893431.2 cDNAFLJ53410,highlys imi lartoEukaryotictrans lationini t 2.062 2.161 1.048
591 IPI00025019.3 Proteasome subunitbeta typeͲ1 2.227 1.719 0.755
592 IPI00335385.4 ScavengermRNAͲdecappingenzyme DcpS 2.141 2.317 1.093
593 IPI00552546.1 Isoform2ofMini Ͳchromosome maintenance complexͲbind 2.857 3.062 1.096
594 IPI00023064.1 NADHdehydrogenase [ubiquinone]1a lpha subcomplexa 2.233 1.979 0.765
595 IPI00556640.1 PSAPprotein 2.281 2.291 1.005
596 IPI00019326.1 Adrenodoxin,mitochondria l 2.843 1.772 0.554
597 IPI01013095.1 cDNA,FLJ79243,highlys imi lartoEukaryotictrans lationini 2.564 1.829 0.707
598 IPI00893219.2 LUC7Ͳl ike 2.395 2.655 1.109
599 IPI00009464.1 Isoform1ofExosome component10 2.320 1.863 0.829
600 IPI01015801.1 cDNAFLJ16138fi s ,clone BRALZ2017531,highlys imi lartoGl 1.550 1.636 1.056
601 IPI00719622.1 40Sribosomal proteinS28 2.497 1.144 0.458
602 IPI00012866.2 RACͲa lpha serine/threonineͲproteinkinase 3.314 2.355 0.711
603 IPI00940656.2 ANP32Aprotein 2.559 2.043 0.798
604 IPI01014610.1 tRNAmethyltrans ferase 11Ͳ2homolog(S.cerevis iae) 2.243 1.697 0.720
605 IPI01011099.1 cDNAFLJ53046,highlys imi larto26Sproteasome nonͲATPa 2.727 1.987 0.737
606 IPI00909299.1 cDNAFLJ51288,highlys imi lartoKines inheavycha in 2.059 2.005 0.974
607 IPI00011770.1 NADHdehydrogenase [ubiquinone]1a lpha subcomplexs 2.354 1.359 0.575
608 IPI01010794.1 cDNAFLJ61096,highlys imi lartoTHOcomplexsubuni t2 2.589 2.183 1.121  
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609 IPI00553165.4 Protein(Peptidylprolyl cis/trans i somerase)NIMAͲinteract 2.601 1.513 0.537
610 IPI00019407.1 Sterol Ͳ4Ͳalpha Ͳcarboxylate 3Ͳdehydrogenase,decarboxylat 2.093 1.727 0.787
611 IPI00910487.1 cDNAFLJ52569,highlys imi lartoCol lagenͲbindingprotein 2.138 1.930 0.980
612 IPI00967473.1 DEKoncogene 2.817 2.494 0.863
613 IPI01010979.1 zincfingerCCCHͲtype conta ining15 3.031 2.044 0.768
614 IPI00550037.3 28Sribosomal proteinS15,mitochondria l 2.172 1.506 0.693
615 IPI00639819.1 TARDNAbindingprotein 2.500 2.116 0.805
616 IPI00983383.1 cDNAFLJ54904,highlys imi lartoHomosapiens dendri ticce 2.542 1.920 0.755
617 IPI00220871.4 60Sribosomal proteinL37 3.575 2.284 0.700
618 IPI00940152.1 ataxinͲ10i soform2 1.994 2.241 1.056
619 IPI00180128.4 Isoform2ofBas icleucine zipperandW2domainͲconta ini 2.787 1.715 0.615
620 IPI00016676.1 Mitochondria l importreceptorsubunitTOM20homolog 2.694 1.775 0.861
621 IPI00646917.1 Cleavage andpolyadenylationspeci fici tyfactorsubuni t5 2.989 2.276 0.762
622 IPI01014783.1 cDNAFLJ58533,highlys imi lartoLeucyl ͲtRNAsynthetase,cy 2.830 1.974 0.691
623 IPI00037448.3 Glyoxylate reductase/hydroxypyruvate reductase 2.200 2.288 0.955
624 IPI00184525.2 Isoform2ofMethyl thioriboseͲ1Ͳphosphate i somerase 2.654 2.219 0.812
625 IPI00007074.5 Tyrosyl ͲtRNAsynthetase,cytoplasmic 2.226 1.571 0.684
626 IPI01018318.1 cDNAFLJ54744,highlys imi lartoScaffoldattachmentfactor 4.256 3.239 0.761
627 IPI01011782.1 cDNAFLJ61430,highlys imi lartoATPͲdependentRNAhel ica 3.549 2.477 0.698
628 IPI00449201.2 Isoform2ofUbiqui tinͲl i keͲconjugatingenzyme ATG3 1.877 1.866 1.004
629 IPI00788781.1 fattyacidbindingprotein5(psorias i s Ͳassociated) 4.128 2.098 0.488
630 IPI00937239.2 40Sribosomal proteinS21 1.875 1.002 0.546
631 IPI00940890.1 Isoform3ofRNAͲbindingprotein4 2.917 2.405 0.824
632 IPI01015427.1 cDNAFLJ58247,highlys imi larto26Sprotease regulatorysu 2.919 1.830 0.627
633 IPI00032957.1 SUMOͲconjugatingenzyme UBC9 3.267 2.100 0.643
634 IPI00025086.4 Cytochrome coxidase subunit5A,mitochondria l 3.883 2.117 0.545
635 IPI00221325.3 E3SUMOͲproteinl i gase RanBP2 4.446 3.044 0.685
636 IPI00472003.1 Isoform4ofBH3Ͳinteractingdomaindeathagonist 3.018 4.338 0.843
637 IPI00167572.4 ProteinFAM98B 2.057 2.368 1.184
638 IPI00937682.1 Opioidgrowthfactorreceptor 2.520 2.275 0.901
639 IPI00003927.5 Peptidyl Ͳprolyl cis Ͳtrans i somerase D 2.491 2.630 1.056
640 IPI00968128.1 ribosomal proteinL9 1.968 1.584 0.780
641 IPI00216770.1 Isoform2of26Sprotease regulatorysubuni t6B 1.890 1.884 0.997
642 IPI00925570.1 regulatorofchromosome condensation1 2.007 1.969 0.981
643 IPI01015278.1 cDNAFLJ58314,highlys imi lartoMitogenͲactivatedprotein 2.838 2.159 0.761
644 IPI00953925.1 Aryl hydrocarbonreceptorinteractingprotein 3.696 3.745 1.013
645 IPI00966482.1 cDNAFLJ36919fi s ,clone BRACE2003987,highlys imi lartoCO 2.641 2.597 0.984
646 IPI00979370.1 KͲRASprotein(Fragment) 2.248 1.704 0.758
647 IPI00946099.1 sorcin 2.460 1.653 0.672
648 IPI00980330.1 RAP2A,memberofRASoncogene fami ly 2.108 1.703 0.808
649 IPI00303207.3 ATPͲbindingcassette subͲfami lyEmember1 2.586 1.565 0.555
650 IPI00289819.5 CationͲindependentmannoseͲ6Ͳphosphate receptor 4.060 3.065 0.755
651 IPI00010896.3 Chloride intracel lularchannel protein1 3.893 2.847 0.731
652 IPI00032900.1 BolAͲl ike protein1 1.672 1.397 0.835
653 IPI00306516.1 Mitochondria l importinnermembrane trans locase subun 2.452 2.514 1.026
654 IPI00792186.4 ATPͲbindingcassette,subͲfami lyF(GCN20),member1 2.301 1.794 0.780
655 IPI00909058.1 cDNAFLJ54246,highlys imi lartoHomosapiens BRCA2and 2.050 2.164 1.107  
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656 IPI01011924.1 ubiqui tinspeci ficpeptidase 7(herpes virus Ͳassociated) 3.215 2.651 0.824
657 IPI00470922.2 Isoform2ofNͲa lpha Ͳacetyl transferase 50,NatEcata lytics 3.337 2.432 0.729
658 IPI00977975.1 chromosome 11openreadingframe 58 2.303 1.720 0.747
659 IPI00978083.1 Uncharacterizedprotein 2.164 1.699 0.785
660 IPI00014238.2 IsoformCytoplasmicofLysyl ͲtRNAsynthetase 2.485 1.985 0.799
661 IPI01008912.1 NADHdehydrogenase (ubiquinone)FeͲSprotein8,23kDa ( 2.285 1.636 0.716
662 IPI00982639.1 chromosome 11openreadingframe 31 2.657 1.695 0.638
663 IPI00967533.1 transmembrane protein33 4.675 3.615 0.773
664 IPI00647084.2 programmedcel l deathprotein4i soform3 4.134 3.036 0.734
665 IPI01014222.1 damageͲspeci ficDNAbindingprotein1,127kDa 2.132 1.831 0.859
666 IPI00917463.1 Isoform3ofAncientubiqui tous protein1 3.145 2.560 0.814
667 IPI00012197.1 dCTPpyrophosphatase 1 2.486 1.875 0.754
668 IPI00014230.1 Complementcomponent1QsubcomponentͲbindingprote 2.123 1.198 0.564
669 IPI00410615.2 Isoform3ofLowmolecularweightphosphotyros ine prote 2.945 2.160 0.734
670 IPI00010414.4 PDZandLIMdomainprotein1 2.268 2.842 1.253
671 IPI00290142.5 CTPsynthase 1 2.521 2.076 0.824
672 IPI00258833.1 sortingnexinͲ6i soforma 2.005 1.829 0.913
673 IPI00646864.1 s igna l sequence receptor,del ta 3.223 2.155 0.669
674 IPI00783302.1 Isoform1ofPentatricopeptide repeatͲconta iningprotein3 2.715 1.697 0.625
675 IPI00017672.4 cDNAFLJ25678fi s ,clone TST04067,highlys imi lartoPURINE 2.141 1.724 0.805
676 IPI00010270.1 Ras ͲrelatedC3botul inumtoxinsubstrate 2 1.842 1.709 0.928
677 IPI00218922.5 Trans locationproteinSEC63homolog 1.813 2.331 1.286
678 IPI00984586.1 tryps inͲ3i soform4preproprotein 1.541 1.084 0.704
679 IPI01012629.1 aspartyl aminopeptidase 2.393 2.180 0.911
680 IPI00642944.1 Poly(A)bindingprotein,cytoplasmic4(Inducible form),i so 2.871 2.563 0.892
681 IPI00440719.2 N(a lpha)Ͳacetyl transferase 10,NatAcata lyticsubunit 2.611 2.049 0.785
682 IPI00973891.1 NudCdomainconta ining2 2.523 1.967 0.780
683 IPI00797679.1 Inos ine triphosphatase (Nucleos ide triphosphate pyropho 2.546 1.718 0.675
684 IPI00294495.5 UbiquitinͲfoldmodifierͲconjugatingenzyme 1 1.754 1.531 0.873
685 IPI00303105.3 Smal l ubiqui tinͲrelatedmodifier1 3.897 2.277 0.584
686 IPI00028004.2 Proteasome subunitbeta typeͲ3 2.801 1.747 0.708
687 IPI00909879.1 cDNAFLJ50886,highlys imi lartoAconi tate hydratase,mito 2.786 2.187 0.785
688 IPI00000606.5 Tetratricopeptide repeatprotein4 2.051 2.048 0.998
689 IPI00879792.1 Cytochrome b5reductase 3 2.312 2.607 1.128
690 IPI00377080.1 COP9s igna losome complexsubunit8i soform2 2.156 1.576 0.731
691 IPI00556611.1 39Sribosomal proteinL22,mitochondria l i soformb 2.767 1.976 0.714
692 IPI00448725.1 RAB4Bprotein 1.865 3.320 1.780
693 IPI00981273.2 cDNAFLJ14161fi s ,clone NT2RM2001803,highlys imi lartoIk 3.562 3.791 1.064
694 IPI00001146.1 U6snRNAͲassociatedSmͲl ike proteinLSm6 2.448 1.326 0.542
695 IPI00645836.1 esterase D 2.445 2.476 1.013
696 IPI00178047.7 prol ine,glutamate andleucine richprotein1 2.174 3.276 1.507
697 IPI00925574.1 COP9consti tutive photomorphogenichomologsubunit6(A 3.088 3.438 1.113
698 IPI00073602.1 Exosome complexcomponentMTR3 3.019 1.679 0.805
699 IPI00879002.1 Tubul intyros ine l i gaseͲl ike fami ly,member12 3.052 2.679 0.878
700 IPI00181728.1 Ribosome biogenes is proteinBRX1homolog 3.432 2.270 0.661
701 IPI00062866.4 Isoform1ofZincfingerCCCHͲtype antivi ra l protein1Ͳl ike 2.590 2.770 1.070
702 IPI00794082.2 cDNAFLJ57650,highlys imi lartoBleomycinhydrolase 2.534 2.463 0.972  
	   218	  
Islam K. et al.  Supporting Information   
 
 S96
703 IPI00291922.2 Proteasome subunitalpha typeͲ5 2.973 2.087 0.702
704 IPI00015838.3 Cel l growthͲregulatingnucleolarprotein 2.101 2.243 1.067
705 IPI01014863.1 Acetyl ͲCoAacetyl transferase,cytosol i c 4.044 2.972 0.735
706 IPI00162330.3 39Sribosomal proteinL37,mitochondria l 2.667 2.284 0.856
707 IPI00022640.1 Neurogranin 3.763 2.308 0.613
708 IPI00976464.1 Sjogrensyndrome/scleroderma autoantigen1 2.177 1.595 0.733
709 IPI00014437.4 Sjoegrensyndrome nuclearautoantigen1 2.575 1.689 0.656
710 IPI00024821.1 26Sproteasome nonͲATPase regulatorysubuni t14 2.690 2.618 0.973
711 IPI00646978.4 lysophosphol ipase I I 2.039 1.463 0.718
712 IPI00925853.1 cDNAFLJ60586,highlys imi lartoNADHͲubiquinone oxidore 5.404 4.810 1.117
713 IPI00235412.7 dynamin1Ͳl i ke 2.466 1.987 0.806
714 IPI00030243.1 Isoform1ofProteasome activatorcomplexsubunit3 3.658 1.704 0.466
715 IPI00966744.1 Ubiquitincarrierprotein 2.630 1.922 0.731
716 IPI00299155.5 Proteasome subunitalpha typeͲ4 2.387 1.962 0.822
717 IPI00794194.1 developmenta l lyregulatedGTPbindingprotein2 2.134 1.856 0.870
718 IPI00016912.1 Tetratricopeptide repeatprotein1 6.247 6.968 1.115
719 IPI00784936.1 septinͲ9i soformc 2.793 2.610 0.935
720 IPI00294398.2 Isoform1ofHydroxyacyl Ͳcoenzyme Adehydrogenase,mito 2.185 1.507 0.690
721 IPI00000873.3 Valyl ͲtRNAsynthetase 2.085 2.211 1.060
722 IPI00032827.1 PreͲmRNAbranchs i te proteinp14 3.887 2.770 0.712
723 IPI00293434.2 Signa l recognitionparticle 14kDa protein 2.967 2.050 0.691
724 IPI00657698.2 cDNAFLJ59884,highlys imi lartoSecerninͲ1 1.915 2.157 1.126
725 IPI00645380.1 Isoform2ofE3ubiqui tinͲproteinl igase CHIP 2.305 2.593 1.125
726 IPI00643317.3 highmobi l i tygroupbox3 2.203 1.336 0.606
727 IPI00448974.2 NUP107protein 2.710 1.857 0.685
728 IPI00028414.3 Gl ia maturationfactorgamma 2.044 1.554 0.760
729 IPI00060715.1 BTB/POZdomainͲconta iningproteinKCTD12 2.609 2.939 1.006
730 IPI00216057.6 Sorbi tol dehydrogenase 2.541 2.083 0.820
731 IPI00939491.1 Isoform2ofCysteinyl ͲtRNAsynthetase,cytoplasmic 2.690 2.003 0.786
732 IPI00290460.3 Eukaryotictrans lationini tiationfactor3subuni tG 2.420 2.037 0.842
733 IPI00896410.1 Ribosomal proteinL36a 5.359 2.556 0.477
734 IPI00936931.2 cDNAFLJ57553,highlys imi lartoSPFHdomainͲconta iningp 2.319 2.025 0.873
735 IPI00412224.2 WDrepeatͲconta iningprotein11 1.928 2.150 1.115
736 IPI00554626.3 CͲterminal Ͳbindingprotein1i soform2 1.644 1.853 1.127
737 IPI00922378.1 cDNAFLJ55038,highlys imi lartoNicotinamide phosphorib 1.455 1.441 0.990
738 IPI00639981.1 Phosphofructokinase,platelet 3.545 2.880 0.812
739 IPI01010750.1 DNAl igase (Fragment) 3.226 2.021 0.866
740 IPI00792207.3 aldehyde dehydrogenase,mitochondria l Isoform2precurs 2.414 2.194 0.909
741 IPI00030320.4 Probable ATPͲdependentRNAhel icase DDX6 1.995 1.821 0.913
742 IPI00009342.1 Ras GTPaseͲactivatingͲl i ke proteinIQGAP1 2.655 2.012 0.758
743 IPI00026964.2 Cytochrome bͲc1complexsubunitRieske,mitochondria l 1.890 1.173 0.620
744 IPI01010035.1 cDNAFLJ52928,highlys imi lartoCOP9s ignalosome comple 1.734 1.844 1.063
745 IPI00218200.8 BͲcel l receptorͲassociatedprotein31 3.167 2.529 0.798
746 IPI01009610.1 cDNAFLJ57998,highlys imi lartoHomosapiens myoͲinos i t 1.925 2.807 1.458
747 IPI00642256.2 Isoform2ofFͲactinͲcappingproteinsubuni tbeta 2.434 1.922 0.789
748 IPI00399170.1 Isoform2ofRegulatorofnonsense transcripts 1 4.314 2.970 0.689
749 IPI00745613.2 Exosome complexcomponentRRP41 2.900 2.337 0.806  
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750 IPI00027547.2 Dermcidin 1.686 0.837 0.496
751 IPI00429689.3 Serine/threonineͲproteinphosphatase 2Acata lyticsubun 3.300 2.694 0.817
752 IPI00018691.1 Isoform1of28Sribosomal proteinS18a,mitochondria l 2.826 2.264 0.801
753 IPI00967112.1 mitochondria l ribosomal proteinS27 2.119 1.786 0.843
754 IPI00011726.1 Isoform1ofRNA3'Ͳterminal phosphate cyclase 2.371 1.781 0.751
755 IPI00014458.1 ProteinSCO2homolog,mitochondria l 2.402 1.707 0.711
756 IPI00006113.1 DNAͲdirectedRNApolymerase I I subunitRPB9 2.582 1.927 0.746
757 IPI00031106.1 Proteasome assemblychaperone 3 6.824 4.055 0.594
758 IPI00383046.3 Carboxymethylenebutenol idase homolog 2.838 1.788 0.690
759 IPI00215777.1 IsoformBofPhosphate carrierprotein,mitochondria l 3.545 2.478 0.699
760 IPI00946474.1 NADHdehydrogenase (ubiquinone)1a lpha subcomplex,5 3.101 1.462 0.924
761 IPI00030877.2 15kDa selenoproteini soform1precursor 2.540 1.853 0.729
762 IPI01012198.1 tRNAmethyltrans ferase 11homolog 2.098 2.159 1.029
763 IPI00921488.1 Isoform4ofCOP9s igna losome complexsubunit1 2.817 1.936 0.687
764 IPI00000335.1 Histidine triadnucleotideͲbindingprotein2,mitochondria 2.578 1.729 0.670
765 IPI00922583.1 phosphatidyl inos i tol Ͳ4Ͳphosphate 5Ͳkinase typeͲ1a lpha i 2.784 1.515 0.544
766 IPI01012747.1 aldehyde dehydrogenase 5fami ly,memberA1 2.159 1.826 0.846
767 IPI00155054.3 cDNAFLJ50635,highlys imi lartoATPͲdependentRNAhel ica 2.616 1.702 0.651
768 IPI00925071.1 nucleoporin205kDa 3.645 3.072 0.843
769 IPI00375533.5 Isoform2ofNEDD8Ͳactivatingenzyme E1catalyticsubuni t 2.371 1.816 0.766
770 IPI00793076.1 genera l transcriptionfactorI IA,2,12kDa 2.122 1.153 0.543
771 IPI00219005.3 Peptidyl Ͳprolyl cis Ͳtrans i somerase FKBP4 2.143 1.773 0.827
772 IPI00303318.2 ProteinFAM49B 2.272 3.090 1.360
773 IPI00003217.3 Proteasome subunitbeta typeͲ7 3.059 1.995 0.652
774 IPI00026970.4 FACTcomplexsubunitSPT16 4.823 3.009 0.624
775 IPI00926917.1 eukaryotictrans lationini tia tionfactor4gamma,1 3.165 2.438 0.770
776 IPI00377233.1 Isoform2of39Sribosomal proteinL11,mitochondria l 2.192 1.692 0.772
777 IPI01011967.1 cDNAFLJ54535,highlys imi lartoRibosomal proteinS6kina 2.600 1.925 0.740
778 IPI00430781.1 chromosome 8openreadingframe 82 2.416 1.799 0.745
779 IPI00220059.5 NADHdehydrogenase [ubiquinone]1beta subcomplexsu 3.058 2.374 0.777
780 IPI00964692.1 exportin5 2.475 2.114 0.854
781 IPI01013481.1 cDNAFLJ50601,highlys imi lartoGlutathione synthetase 2.255 2.475 1.097
782 IPI00966735.1 28kDa protein 2.747 2.290 0.834
783 IPI00966258.1 ubiqui tincarboxyl Ͳtermina l esterase L1(ubiquitinthioles 2.146 1.764 0.822
784 IPI00940901.1 Isoform2ofRRP12Ͳl ike protein 5.202 2.854 0.549
785 IPI00093057.6 CoproporphyrinogenͲI I I oxidase,mitochondria l 2.577 2.605 1.011
786 IPI00031526.3 chromosome 19openreadingframe 43 1.864 1.295 0.695
787 IPI00908327.1 Isoform2ofRINGfingerprotein114 2.511 2.192 0.873
788 IPI01013918.1 mannoseͲ6Ͳphosphate receptor(cationdependent) 2.134 1.635 0.766
789 IPI00397700.5 Isoform2ofPHDfingerprotein6 3.123 2.048 0.656
790 IPI00916535.1 prolyl 4Ͳhydroxylase subunitalpha Ͳ1i soform3precursor 2.800 2.054 0.734
791 IPI00909399.2 xaa ͲProdipeptidase i soform3 2.437 2.567 1.053
792 IPI01011453.1 SUMOͲactivatingenzyme subunit1i soformc 2.662 2.479 0.931
793 IPI00513841.1 Nicas trin 2.749 2.277 0.828
794 IPI00022648.2 Eukaryotictrans lationini tiationfactor5 3.182 3.422 1.075
795 IPI00014263.1 IsoformLongofEukaryotictrans lationini tia tionfactor4H 2.299 1.646 0.716
796 IPI00719256.2 SART3protein 3.351 3.069 0.916  
	   220	  
Islam K. et al.  Supporting Information   
 
 S98
797 IPI00292020.3 Spermidine synthase 2.230 2.343 1.051
798 IPI00514522.1 chromosome 1openreadingframe 123 2.005 1.453 0.725
799 IPI00947116.1 dihydrofolate reductaseͲl i ke 1 2.313 1.752 0.758
800 IPI00966243.1 cytochrome b5type B(outermitochondria l membrane) 2.299 1.775 0.772
801 IPI00894110.1 polyribonucleotide nucleotidyltrans ferase 1 2.189 1.886 0.861
802 IPI00514669.1 SH3domainbindingglutamicacidͲrichproteinl ike 3 1.780 1.033 0.581
803 IPI00003326.4 ADPͲribosylationfactorͲl i ke protein2 2.511 1.969 0.784
804 IPI00909691.1 cDNAFLJ50174,highlys imi lartoHomosapiens SNAREprot 3.220 2.524 0.784
805 IPI00980207.1 s igna l recognitionparticle 19kDa proteini soform3 3.782 2.620 0.693
806 IPI00940222.2 Isoform3ofAͲkinase anchorprotein12 4.888 3.044 0.623
807 IPI00182289.6 40Sribosomal proteinS29 2.108 1.108 0.525
808 IPI00939707.1 clusteredmitochondria (cluA/CLU1)homolog 2.519 2.489 0.988
809 IPI00005675.3 NFͲkappa ͲBͲrepress ingfactor 1.993 2.072 1.040
810 IPI00396329.1 Ribosome productionfactor2homolog 2.990 2.136 0.714
811 IPI00299214.7 Thymidine kinase,cytosol i c 4.849 4.582 0.945
812 IPI00023728.1 Gamma Ͳglutamyl hydrolase 2.484 2.858 1.150
813 IPI00643709.1 Solute carrierfami ly16,member1 3.415 2.668 0.781
814 IPI00917193.1 hexokinase 2 2.090 1.811 0.867
815 IPI00943181.1 proteasome (prosome,macropain)activatorsubunit2(PA2 2.981 2.827 0.948
816 IPI00013180.2 ProteinBUD31homolog 2.944 2.154 0.732
817 IPI00892533.1 chromosome 7openreadingframe 50 2.682 1.828 0.681
818 IPI00005050.1 28Sribosomal proteinS14,mitochondria l 0.343
819 IPI00978325.1 catheps inC 2.305 1.492 0.647
820 IPI00452731.6 NADHdehydrogenase [ubiquinone]1a lpha subcomplexs 3.039 1.675 0.551
821 IPI00641181.5 MARCKSͲrelatedprotein 3.731 3.671 0.984
822 IPI00006754.1 DDB1ͲandCUL4Ͳassociatedfactor7 2.423 1.968 0.812
823 IPI01015967.1 DnaJ(Hsp40)homolog,subfami lyA,member1 2.114 1.915 0.906
824 IPI00002824.7 Cysteine andglycineͲrichprotein2 2.587 1.514 0.585
825 IPI00021266.1 60Sribosomal proteinL23a 3.833 1.775 0.463
826 IPI00964725.1 succinate dehydrogenase complex,subuni tA,flavoprotein 0.869
827 IPI00967916.1 cytochrome coxidase subuni tVIIc 2.410 1.109 0.460
828 IPI00219351.3 Isoform3of28Sribosomal proteinS11,mitochondria l 3.212 2.152 0.670
829 IPI00604652.1 NEDD8Ͳactivatingenzyme E1regulatorysubuniti soformc 2.773 1.721 0.621
830 IPI00514049.1 Cytidine monophosphate (UMPͲCMP)kinase 1,cytosol i c 3.965 2.380 0.600
831 IPI00016339.4 Ras ͲrelatedproteinRabͲ5C 1.869 0.801 0.429
832 IPI00847896.1 Simi lartoGlutamateͲri chWDrepeatͲcontainingprotein1 7.164 5.378 0.751
833 IPI00217563.4 IsoformBeta Ͳ1AofIntegrinbeta Ͳ1 3.743 3.076 0.822
834 IPI01009997.1 cDNAFLJ51981,highlys imi lartoHistone deacetylase 1 2.711 1.364 0.503
835 IPI00032533.3 WDrepeatͲconta iningprotein18 2.950 2.088 0.708
836 IPI01018037.1 repl icationfactorCsubunit5i soform4 2.413 2.617 1.084
837 IPI00023530.7 Cycl inͲdependentkinase 5 2.616 2.035 0.778
838 IPI00844040.2 cDNAFLJ59759,highlys imi lartoProteinSET 3.080 2.531 0.821
839 IPI00965548.1 thyroidhormone receptorinteractor13 1.950 2.213 1.135
840 IPI01015295.1 cDNAFLJ30049fi s ,clone ADRGL1000033,highlys imi larto26 2.738 2.641 0.965
841 IPI00745105.1 chromosome 16openreadingframe 13 2.094 1.559 0.745
842 IPI00964335.1 eukaryotictrans lationterminationfactor1 3.823 4.749 1.242
843 IPI00641266.4 ca lpa inͲ2catalyticsubuni ti soform2 2.380 2.177 0.915  
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844 IPI00902463.1 cDNAFLJ46898fi s ,clone UTERU3022168,highlys imi lartoProteinFAM62A 0.759
845 IPI00916207.1 3Ͳhydroxyisobutyryl ͲCoAhydrolase 2.806 2.330 0.830
846 IPI00854677.1 fusedinsarcoma 2.574 2.182 0.848
847 IPI00966135.1 his tidine triadnucleotide bindingprotein1 3.201 2.255 0.704
848 IPI00979071.1 tumorprotein,trans lational lyͲcontrol led1 2.653 1.824 0.687
849 IPI00797616.2 Isoform3ofBRCA1ͲassociatedATMactivator1 3.946 2.358 0.598
850 IPI00908614.1 cDNAFLJ51287,highlys imi lartoWDrepeatprotein39 2.637 1.951 0.740
851 IPI00798211.1 tubul infoldingcofactorB 2.433 1.925 0.791
852 IPI00185146.5 ImportinͲ9 2.664 0.929 0.349
853 IPI00008557.6 Insul inͲl i ke growthfactor2mRNAͲbindingprotein1 2.263 0.748 0.330
854 IPI00980519.1 Conservedhypothetica l protein 2.025 1.969 0.972
855 IPI00927827.1 repl icationfactorC(activator1)4,37kDa 2.698 2.152 0.798
856 IPI00917166.1 dynactin1 0.397
857 IPI00980429.1 chloride channel ,nucleotideͲsens i tive,1A 2.701 2.561 0.948
858 IPI00791490.1 pyridoxa l (pyridoxine,vi taminB6)kinase 4.426 4.951 1.119
859 IPI00641815.1 Isoform2ofTIP41Ͳl i ke protein 3.098 2.525 0.815
860 IPI00005969.3 FͲactinͲcappingproteinsubunitalpha Ͳ1 3.799 3.596 0.946
861 IPI00443657.2 coldinducible RNAbindingprotein 3.701 2.239 0.605
862 IPI00024911.1 Endoplasmicreticulumres identprotein29 2.356 1.632 0.693
863 IPI00964348.1 DTWdomainconta ining2 3.410 5.144 1.509
864 IPI00848298.1 Isoform2ofApol ipoproteinAͲIͲbindingprotein 2.322 1.784 0.768
865 IPI00925058.1 Ribosomal proteinL15 2.993 2.573 0.860
866 IPI00410714.5 Hemoglobinsubuni ta lpha 2.568 1.389 0.541
867 IPI00917535.1 mitochondria l ribosomal proteinL30 2.769 1.834 0.662
868 IPI01015489.1 cDNAFLJ60345,highlys imi lartoProteintransportproteinS 2.280 1.720 0.755
869 IPI00174852.4 MediatorofRNApolymerase I I transcriptionsubunit20 2.548 1.985 0.779
870 IPI00012315.2 Nucleos ide diphosphate kinase 3 1.893 1.639 0.866
871 IPI01012187.1 cDNA,FLJ79426,highlys imi lartoSerine/threonineͲprotein 3.187 4.229 1.327
872 IPI00747810.3 fascinhomolog1,actinͲbundl ingprotein(Strongylocentrot 4.249 6.229 1.466
873 IPI00924813.1 Simi lartoRibosomal proteinL37a 3.527 2.034 0.577
874 IPI00025178.3 PreͲmRNAͲspl i cingfactorSPF27 3.303 1.948 0.590
875 IPI00030929.4 myos inregulatoryl i ghtpolypeptide 9i soformb 2.667 1.790 0.671
876 IPI00029114.1 Peptidyl ͲtRNAhydrolase ICT1,mitochondria l 2.846 1.963 0.690
877 IPI00922290.1 cDNAFLJ53094,highlys imi lartoReceptorexpress ionͲenha 3.823 2.661 0.696
878 IPI00018203.1 IsoformSRP55Ͳ2ofSerine/arginine Ͳri chspl i cingfactor6 2.375 1.707 0.719
879 IPI00016532.4 chromosome 4openreadingframe 27 0.927
880 IPI00844002.1 LYSTͲinteractingproteinLIP5(Fragment) 3.452 3.185 0.923
881 IPI00026496.3 NucleoplasminͲ3 2.001 1.537 0.768
882 IPI00419797.5 s igna l recognitionparticle 9kDa 1.806 0.879 0.487
883 IPI00029239.2 Isoform2ofLͲ2Ͳhydroxyglutarate dehydrogenase,mitocho 4.814 4.519 0.939
884 IPI00917449.1 gamma Ͳglutamylcyclotrans ferase 2.296 1.721 0.750
885 IPI00910220.1 cDNAFLJ60230,highlys imi lartoArsenica l pumpͲdrivingAT 3.281 2.688 0.819
886 IPI00981356.1 3Ͳhydroxyacyl ͲCoAdehydratase 3Ͳl ike i soform3,partia l 4.172 2.903 0.696
887 IPI00868858.1 Isoform3ofMYCͲinducednuclearantigen 2.429 2.772 1.141
888 IPI00925203.1 glutaminyl ͲtRNAsynthetase 2.922
889 IPI00892788.1 highdens ityl ipoproteinbindingprotein 7.226 2.066 0.286
890 IPI01015780.1 cDNAFLJ57449,highlys imi lartoNotchless homolog1 1.859 2.084 1.121  
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891 IPI00909038.1 cDNAFLJ58068,highlys imi lartoSeryl ͲtRNAsynthetase,mit 1.866 2.015 1.080
892 IPI00219783.7 UbiquitinͲconjugatingenzyme E2G1 2.591 2.192 0.846
893 IPI00925737.1 phosphoserine phosphatase 2.759 2.181 0.791
894 IPI00100984.4 Isoform1ofHEATrepeatͲcontainingprotein3 2.466 2.494 1.011
895 IPI00004454.3 Isoform1ofDol ichol Ͳphosphate mannosyltransferase sub 2.544 2.135 0.839
896 IPI00915874.1 partnerofNOB1homolog(S.cerevis iae) 3.406 0.889 0.261
897 IPI00006379.1 Nucleolarprotein58 2.835 0.970 0.342
898 IPI00184854.1 FK506bindingprotein10,65kDa 2.422 2.057 0.849
899 IPI00101734.5 fami lywithsequence s imi lari ty105,memberB 2.016 1.417 0.703
900 IPI00186338.1 barrierͲtoͲautointegrationfactorͲl i ke 1.924 0.551 0.287
901 IPI00926139.1 mitochondria l ribosomal proteinS25 4.682 3.599 0.769
902 IPI00409639.1 Isoform4ofMethyl transferaseͲl i ke protein13 1.656 1.871 1.130
903 IPI00910420.1 Isoform3ofAlpha Ͳaminoadipicsemia ldehyde dehydroge 1.686 1.962 1.164
904 IPI00924740.1 programmedcel l death6interactingprotein 1.860 1.837 0.988
905 IPI00301051.3 Isoform1ofNHLrepeatͲconta iningprotein2 3.799 2.256 0.594
906 IPI00335589.5 RNAmethyl transferaseͲl i ke protein1 1.915 2.480 1.295
907 IPI00032849.2 Nucleolarprotein16 1.942 1.526 0.785
908 IPI00032903.3 Peptidyl ͲtRNAhydrolase 2,mitochondria l 3.312 3.700 1.117
909 IPI00552190.1 Proteasome (Prosome,macropain)26Ssubunit,nonͲATPas 2.192 1.287 0.587
910 IPI00940264.1 Galactokinase 2.557 3.010 1.177
911 IPI00218112.1 IsoformShortofGlutaryl ͲCoAdehydrogenase,mitochondri 2.354 1.449 0.616
912 IPI00983446.1 UVradiationres is tance associated 4.931 1.856 0.376
913 IPI00061525.3 Glucosamine 6Ͳphosphate NͲacetyl transferase 2.142 1.885 0.880
914 IPI00017704.3 Coactos inͲl i ke protein 3.031 1.794 0.592
915 IPI00792829.1 cDNAFLJ57094,highlys imi lartoProbable ATPͲdependentR 2.587 2.343 0.906
916 IPI00926756.1 Isoform4ofTBC1domainfami lymember4 3.090 2.892 0.936
917 IPI00910540.1 cDNAFLJ51496,highlys imi lartoTyros ineͲproteinkinase CS 1.915 2.219 1.159
918 IPI00922322.1 cDNAFLJ54129,highlys imi lartoNucleosome assemblypro 3.344 2.988 0.894
919 IPI00940293.5 cDNAFLJ56433,highlys imi lartoCol lagena lpha Ͳ2(IV)chain 2.944 1.794 0.609
920 IPI01011794.1 cDNAFLJ55643,highlys imi lartoSEC23Ͳinteractingprotein 1.859 1.320 0.710
921 IPI00965185.1 aminoacyl tRNAsynthetase complexͲinteractingmulti func 2.288 3.295 1.440
922 IPI00395779.4 chromosome 20openreadingframe 27 2.534 1.686 0.666
923 IPI01015329.1 cDNAFLJ52203,highlys imi larto3'(2'),5'Ͳbisphosphate nuc 3.475 3.103 0.893
924 IPI00976190.1 spl icingfactor3b,subuni t2,145kDa 4.347 3.358 0.772
925 IPI00023542.6 Transmembrane emp24domainͲconta iningprotein9 1.739 1.681 0.967
926 IPI01014928.1 cDNAFLJ55328,highlys imi lartoHomosapiens BPY2intera 3.894 2.818 0.724
927 IPI00845493.1 Braintype muͲglutathione SͲtransferase 4.100 3.005 0.733
928 IPI00219065.2 Isoform5ofGlycogendebranchingenzyme 3.575 2.946 0.824
929 IPI00979951.1 proteasome (prosome,macropain)26Ssubunit,ATPase,3 1.682 1.423 0.846
930 IPI00549993.3 Isoform1ofProteinFAM188A 2.963 3.028 1.022
931 IPI00791680.1 cortactin 2.526 2.019 0.799
932 IPI01009790.1 cDNA,FLJ79293,highlys imi lartoWDrepeatprotein71 2.719 2.069 0.761
933 IPI00946316.1 karyopherina lpha 4(importina lpha 3) 2.852 1.685 0.591
934 IPI01014354.1 cDNAFLJ54039,highlys imi lartoProteinarginine NͲmethyl transferase 5 0.301
935 IPI00910350.1 cDNAFLJ52068,highlys imi lartoMicrotubuleͲassociatedp 2.320 1.855 0.799
936 IPI00384155.1 Ful l ͲlengthcDNAclone CS0DI002YH20ofPlacenta ofHomo 2.855 3.138 1.099
937 IPI00981694.1 ATX1antioxidantprotein1homolog(yeast) 2.160 1.436 0.665  
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938 IPI00946674.1 aldoͲketoreductase fami ly7,memberA2(a flatoxinaldeh 8.035 7.719 0.961
939 IPI00001655.1 chromosome 16openreadingframe 80 2.139 1.582 0.740
940 IPI00654793.2 NADkinase domaincontaining1 6.247 3.579 0.573
941 IPI01015376.1 ATPsynthase gamma chain 1.992 1.458 0.732
942 IPI00002214.1 Importinsubunita lpha Ͳ2 3.253 2.384 0.733
943 IPI00908375.1 cDNAFLJ52821,highlys imi lartoProteintransportproteinS 3.052 1.676 0.549
944 IPI00978272.1 methylcrotonoyl ͲCoAcarboxylase beta cha in,mitochondria 3.035 1.741 0.574
945 IPI00945912.1 cDNAFLJ59963,highlys imi lartoHomosapiens multiple su 2.105 2.442 1.160
946 IPI00927809.1 DEAH(AspͲGluͲAla ͲHis)boxpolypeptide 30 3.310 2.757 0.833
947 IPI00927458.1 ribosomal proteinL32 4.089 3.120 0.763
948 IPI00183603.3 Ol igosaccharyl transferase complexsubuni tOSTC 8.362 4.496 0.538
949 IPI00894139.1 golgi toERtra fficprotein4homolog(S.cerevis iae) 5.418 5.435 1.003
950 IPI00878039.2 coi ledͲcoi l domaincontaining117 2.228 2.479 1.112
951 IPI00795057.1 mitochondria l ribosomal proteinS28 2.925 2.252 0.770
952 IPI00641692.3 Ribonuclease P 3.031 1.810 0.597
953 IPI00642048.2 GDPͲmannose 4,6Ͳdehydratase 3.094 2.520 0.815
954 IPI00334282.2 ProteinFAM3C 1.020
955 IPI01008950.1 Isoform4ofUDPͲNͲacetylglucosamineͲͲpeptide NͲacetylgl 2.168 1.951 0.900
956 IPI00885131.1 Isoform3oftRNA(adenineͲN(1)Ͳ)Ͳmethyltransferase nonͲc 2.616 1.633 0.624
957 IPI00903191.1 Eukaryotictrans lationini tiationfactor3,subuni tD 2.972 2.215 0.745
958 IPI00886797.1 Isoform2of2',5'Ͳphosphodiesterase 12 2.582 2.133 0.826
959 IPI01015636.1 pogotransposable elementwithZNFdomain 3.742 3.187 0.852
960 IPI00871780.1 RNAͲbindingprotein12B 3.431 3.040 0.886
961 IPI00908741.1 FADͲdependentoxidoreductase domainconta ining1 1.919 2.585 1.347
962 IPI00893867.1 hydroxyacyl ͲCoAdehydrogenase/3Ͳketoacyl ͲCoAthiolase/e 1.488 1.894 1.273
963 IPI00940816.2 Isoform3ofRhoguanine nucleotide exchange factor2 2.306 1.978 0.858
964 IPI00007019.1 Peptidyl Ͳprolyl cis Ͳtrans i someraseͲl i ke 1 2.867 1.869 0.652
965 IPI00945733.1 karyopherina lpha 1(importina lpha 5) 4.379 5.617 1.283
966 IPI00399089.4 LDLRchaperone MESD 1.868 1.485 0.795
967 IPI01014449.1 chromoboxhomolog1 2.312 1.698 0.734
968 IPI00292894.5 PreͲrRNAͲprocess ingproteinTSR1homolog 1.797 1.876 1.044
969 IPI00008436.4 DNApolymerase eps i lonsubunit4 2.749 2.284 0.831
970 IPI00981292.1 cDNAFLJ53391,highlys imi lartoATPͲbindingcassette subͲ 4.960 3.100 0.625
971 IPI00220835.7 ProteintransportproteinSec61subuni tbeta 5.362 3.242 0.605
972 IPI00061531.4 39Sribosomal proteinL53,mitochondria l 3.948 2.101 0.532
973 IPI00297626.4 SyntaxinͲbindingprotein3 2.726 1.236 0.453
974 IPI01014726.1 cDNA,FLJ79305,highlys imi lartoCalponinͲ1 2.413 1.579 0.654
975 IPI00024284.6 BasementmembraneͲspeci ficheparansul fate proteoglyca 2.833 2.348 0.829
976 IPI00329373.3 ProteinQIL1 1.913 0.926 0.484
977 IPI00015833.1 Coi ledͲcoi l Ͳhel ixͲcoi ledͲcoi l Ͳhel ixdomainͲcontainingprot 2.578 1.907 0.740
978 IPI00874145.2 dyskeratos is congenita 1,dyskerin 2.384 1.598 0.670
979 IPI00788157.1 Isoform2of5'Ͳ3'exoribonuclease 2 2.102 2.014 0.958
980 IPI00306290.5 ExportinͲT 1.257 0.808 0.643
981 IPI00783001.1 Isoform1ofProbable methyltrans feraseͲl ike protein15 2.824 2.151 0.762
982 IPI00477853.2 zincfingerprotein235 3.082 2.182 0.708
983 IPI00926599.1 glycerol Ͳ3Ͳphosphate dehydrogenase 1Ͳl i ke 2.512 2.391 0.951
984 IPI00908410.1 cDNAFLJ56566,highlys imi lartoSmal l glutamineͲri chtetra 1.720 1.936 1.126  
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985 IPI00032881.2 28Sribosomal proteinS23,mitochondria l 2.074 1.587 0.765
986 IPI00794240.1 mitochondria l ribosomal proteinL39 2.990 2.768 0.926
987 IPI00966215.1 TROVEdomainfami ly,member2 2.401 1.678 0.699
988 IPI00868803.2 Simi lartoSurviva l ofmotorneuron2,centromerici soform 2.784 3.119 1.120
989 IPI00985284.1 La ribonucleoproteindomainfami ly,member1 2.129 1.816 0.853
990 IPI01015748.1 cDNAFLJ54999,highlys imi lartoMitochondria l Ͳprocess ing 1.620 1.476 0.911
991 IPI00845477.1 Isoform2ofAlpha ͲketoglutarateͲdependentdioxygenase  2.884 2.061 0.715
992 IPI00062882.4 CytoplasmictRNA2Ͳthiolationprotein1 2.931 2.506 0.855
993 IPI00941385.2 Isoform3ofUbiqui tincarboxyl Ͳterminal hydrolase 10 2.074 1.522 0.734
994 IPI01011431.1 cDNAFLJ60167,highlys imi lartoCytosol i cacyl coenzyme Athioesterhydrolase 0.666
995 IPI01009918.1 Protease serine 1 1.671 1.127 0.674
996 IPI00642982.1 LONP1protein 3.097 2.134 0.689
997 IPI00647368.1 isocitrate dehydrogenase 3(NAD+)gamma 2.886 2.075 0.719
998 IPI00446669.1 Isoform2ofMultiple myeloma tumorͲassociatedprotein2 2.754 3.241 1.177
999 IPI00398758.1 Isoform2ofEnoyl ͲCoAdel ta i somerase 1,mitochondria l 2.832 2.088 0.737
1000 IPI01015385.1 Isoci trate dehydrogenase 8.725 4.943 0.566
1001 IPI00797738.1 Cytochrome coxidase subunit6B1 2.063 1.310 0.635
1002 IPI00946017.1 ubiqui tinspeci ficpeptidase 9,XͲl inked 3.737 2.796 0.748
1003 IPI00030968.4 chromosome 9openreadingframe 142 2.547 1.776 0.697
1004 IPI01013430.1 Selenophosphate synthetase 1+E9a variant 4.037 3.503 0.868
1005 IPI00107339.4 Isoform1ofGuanine nucleotideͲbindingproteinsubunit 2.983 3.335 1.118
1006 IPI00967384.2 trans locase ofinnermitochondria l membrane 8homolog 1.961 0.883 0.450
1007 IPI00644506.1 cDNAFLJ58756,highlys imi lartoNuclearpore complexprot 2.598 2.234 0.860
1008 IPI00328298.6 Isoform2ofStructura l maintenance ofchromosomes prote 3.847 2.616 0.680
1009 IPI00514902.1 Ubiquitinproteinl igase E3componentnͲrecognin4 2.907 2.482 0.854
1010 IPI00018331.3 SNAREͲassociatedproteinSnapin 3.185 2.799 0.879
1011 IPI00975492.1 pyruvate dehydrogenase complex,componentX 1.710 1.605 0.939
1012 IPI00880148.1 lectin,galactos ideͲbinding,soluble,1 2.954 1.842 0.624
1013 IPI00878100.2 GTPbindingprotein1 2.220 1.955 0.881
1014 IPI00221089.5 40Sribosomal proteinS13 2.269 2.011 0.886
1015 IPI00793395.1 cDNAFLJ37679fi s ,clone BRHIP2012922,highlys imi lartoCo 2.913 2.314 0.794
1016 IPI00291755.6 Isoform1ofNuclearpore membrane glycoprotein210 3.019 2.519 0.834
1017 IPI00974419.1 minichromosome maintenance complexcomponent4 1.937 2.194 1.132
1018 IPI00025285.3 VͲtype protonATPase subuni tG1 3.081 1.949 0.633
1019 IPI01011252.2 phosphatidyl inos i tol transferprotein,a lpha 2.155 3.220 1.494
1020 IPI00893025.1 mutShomolog6(E.col i ) 4.563 3.178 0.696
1021 IPI00916549.1 buddinguninhibi tedbybenzimidazoles 1homolog(yeast 1.859 1.930 1.038
1022 IPI00947340.1 FKBP8i soform1 2.999 1.948 0.650
1023 IPI00301609.8 Serine/threonineͲproteinkinase Nek9 2.673 2.473 0.925
1024 IPI00980165.2 Mesencephal i castrocyteͲderivedneurotrophicfactor 1.674 1.749 1.045
1025 IPI00894420.1 dihydropyrimidinaseͲl ike 5 3.363 2.218 0.660
1026 IPI00915422.1 coatomersubuni tdelta i soform2 2.156 1.560 0.724
1027 IPI00940506.2 cDNAFLJ58519,highlys imi lartoHermanskyͲPudlaksyndro 2.425 1.603 0.661
1028 IPI01011998.1 NADHdehydrogenase (ubiquinone)1a lpha subcomplex,8 2.381 1.972 0.828
1029 IPI00945124.1 Brainmy045protein 2.495 2.240 0.898
1030 IPI00300299.6 Signa l peptidase complexsubunit3 2.157 1.833 0.850
1031 IPI00940755.2 dens ityͲregulatedprotein 2.503 1.962 0.784  
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1032 IPI00909010.1 cDNAFLJ59356,highlys imi lartoNͲacetyl serotoninOͲmeth 2.876 2.446 0.851
1033 IPI00916807.1 MKI67(FHAdomain)interactingnucleolarphosphoprotein 2.286 2.563 1.121
1034 IPI00644418.3 endophi l inͲA2i soform3 2.160 1.980 0.917
1035 IPI00890793.1 ironͲsul furclus terscaffoldhomolog(E.col i ) 2.828 1.839 0.650
1036 IPI00477468.1 RNApolymeraseͲassociatedproteinCTR9homolog 3.616 3.113 0.861
1037 IPI00984662.1 28Sribosomal proteinS29,mitochondria l i soform3 2.792 2.050 0.734
1038 IPI00015809.1 Probable tRNAthreonylcarbamoyladenos ine biosynthes is 2.388 2.535 1.062
1039 IPI00219411.3 Isoform2ofRACͲgamma serine/threonineͲproteinkinase 2.772 1.837 0.663
1040 IPI00385642.1 WDrepeatdomain57(U5snRNPspeci fic),i soformCRA_b 2.357 2.232 0.947
1041 IPI00032851.1 Coatomersubunitzeta Ͳ1 1.899 1.618 0.852
1042 IPI00514469.1 NͲacetylneuraminicacidsynthase 2.521 2.133 0.846
1043 IPI00001539.8 3Ͳketoacyl ͲCoAthiolase,mitochondria l 2.258 1.561 0.691
1044 IPI00514444.1 Insul inͲdegradingenzyme 2.201 1.840 0.836
1045 IPI00017592.1 Isoform1ofLETM1andEFͲhanddomainͲcontainingprotei 2.241 1.815 0.810
1046 IPI00983309.1 STT3,subuni tofthe ol igosaccharyl transferase complex,ho 5.327 3.403 0.639
1047 IPI00145260.3 Putative trans ferase CAF17,mitochondria l 2.385 2.180 0.914
1048 IPI00374272.3 chromosome 5openreadingframe 51 2.387 2.624 1.100
1049 IPI00655644.4 innermembrane protein,mitochondria l 2.790 2.286 0.819
1050 IPI01011236.1 TUFT1 4.813 2.885 0.599
1051 IPI00643078.1 RAD23homologB 2.952 2.205 0.747
1052 IPI00025115.1 APͲ3complexsubunits igma Ͳ2 2.215 1.542 0.696
1053 IPI00220648.5 Phosphomevalonate kinase 4.776 5.338 1.118
1054 IPI00641843.3 cDNA,FLJ78963,highlys imi lartoUbiquitincarboxyl Ͳtermin 2.141 2.189 1.022
1055 IPI00830039.1 Isoform2ofSpl icingfactorU2AF65kDa subuni t 3.215 1.907 0.593
1056 IPI01012107.1 defenderaga instcel l death1 2.112 1.590 0.753
1057 IPI00305668.7 28Sribosomal proteinS6,mitochondria l 2.905 1.502 0.517
1058 IPI00643648.1 Phosphatidylserine decarboxylase 2.530 2.148 0.849
1059 IPI00028091.3 ActinͲrelatedprotein3 2.257 2.091 0.927
1060 IPI00427502.1 Isoform2ofGH3domainͲconta iningprotein 2.474 2.172 0.878
1061 IPI00029629.4 E3ubiqui tin/ISG15l igase TRIM25 2.987 2.558 0.856
1062 IPI01010716.1 cDNAFLJ90324fi s ,clone NT2RP2001817,highlys imi lartoNA 2.060 1.771 0.860
1063 IPI00396090.3 Isoform3ofDiphosphoinos i tol polyphosphate phosphoh 2.252 1.608 0.714
1064 IPI00902580.1 cDNAFLJ11050fi s ,clone PLACE1004564,highlys imi lartoCle 2.217 2.106 0.950
1065 IPI00022865.2 Cycl inͲA2 2.254 2.302 1.021
1066 IPI00401804.3 Isoform3ofVes icleͲassociatedmembrane protein7 2.024 1.739 0.859
1067 IPI00658162.2 cDNAFLJ36570fi s ,clone TRACH2011302,highlys imi lartoSE 2.301 2.826 1.228
1068 IPI00974168.1 heatͲrespons ive protein12 3.834 2.102 0.548
1069 IPI00893645.1 septin2 2.320 1.886 0.813
1070 IPI00005692.1 28Sribosomal proteinS12,mitochondria l 4.084 1.917 0.469
1071 IPI00902652.1 cDNAFLJ37148fi s ,clone BRACE2025333,highlys imi lartoHo 2.207 1.890 0.856
1072 IPI00977065.1 coldshockdomainconta iningE1,RNAͲbinding 2.890 1.940 0.671
1073 IPI00398822.1 Isoform2ofZincphosphodiesterase ELACprotein2 1.850 2.177 1.177
1074 IPI00219090.1 Isoform2ofProteinarginine NͲmethyltrans ferase 7 2.640 2.296 0.869
1075 IPI00219604.3 Isoform1ofDual speci fi ci tymitogenͲactivatedproteinkin 2.618 1.778 0.679
1076 IPI00411886.5 Nucleolarcomplexprotein2homolog 2.064 1.977 0.958
1077 IPI00973882.1 ATPase,H+transporting,lysosomal 50/57kDa,V1subuni tH 2.737 2.126 0.777
1078 IPI00025329.1 60Sribosomal proteinL19 3.648 2.929 0.803  
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1079 IPI00041325.1 H/ACAribonucleoproteincomplexsubunit2 2.331 1.286 0.552
1080 IPI01013434.1 superoxide dismutase 2,mitochondria l 1.510 1.248 0.826
1081 IPI00176527.1 ATPsynthase subuniteps i lonͲl ike protein,mitochondria l 2.254 1.263 0.560
1082 IPI00797314.1 COP9consti tutive photomorphogenichomologsubunit3(A 2.457 1.857 0.756
1083 IPI00943212.2 ATPase,H+transporting,lysosomal 38kDa,V0subuni td1 1.992 2.495 1.252
1084 IPI00556437.1 Dynamin2i soform4variant(Fragment) 3.066 2.248 0.733
1085 IPI00026219.4 Cleavage andpolyadenylationspeci fici tyfactorsubuni t1 3.868 2.734 0.707
1086 IPI00219718.3 retinol Ͳbindingprotein1i soforma 4.374 2.082 0.476
1087 IPI01012894.1 cel l divi s ioncycle andapoptos is regulator1 5.202 7.323 1.408
1088 IPI00847986.1 Isoform2of40Sribosomal proteinS24 2.579 2.005 0.777
1089 IPI00514217.6 SuccinateͲCoAl igase,ADPͲforming,beta subuni t 2.566 1.815 0.707
1090 IPI00926706.1 actinrelatedprotein2/3complex,subunit1A,41kDa 2.145 1.594 0.743
1091 IPI00549942.3 cDNAFLJ30306fi s ,clone BRACE2003319 3.656 1.979 0.541
1092 IPI00979224.1 fami lywithsequence s imi lari ty203,memberA 5.407 2.194 0.406
1093 IPI01009730.1 Putative uncharacterizedproteinDKFZp547A1913 3.538 3.570 1.009
1094 IPI00103263.3 Wings apartͲl i ke homolog 3.612 2.862 0.792
1095 IPI00742682.2 NucleoproteinTPR 2.504 2.441 0.975
1096 IPI00003815.3 RhoGDPͲdissociationinhibi tor1 2.717 2.175 0.800
1097 IPI01010344.1 PRP8preͲmRNAprocess ingfactor8homolog(S.cerevis iae) 5.064 2.906 0.574
1098 IPI00879774.1 CysteineͲrichwithEGFͲl i ke domains 2 2.940 2.228 0.758
1099 IPI00005162.3 ActinͲrelatedprotein2/3complexsubuni t3 3.401 2.155 0.634
1100 IPI00984053.1 serine hydroxymethyltransferase 1(soluble) 1.908 1.579 0.828
1101 IPI00658053.1 catheps inD 3.031 1.859 0.613
1102 IPI00873515.2 Isoform2ofProbable bifunctiona l methylenetetrahydrofo 2.020 2.302 1.139
1103 IPI00925248.1 Uncharacterizedprotein 2.724 2.571 0.944
1104 IPI00376117.1 Isoform2ofMitochondria l importreceptorsubunitTOM40 2.882 1.931 0.670
1105 IPI00916763.1 heatshock10kDa protein1(chaperonin10) 1.971 1.339 0.679
1106 IPI00423157.4 Isoform11ofSerine/threonineͲproteinkinase Chk2 2.785 1.322 0.475
1107 IPI00216237.5 60Sribosomal proteinL36 2.494 1.878 0.753
1108 IPI00784650.3 uncharacteri zedLOC100131551 5.900 3.021 0.512
1109 IPI00917636.1 acyl ͲCoAsynthetase longͲchainfami lymember3 2.455 2.460 1.002
1110 IPI00061282.2 Proteinkinase,AMPͲactivated,a lpha 1catalyticsubuni t,i s 3.425 2.043 0.596
1111 IPI00977736.1 ca lcycl inͲbindingproteini soform2 2.736 2.001 0.732
1112 IPI00220919.1 Isoform3ofDNA(cytos ineͲ5)Ͳmethyltransferase 1 2.816 2.448 0.869
1113 IPI00014603.1 Ras ͲrelatedproteinRabͲ9B 2.963 1.662 0.561
1114 IPI00418290.1 39Sribosomal proteinL14,mitochondria l 1.284
1115 IPI00903276.1 cDNAFLJ36073fi s ,clone TESTI2019697,highlys imi lartoTH 2.725 1.973 0.724
1116 IPI00902466.1 cDNAFLJ11861fi s ,clone HEMBA1006885,highlys imi lartoP 2.473 1.926 0.779
1117 IPI00419898.1 uncharacteri zedLOC440157 2.161 1.533 0.709
1118 IPI00789985.1 Isoform2ofRanguanine nucleotide release factor 1.916 1.429 0.746
1119 IPI00975997.1 cancer/testi s antigenfami ly45memberA5Ͳl i ke i soform2, 2.885 2.298 0.796
1120 IPI00790648.2 transferrin 1.675 2.094 1.250
1121 IPI00978109.1 DIS3mitoticcontrol homolog(S.cerevis iae) 1.909 1.668 0.874
1122 IPI00017283.2 Isoleucyl ͲtRNAsynthetase,mitochondria l 1.646 1.887 1.147
1123 IPI00939558.2 cDNAFLJ38696fi s ,clone KIDNE2001931,highlys imi lartoHE 2.542 1.978 0.778
1124 IPI00294742.7 Isoform1ofLa Ͳrelatedprotein7 2.653 2.077 0.783
1125 IPI00973715.2 dihydropyrimidinase 5.058 2.835 0.561  
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1126 IPI00909332.2 repl icationterminationfactor2domaincontaining1 2.124 2.600 1.224
1127 IPI00301323.1 ATPͲdependentRNAhel icase DDX18 2.578 1.525 0.591
1128 IPI00788612.2 LIMandsenescentcel l antigenͲl ikeͲconta iningdomainpr 2.453 2.440 0.995
1129 IPI00247439.3 Isoform2ofSTE20Ͳl i ke serine/threonineͲproteinkinase 3.760 2.860 0.761
1130 IPI00219197.3 IsoformI ofUbiqui tinͲproteinl igase E3A 2.008 2.234 1.112
1131 IPI00893703.1 ribosomal proteinS7 2.254 2.147 0.953
1132 IPI00872684.2 cDNAFLJ54141,highlys imi lartoEzrin 2.026 1.668 0.823
1133 IPI00514858.1 Adenylyl cyclaseͲassociatedprotein 2.345 2.532 1.080
1134 IPI00909477.1 cDNAFLJ54108,highlys imi lartoHomosapiens smoothmu 1.346 2.272 1.687
1135 IPI01009526.1 cDNAFLJ61034,highlys imi lartoMitochondria l dicarboxyla 2.514 1.811 0.720
1136 IPI00220716.2 Isoform2ofPutative RNAͲbindingprotein15 2.848 2.472 0.868
1137 IPI00914006.2 cDNAFLJ56235,highlys imi lartoDynactinsubunit4 2.767 2.768 1.000
1138 IPI00219833.2 Mitochondria l importinnermembrane trans locase subun 2.900 2.237 0.771
1139 IPI00796237.1 DUSP3protein 2.766 1.800 0.651
1140 IPI00443909.1 Isoform1ofProteincanopyhomolog2 2.782 2.130 0.766
1141 IPI00910004.1 cDNAFLJ59139,highlys imi lartoVes icleͲassociatedmemb 3.625 2.229 0.615
1142 IPI01012992.1 Coi ledͲcoi l domainͲconta iningprotein12 2.621 2.533 0.966
1143 IPI00020793.3 Isoform2of60Sribosome subunitbiogenes is proteinNIP 1.861 1.630 0.876
1144 IPI00922847.1 cDNAFLJ50115,moderatelys imi lartoMembraneͲassociate 1.854 1.264 0.682
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Table A7. Positive proteins identified in HEK293T cell lysates treated with ProSeAM. 
Proteomic data sets from HEK293T lysate treated with ProSeAM or the lysates treated 
with ProSeAM and the pan-methyltransferase inhibitor, SAH, were cross-referenced to 
identify targets uniquely present in the non-inhibitor-treated sample. The listed proteins 
are present in HEK293T cell lysates treated with ProSeAM but not in the HEK293T cell 
lysates treated with ProSeAM and SAH, and arranged according to their accession 
number. 
Accession Description Score MW [kDa] 
IPI00002824.7 Cysteine and glycine-rich protein 2 1.79 20.9 
IPI00003783.1 Dual specificity mitogen-activated protein kinase 
kinase 2 
3.48 44.4 
IPI00003815.3 Rho GDP-dissociation inhibitor 1 5.78 23.2 
IPI00003949.1 Ubiquitin-conjugating enzyme E2 N 6.87 17.1 
IPI00005511.1 PHD finger-like domain-containing protein 5A 1.99 12.4 
IPI00005719.1 Isoform 1 of Ras-related protein Rab-1A 2.21 22.7 
IPI00007611.1 ATP synthase subunit O, mitochondrial 4.19 23.3 
IPI00009342.1 Ras GTPase-activating-like protein IQGAP1 2.80 189.1 
IPI00010105.1 Eukaryotic translation initiation factor 6 3.55 26.6 
IPI00010153.5 60S ribosomal protein L23 2.16 14.9 
IPI00011454.1 Isoform 2 of Neutral alpha-glucosidase AB 20.82 109.4 
IPI00012340.1 Serine/arginine-rich splicing factor 9 3.68 25.5 
IPI00012493.1 40S ribosomal protein S20 7.83 13.4 
IPI00012866.2 RAC-alpha serine/threonine-protein kinase 7.39 55.7 
IPI00013184.1 N-alpha-acetyltransferase 10, NatA catalytic subunit 1.92 26.4 
IPI00013789.5 SET and MYND domain-containing protein 5 11.11 47.3 
IPI00013885.1 Caspase-14 3.49 27.7 
IPI00013933.2 Isoform DPI of Desmoplakin 1.87 331.6 
IPI00013946.1 Synaptogyrin-2 3.52 24.8 
IPI00014150.1 Isoform 2 of Pre-mRNA-splicing regulator WTAP 4.36 17.8 
IPI00014424.1 Elongation factor 1-alpha 2 259.79 50.4 
IPI00014808.1 Platelet-activating factor acetylhydrolase IB subunit 
gamma 
4.39 25.7 
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IPI00015351.2 Isoform 1 of PITH domain-containing protein 1 6.26 24.2 
IPI00015833.1 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial 
6.04 26.1 
IPI00016342.1 Ras-related protein Rab-7a 7.75 23.5 
IPI00016786.1 Isoform 2 of Cell division control protein 42 homolog 1.61 21.2 
IPI00018534.4 Histone H2B type 1-L 7.86 13.9 
IPI00019385.4 Translocon-associated protein subunit delta 2.23 19.0 
IPI00020194.1 Isoform Short of TATA-binding protein-associated 
factor 2N 
16.16 61.5 
IPI00021290.5 ATP-citrate synthase 57.88 120.8 
IPI00021828.1 Cystatin-B 2.15 11.1 
IPI00022149.1 Isoform 2 of Phosphatidylinositol-4-phosphate 5-
kinase type-1 alpha 
7.24 56.0 
IPI00022334.1 Ornithine aminotransferase, mitochondrial 2.08 48.5 
IPI00022430.1 Glyceraldehyde-3-phosphate dehydrogenase, testis-
specific 
23.12 44.5 
IPI00022597.1 NEDD8-conjugating enzyme Ubc12 5.33 20.9 
IPI00022648.2 Eukaryotic translation initiation factor 5 3.50 49.2 
IPI00024266.3 Microsomal glutathione S-transferase 3 2.17 16.5 
IPI00025039.1 rRNA 2'-O-methyltransferase fibrillarin 6.36 33.8 
IPI00025512.2 Heat shock protein beta-1 1.92 22.8 
IPI00026215.1 Flap endonuclease 1 4.57 42.6 
IPI00027251.1 Serine/threonine-protein kinase 38 26.26 54.2 
IPI00027497.5 Glucose-6-phosphate isomerase 18.84 63.1 
IPI00027547.2 Dermcidin 9.51 11.3 
IPI00028481.1 Ras-related protein Rab-8A 4.45 23.7 
IPI00029643.3 Isoform 2 of Mitogen-activated protein kinase kinase 
kinase MLT 
6.09 51.5 
IPI00030182.1 Guanidinoacetate N-methyltransferase 13.20 26.3 
IPI00031169.1 Ras-related protein Rab-2A 4.50 23.5 
IPI00031526.3 Uncharacterized protein C19orf43 1.80 18.4 
IPI00031820.3 Phenylalanyl-tRNA synthetase alpha chain 4.09 57.5 
IPI00032158.3 Isoform 2 of N-alpha-acetyltransferase 15, NatA 
auxiliary subunit 
9.44 101.1 
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IPI00032827.1 Pre-mRNA branch site protein p14 1.84 14.6 
IPI00032995.1 LanC-like protein 2 7.01 50.8 
IPI00045498.4 Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
D-like 
4.28 27.2 
IPI00081836.3 Histone H2A type 1-H 3.46 13.9 
IPI00101357.2 Protein RRNAD1 7.05 52.9 
IPI00102128.1 Isoform 1 of Protein arginine N-methyltransferase 6 42.62 41.9 
IPI00103467.5 Aldehyde dehydrogenase X, mitochondrial 6.24 57.2 
IPI00104050.3 Thyroid hormone receptor-associated protein 3 1.75 108.6 
IPI00140420.4 Staphylococcal nuclease domain-containing protein 1 15.68 101.9 
IPI00166153.3 Cap-specific mRNA (nucleoside-2'-O-)-
methyltransferase 1 
30.38 95.3 
IPI00180128.4 Isoform 2 of Basic leucine zipper and W2 domain-
containing protein 1 
2.00 40.5 
IPI00184533.1 Ubiquitin carboxyl-terminal hydrolase 11 1.64 109.7 
IPI00185146.5 Importin-9 2.32 115.9 
IPI00215884.4 Isoform ASF-1 of Serine/arginine-rich splicing factor 
1 
6.07 27.7 
IPI00216393.1 Isoform Non-brain of Clathrin light chain A 4.62 23.6 
IPI00216493.1 Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
H3 
16.42 31.5 
IPI00216770.1 Isoform 2 of 26S protease regulatory subunit 6B 1.74 43.5 
IPI00217465.5 Histone H1.2 6.24 21.4 
IPI00217661.4 ribonucleoprotein PTB-binding 1 1.92 79.5 
IPI00217816.3 Isoform AGX1 of UDP-N-acetylhexosamine 
pyrophosphorylase 
1.82 57.0 
IPI00218070.1 Isoform GRB3-3 of Growth factor receptor-bound 
protein 2 
3.92 20.5 
IPI00218435.1 Isoform 2 of U4/U6 small nuclear ribonucleoprotein 
Prp4 
2.14 58.3 
IPI00218922.5 Translocation protein SEC63 homolog 8.51 87.9 
IPI00219025.3 Glutaredoxin-1 6.62 11.8 
IPI00219160.3 60S ribosomal protein L34 4.31 13.3 
IPI00219617.5 Isoform 1 of Ribose-phosphate pyrophosphokinase 2 6.81 34.7 
IPI00219669.5 Carbonic anhydrase-related protein 3.26 33.0 
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IPI00219762.4 Cellular apoptosis susceptibility protein variant 2 24.65 103.8 
IPI00220336.1 Isoform 2 of Exosome component 10 4.49 98.0 
IPI00220373.5 Insulin-degrading enzyme 3.92 117.9 
IPI00220919.1 Isoform 3 of DNA (cytosine-5)-methyltransferase 1 38.28 144.4 
IPI00221091.9 40S ribosomal protein S15a 9.51 14.8 
IPI00221093.7 40S ribosomal protein S17 1.68 15.5 
IPI00247583.5 60S ribosomal protein L21 6.26 18.6 
IPI00249080.2 Isoform 2 of N-acetylserotonin O-methyltransferase-
like protein 
94.26 67.2 
IPI00289800.7 Isoform Short of Glucose-6-phosphate 1-
dehydrogenase 
7.99 59.2 
IPI00290341.1 Isoform 2 of Protein FAM86A 1.63 33.0 
IPI00292135.1 Lamin-B receptor 3.59 70.7 
IPI00292499.4 Heat shock 70 kDa protein 14 3.53 54.8 
IPI00294696.4 Cyclin B1 5.73 44.1 
IPI00296157.6 Isoform 1 of All-trans-retinol 13,14-reductase 22.53 66.8 
IPI00296370.2 Uncharacterized protein 22.14 38.8 
IPI00297265.1 Protein arginine N-methyltransferase 2 4.44 49.0 
IPI00301434.4 BolA-like protein 2 5.47 16.9 
IPI00302605.3 Zinc transporter 7 2.20 41.6 
IPI00302850.4 Small nuclear ribonucleoprotein Sm D1 3.80 13.3 
IPI00303397.5 Isoform 6 of C-Jun-amino-terminal kinase-interacting 
protein 4 
1.81 95.8 
IPI00304932.2 Ribosomal RNA-processing protein 8 20.95 50.7 
IPI00306369.3 tRNA (cytosine(34)-C(5))-methyltransferase 99.19 86.4 
IPI00333410.1 Isoform 1 of Ubiquitin-conjugating enzyme E2 Q1 3.61 46.1 
IPI00334907.3 Isoform 1 of Phosphatidylinositol transfer protein beta 
isoform 
1.73 31.5 
IPI00335101.1 Ribosomal protein S6 kinase alpha-5 13.58 89.8 
IPI00336094.5 Isoform 2 of 3-hydroxyacyl-CoA dehydrogenase type-
2 
5.36 26.0 
IPI00375513.3 Isoform Soluble of Catechol O-methyltransferase 2.20 24.4 
IPI00376228.2 Probable methyltransferase BCDIN3D 4.23 33.2 
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IPI00376503.2 pyrroline-5-carboxylate reductase 1, mitochondrial 
isoform 2 
4.15 33.3 
IPI00382458.1 Isoform 2 of Cullin-3 1.71 86.2 
IPI00383680.3 dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 isoform 2 precursor 
2.57 67.7 
IPI00384016.1 Full-length cDNA 5-PRIME end of clone 
CS0DJ009YL13 of T cells (Jurkat cell line) of Homo 
sapiens (Fragment) 
6.63 29.6 
IPI00386975.3 Isoform 1B of Desmocollin-1 2.93 93.8 
IPI00397526.3 Isoform 1 of Myosin-10 12.37 228.9 
IPI00397801.4 Filaggrin-2 9.75 247.9 
IPI00410615.2 Isoform 3 of Low molecular weight phosphotyrosine 
protein phosphatase 
5.50 14.3 
IPI00411680.11 Isoform 1 of Protein-L-isoaspartate(D-aspartate) O-
methyltransferase 
42.01 24.6 
IPI00412714.3 Isoform 4 of Plasminogen activator inhibitor 1 RNA-
binding protein 
30.69 42.4 
IPI00412880.2 Isoform 1 of Histone-arginine methyltransferase 
CARM1 
231.14 63.4 
IPI00418313.3 interleukin enhancer-binding factor 3 isoform d 48.36 95.7 
IPI00419258.4 High mobility group protein B1 10.97 24.9 
IPI00427330.3 Ribosome maturation protein SBDS 5.45 28.7 
IPI00429689.3 Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isoform 
7.00 35.6 
IPI00432865.1 Putative 60S ribosomal protein L13a-like MGC87657 5.20 12.1 
IPI00443485.2 Isoform 2 of CDK5 regulatory subunit-associated 
protein 1-like 1 
8.88 54.6 
IPI00449112.3 OGFR protein 6.34 54.1 
IPI00455457.4 Histone H3 18.21 15.4 
IPI00470629.4 Isoform 1 of Calmodulin-lysine N-methyltransferase 1.81 36.1 
IPI00472106.4 Isoform D of Endothelin-converting enzyme 2 2.32 28.3 
IPI00472176.1 Isoform 2 of tRNA (uracil-5-)-methyltransferase 
homolog A (Fragment) 
1.85 61.9 
IPI00477179.1 Isoform 2 of Nucleolar RNA helicase 2 6.43 79.6 
IPI00477803.4 Putative uncharacterized protein DKFZp781L0540 
(Fragment) 
3.63 90.0 
IPI00479209.2 cDNA FLJ54590, highly similar to KH domain-
containing, RNA-binding, signaltransduction-
associated protein 1 
3.71 46.4 
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IPI00479595.3 Isoform 3 of Nuclear-interacting partner of ALK 3.92 47.7 
IPI00514436.1 General transcription factor IIIC, polypeptide 5, 
63kDa, isoform CRA_c 
10.78 52.3 
IPI00549467.3 Omega-amidase NIT2 2.11 30.6 
IPI00553185.2 T-complex protein 1 subunit gamma 77.36 60.5 
IPI00554737.3 Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
20.22 65.3 
IPI00555749.1 Proteasome 26S ATPase subunit 5 variant (Fragment) 8.96 38.7 
IPI00639819.1 TAR DNA binding protein 4.86 33.4 
IPI00640462.1 Guanine nucleotide binding protein (G protein), beta 
polypeptide 1 
1.83 12.3 
IPI00641266.4 calpain-2 catalytic subunit isoform 2 1.84 71.4 
IPI00642549.2 cDNA FLJ56531, highly similar to UV excision repair 
protein RAD23 homolog B 
7.63 42.3 
IPI00643634.2 Isoform 4 of Protein arginine N-methyltransferase 7 3.55 63.8 
IPI00645053.1 Isoform 3 of E3 ubiquitin-protein ligase NEDD4-like 1.81 100.7 
IPI00645836.1 Protein 6.09 25.5 
IPI00651621.1 Isoform B of Histone acetyltransferase type B 
catalytic subunit 
9.66 39.8 
IPI00658162.2 cDNA FLJ36570 fis, clone TRACH2011302, highly 
similar to SELENIDE,WATER DIKINASE 2 
5.55 41.3 
IPI00719345.1 Isoform 3 of Serine/threonine-protein phosphatase 6 
regulatory subunit 3 
1.88 88.9 
IPI00741576.1 Isoform 2 of tRNA guanosine-2'-O-methyltransferase 
TRM11 homolog 
17.84 52.8 
IPI00745893.2 small ubiquitin-related modifier 2 isoform b precursor 4.78 8.1 
IPI00746062.1 Isoform 2 of Serine/threonine-protein phosphatase 4 
regulatory subunit 2 
1.84 40.2 
IPI00746438.2 Isoform 2 of 60S ribosomal protein L11 3.75 20.1 
IPI00759575.1 Isoform Cytoplasmic of Glutathione reductase, 
mitochondrial 
6.86 51.7 
IPI00759596.1 Isoform 4 of Heterogeneous nuclear 
ribonucleoproteins C1/C2 
10.49 27.8 
IPI00759663.1 Isoform Cytoplasmic+peroxisomal of Peroxiredoxin-
5, mitochondrial 
4.31 17.0 
IPI00759723.1 Isoform Monomeric of Arginyl-tRNA synthetase, 
cytoplasmic 
1.76 67.1 
IPI00760722.1 serine/threonine-protein kinase MST4 isoform 2 1.73 37.7 
IPI00783781.2 Nuclear pore complex protein Nup205 1.62 227.8 
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IPI00787559.1 thymidylate kinase isoform 2 1.62 21.1 
IPI00789037.1 COUP transcription factor 2 isoform b 3.63 31.5 
IPI00789428.1 Isoform 2 of Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial 
2.13 57.5 
IPI00792135.2 ATP5H protein (Fragment) 1.75 11.5 
IPI00792207.3 aldehyde dehydrogenase, mitochondrial Isoform 2 
precursor 
2.04 51.0 
IPI00792482.1 Isoform 1 of 5'-AMP-activated protein kinase catalytic 
subunit alpha-1 
2.05 64.0 
IPI00793102.1 Uncharacterized protein 6.04 10.6 
IPI00794545.1 deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial isoform 3 
2.41 15.4 
IPI00794951.1 peptide methionine sulfoxide reductase isoform b 2.72 21.7 
IPI00798211.1 Uncharacterized protein 2.07 23.6 
IPI00798375.2 cDNA FLJ59357, highly similar to Probable ATP-
dependent RNA helicase DDX5 
20.21 61.5 
IPI00807524.1 BZW2 protein 3.79 21.5 
IPI00807545.1 Isoform 3 of Heterogeneous nuclear ribonucleoprotein 
K 
196.62 48.5 
IPI00829824.1 PRKCSH protein (Fragment) 2.52 20.3 
IPI00843984.2 Isoform 2 of Zinc finger protein 503 5.26 59.3 
IPI00848298.1 Isoform 2 of Apolipoprotein A-I-binding protein 1.74 20.4 
IPI00852631.1 Uncharacterized protein 1.64 21.6 
IPI00853093.3 Isoform 1 of Methyltransferase-like protein 2B 1.68 43.4 
IPI00853290.2 Uncharacterized protein 4.30 96.4 
IPI00854834.2 echinoderm microtubule-associated protein-like 4 
isoform b 
4.37 102.4 
IPI00871418.1 Uncharacterized protein 1.81 53.1 
IPI00872684.2 cDNA FLJ54141, highly similar to Ezrin 3.78 65.5 
IPI00872909.1 Isoform 2 of Putative ribosomal RNA 
methyltransferase NOP2 
26.68 88.9 
IPI00877935.2 Uncharacterized protein 1.95 21.7 
IPI00878484.1 Protein 1.82 32.2 
IPI00878876.1 cDNA FLJ51872, highly similar to Small nuclear 
ribonucleoprotein Sm D3 
4.94 13.3 
IPI00892653.2 cDNA FLJ61481, highly similar to PAS domain-
containing serine/threonine-protein kinase 
1.74 119.8 
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IPI00893179.1 X-ray repair complementing defective repair in 
Chinese hamster cells 6 
4.23 64.0 
IPI00900327.2 cDNA FLJ58339, highly similar to Poly(rC)-binding 
protein 2 
7.47 33.9 
IPI00903024.1 Uncharacterized protein 1.72 15.6 
IPI00903259.2 cDNA FLJ54005, highly similar to Transcription 
elongation factor SPT5 
1.95 96.9 
IPI00908375.1 cDNA FLJ52821, highly similar to Protein transport 
protein Sec23A 
3.49 45.0 
IPI00908513.1 cDNA FLJ60039, highly similar to Proteasome 
subunit beta type 7 
3.82 15.3 
IPI00908582.1 cDNA FLJ50164, highly similar to Protein flightless-
1 homolog 
6.71 135.1 
IPI00908824.1 Serine hydroxymethyltransferase 6.77 41.6 
IPI00909251.1 cDNA FLJ51165, highly similar to DNA damage-
binding protein 1 
11.80 91.9 
IPI00909525.1 cDNA FLJ51260, highly similar to DNA polymerase 
subunit delta 2 
4.76 47.1 
IPI00909694.2 alpha-aminoadipic semialdehyde dehydrogenase 
isoform 3 
10.18 54.0 
IPI00910140.2 tRNA wybutosine-synthesizing protein 3 homolog 
isoform 2 
6.35 26.1 
IPI00910614.1 heterogeneous nuclear ribonucleoprotein R isoform 4 6.21 59.6 
IPI00910719.1 cDNA FLJ55705, highly similar to Threonyl-tRNA 
synthetase, cytoplasmic 
6.45 70.3 
IPI00910830.1 cDNA FLJ57715, highly similar to Voltage-dependent 
anion-selective channel protein 1 
4.33 16.7 
IPI00914573.1 cDNA FLJ50701 2.00 48.4 
IPI00915960.1 Uncharacterized protein 1.78 252.0 
IPI00916159.1 42 kDa protein 2.62 41.8 
IPI00916572.1 Protein 2.06 12.8 
IPI00916599.1 27 kDa protein 1.64 26.7 
IPI00917605.1 Uncharacterized protein 12.40 11.3 
IPI00921584.1 Uncharacterized protein 1.78 34.4 
IPI00922165.1 Isoform 5 of Adenylate kinase 2, mitochondrial 6.27 24.6 
IPI00922175.1 cDNA FLJ51678, highly similar to Ras-related 
protein Rab-18 
1.89 22.4 
IPI00922562.1 cDNA FLJ55085, highly similar to Glucosamine-6-
phosphate isomerase 
2.03 24.0 
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IPI00924801.1 9 kDa protein 1.81 9.3 
IPI00924816.1 Myotrophin 8.84 12.9 
IPI00924884.1 Protein 4.23 30.3 
IPI00924895.1 SNRPG protein 4.47 7.1 
IPI00925237.1 Uncharacterized protein 6.05 81.5 
IPI00925511.1 cDNA FLJ54314, highly similar to Glutaminyl-tRNA 
synthetase 
3.54 86.5 
IPI00925539.1 57 kDa protein 1.81 56.7 
IPI00926241.1 Isoform 2 of TBC1 domain family member 4 1.93 139.5 
IPI00927374.1 cDNA FLJ52346, highly similar to Makorin-2 3.96 42.0 
IPI00927648.1 cDNA FLJ57901, highly similar to Methyltransferase-
like protein 6 
13.09 28.2 
IPI00927809.1 Uncharacterized protein 3.54 130.5 
IPI00929464.1 signal recognition particle 54 kDa protein isoform 2 2.40 50.3 
IPI00937239.2 40S ribosomal protein S21 3.84 8.8 
IPI00939560.1 thioredoxin domain-containing protein 5 isoform 3 34.40 36.2 
IPI00939707.1 Protein KIAA0664 1.70 146.6 
IPI00940292.1 Isoform C of AP-1 complex subunit beta-1 7.88 103.5 
IPI00940673.1 cDNA FLJ53217, highly similar to Transketolase 8.39 49.9 
IPI00942236.1 cDNA FLJ59313, highly similar to Homo sapiens 
target of EGR1, member 1 (nuclear) (TOE1), mRNA 
1.99 47.9 
IPI00943071.2 cDNA FLJ57184, highly similar to Bromodomain and 
WD repeat domain-containing protein 2 
1.80 84.6 
IPI00943563.1 Isoform 2 of Filamin-B 9.36 275.5 
IPI00943894.1 glycogen phosphorylase, liver form isoform 2 17.20 93.1 
IPI00946257.1 Isoform 4 of Ubiquitin-associated protein 2-like 17.76 103.1 
IPI00946476.1 Uncharacterized protein 1.95 24.2 
IPI00947266.1 Uncharacterized protein 3.55 51.0 
IPI00952872.2 Uncharacterized protein 3.43 14.7 
IPI00955854.1 POU domain, class 4, transcription factor 3, isoform 
CRA_a 
2.29 84.1 
IPI00963822.1 Uncharacterized protein 10.62 43.1 
IPI00964409.3 Uncharacterized protein 21.20 91.9 
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IPI00964648.1 30 kDa protein 12.47 29.7 
IPI00964855.1 Uncharacterized protein 27.59 56.8 
IPI00964903.2 26 kDa protein 3.99 26.4 
IPI00965314.1 Uncharacterized protein 3.84 47.0 
IPI00965782.1 Uncharacterized protein 1.61 19.0 
IPI00967721.1 Uncharacterized protein 20.01 88.3 
IPI00968146.1 Uncharacterized protein 6.28 22.6 
IPI00969375.1 Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(Trifunctional protein), beta subunit, isoform CRA_b 
3.61 40.4 
IPI00974544.1 Isoform SV of 14-3-3 protein epsilon 33.78 26.5 
IPI00975868.1 Annexin family protein 2.17 58.4 
IPI00975903.1 cDNA FLJ55679, highly similar to Mus musculus 
cytoplasmic FMR1 interacting protein 2 (Cyfip2), 
mRNA 
7.06 122.4 
IPI00976162.1 Conserved hypothetical protein 2.08 9.9 
IPI00977736.1 calcyclin-binding protein isoform 2 6.86 21.2 
IPI00977844.1 17 kDa protein 3.67 16.7 
IPI00978109.1 Uncharacterized protein 6.95 63.6 
IPI00979915.1 Uncharacterized protein 9.06 15.3 
IPI00980175.1 proteasome subunit beta type-2 isoform 3 3.56 9.6 
IPI00980658.1 cDNA FLJ58444, highly similar to Vacuolar ATP 
synthase subunit H 
2.59 52.7 
IPI00980681.1 Uncharacterized protein 2.99 18.2 
IPI00981395.1 cDNA FLJ53442, highly similar to Poly (ADP-ribose) 
polymerase 1 
35.56 111.1 
IPI00982610.1 Protein 2.01 95.7 
IPI00983324.1 protein FAM115A-like 1.72 53.6 
IPI00984067.1 Uncharacterized protein 2.02 7.3 
IPI00984387.1 cDNA FLJ53166, highly similar to 
Dihydropyrimidinase-related protein 2 
2.34 58.1 
IPI00985068.1 Uncharacterized protein 5.40 21.7 
IPI01009039.1 Isoform 5 of Cellular tumor antigen p53 5.83 33.5 
IPI01009061.1 Truncated tumor suppressor protein P16 2.40 14.9 
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IPI01009435.1 THO complex subunit 2 1.78 169.5 
IPI01010035.1 cDNA FLJ52928, highly similar to COP9 
signalosome complex subunit 2 
6.73 44.2 
IPI01010050.1 cDNA, FLJ78818, highly similar to Voltage-
dependent anion-selective channel protein 2 
10.97 27.5 
IPI01010316.1 cDNA, FLJ96168, Homo sapiens formin binding 
protein 3 (FNBP3), mRNA 
1.94 95.0 
IPI01010979.1 45 kDa protein 4.22 44.9 
IPI01011132.1 Isoform 1 of DNA topoisomerase 2-alpha 3.88 174.3 
IPI01011356.1 cDNA FLJ51818, highly similar to 
Phosphoglucomutase-1 
6.36 58.7 
IPI01011751.1 EIF-2B-delta-like protein 2.06 57.5 
IPI01012026.1 215 kDa protein 6.15 215.2 
IPI01012107.1 10 kDa protein 4.38 9.5 
IPI01012250.1 13 kDa protein 5.01 13.3 
IPI01012853.1 cDNA FLJ57898, highly similar to Adaptor-
relatedprotein complex 1 mu-1 subunit 
2.24 40.2 
IPI01012872.1 58 kDa protein 119.11 58.3 
IPI01013010.1 22 kDa protein 2.36 22.3 
IPI01013230.1 cDNA FLJ51319, highly similar to tRNA (adenine-
N(1)-)-methyltransferase non-catalytic subunit TRM6 
2.70 36.4 
IPI01013273.1 cDNA, FLJ79129, highly similar to T-complex 
protein 1 subunit zeta 
40.78 54.8 
IPI01013392.1 Uncharacterized protein 1.78 47.1 
IPI01013927.1 51 kDa protein 1.86 50.9 
IPI01013941.1 cDNA FLJ58196, highly similar to Zinc finger CCCH 
domain-containing protein 11A 
3.48 82.7 
IPI01014130.1 cDNA FLJ52538, highly similar to Dual specificity 
mitogen-activated proteinkinase kinase 4 
6.51 42.5 
IPI01014209.1 cDNA FLJ51843, highly similar to 14-3-3 protein 
gamma 
13.95 25.6 
IPI01014223.1 cDNA FLJ50851, highly similar to Tyrosine-protein 
phosphatase non-receptor type1 
6.01 41.2 
IPI01014382.1 cDNA FLJ55493, highly similar to Glutamate 
dehydrogenase 1, mitochondrial 
2.05 56.6 
IPI01014633.1 cDNA FLJ16322 fis, clone SPLEN2037678, highly 
similar to Protein D11Lgp1 homolog 
3.35 50.9 
IPI01014727.1 cDNA FLJ51983, highly similar to Phosphoglycerate 
mutase 1 
9.63 27.1 
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IPI01015047.1 NUP153 variant protein (Fragment) 2.03 151.4 
IPI01015228.1 86 kDa protein 2.16 85.6 
IPI01015329.1 cDNA FLJ52203, highly similar to 3'(2'),5'-
bisphosphate nucleotidase 1 
1.74 27.5 
IPI01015364.1 eukaryotic translation initiation factor 4 gamma 1 
isoform 4 
14.89 154.8 
IPI01015380.1 cDNA FLJ33094 fis, clone TRACH2000703, highly 
similar to Mitochondrial-processing peptidase subunit 
beta, mitochondrial 
5.15 37.9 
IPI01015447.1 47 kDa protein 3.25 46.7 
IPI01015928.1 106 kDa protein 5.57 106.1 
IPI01015974.1 12 kDa protein 1.93 12.1 
IPI01018104.1 cDNA FLJ52561, highly similar to Four and a half 
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Figure A1. MALDI-MS spectra demonstrating a lack of modification of H3 peptide substrates by cofactor 
analogues in the absence of methyltransferase.  Spectra in the left hand column are derived from reactions 
containing sulfur-based analogues (red labels); spectra in the right hand column are from the reactions 
containing selenium-based analogues (green labels). 
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Figure A2. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with native G9a.  Spectra in the left hand column are derived from the reactions containing sulfur-based 
analogues (red labels); spectra in the right hand column are from the reactions containing selenium-based 
analogues (green labels). 
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Figure A3. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with the G9a Y1154A mutant.  Spectra in the left hand column are derived from the reactions containing 
sulfur-based analogues (red labels), while spectra in the right hand column are from the reactions 
containing selenium-based analogues (green labels). 
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Figure A4. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with native GLP1.  Spectra in the left hand column are derived from the reactions containing sulfur-based 
analogues (red labels); spectra in the right hand column are from the reactions containing selenium-based 
analogues (green labels). 
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Figure A5. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with the GLP1 Y1211A mutant.  Spectra in the left hand column are derived from the reactions containing 
sulfur-based analogues (red labels); spectra in the right hand column are from the reactions containing 
selenium-based analogues (green labels). 
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Figure A6. MALDI-MS spectra demonstrating a lack of modification of RGG-Biotin peptide substrates by 
cofactor analogues in the absence of methyltransferase.  Spectra in the left hand column are derived from 
the reactions containing sulfur-based analogues (red labels); spectra in the right hand column are from the 
reactions containing selenium-based analogues (green labels). 
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Figure A7. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with native PRMT1.  Spectra in the left hand column are derived from the reactions containing sulfur-based 
analogues (red labels); spectra in the right hand column are from the reactions containing selenium-based 
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Figure A8. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with the PRMT1 Y39FM48G mutant.  Spectra in the left hand column are derived from the reactions 
containing sulfur-based analogues (red labels); spectra in the right hand column are from the reactions 
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Figure A9. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with native PRMT3.  Spectra in the left hand column are derived from the reactions containing sulfur-based 
analogues (red labels), while spectra in the right hand column are from the reactions containing selenium-
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Figure A10. MALDI-MS spectra demonstrating sulfur and selenium-based cofactor analogue compatibility 
with the PRMT3 M233G mutant.  Spectra in the left hand column are derived from the reactions containing 
sulfur-based analogues (red labels); spectra in the right hand column are from the reactions containing 
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